{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 1,
   "metadata": {},
   "outputs": [],
   "source": [
    "# 0-10 : KRAS, 11-21: EGFR, 22-32: ROS1\n",
    "nct_ids = ['NCT02964689',\n",
    "'NCT07020221',\n",
    "'NCT06385925',\n",
    "'NCT06936644',\n",
    "'NCT05786924',\n",
    "'NCT05737706',\n",
    "'NCT05347797',\n",
    "'NCT06607185',\n",
    "'NCT06497556',\n",
    "'NCT05480865',\n",
    "'NCT06599502',\n",
    "'NCT04912687',\n",
    "'NCT06595498',\n",
    "'NCT02769286',\n",
    "'NCT04552613',\n",
    "'NCT06071013',\n",
    "'NCT03755102',\n",
    "'NCT05166616',\n",
    "'NCT02926768',\n",
    "'NCT02504346',\n",
    "'NCT06924398',\n",
    "'NCT06043817',\n",
    "'NCT04084717',\n",
    "'NCT05845671',\n",
    "'NCT01639508',\n",
    "'NCT06315010',\n",
    "'NCT04621188',\n",
    "'NCT05681780',\n",
    "'NCT05351320',\n",
    "'NCT07110259',\n",
    "'NCT04042558',\n",
    "'NCT03721120',\n",
    "'NCT04777084']\n",
    "\n",
    "# List of gene mutations : KRAS for first 11, EGFR for next 11, ROS1 for last 11\n",
    "gene_mutations = ['KRAS' for _ in range(11)] + \\\n",
    "                    ['EGFR' for _ in range(11)] + \\\n",
    "                    ['ROS1' for _ in range(11)]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "['KRAS',\n",
       " 'KRAS',\n",
       " 'KRAS',\n",
       " 'KRAS',\n",
       " 'KRAS',\n",
       " 'KRAS',\n",
       " 'KRAS',\n",
       " 'KRAS',\n",
       " 'KRAS',\n",
       " 'KRAS',\n",
       " 'KRAS',\n",
       " 'EGFR',\n",
       " 'EGFR',\n",
       " 'EGFR',\n",
       " 'EGFR',\n",
       " 'EGFR',\n",
       " 'EGFR',\n",
       " 'EGFR',\n",
       " 'EGFR',\n",
       " 'EGFR',\n",
       " 'EGFR',\n",
       " 'EGFR',\n",
       " 'ROS1',\n",
       " 'ROS1',\n",
       " 'ROS1',\n",
       " 'ROS1',\n",
       " 'ROS1',\n",
       " 'ROS1',\n",
       " 'ROS1',\n",
       " 'ROS1',\n",
       " 'ROS1',\n",
       " 'ROS1',\n",
       " 'ROS1']"
      ]
     },
     "execution_count": 2,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "gene_mutations"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "['./NCT02964689.json', './NCT07020221.json', './NCT06385925.json', './NCT06936644.json', './NCT05786924.json', './NCT05737706.json', './NCT05347797.json', './NCT06607185.json', './NCT06497556.json', './NCT05480865.json', './NCT06599502.json', './NCT04912687.json', './NCT06595498.json', './NCT02769286.json', './NCT04552613.json', './NCT06071013.json', './NCT03755102.json', './NCT05166616.json', './NCT02926768.json', './NCT02504346.json', './NCT06924398.json', './NCT06043817.json', './NCT04084717.json', './NCT05845671.json', './NCT01639508.json', './NCT06315010.json', './NCT04621188.json', './NCT05681780.json', './NCT05351320.json', './NCT07110259.json', './NCT04042558.json', './NCT03721120.json', './NCT04777084.json']\n"
     ]
    }
   ],
   "source": [
    "import os\n",
    "\n",
    "os.chdir('/scratch/mgeorges/TrialMatchAI/TrialMatchAI/data/cluster_trials')\n",
    "# Search for the IDs in processed_trials and open the jsons\n",
    "def find_json_files(nct_ids, directory):\n",
    "    json_files = []\n",
    "    for nct_id in nct_ids:\n",
    "        filename = f\"{nct_id}.json\"\n",
    "        file_path = os.path.join(directory, filename)\n",
    "        if os.path.exists(file_path):\n",
    "            json_files.append(file_path)\n",
    "        else:\n",
    "            print(f\"File {filename} not found in {directory}\")\n",
    "    return json_files\n",
    "\n",
    "# Directory where the JSON files are stored\n",
    "directory = './'\n",
    "# Find the JSON files\n",
    "json_files = find_json_files(nct_ids, directory)\n",
    "# Print the found JSON files\n",
    "print(json_files)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "['derivedSection', 'hasResults', 'protocolSection']"
      ]
     },
     "execution_count": 3,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "# Read the JSON files and print their content\n",
    "import json\n",
    "def read_json_files(json_files):\n",
    "    json_contents = []\n",
    "    for file_path in json_files:\n",
    "        with open(file_path, 'r') as file:\n",
    "            content = json.load(file)\n",
    "            json_contents.append(content)\n",
    "    return json_contents\n",
    "\n",
    "# Get the dictionary keys from the first JSON file\n",
    "def get_unique_json_keys(json_contents):\n",
    "    if json_contents:\n",
    "        keys = set()\n",
    "        for content in json_contents:\n",
    "            keys.update(content.keys())\n",
    "        return list(keys)\n",
    "    else:\n",
    "        print(\"No JSON contents to process.\")\n",
    "    return []\n",
    "\n",
    "json_contents = read_json_files(json_files)\n",
    "json_keys = get_unique_json_keys(json_contents)\n",
    "json_keys"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Keys for NCT02964689:\n",
      "dict_keys(['protocolSection', 'derivedSection', 'hasResults'])\n",
      "Content for NCT02964689:\n",
      "{'protocolSection': {'identificationModule': {'nctId': 'NCT02964689', 'orgStudyIdInfo': {'id': 'SAKK 19/16'}, 'organization': {'fullName': 'Swiss Cancer Institute', 'class': 'OTHER'}, 'briefTitle': 'Binimetinib in Addition to Standard Chemotherapy in KRAS Mutated NSCLC.', 'officialTitle': 'Binimetinib, Pemetrexed and Cisplatin, Followed by Maintenance With Binimetinib and Pemetrexed, in Patients With Advanced Non-small Cell Lung Cancer NSCLC With KRAS Mutations. A Multicenter Phase IB Trial.'}, 'statusModule': {'statusVerifiedDate': '2021-07', 'overallStatus': 'COMPLETED', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2017-04-12', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2021-07-02', 'type': 'ACTUAL'}, 'completionDateStruct': {'date': '2021-07-02', 'type': 'ACTUAL'}, 'studyFirstSubmitDate': '2016-11-14', 'studyFirstSubmitQcDate': '2016-11-14', 'studyFirstPostDateStruct': {'date': '2016-11-16', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2021-07-13', 'lastUpdatePostDateStruct': {'date': '2021-07-14', 'type': 'ACTUAL'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'}, 'leadSponsor': {'name': 'Swiss Cancer Institute', 'class': 'OTHER'}}, 'oversightModule': {'oversightHasDmc': False, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'descriptionModule': {'briefSummary': 'The aim is to determine the recommended phase 2 dose (RP2D) of binimetinib in combination with pemetrexed and cisplatin, and to demonstrate that the combination is feasible and has preliminary activity in previously untreated patients with advanced NSCLC and documented KRAS mutations.', 'detailedDescription': 'There is a need for more effective therapies for patients with advanced NSCLC driven by the RAS/MEK/ERK pathway. These tumors are generally aggressive, are almost exclusively of non-squamous histology, and represent the largest group of patients with advanced NSCLC harboring specific driver mutations in Western populations.\\n\\nBased on recent preclinical and clinical evidence, mitogen-activated protein kinase kinase (MEK)-inhibition plus first-line chemotherapy is a promising new treatment for patients with NSCLC and KRAS \\\\[v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog\\\\] mutations.\\n\\nBinimetinib is a medication without marketing authorization. Pemetrexed and cisplatin have marketing authorization in Switzerland and in EU for the treatment of non-small cell lung cancer (NSCLC) and will be administered as standard backbone treatment according to their Swissmedic-approved indication, dose and route of administration. Binimetinib, pemetrexed and cisplatin are IMP in the context of this phase I trial.'}, 'conditionsModule': {'conditions': ['Advanced Non-small Cell Lung Cancer', 'KRAS Gene Mutation', 'Lung Cancer'], 'keywords': ['Advanced non-small cell lung cancer', 'KRAS mutations', 'Binimetinib', 'Pemetrexed', 'Cisplatin', 'Phase IB trial']}, 'designModule': {'studyType': 'INTERVENTIONAL', 'phases': ['PHASE1'], 'designInfo': {'allocation': 'NA', 'interventionModel': 'SINGLE_GROUP', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 18, 'type': 'ACTUAL'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'Combination of binimetinib, pemetrexed and cisplatin', 'type': 'EXPERIMENTAL', 'description': 'The trial consists of two parts:\\n\\n* Part 1: dose escalation based on the 3+3 design with 2 doses of binimetinib\\n* Part 2: expansion cohort at the recommended maximum tolerated dose (MTD) level of binimetinib', 'interventionNames': ['Drug: Binimetinib', 'Drug: Pemetrexed', 'Drug: Cisplatin']}], 'interventions': [{'type': 'DRUG', 'name': 'Binimetinib', 'description': 'Binimetinib will be administered in combination with pemetrexed and cisplatin (induction therapy), and with pemetrexed only (maintenance therapy), during the first 2 weeks of each cycle. Cycles will be repeated every 21 days.', 'armGroupLabels': ['Combination of binimetinib, pemetrexed and cisplatin'], 'otherNames': ['MEK162']}, {'type': 'DRUG', 'name': 'Pemetrexed', 'description': 'Pemetrexed 500 mg/m2 i.v. is applied on day 1 of each cycle, before cisplatin administration', 'armGroupLabels': ['Combination of binimetinib, pemetrexed and cisplatin']}, {'type': 'DRUG', 'name': 'Cisplatin', 'description': 'Cisplatin 75 mg/m2 i.v. is applied on day 1 of each induction therapy cycle. The drug must be administered after pemetrexed infusion', 'armGroupLabels': ['Combination of binimetinib, pemetrexed and cisplatin']}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Dose-limiting toxicities (DLTs)', 'description': 'A DLT is defined as an AE or abnormal laboratory value assessed as at least possibly related to trial treatment (binimetinib in combination with pemetrexed and cisplatin), which occurs ≤ 21 days following the first dose of trial treatment during cycle 1.', 'timeFrame': 'within 21 days from the first dose'}], 'secondaryOutcomes': [{'measure': 'Objective response (OR)', 'description': 'OR will include complete and partial responses based on RECIST 1.1 criteria. Best response will be the best result by investigator and RECIST 1.1 in the planned follow-up CT scans.', 'timeFrame': 'at 30 months after start of trial'}, {'measure': 'Progression-free survival (PFS)', 'description': 'PFS will be calculated from registration until documented tumor progression according to RECIST 1.1 or death due to any reason, whichever occurs first.', 'timeFrame': 'at 30 months after start of trial'}, {'measure': 'Overall survival (OS)', 'description': 'OS will be calculated from registration until death due to any reason.', 'timeFrame': 'at 30 months after start of trial'}, {'measure': 'Adverse events (AEs)', 'description': 'AEs will be assessed according to NCI CTCAE V.4.03.', 'timeFrame': 'at 30 months after start of trial'}]}, 'eligibilityModule': {'eligibilityCriteria': \"Inclusion Criteria:\\n\\n* Written informed consent according to the Swiss HRA and ICH-GCP regulation before registration and prior to any trial-specific procedure.\\n* Histologically or cytologically confirmed diagnosis of NSCLC, predominantly non-squamous subtype (adenocarcinoma, large cell carcinoma, NOS).\\n* Locally advanced or metastatic stage III-IV disease according to the 7th TNM classification, ineligible for curative treatment.\\n* Presence of KRAS exon 2 or 3 (codon 12, 13 or 61) mutations by local testing (concomitant EGFR and ALK mutations are excluded).\\n* CT scan showing measurable disease, which is defined as at least one lesion that can be measured in at least one dimension (non-nodal lesions ≥10 mm in longest diameter, lymph nodes ≥15 mm in short axis) according to RECIST 1.1.\\n* Eligible for cisplatin-based chemotherapy and able to take oral medications.\\n* WHO performance status 0-1.\\n* Age from 18 to 75 years.\\n* Adequate hematological values: hemoglobin ≥ 90 g/L, ANC ≥ 1.5 x 109/L, platelets ≥ 100 x 109/L.\\n* Adequate hepatic function: total bilirubin ≤ 1.5 x ULN and \\\\< 34.2 μmol/L; ALT and alkaline phosphatase ≤ 2.5 x ULN.\\n* Adequate renal function: calculated creatinine clearance ≥ 60 mL/min, according to the formula of Cockcroft-Gault.\\n* Adequate cardiac function: left ventricular ejection fraction (LVEF) ≥ 50% as determined by echocardiogram; QTcF interval must be ≤ 480 ms.\\n* Women with child-bearing potential are using effective contraception, are not pregnant or lactating and agree not to become pregnant during trial treatment and 6 months thereafter. A negative serum pregnancy test before inclusion into the trial is required for all women with child-bearing potential.\\n* Men agree not to father a child during trial treatment and 6 months thereafter.\\n\\nExclusion Criteria:\\n\\n* NSCLC with any additional small cell carcinoma (SCLC) component by local diagnostic pathology report.\\n* Meningeosis carcinomatosa, symptomatic or untreated central nervous system (CNS) metastases. Patients with treated, controlled CNS metastases can be enrolled 2 weeks after the end of radiotherapy if asymptomatic (no residual neurologic deficits) and no longer on corticosteroids.\\n* Previous or concurrent malignancy with the following exceptions:\\n\\n  * adequately treated basal cell or squamous cell carcinoma of the skin (adequate wound healing is required prior registration),\\n  * in situ carcinoma of the cervix, treated curatively and without evidence of recurrence for at least 5 years prior registration,\\n  * superficial bladder cancer, prostate intraepithelial neoplasm, other noninvasive or indolent malignancy, or other solid tumor treated curatively and without evidence of recurrence for at least 5 years prior registration.\\n* Leptomeningeal disease.\\n* Concurrent radiotherapy (patients with prior radiotherapy other than for brain metastases ≥ 7 days prior to registration can be enrolled).\\n* Previous systemic therapy for advanced NSCLC; previous adjuvant or neoadjuvant chemotherapy allowed if last dose was administered at least 6 months ago.\\n* Major surgery within 3 weeks before registration.\\n* Concurrent treatment with any other experimental drug or other anticancer therapy.\\n* Impaired cardiovascular function or clinically severe or uncontrolled cardiovascular diseases, including any of the following:\\n\\n  * congestive heart failure NYHA III or IV,\\n  * history of acute coronary syndromes (including myocardial infarction, unstable angina, coronary artery bypass grafting, coronary angioplasty, or stenting) \\\\< 6 months prior to registration,\\n  * symptomatic chronic heart failure (G2 or higher), history or current evidence of clinically significant cardiac arrhythmia requiring medication and/or conduction abnormality \\\\< 6 months prior to registration except atrial fibrillation and paroxysmal supraventricular tachycardia.\\n* Uncontrolled arterial hypertension defined as persistent elevation of systolic blood pressure ≥ 150 mmHg or diastolic blood pressure ≥ 100 mmHg despite medical treatment.\\n* History or current evidence of retinal vein occlusion (RVO) or current risk factors to RVO (e.g. uncontrolled glaucoma or ocular hypertension, history of hyper-viscosity or hypercoagulability syndromes); history of retinal degenerative disease.\\n* History of Gilbert's syndrome.\\n* Neuromuscular disorders that are associated with elevated creatine phosphokinase (CPK; e.g. inflammatory myopathies, muscular dystrophy, amyotrophic lateral sclerosis, spinal muscular atrophy).\\n* Neuropathy (\\\\> G1) or hearing impairment/ tinnitus (\\\\> G1).\\n* Impairment of gastrointestinal function or gastrointestinal disease (e.g. ulcerative disease, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, small bowel resection).\\n* History of thromboembolic or cerebrovascular events within 6 months prior to registration, including transient ischemic attacks, cerebrovascular accidents, deep vein thrombosis or pulmonary emboli.\\n* Known history of acute or chronic pancreatitis.\\n* History of chronic inflammatory bowel disease or Crohn's disease requiring medical intervention (immunomodulatory or immunosuppressive medications or surgery) within 12 months prior to registration.\\n* Known positive serology for HIV (human immunodeficiency virus), active hepatitis B, and/or active hepatitis C infection.\\n* Active infection within 14 days prior to registration.\\n* Planning on embarking on a new strenuous exercise regimen after first dose of binimetinib (NB: muscular activities, such as strenuous exercise, that can result in significant increases in plasma CPK levels should be avoided while on binimetinib treatment).\\n* Known lactose intolerance.\\n* Known hypersensitivity to the trial drugs or hypersensitivity to any other component of the trial treatment, including premedication.\\n* Any concomitant drugs contraindicated for use with pemetrexed and cisplatin according to the Swissmedic-approved current product information or with binimetinib according to the latest version of the Investigator's Brochure.\\n* Any other serious underlying medical, psychiatric, psychological, familial or geographical condition, which in the judgment of the investigator may interfere with the planned staging, treatment and follow-up, affect patient compliance or place the patient at high risk from treatment-related complications.\", 'healthyVolunteers': False, 'sex': 'ALL', 'minimumAge': '18 Years', 'maximumAge': '75 Years', 'stdAges': ['ADULT', 'OLDER_ADULT']}, 'contactsLocationsModule': {'overallOfficials': [{'name': 'Martin Früh, MD', 'affiliation': 'Cantonal Hospital of St. Gallen', 'role': 'STUDY_CHAIR'}], 'locations': [{'facility': 'Universitaetsspital Basel', 'city': 'Basel', 'zip': '4031', 'country': 'Switzerland', 'geoPoint': {'lat': 47.55839, 'lon': 7.57327}}, {'facility': 'IOSI Ospedale Regionale di Bellinzona e Valli', 'city': 'Bellinzona', 'zip': '6500', 'country': 'Switzerland', 'geoPoint': {'lat': 46.19278, 'lon': 9.01703}}, {'facility': 'Kantonsspital Graubuenden', 'city': 'Chur', 'zip': 'CH-7000', 'country': 'Switzerland', 'geoPoint': {'lat': 46.84986, 'lon': 9.53287}}, {'facility': 'Kantonsspital St. Gallen', 'city': 'St. Gallen', 'zip': '9007', 'country': 'Switzerland', 'geoPoint': {'lat': 47.42391, 'lon': 9.37477}}]}, 'ipdSharingStatementModule': {'ipdSharing': 'NO'}}, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-08-21'}, 'conditionBrowseModule': {'meshes': [{'id': 'D008175', 'term': 'Lung Neoplasms'}, {'id': 'D002289', 'term': 'Carcinoma, Non-Small-Cell Lung'}], 'ancestors': [{'id': 'D012142', 'term': 'Respiratory Tract Neoplasms'}, {'id': 'D013899', 'term': 'Thoracic Neoplasms'}, {'id': 'D009371', 'term': 'Neoplasms by Site'}, {'id': 'D009369', 'term': 'Neoplasms'}, {'id': 'D008171', 'term': 'Lung Diseases'}, {'id': 'D012140', 'term': 'Respiratory Tract Diseases'}, {'id': 'D002283', 'term': 'Carcinoma, Bronchogenic'}, {'id': 'D001984', 'term': 'Bronchial Neoplasms'}], 'browseLeaves': [{'id': 'M11172', 'name': 'Lung Neoplasms', 'asFound': 'Lung Cancer', 'relevance': 'HIGH'}, {'id': 'M5546', 'name': 'Carcinoma, Non-Small-Cell Lung', 'asFound': 'Non-small Cell Lung Cancer', 'relevance': 'HIGH'}, {'id': 'M5534', 'name': 'Carcinoma', 'relevance': 'LOW'}, {'id': 'M14979', 'name': 'Respiratory Tract Neoplasms', 'relevance': 'LOW'}, {'id': 'M16658', 'name': 'Thoracic Neoplasms', 'relevance': 'LOW'}, {'id': 'M11168', 'name': 'Lung Diseases', 'relevance': 'LOW'}, {'id': 'M14977', 'name': 'Respiratory Tract Diseases', 'relevance': 'LOW'}, {'id': 'M5540', 'name': 'Carcinoma, Bronchogenic', 'relevance': 'LOW'}, {'id': 'M5260', 'name': 'Bronchial Neoplasms', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'BC04', 'name': 'Neoplasms'}, {'abbrev': 'BC08', 'name': 'Respiratory Tract (Lung and Bronchial) Diseases'}, {'abbrev': 'All', 'name': 'All Conditions'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'D000068437', 'term': 'Pemetrexed'}], 'ancestors': [{'id': 'D000970', 'term': 'Antineoplastic Agents'}, {'id': 'D004791', 'term': 'Enzyme Inhibitors'}, {'id': 'D045504', 'term': 'Molecular Mechanisms of Pharmacological Action'}, {'id': 'D005493', 'term': 'Folic Acid Antagonists'}, {'id': 'D019384', 'term': 'Nucleic Acid Synthesis Inhibitors'}], 'browseLeaves': [{'id': 'M264', 'name': 'Pemetrexed', 'asFound': 'Assigned', 'relevance': 'HIGH'}, {'id': 'M6182', 'name': 'Cisplatin', 'relevance': 'LOW'}, {'id': 'M7951', 'name': 'Enzyme Inhibitors', 'relevance': 'LOW'}, {'id': 'M8618', 'name': 'Folic Acid', 'relevance': 'LOW'}, {'id': 'M17546', 'name': 'Vitamin B Complex', 'relevance': 'LOW'}, {'id': 'M8619', 'name': 'Folic Acid Antagonists', 'relevance': 'LOW'}, {'id': 'T447', 'name': 'Folinic Acid', 'relevance': 'LOW'}, {'id': 'T475', 'name': 'Vitamin B9', 'relevance': 'LOW'}, {'id': 'T446', 'name': 'Folic Acid', 'relevance': 'LOW'}, {'id': 'T448', 'name': 'Folate', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'ANeo', 'name': 'Antineoplastic Agents'}, {'abbrev': 'All', 'name': 'All Drugs and Chemicals'}, {'abbrev': 'Micro', 'name': 'Micronutrients'}, {'abbrev': 'Hemat', 'name': 'Hematinics'}, {'abbrev': 'Vi', 'name': 'Vitamins'}]}}, 'hasResults': False}\n",
      "Keys for NCT07020221:\n",
      "dict_keys(['protocolSection', 'derivedSection', 'hasResults'])\n",
      "Content for NCT07020221:\n",
      "{'protocolSection': {'identificationModule': {'nctId': 'NCT07020221', 'orgStudyIdInfo': {'id': 'VS-7375-101'}, 'organization': {'fullName': 'Verastem, Inc.', 'class': 'INDUSTRY'}, 'briefTitle': 'A Phase 1/2a Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors', 'officialTitle': 'A Phase 1/2a, Open-label Study of VS-7375, a KRAS G12D (ON/OFF) Inhibitor, as Monotherapy and in Combination, in Patients With Advanced KRAS G12D-Mutated Solid Tumors'}, 'statusModule': {'statusVerifiedDate': '2025-07', 'overallStatus': 'RECRUITING', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2025-06-24', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2028-09', 'type': 'ESTIMATED'}, 'completionDateStruct': {'date': '2028-09', 'type': 'ESTIMATED'}, 'studyFirstSubmitDate': '2025-05-26', 'studyFirstSubmitQcDate': '2025-06-04', 'studyFirstPostDateStruct': {'date': '2025-06-13', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2025-07-15', 'lastUpdatePostDateStruct': {'date': '2025-07-18', 'type': 'ACTUAL'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'}, 'leadSponsor': {'name': 'Verastem, Inc.', 'class': 'INDUSTRY'}}, 'oversightModule': {'oversightHasDmc': False, 'isFdaRegulatedDrug': True, 'isFdaRegulatedDevice': False}, 'descriptionModule': {'briefSummary': 'This study will assess the safety and efficacy of VS-7375 alone and in combination in patients with advanced solid tumors harboring a KRAS G12D-mutation.'}, 'conditionsModule': {'conditions': ['Pancreatic Ductal Adenocarcinoma', 'Non Small Cell Lung Cancer', 'Colorectal Cancer', 'Solid Tumor, Adult', 'G12D Mutated KRAS'], 'keywords': ['KRAS G12D mutation', 'Solid tumors', 'Non Small Cell Lung Cancer', 'Lung Cancer', 'Colorectal Cancer', 'Metastatic Cancer', 'Pancreatic Cancer', 'Pancreatic Ductal Adenocarcinoma', 'NSCLC', 'CRC', 'PDAC', 'Pancreatic Neoplasms', 'Colorectal Neoplasms', 'Lung Neoplasms', 'Gastrointestinal Neoplasms', 'KRAS', 'RAS']}, 'designModule': {'studyType': 'INTERVENTIONAL', 'phases': ['PHASE1', 'PHASE2'], 'designInfo': {'allocation': 'NON_RANDOMIZED', 'interventionModel': 'SEQUENTIAL', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 130, 'type': 'ESTIMATED'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'VS-7375 Dose Escalation', 'type': 'EXPERIMENTAL', 'description': 'To determine the recommended phase 2 dose (RP2D) for VS-7375 in patients with advanced solid tumors harboring a KRAS G12D mutation.', 'interventionNames': ['Drug: VS-7375']}, {'label': 'Cetuximab + VS-7375 Dose Escalation', 'type': 'EXPERIMENTAL', 'description': 'To determine the recommended phase 2 dose (RP2D) for cetuximab + VS-7375 in patients with advanced solid tumors harboring a KRAS G12D mutation.', 'interventionNames': ['Drug: VS-7375', 'Drug: Cetuximab']}, {'label': 'VS-7375 Recommended Phase 2 Dose Expansion', 'type': 'EXPERIMENTAL', 'description': 'To determine the efficacy of VS-7375 at the recommended phase 2 dose (RP2D) in patients with advanced PDAC and NSCLC harboring a KRAS G12D mutation.', 'interventionNames': ['Drug: VS-7375']}, {'label': 'Cetuximab + VS-7375 Recommended Phase 2 Dose Expansion', 'type': 'EXPERIMENTAL', 'description': 'To determine the efficacy of cetuximab +VS-7375 at the recommended phase 2 dose (RP2D) in patients with advanced CRC harboring a KRAS G12D mutation.', 'interventionNames': ['Drug: VS-7375', 'Drug: Cetuximab']}], 'interventions': [{'type': 'DRUG', 'name': 'VS-7375', 'description': 'VS-7375 is a highly selective oral, non-covalent, small molecule KRAS G12D (ON/OFF) inhibitor.', 'armGroupLabels': ['Cetuximab + VS-7375 Dose Escalation', 'Cetuximab + VS-7375 Recommended Phase 2 Dose Expansion', 'VS-7375 Dose Escalation', 'VS-7375 Recommended Phase 2 Dose Expansion']}, {'type': 'DRUG', 'name': 'Cetuximab', 'description': 'Cetuximab is a monoclonal antibody targeting the epidermal growth factor receptor (EGFR).', 'armGroupLabels': ['Cetuximab + VS-7375 Dose Escalation', 'Cetuximab + VS-7375 Recommended Phase 2 Dose Expansion'], 'otherNames': ['Erbitux']}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Part A: To characterize the safety, tolerability, and AE profile of escalating doses of VS-7375', 'description': 'To characterize the safety, tolerability, and AE profile of escalating doses of VS-7375 administered on a daily oral schedule in participants with advanced solid tumors harboring a KRAS G12D mutation.\\n\\nProportion/number of participants with AEs, TEAEs, TRAEs, SAEs, DLTs, and dose interruptions/reductions.', 'timeFrame': 'Up to 2.5 years'}, {'measure': 'Part A: To identify the MTD or MFD', 'description': 'To identify the MTD or MFD using a BOIN design and recommend a dose for subsequent studies of VS-7375 on a daily oral schedule in participants with any KRAS G12D-mutated solid tumor.\\n\\nProportion/number of participants with DLTs during the DLT assessment period (through C1D21).', 'timeFrame': 'Cycle 1 (each cycle is 21 days)'}, {'measure': 'Part B: To evaluate the preliminary anticancer activity of the optimal VS-7375 regimen', 'description': 'To evaluate the preliminary anticancer activity of the optimal VS-7375 regimen identified from Part A in participants with advanced KRAS G12D-mutated PDAC (cohort B1) and NSCLC (cohort B2).\\n\\nConfirmed ORR, PFS rate, unconfirmed PR and CR rates, DCR, DOR, and PFS per RECIST v1.1.\\n\\nOverall Survival', 'timeFrame': 'Up to 2.5 years'}, {'measure': 'Part C: To characterize the safety, tolerability, and AE profile of the combination of cetuximab with VS-7375', 'description': 'To characterize the safety, tolerability, and AE profile of the combination of cetuximab with VS-7375 in participants with any solid tumor harboring a KRAS G12D mutation.\\n\\nProportion/number of participants with AEs, TEAEs, TRAEs, SAEs, DLTs, and dose interruptions/reductions.', 'timeFrame': 'From enrollment to the end of treatment; an average of 9 months'}, {'measure': 'Part C: To identify a recommended VS-7375 dose for subsequent studies of VS-7375 in combination with cetuximab.', 'description': 'To identify a recommended VS-7375 dose for subsequent studies of VS-7375 in combination with cetuximab in participants with any solid tumor harboring a KRAS G12D mutation.\\n\\nProportion/number of participants with DLTs during the DLT assessment period (through C1D21).', 'timeFrame': 'Cycle 1 (each cycle is 21 days)'}, {'measure': 'Part D: To determine the preliminary anticancer activity of the optimal cetuximab + VS-7375', 'description': 'To determine the preliminary anticancer activity of the optimal cetuximab + VS-7375 regimen identified from Part C in participants with advanced KRAS G12D mutated CRC.\\n\\nConfirmed ORR, PFS rate, unconfirmed PR and CR rates, DCR, DOR, and PFS per RECIST v1.1.\\n\\nOverall survival', 'timeFrame': 'Up to 2.5 years'}], 'secondaryOutcomes': [{'measure': 'To characterize the PK of VS-7375 administered on a daily oral schedule', 'description': 'To characterize the PK of VS-7375 administered on a daily oral schedule alone or in combination in participants with any KRAS G12D-mutated solid tumor.\\n\\nCmax derived from plasma concentrations of VS-7375.', 'timeFrame': 'Up to 2.5 years'}, {'measure': 'To characterize the PK of VS-7375 administered on a daily oral schedule', 'description': 'To characterize the PK of VS-7375 administered on a daily oral schedule alone or in combination in participants with any KRAS G12D-mutated solid tumor.\\n\\nAUC derived from plasma concentrations of VS-7375.', 'timeFrame': 'Up to 2.5 years'}]}, 'eligibilityModule': {'eligibilityCriteria': 'Key Inclusion Criteria:\\n\\n* Individuals ≥18 years of age.\\n* Agreement to sign and date an informed consent form (ICF) approved by the Institutional Review Board (IRB)/Independent Ethics Committee (IEC).\\n* Histologic or cytologic evidence of locally advanced unresectable or metastatic solid tumor harboring a KRAS G12D mutation.\\n* Must have received ≥1 prior line of standard systemic therapy for advanced or metastatic disease or experienced cancer progression within 6 months of neoadjuvant or adjuvant therapy.\\n* Measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.\\n* Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1\\n* Adequate organ function\\n* Adequate cardiac function\\n* Recovered from all AEs due to previous therapies to Grade ≤1 or baseline.\\n* Agreement to use highly effective contraception\\n\\nKey Exclusion Criteria:\\n\\n* Underwent major surgical procedure as defined by the Investigator, other than for diagnosis, within 4 weeks prior to Cycle 1 Day 1,\\n* Receipt of chemotherapy, targeted therapy, or radiotherapy (excluding palliative radiation) within 4 weeks or 5 half-lives, whichever is shorter, or immunotherapy within 4 weeks prior to Cycle 1 Day 1\\n* Treatment with any investigational drug at least 4 weeks or 5 half-lives, whichever is shorter, prior to Cycle 1 Day 1.\\n* History of treatment with direct and specific KRAS G12D inhibitors.\\n* Symptomatic, untreated, or actively progressing known central nervous system (CNS) metastases.\\n* Inability to swallow oral medications.\\n* Evidence or history of uncontrolled, clinically significant hematological, renal, hepatic, endocrine, pulmonary, gastrointestinal, cardiovascular, psychiatric, coagulation, neurologic, dermatologic, autoimmune, or allergic disease\\n* Individuals who are pregnant or breastfeeding.', 'healthyVolunteers': False, 'sex': 'ALL', 'minimumAge': '18 Years', 'stdAges': ['ADULT', 'OLDER_ADULT']}, 'contactsLocationsModule': {'centralContacts': [{'name': 'Verastem Call Center', 'role': 'CONTACT', 'phone': '1 781 292 4204', 'email': 'clinicaltrials@verastem.com'}], 'locations': [{'facility': 'Massachusetts General Hospital', 'status': 'RECRUITING', 'city': 'Boston', 'state': 'Massachusetts', 'zip': '02114', 'country': 'United States', 'contacts': [{'name': 'Leon Pappas, MD', 'role': 'CONTACT', 'phone': '617-724-4000', 'email': 'lpappas3@mgb.org'}, {'name': 'Leon Pappas, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 42.35843, 'lon': -71.05977}}, {'facility': 'Washington University School of Medicine', 'status': 'RECRUITING', 'city': 'Saint Louis', 'state': 'Missouri', 'zip': '63110', 'country': 'United States', 'contacts': [{'name': 'Katlyn Kraft', 'role': 'CONTACT', 'phone': '314-747-5440', 'email': 'Katlyn.kraft@wustl.edu'}, {'name': 'Kian-Huat Lim, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 38.62727, 'lon': -90.19789}}, {'facility': 'SCRI Oncology Partners', 'status': 'RECRUITING', 'city': 'Nashville', 'state': 'Tennessee', 'zip': '37203', 'country': 'United States', 'contacts': [{'name': 'SCRI Referral Team', 'role': 'CONTACT', 'phone': '615-341-7844', 'email': 'SCRI.DDUreferrals@scri.com'}, {'name': 'Melissa Johnson', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 36.16589, 'lon': -86.78444}}, {'facility': 'MD Anderson Cancer Center', 'status': 'RECRUITING', 'city': 'Houston', 'state': 'Texas', 'zip': '77030', 'country': 'United States', 'contacts': [{'name': 'Ly M Nguyen', 'role': 'CONTACT', 'phone': '832-794-3672', 'email': 'lmnguyen1@mdanderson.org'}, {'name': 'David Hong', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 29.76328, 'lon': -95.36327}}, {'facility': 'Virginia Mason Medical Center', 'status': 'RECRUITING', 'city': 'Seattle', 'state': 'Washington', 'zip': '98101', 'country': 'United States', 'contacts': [{'name': 'Colleen Soleau', 'role': 'CONTACT', 'phone': '206-287-6272', 'email': 'colleen.soleau@commonspirit.org'}, {'name': 'Vincent Picozzi', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 47.60621, 'lon': -122.33207}}]}, 'ipdSharingStatementModule': {'ipdSharing': 'NO'}}, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-08-20'}, 'conditionBrowseModule': {'meshes': [{'id': 'D008175', 'term': 'Lung Neoplasms'}, {'id': 'D002289', 'term': 'Carcinoma, Non-Small-Cell Lung'}, {'id': 'D015179', 'term': 'Colorectal Neoplasms'}, {'id': 'D000230', 'term': 'Adenocarcinoma'}], 'ancestors': [{'id': 'D009369', 'term': 'Neoplasms'}, {'id': 'D012142', 'term': 'Respiratory Tract Neoplasms'}, {'id': 'D013899', 'term': 'Thoracic Neoplasms'}, {'id': 'D009371', 'term': 'Neoplasms by Site'}, {'id': 'D008171', 'term': 'Lung Diseases'}, {'id': 'D012140', 'term': 'Respiratory Tract Diseases'}, {'id': 'D002283', 'term': 'Carcinoma, Bronchogenic'}, {'id': 'D001984', 'term': 'Bronchial Neoplasms'}, {'id': 'D007414', 'term': 'Intestinal Neoplasms'}, {'id': 'D005770', 'term': 'Gastrointestinal Neoplasms'}, {'id': 'D004067', 'term': 'Digestive System Neoplasms'}, {'id': 'D004066', 'term': 'Digestive System Diseases'}, {'id': 'D005767', 'term': 'Gastrointestinal Diseases'}, {'id': 'D003108', 'term': 'Colonic Diseases'}, {'id': 'D007410', 'term': 'Intestinal Diseases'}, {'id': 'D012002', 'term': 'Rectal Diseases'}, {'id': 'D002277', 'term': 'Carcinoma'}, {'id': 'D009375', 'term': 'Neoplasms, Glandular and Epithelial'}, {'id': 'D009370', 'term': 'Neoplasms by Histologic Type'}], 'browseLeaves': [{'id': 'M13110', 'name': 'Pancreatic Neoplasms', 'relevance': 'LOW'}, {'id': 'M3585', 'name': 'Adenocarcinoma', 'asFound': 'Adenocarcinoma', 'relevance': 'HIGH'}, {'id': 'M12307', 'name': 'Neoplasm Metastasis', 'relevance': 'LOW'}, {'id': 'M11172', 'name': 'Lung Neoplasms', 'asFound': 'Lung Cancer', 'relevance': 'HIGH'}, {'id': 'M5546', 'name': 'Carcinoma, Non-Small-Cell Lung', 'asFound': 'Non-small Cell Lung Cancer', 'relevance': 'HIGH'}, {'id': 'M17890', 'name': 'Colorectal Neoplasms', 'asFound': 'Colorectal Cancer', 'relevance': 'HIGH'}, {'id': 'M8886', 'name': 'Gastrointestinal Neoplasms', 'relevance': 'LOW'}, {'id': 'M7256', 'name': 'Digestive System Neoplasms', 'relevance': 'LOW'}, {'id': 'M5534', 'name': 'Carcinoma', 'relevance': 'LOW'}, {'id': 'M14979', 'name': 'Respiratory Tract Neoplasms', 'relevance': 'LOW'}, {'id': 'M16658', 'name': 'Thoracic Neoplasms', 'relevance': 'LOW'}, {'id': 'M11168', 'name': 'Lung Diseases', 'relevance': 'LOW'}, {'id': 'M14977', 'name': 'Respiratory Tract Diseases', 'relevance': 'LOW'}, {'id': 'M5540', 'name': 'Carcinoma, Bronchogenic', 'relevance': 'LOW'}, {'id': 'M5260', 'name': 'Bronchial Neoplasms', 'relevance': 'LOW'}, {'id': 'M10448', 'name': 'Intestinal Neoplasms', 'relevance': 'LOW'}, {'id': 'M8883', 'name': 'Gastrointestinal Diseases', 'relevance': 'LOW'}, {'id': 'M7255', 'name': 'Digestive System Diseases', 'relevance': 'LOW'}, {'id': 'M6336', 'name': 'Colonic Diseases', 'relevance': 'LOW'}, {'id': 'M10444', 'name': 'Intestinal Diseases', 'relevance': 'LOW'}, {'id': 'M14844', 'name': 'Rectal Diseases', 'relevance': 'LOW'}, {'id': 'M12320', 'name': 'Neoplasms, Glandular and Epithelial', 'relevance': 'LOW'}, {'id': 'M12315', 'name': 'Neoplasms by Histologic Type', 'relevance': 'LOW'}, {'id': 'T4387', 'name': 'Pancreatic Cancer', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'BC04', 'name': 'Neoplasms'}, {'abbrev': 'BC06', 'name': 'Digestive System Diseases'}, {'abbrev': 'BC19', 'name': 'Gland and Hormone Related Diseases'}, {'abbrev': 'All', 'name': 'All Conditions'}, {'abbrev': 'BC23', 'name': 'Symptoms and General Pathology'}, {'abbrev': 'BC08', 'name': 'Respiratory Tract (Lung and Bronchial) Diseases'}, {'abbrev': 'Rare', 'name': 'Rare Diseases'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'D000068818', 'term': 'Cetuximab'}], 'ancestors': [{'id': 'D000074322', 'term': 'Antineoplastic Agents, Immunological'}, {'id': 'D000970', 'term': 'Antineoplastic Agents'}], 'browseLeaves': [{'id': 'M4225', 'name': 'Antibodies', 'relevance': 'LOW'}, {'id': 'M4230', 'name': 'Antibodies, Monoclonal', 'relevance': 'LOW'}, {'id': 'M11900', 'name': 'Mitogens', 'relevance': 'LOW'}, {'id': 'M10184', 'name': 'Immunoglobulins', 'relevance': 'LOW'}, {'id': 'M315', 'name': 'Cetuximab', 'asFound': 'Observational', 'relevance': 'HIGH'}, {'id': 'M1346', 'name': 'Antineoplastic Agents, Immunological', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'All', 'name': 'All Drugs and Chemicals'}, {'abbrev': 'ANeo', 'name': 'Antineoplastic Agents'}]}}, 'hasResults': False}\n",
      "Keys for NCT06385925:\n",
      "dict_keys(['protocolSection', 'derivedSection', 'hasResults'])\n",
      "Content for NCT06385925:\n",
      "{'protocolSection': {'identificationModule': {'nctId': 'NCT06385925', 'orgStudyIdInfo': {'id': 'TSN1611-2023-101'}, 'organization': {'fullName': 'Tyligand Pharmaceuticals (Suzhou) Limited', 'class': 'INDUSTRY'}, 'briefTitle': 'A Study of TSN1611 Treating Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation', 'officialTitle': 'Phase 1/2 Study of TSN1611 in Subjects With Advanced Solid Tumors Harboring KRAS G12D Mutation'}, 'statusModule': {'statusVerifiedDate': '2025-03', 'overallStatus': 'RECRUITING', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2024-04-29', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2026-10-30', 'type': 'ESTIMATED'}, 'completionDateStruct': {'date': '2027-04-30', 'type': 'ESTIMATED'}, 'studyFirstSubmitDate': '2024-04-18', 'studyFirstSubmitQcDate': '2024-04-23', 'studyFirstPostDateStruct': {'date': '2024-04-26', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2025-03-19', 'lastUpdatePostDateStruct': {'date': '2025-03-24', 'type': 'ACTUAL'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'}, 'leadSponsor': {'name': 'Tyligand Pharmaceuticals (Suzhou) Limited', 'class': 'INDUSTRY'}}, 'oversightModule': {'oversightHasDmc': False, 'isFdaRegulatedDrug': True, 'isFdaRegulatedDevice': False, 'isUsExport': False}, 'descriptionModule': {'briefSummary': 'The study is a first-in-human (FIH), open-label, multi-center phase 1/2 study of TSN1611 in subjects with KRAS G12D mutant advanced solid tumors. This study will consist of a phase 1 dose escalation part and phase 2 dose expansion part.', 'detailedDescription': 'Phase 1 Part:\\n\\nThe phase 1 part will evaluate the prespecified dose levels of TSN1611. Dose escalation will continue until up to the highest planned dose or the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D) is determined. Dose optimization could be performed as indicated by the emerging data.\\n\\nPhase 2 Part:\\n\\nPhase 2 part will evaluate the efficacy and safety of TSN1611 as monotherapy at the recommended dose in separate groups of patients with pancreatic cancer, colorectal cancer, non-small cell lung cancer, or other solid tumors, harboring KRAS G12D mutations.'}, 'conditionsModule': {'conditions': ['Malignant Neoplasm'], 'keywords': ['solid tumor', 'KRAS G12D mutation', 'pancreatic cancer', 'colorectal cancer', 'non-small cell lung cancer', 'malignant neoplasm']}, 'designModule': {'studyType': 'INTERVENTIONAL', 'phases': ['PHASE1', 'PHASE2'], 'designInfo': {'allocation': 'NON_RANDOMIZED', 'interventionModel': 'SEQUENTIAL', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 150, 'type': 'ESTIMATED'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'Phase 1: Dose-finding/evaluation of TSN1611 monotherapy', 'type': 'EXPERIMENTAL', 'description': 'The phase 1 part will evaluate the prespecified sequential dose levels of TSN1611 in subjects with KRAS G12D mutant advanced solid tumors to determine the recommended dose of TSN1611 for further investigation.', 'interventionNames': ['Drug: TSN1611']}, {'label': 'Phase 2: Dose expansion of TSN1611 monotherapy', 'type': 'EXPERIMENTAL', 'description': 'Phase 2 part will evaluate the efficacy and safety of TSN1611 as monotherapy at the recommended dose level in separate groups of patients with pancreatic cancer, colorectal cancer, non-small cell lung cancer, or other solid tumors, harboring KRAS G12D mutations.', 'interventionNames': ['Drug: TSN1611']}], 'interventions': [{'type': 'DRUG', 'name': 'TSN1611', 'description': 'TSN1611 will be administered at the assigned dose level, orally, until disease progression or intolerable toxicity.', 'armGroupLabels': ['Phase 1: Dose-finding/evaluation of TSN1611 monotherapy', 'Phase 2: Dose expansion of TSN1611 monotherapy']}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Dose limiting toxicities (DLTs) in phase 1 part', 'description': 'To determine the maximum tolerated dose (MTD) and/or recommended phase 2 dose(s) (RP2D\\\\[s\\\\]) of TSN1611 as monotherapy in subjects with KRAS G12D mutant advanced solid tumors.', 'timeFrame': '21 days'}, {'measure': 'Objective response rate (ORR) in phase 2 part', 'description': 'To evaluate the anti-tumor activity of TSN1611 using Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.', 'timeFrame': 'Up to 3 years'}], 'secondaryOutcomes': [{'measure': 'Adverse events', 'description': 'To assess the safety profile and tolerability of TSN1611 as monotherapy in subjects with KRAS G12D mutant advanced solid tumors.', 'timeFrame': 'Up to 3 years'}, {'measure': 'Area under the plasma concentration-time curve (AUC)', 'description': 'To characterize the pharmacokinetic (PK) profile of TSN1611.', 'timeFrame': '9 weeks'}, {'measure': 'Maximum blood concentrations (Cmax)', 'description': 'To characterize the PK profile of TSN1611.', 'timeFrame': '9 weeks'}, {'measure': 'Time to maximum blood concentration (Tmax)', 'description': 'To characterize the PK profile of TSN1611.', 'timeFrame': '9 weeks'}, {'measure': 'Duration of response (DOR)', 'description': 'To evaluate the anti-tumor activity of TSN1611 using RECIST version 1.1.', 'timeFrame': 'Up to 3 years'}, {'measure': 'Time to response (TTR)', 'description': 'To evaluate the anti-tumor activity of TSN1611 using RECIST version 1.1.', 'timeFrame': 'Up to 3 years'}, {'measure': 'Disease control rate (DCR)', 'description': 'To evaluate the anti-tumor activity of TSN1611 using RECIST version 1.1.', 'timeFrame': 'Up to 3 years'}, {'measure': 'Progression free survival (PFS)', 'description': 'To evaluate the anti-tumor activity of TSN1611 using RECIST version 1.1.', 'timeFrame': 'Up to 3 years'}, {'measure': 'Overall survival', 'timeFrame': 'Up to 3 years'}]}, 'eligibilityModule': {'eligibilityCriteria': \"Subjects must meet all the following inclusion criteria to be eligible for participation in this study:\\n\\n* The subject fully understands the requirements of the study and voluntarily signs the ICF.\\n* At least 18 years of age at the time of informed consent.\\n* Life expectancy of 3 months or more.\\n* Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.\\n* Subjects with histologically or cytologically confirmed locally advanced or metastatic solid tumor harboring KRAS G12D mutation; subjects must be refractory or intolerable to standard treatment, or have no standard treatment available, etc.\\n* Patients with adequate cardiac, liver, renal function, etc.\\n\\nExclusion Criteria\\n\\nSubjects will be excluded if they meet any of the following criteria:\\n\\n* Leptomeningeal disease or Active central nervous system (CNS) metastases.\\n* Prior systemic anti-cancer treatment within 21 days or 5 half-lives (whichever is shorter will be used as the criteria) prior to the first dose of study drug.\\n* Radical radiation within 4 weeks prior to the first dose of study drug; palliative radiotherapy within 1 week prior to the first dose of study drug.\\n* Any unresolved Grade 2 or higher toxicity from previous anticancer therapy except alopecia.\\n* Has participated in a study of investigational agent and received the investigational agent within 21 days or 5 half-lives, if known (whichever is shorter) prior to the first dose of study drug.\\n* History of interstitial lung disease (ILD), drug induced IDL, or current active pneumonitis, radiation pneumonitis requiring therapeutic intervention, or uncontrolled other lung disease.\\n* Any of the following in the past 6 months: myocardial infarction, unstable angina, symptomatic congestive heart failure, stroke or transient ischemic attack, pulmonary embolism.\\n* Prior treatment with KRAS G12D targeted therapy.\\n* Has a history or current evidence of any severe condition, concurrent therapy, or laboratory abnormality that might confound the interpretation of the study results, interfere with the subject's participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the investigator.\", 'healthyVolunteers': False, 'sex': 'ALL', 'minimumAge': '18 Years', 'stdAges': ['ADULT', 'OLDER_ADULT']}, 'contactsLocationsModule': {'centralContacts': [{'name': 'Tyligand Clinical Trial Info', 'role': 'CONTACT', 'phone': '+86 021-50720081', 'email': 'clinical_trial@tyligand.com'}], 'overallOfficials': [{'name': 'Cindy Li', 'affiliation': 'Tyligand Bioscience (Shanghai) Limited', 'role': 'STUDY_DIRECTOR'}], 'locations': [{'facility': 'MD Anderson Cancer Center', 'status': 'RECRUITING', 'city': 'Houston', 'state': 'Texas', 'zip': '77030', 'country': 'United States', 'contacts': [{'name': 'Siqing Fu, MD,PhD', 'role': 'CONTACT'}], 'geoPoint': {'lat': 29.76328, 'lon': -95.36327}}, {'facility': 'NEXT Oncology', 'status': 'RECRUITING', 'city': 'San Antonio', 'state': 'Texas', 'zip': '78229', 'country': 'United States', 'contacts': [{'name': 'David Sommerhalder, MD', 'role': 'CONTACT'}], 'geoPoint': {'lat': 29.42412, 'lon': -98.49363}}, {'facility': 'NEXT Virginia', 'status': 'RECRUITING', 'city': 'Fairfax', 'state': 'Virginia', 'zip': '22031', 'country': 'United States', 'contacts': [{'name': 'Alexander Spira, MD', 'role': 'CONTACT'}], 'geoPoint': {'lat': 38.84622, 'lon': -77.30637}}, {'facility': 'Beijing Cancer Hospital, Beijing, China', 'status': 'RECRUITING', 'city': 'Beijing', 'zip': '100142', 'country': 'China', 'contacts': [{'name': 'Lin Shen', 'role': 'CONTACT'}, {'name': 'Lin Shen, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 39.9075, 'lon': 116.39723}}, {'facility': 'Shanghai Chest Hospital, Shanghai, China', 'status': 'RECRUITING', 'city': 'Shanghai', 'zip': '200030', 'country': 'China', 'contacts': [{'name': 'Shun Lu', 'role': 'CONTACT'}, {'name': 'Shun Lu, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 31.22222, 'lon': 121.45806}}, {'facility': 'Shanghai Zhongshan Hospital, Shanghai, China', 'status': 'RECRUITING', 'city': 'Shanghai', 'zip': '200032', 'country': 'China', 'contacts': [{'name': 'Tianshu Liu', 'role': 'CONTACT'}, {'name': 'Tianshu Liu, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 31.22222, 'lon': 121.45806}}]}, 'ipdSharingStatementModule': {'ipdSharing': 'NO'}}, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-08-21'}, 'conditionBrowseModule': {'meshes': [{'id': 'D009369', 'term': 'Neoplasms'}], 'browseLeaves': [{'id': 'M11172', 'name': 'Lung Neoplasms', 'relevance': 'LOW'}, {'id': 'M5546', 'name': 'Carcinoma, Non-Small-Cell Lung', 'relevance': 'LOW'}, {'id': 'M13110', 'name': 'Pancreatic Neoplasms', 'relevance': 'LOW'}, {'id': 'T4387', 'name': 'Pancreatic Cancer', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'BC04', 'name': 'Neoplasms'}, {'abbrev': 'BC08', 'name': 'Respiratory Tract (Lung and Bronchial) Diseases'}, {'abbrev': 'All', 'name': 'All Conditions'}, {'abbrev': 'BC06', 'name': 'Digestive System Diseases'}, {'abbrev': 'BC19', 'name': 'Gland and Hormone Related Diseases'}, {'abbrev': 'Rare', 'name': 'Rare Diseases'}]}}, 'hasResults': False}\n",
      "Keys for NCT06936644:\n",
      "dict_keys(['protocolSection', 'derivedSection', 'hasResults'])\n",
      "Content for NCT06936644:\n",
      "{'protocolSection': {'identificationModule': {'nctId': 'NCT06936644', 'orgStudyIdInfo': {'id': 'CIBI351IIS006'}, 'organization': {'fullName': 'Shanghai Chest Hospital', 'class': 'OTHER'}, 'briefTitle': 'A Multicenter, Single-arm Phase II Study to Evaluate the Efficacy and Safety of Fulzerasib (IBI351) in Combination With Ivonescimab (AK-112) in First-line Treatment of Advanced or Metastatic Non-small Cell Lung Cancer Patients With KRAS G12C Mutation', 'officialTitle': 'A Multicenter, Single-arm Phase II Study to Evaluate the Efficacy and Safety of Fulzerasib (IBI351) in Combination With Ivonescimab (AK-112) in First-line Treatment of Advanced or Metastatic Non-small Cell Lung Cancer Patients With KRAS G12C Mutation'}, 'statusModule': {'statusVerifiedDate': '2025-04', 'overallStatus': 'NOT_YET_RECRUITING', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2025-04-30', 'type': 'ESTIMATED'}, 'primaryCompletionDateStruct': {'date': '2027-04-30', 'type': 'ESTIMATED'}, 'completionDateStruct': {'date': '2028-03-30', 'type': 'ESTIMATED'}, 'studyFirstSubmitDate': '2025-04-14', 'studyFirstSubmitQcDate': '2025-04-14', 'studyFirstPostDateStruct': {'date': '2025-04-20', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2025-04-14', 'lastUpdatePostDateStruct': {'date': '2025-04-20', 'type': 'ACTUAL'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'PRINCIPAL_INVESTIGATOR', 'investigatorFullName': 'Zhong Runbo', 'investigatorTitle': 'The chief physician of pneumology department', 'investigatorAffiliation': 'Shanghai Chest Hospital'}, 'leadSponsor': {'name': 'Shanghai Chest Hospital', 'class': 'OTHER'}, 'collaborators': [{'name': 'Innovent Biologics, Inc.', 'class': 'OTHER'}, {'name': 'Akesobio', 'class': 'INDUSTRY'}]}, 'oversightModule': {'oversightHasDmc': False, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'descriptionModule': {'briefSummary': 'A multicenter, single-arm Phase II study to evaluate the efficacy and safety of fulzerasib (IBI351) in combination with ivonescimab (AK-112) in first-line treatment of advanced or metastatic non-small cell lung cancer patients with KRAS G12C mutation'}, 'conditionsModule': {'conditions': ['KRAS G12C Lung Cancer']}, 'designModule': {'studyType': 'INTERVENTIONAL', 'phases': ['PHASE2'], 'designInfo': {'allocation': 'NON_RANDOMIZED', 'interventionModel': 'SINGLE_GROUP', 'interventionModelDescription': 'the combination of IBI351 plus AK112', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 39, 'type': 'ESTIMATED'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'The combination of IBI351 plus AK112', 'type': 'EXPERIMENTAL', 'interventionNames': ['Drug: IBI351+AK112']}], 'interventions': [{'type': 'DRUG', 'name': 'IBI351+AK112', 'description': 'The advanced or metastatic non-small cell lung cancer patients with KRAS G12C mutation will receive the combination of fulzerasib (IBI351) with ivonescimab (AK-112) in first-line treatment', 'armGroupLabels': ['The combination of IBI351 plus AK112'], 'otherNames': ['fulzerasib', 'ivonescimab']}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'ORR', 'description': 'the investigator assessed objective response rate', 'timeFrame': 'about 6 month'}]}, 'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\n\\n1. Sign the Informed Consent Form (ICF) and be able to comply with the visit and related procedures as stipulated in the protocol.\\n2. Be male or female, aged ≥18 and ≤75 years old.\\n3. Have an expected survival time of ≥6 months.\\n4. Have histologically or cytologically confirmed locally advanced (IIIB/IIIC stage), metastatic or recurrent (IV stage) non-small cell lung cancer (NSCLC) that is not operable and not suitable for radical concurrent chemoradiotherapy, as classified by the 8th edition of the TNM staging system of the International Association for the Study of Lung Cancer and the American Joint Committee on Cancer.\\n5. All subjects must have a written test report before enrollment to prove the presence of KRAS G12C mutation; and must have no sensitive mutations of Epidermal Growth Factor Receptor (EGFR), Anaplastic Lymphoma Kinase (ALK), or other gene mutation types approved by the National Medical Products Administration (NMPA) for first-line treatment of NSCLC.\\n6. Have at least one measurable lesion according to RECIST 1.1 criteria.\\n7. Have not received any systemic anti-tumor treatment for locally advanced or metastatic NSCLC before; previous adjuvant therapy is allowed, but the interval between the last adjuvant therapy or last radical radiotherapy and disease recurrence should be at least 6 months.\\n8. Have an Eastern Cooperative Oncology Group Performance Status (ECOG PS) score of 0 or 1.\\n9. Have adequate organ and bone marrow function (subjects who have received any cell or growth factor therapy within 2 weeks before the first administration of the study drug should be excluded), defined as follows:\\n\\n1) Blood routine: Absolute neutrophil count (ANC) ≥1.5×109/L or within the normal range; platelet (PLT) count ≥100×109/L; hemoglobin (HGB) content ≥9.0 g/dL.\\n\\n2) Liver function: Serum total bilirubin (TBIL) ≤1.5×Upper Limit of Normal Value (ULN); alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤2.5×ULN.\\n\\n3) Renal function: Serum creatinine (Cr) ≤1.5×ULN or clearance of creatinine (CCr) ≥50 mL/min, calculated by the Cockcroft-Gault formula (using actual body weight); urine routine test shows urine protein \\\\<2+; for subjects with urine protein ≥2+ at baseline as detected by urine test strips, a 24-hour urine collection should be performed and the protein content in 24-hour urine should be \\\\<1 g (if both methods are used, the value obtained from 24-hour urine collection will be used to determine eligibility). 4) Coagulation function: Activated Partial Thromboplastin Time (APTT) ≤ 1.5×ULN and International Normalized Ratio (INR) ≤ 1.5; 10. Female subjects of childbearing age or male subjects whose partners are of childbearing age must take effective contraceptive measures throughout the treatment period and for 180 days after the treatment.\\n\\n11. Female subjects have evidence of postmenopausal status, or the urine or serum pregnancy test results of premenopausal female subjects are negative.\\n\\nExclusion Criteria:\\n\\nSubjects should not be enrolled in this study if they meet any of the following criteria:\\n\\n1. Histological or cytological pathology confirms the presence of small cell carcinoma, neuroendocrine carcinoma, sarcoma, lymphoepithelioma-like carcinoma, salivary gland tumors, or mesenchymal tumor components.\\n\\n2. Have significant cardiovascular or cerebrovascular diseases, such as:\\n\\n1. Experienced definite cardiovascular abnormal events within 6 months, such as myocardial infarction, angina pectoris, heart failure, severe arrhythmia, or undergone angioplasty, vascular stent implantation, coronary artery bypass surgery, etc.\\n2. Have clinically significant QT/QTcF interval prolongation (QTcF \\\\> 470ms for females or \\\\> 450ms for males).\\n3. Experienced definite cerebrovascular abnormal events within 3 months, such as cerebral hemorrhage or cerebral infarction.\\n\\n3. Active central nervous system metastases (such as brain metastases or leptomeningeal metastases) are not eligible for enrollment. For subjects with brain metastases who have received radiotherapy or local treatment, if no hormones or antiepileptic drugs are used, they must be asymptomatic within at least 7 days after radiotherapy to be eligible for enrollment; if hormones or antiepileptic drugs are used, they must be asymptomatic within at least 7 days after drug withdrawal and the investigator deems the brain metastases to be stable, they can be eligible for enrollment; if stable brain metastases patients have not received radiotherapy or hormone or antiepileptic drug treatment, they can be eligible for enrollment after the investigator deems the brain metastases to be stable.\\n\\n4. Currently have clinically significant interstitial lung disease, radiation pneumonitis, drug-related pneumonitis, active pulmonary tuberculosis, pneumoconiosis, or have ≥ grade 2 other types of pneumonia, or have severe lung function impairment confirmed by pulmonary function tests (FEV1 or DLCO or DLCO/VA \\\\< 40% of predicted values).\\n\\n5. Have significant gastrointestinal diseases, such as intractable hiccups, nausea, vomiting, severe gastrointestinal ulcers, liver cirrhosis, active gastrointestinal bleeding, or other diseases that affect swallowing tablets or significantly affect the absorption of oral drugs.\\n\\n6. Have major acute or chronic infections, including:\\n\\n1. Active infections requiring systemic treatment;\\n2. Positive human immunodeficiency virus antibody (HIV-Ab) at baseline, acute or chronic active hepatitis B (defined as positive HBsAg and/or HBcAb and HBV-DNA copy number higher than 2500 copies/ml or 500IU/ml), or acute or chronic active hepatitis C (positive HCV antibody and HCV-RNA higher than the detection limit of the analytical method);\\n3. Active pulmonary tuberculosis. 7. Accompanied by recurrent drainage or refractory pleural or peritoneal effusion or pericardial effusion.\\n\\n8. Accompanied by other poorly controlled systemic diseases, such as uncontrolled hypertension (systolic blood pressure ≥ 150 mmHg or diastolic blood pressure ≥ 100 mmHg) or diabetes despite standard treatment.\\n\\n9. Have a history of significant bleeding tendency or coagulation disorders; have significant clinical bleeding symptoms within 4 weeks before enrollment, including but not limited to gastrointestinal bleeding, hemoptysis (defined as coughing or expectorating ≥ 1 teaspoon of fresh blood or small blood clots or only coughing blood without sputum, subjects with blood in sputum are allowed to enroll), nasal bleeding (excluding epistaxis and retracted nasal blood); imaging studies during the screening period show that the tumor surrounds important blood vessels or has obvious necrosis or cavities, and the investigator deems that enrollment in the study would cause a bleeding risk.\\n\\n10. Tumor invades or compresses surrounding important organs (such as the aorta, heart and pericardium, superior vena cava, trachea, esophagus, etc.) or has a risk of esophagotracheal fistula or esophagopleural fistula; mediastinal lymph node metastasis of the tumor invades the trachea or main bronchus. 11. Participants with other malignant tumors within 2 years before entering the study, except for appropriately treated cervical carcinoma in situ, focal cutaneous squamous cell carcinoma, basal cell carcinoma, prostate cancer that does not require treatment, ductal carcinoma in situ of the breast, and superficial non-muscle-invasive urothelial carcinoma.\\n\\n12. Participants who have previously received KRAS G12C inhibitor treatment. 13. Participants who have previously received immunotherapy, including immune checkpoint inhibitors (such as anti-PD-1/L1 antibodies, anti-CTLA-4 antibodies, etc.), immune checkpoint agonists (such as ICOS, CD40, CD137, GITR, OX40 antibodies, etc.), and any other treatments targeting tumor immune mechanisms.\\n\\n14. Participants who have previously received systemic anti-angiogenic therapy, including but not limited to bevacizumab and its biosimilars, endostar, small molecule TKIs, ramucirumab, etc.\\n\\n15. Participants who have received systemic treatment with traditional Chinese medicine with anti-tumor indications within 1 week before the first dose or with drugs that have immunomodulatory effects within 2 weeks before the first dose (including thymosin, interferon, interleukin, except for local use to control pleural effusion).\\n\\n16. Participants who have received therapeutic or palliative radiotherapy (excluding cranial radiotherapy) or local treatment within 14 days before the first dose of this study.\\n\\n17. Participants who have received chemotherapy, targeted therapy, immunotherapy, other investigational drugs or investigational devices, or other anti-tumor treatments within 28 days or 5 half-lives (whichever is shorter) before the first dose of this study.\\n\\n18. Participants who have undergone surgery that may affect the administration or evaluation of this study within 28 days before enrollment (excluding biopsy).\\n\\n19. Participants who have received known CYP2D6, CYP3A4, P-gp, and BCRP sensitive substrates within 14 days or 5 half-lives (whichever is longer) before the first dose of this study, and the therapeutic window of the substrate is narrow, unless agreed by the investigator and the sponsor to be enrolled.\\n\\n20. Participants who are simultaneously involved in another interventional clinical study, except for observational (non-interventional) clinical studies or those in the follow-up stage after the end of an interventional study.\\n\\n21. Participants who have used immunosuppressive drugs within 4 weeks before the first dose of study treatment, excluding nasal sprays, inhalation or other local routes of glucocorticoids or systemic glucocorticoids at physiological doses (i.e., no more than 10mg/day of prednisone or equivalent doses of other glucocorticoids), or glucocorticoids used to prevent contrast agent allergy.\\n\\n22. Participants who have received live attenuated vaccines within 4 weeks before the first dose of study treatment or plan to receive them during the study period.\\n\\n23. Note: Inactivated virus vaccines for seasonal influenza by injection are allowed within 4 weeks before the first dose of study treatment; however, live attenuated influenza vaccines are not allowed.\\n\\n24. Participants with known or suspected autoimmune diseases or a history of such diseases within the past 2 years (participants with vitiligo, psoriasis, alopecia, or Graves\\' disease that did not require systemic treatment in the past 2 years, hypothyroidism requiring only thyroid hormone replacement therapy, and type 1 diabetes requiring only insulin replacement therapy can be enrolled).\\n\\n25. Participants with active or a history of definite inflammatory bowel disease (such as Crohn\\'s disease, ulcerative colitis, or chronic diarrhea).\\n\\n26. Participants with a known history of primary immunodeficiency. 27. Participants with a known history of allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation.\\n\\n28. Participants with a history of deep vein thrombosis, pulmonary embolism, or any other serious thromboembolic event within 3 months before enrollment (implantable venous access ports or catheter-related thrombosis, or superficial venous thrombosis are not considered \"serious\" thromboembolic events).\\n\\n29. Participants with known allergies to study treatment or any of its components.\\n\\n30. Pregnant or lactating women. 31. Other situations that the researcher deems unsuitable for participation in this study.', 'healthyVolunteers': False, 'sex': 'ALL', 'minimumAge': '18 Years', 'maximumAge': '75 Years', 'stdAges': ['ADULT', 'OLDER_ADULT']}, 'contactsLocationsModule': {'centralContacts': [{'name': 'Zhong Runbo, MD', 'role': 'CONTACT', 'phone': '+86 021-62821990', 'email': 'zhongrb@shchest.org'}]}, 'ipdSharingStatementModule': {'ipdSharing': 'UNDECIDED'}}, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-08-20'}, 'conditionBrowseModule': {'meshes': [{'id': 'D008175', 'term': 'Lung Neoplasms'}], 'ancestors': [{'id': 'D012142', 'term': 'Respiratory Tract Neoplasms'}, {'id': 'D013899', 'term': 'Thoracic Neoplasms'}, {'id': 'D009371', 'term': 'Neoplasms by Site'}, {'id': 'D009369', 'term': 'Neoplasms'}, {'id': 'D008171', 'term': 'Lung Diseases'}, {'id': 'D012140', 'term': 'Respiratory Tract Diseases'}], 'browseLeaves': [{'id': 'M11172', 'name': 'Lung Neoplasms', 'asFound': 'Lung Cancer', 'relevance': 'HIGH'}, {'id': 'M5546', 'name': 'Carcinoma, Non-Small-Cell Lung', 'relevance': 'LOW'}, {'id': 'M14979', 'name': 'Respiratory Tract Neoplasms', 'relevance': 'LOW'}, {'id': 'M16658', 'name': 'Thoracic Neoplasms', 'relevance': 'LOW'}, {'id': 'M11168', 'name': 'Lung Diseases', 'relevance': 'LOW'}, {'id': 'M14977', 'name': 'Respiratory Tract Diseases', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'BC04', 'name': 'Neoplasms'}, {'abbrev': 'BC08', 'name': 'Respiratory Tract (Lung and Bronchial) Diseases'}, {'abbrev': 'All', 'name': 'All Conditions'}]}}, 'hasResults': False}\n",
      "Keys for NCT05786924:\n",
      "dict_keys(['protocolSection', 'derivedSection', 'hasResults'])\n",
      "Content for NCT05786924:\n",
      "{'protocolSection': {'identificationModule': {'nctId': 'NCT05786924', 'orgStudyIdInfo': {'id': 'BDTX-4933-101'}, 'organization': {'fullName': 'Servier', 'class': 'INDUSTRY'}, 'briefTitle': 'A Study of BDTX-4933 in Patients With KRAS, BRAF and Select RAS/MAPK Mutation-Positive Cancers', 'officialTitle': 'A Phase 1, Open-label Study of Oral BDTX-4933 in Patients With KRAS, BRAF and Other Select RAS/MAPK Mutation Positive Neoplasms'}, 'statusModule': {'statusVerifiedDate': '2025-05', 'overallStatus': 'RECRUITING', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2023-04-18', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2026-06', 'type': 'ESTIMATED'}, 'completionDateStruct': {'date': '2026-12', 'type': 'ESTIMATED'}, 'studyFirstSubmitDate': '2023-03-06', 'studyFirstSubmitQcDate': '2023-03-15', 'studyFirstPostDateStruct': {'date': '2023-03-28', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2025-05-22', 'lastUpdatePostDateStruct': {'date': '2025-05-28', 'type': 'ACTUAL'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'}, 'leadSponsor': {'name': 'Institut de Recherches Internationales Servier', 'class': 'OTHER'}}, 'oversightModule': {'isFdaRegulatedDrug': True, 'isFdaRegulatedDevice': False}, 'descriptionModule': {'briefSummary': 'BDTX-4933-101 is a first-in-human, open-label, Phase 1 dose escalation and an expansion cohort study designed to evaluate the safety and tolerability, maximum tolerated dose (MTD) and the preliminary recommended Phase 2 dose (RP2D), and antitumor activity of BDTX-4933. The study population for the Dose Escalation part of the study comprises adults with recurrent advanced/metastatic non-small cell lung cancer (NSCLC) harboring KRAS non-G12C mutations, BRAF, or CRAF (RAF1) mutations, advanced/metastatic melanoma harboring BRAF or NRAS mutations, histiocytic neoplasms harboring BRAF, CRAF, or NRAS mutations, and other solid tumors harboring BRAF mutations. The study population for the Dose Expansion part of the study comprises adults with recurrent advanced/metastatic NSCLC harboring KRAS non-G12C mutations. All patients will self-administer BDTX-4933 orally in 28-day cycles until disease progression, toxicity, withdrawal of consent, or termination of the study.'}, 'conditionsModule': {'conditions': ['Non-small Cell Lung Cancer', 'Histiocytic Neoplasm', 'Histiocytosis', 'Melanoma', 'Melanoma (Skin)', 'BRAF Gene Mutation', 'BRAF V600E', 'BRAF V600 Mutation', 'BRAF Mutation-Related Tumors', 'BRAF', 'Metastatic Lung Non-Small Cell Carcinoma', 'Metastatic Melanoma', 'Metastatic Lung Cancer', 'Recurrent Melanoma', 'Recurrent Lung Cancer', 'Recurrent Lung Non-Small Cell Carcinoma', 'NSCLC', 'Solid Tumor', 'Solid Carcinoma', 'KRAS G12D', 'KRAS G12V', 'KRAS Mutation-Related Tumors', 'NRAS Gene Mutation', 'Thyroid Cancer', 'Thyroid Carcinoma', 'Colorectal Cancer', 'Colorectal Carcinoma', 'Recurrent Histiocytic and Dendritic Cell Neoplasm', 'Brain Metastases', 'Recurrent NSCLC', 'KRAS G13C', 'Acquired Resistance to KRAS G12C Inhibitor', 'KRAS G12A', 'KRAS G12F', 'KRAS G12R', 'KRAS G13D'], 'keywords': ['BRAF Class I', 'BRAF Class II', 'BRAF Class III', 'KRAS', 'Intolerant histiocytic neoplasm', 'BDTX-4933', 'Phase 1', 'dose escalation', 'dose expansion', 'MAPK', 'mitogen-activated protein kinase', 'RAS', 'RAF', 'Upstream oncogenic alterations', 'RAF inhibitor', 'intracranial disease', 'CRAF', 'NRAS', 'RAF fusions']}, 'designModule': {'studyType': 'INTERVENTIONAL', 'phases': ['PHASE1'], 'designInfo': {'allocation': 'NON_RANDOMIZED', 'interventionModel': 'SEQUENTIAL', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 100, 'type': 'ESTIMATED'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'Phase 1 Dose Escalation', 'type': 'EXPERIMENTAL', 'description': 'BDTX-4933 will be administered at escalating dose levels until the maximum tolerated dose (MTD) is reached and the preliminary recommended Phase 2 dose (RP2D) is determined.', 'interventionNames': ['Drug: BDTX-4933']}, {'label': 'Phase 1 Dose Expansion', 'type': 'EXPERIMENTAL', 'description': 'BDTX-4933 will be administered at the RP2D.', 'interventionNames': ['Drug: BDTX-4933']}], 'interventions': [{'type': 'DRUG', 'name': 'BDTX-4933', 'description': 'RAF inhibitor targeting all classes of oncogenic BRAF alterations (Classes I, II, and III) and constitutively active CRAF, KRAS or NRAS mutations', 'armGroupLabels': ['Phase 1 Dose Escalation', 'Phase 1 Dose Expansion']}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Dose Escalation: Incidence of dose-limiting toxicities (DLTs) to estimate the preliminary RP2D and/or MTD of BDTX-4933', 'description': 'A DLT is defined as any event meeting the DLT criteria occurring within the first 28-day cycle', 'timeFrame': 'The first 28-day cycle (Cycle 1)'}, {'measure': 'Dose Expansion: Objective response rate (ORR) including extracranial and intracranial', 'timeFrame': 'Day 1 of every 2 cycles to Cycle 13 Day 1, then Day 1 of every 3 cycles thereafter to study completion, approximately 1 year (each cycle is 28 days)'}, {'measure': 'Dose Expansion: Duration of response (DOR)', 'timeFrame': 'Day 1 of every 2 cycles to Cycle 13 Day 1, then Day 1 of every 3 cycles thereafter to study completion, approximately 1 year (each cycle is 28 days)'}, {'measure': 'Dose Expansion: Time-to-response (TTR)', 'timeFrame': 'Day 1 of every 2 cycles to Cycle 13 Day 1, then Day 1 of every 3 cycles thereafter to study completion, approximately 1 year (each cycle is 28 days)'}, {'measure': 'Dose Expansion: Progression-free survival (PFS)', 'timeFrame': 'Day 1 of every 2 cycles to Cycle 13 Day 1, then Day 1 of every 3 cycles thereafter to study completion, approximately 1 year (each cycle is 28 days)'}], 'secondaryOutcomes': [{'measure': 'Dose Escalation/Expansion: Incidence and severity of treatment-emergent adverse events (TEAEs)', 'timeFrame': 'Through study completion, approximately 1 year'}, {'measure': 'Dose Escalation/Expansion: Maximum plasma concentration (Cmax) of BDTX-4933 and its metabolite', 'timeFrame': 'Cycle 1 Days 1 and 15, Day 1 of Cycle 2 through Cycle 5, and Day 1 of every other cycle thereafter to study completion, approximately 1 year (each cycle is 28 days)'}, {'measure': 'Dose Escalation/Expansion: Time of maximum plasma concentration (Tmax) of BDTX-4933 and its metabolite', 'timeFrame': 'Cycle 1 Days 1 and 15, Day 1 of Cycle 2 through Cycle 5, and Day 1 of every other cycle thereafter to study completion, approximately 1 year (each cycle is 28 days)'}, {'measure': 'Dose Escalation/Expansion: Area under the plasma drug concentration-time curve (AUC) of BDTX-4933 and its metabolite', 'timeFrame': 'Cycle 1 Days 1 and 15, Day 1 of Cycle 2 through Cycle 5, and Day 1 of every other cycle thereafter to study completion, approximately 1 year (each cycle is 28 days)'}, {'measure': 'Dose Escalation/Expansion: Half-life (t1/2) of BDTX-4933 and its metabolite', 'timeFrame': 'Cycle 1 Days 1 and 15, Day 1 of Cycle 2 through Cycle 5, and Day 1 of every other cycle thereafter to study completion, approximately 1 year (each cycle is 28 days)'}, {'measure': 'Dose Escalation: Objective response rate (ORR) including extracranial and intracranial', 'timeFrame': 'Day 1 of every 2 cycles to Cycle 13 Day 1, then Day 1 of every 3 cycles thereafter to study completion, approximately 1 year (each cycle is 28 days)'}, {'measure': 'Dose Escalation: Duration of response (DOR)', 'timeFrame': 'Day 1 of every 2 cycles to Cycle 13 Day 1, then Day 1 of every 3 cycles thereafter to study completion, approximately 1 year (each cycle is 28 days)'}, {'measure': 'Dose Escalation: Time to response', 'timeFrame': 'Day 1 of every 2 cycles to Cycle 13 Day 1, then Day 1 of every 3 cycles thereafter to study completion, approximately 1 year (each cycle is 28 days)'}, {'measure': 'Dose Escalation: PFS', 'timeFrame': 'Day 1 of every 2 cycles to Cycle 13 Day 1, then Day 1 of every 3 cycles thereafter to study completion, approximately 1 year (each cycle is 28 days)'}, {'measure': 'Dose Escalation/Expansion: Overall survival', 'timeFrame': 'First dose of study drug to death due to any cause or for 12 months from last dose'}]}, 'eligibilityModule': {'eligibilityCriteria': 'Key Inclusion Criteria:\\n\\n1. Disease criteria:\\n\\n   1. Histologically or cytologically confirmed recurrent/advanced (unresectable) or metastatic solid tumors or histiocytic neoplasms with documented RAS or BRAF mutations.\\n\\n      Note: Patients may have stable central nervous system (CNS) metastases. Patients with active CNS metastases or primary CNS tumors associated with progressive neurological symptoms or needing increased doses of corticosteroids to control the CNS disease are excluded from the study.\\n   2. Dose Escalation cohorts:\\n\\n      * NSCLC with KRAS non-G12C mutations, including other mutations at KRAS-G12 (eg, G12V/G12D) and other oncogenic variants of KRAS mutations on G13 and Q61 amino acid residues, BRAF, or CRAF mutations.\\n      * Melanoma with BRAF, CRAF, or NRAS mutations.\\n      * Histiocytic neoplasms with BRAF or NRAS mutations.\\n      * Thyroid carcinoma with BRAF mutations.\\n      * Colorectal carcinoma with BRAF (Class II or III) mutations with Sponsor approval.\\n      * Other solid tumors with BRAF Class I mutations after prior treatment with a BRAF/MEK inhibitor or local standard-of-care with Sponsor approval.\\n   3. Dose Expansion cohort:\\n\\n   Recurrent advanced/metastatic NSCLC with KRAS non-G12C mutations without small cell lung cancer transformation with progressive disease confirmed by radiographic assessment.\\n2. Prior standard-of-care\\n\\n   For dose levels \\\\<200 mg once daily and/or not at preliminary RP2D(s):\\n   1. Exhausted all available standard-of-care therapies or, in the opinion of the Investigator, would be unlikely to tolerate or derive clinically meaningful benefit from available standard-of-care therapy.\\n   2. Patients with eligible tumors harboring BRAF V600E mutations must have received FDA approved BRAF targeted therapy, BRAF/MEK inhibitors combination, or BRAF inhibitors combination.\\n\\n   For dose levels ≥200 mg once daily or at preliminary RP2D(s):\\n\\n   a. Patients must have received at least 1 but no more than 2 prior lines of systemic therapy for metastatic/advanced disease (adjuvant and maintenance therapy do not count towards the limit).\\n3. Evaluable or measurable disease in dose escalation and measurable disease only for dose expansion cohorts.\\n4. Adequate bone marrow and organ function.\\n5. Recovered from toxicity to prior anti-cancer therapy.\\n6. Appropriate candidate for BDTX-4933 monotherapy.\\n7. Life expectancy of \\\\>=12 weeks in the opinion of the Investigator.\\n\\nKey Exclusion Criteria:\\n\\n1. Cancer that has a known MEK1/2 mutation.\\n2. Major surgery within 4 weeks of study entry or planned during study.\\n3. Ongoing anticancer therapy.\\n4. Ongoing radiation therapy.\\n5. Uncontrolled or active clinically relevant bacterial, fungal, or specific viral infection requiring systemic therapy.\\n6. Symptomatic spinal cord compression.\\n7. Evidence of active malignancy (other than study-specific malignancies) requiring systemic therapy within the next 2 years.\\n8. History or current evidence of retinal vein occlusion (RVO) or current risk factors for RVO.\\n9. Females who are pregnant or breastfeeding.\\n10. Actively receiving systemic treatment or direct medical intervention on another therapeutic clinical study.\\n11. Prior use of experimental agents that target the KRAS/BRAF/MEK/ERK pathway.', 'healthyVolunteers': False, 'sex': 'ALL', 'minimumAge': '18 Years', 'stdAges': ['ADULT', 'OLDER_ADULT']}, 'contactsLocationsModule': {'centralContacts': [{'name': 'Institut de Recherches Internationales Servier (I.R.I.S.), Clinical Studies Department', 'role': 'CONTACT', 'phone': '+33 1 55 72 60 00', 'email': 'scientificinformation@servier.com'}], 'locations': [{'facility': 'Banner Health- MD Anderson Cancer Center', 'status': 'RECRUITING', 'city': 'Gilbert', 'state': 'Arizona', 'zip': '85234', 'country': 'United States', 'contacts': [{'name': 'Brandi Luzania', 'role': 'CONTACT', 'phone': '480-256-5488', 'email': 'Brandi.Luzania@bannerhealth.com'}, {'name': 'Jiaxin Niu, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 33.35283, 'lon': -111.78903}}, {'facility': 'University of Colorado - Aurora Cancer Center', 'status': 'RECRUITING', 'city': 'Aurora', 'state': 'Colorado', 'zip': '80045', 'country': 'United States', 'contacts': [{'name': 'Halle Kuykendall', 'role': 'CONTACT', 'phone': '720-848-0356', 'email': 'halle.kuykendall@cuanschutz.edu'}], 'geoPoint': {'lat': 39.72943, 'lon': -104.83192}}, {'facility': 'Georgetown University Lombardi Cancer Center', 'status': 'RECRUITING', 'city': 'Washington', 'state': 'District of Columbia', 'zip': '20007', 'country': 'United States', 'contacts': [{'role': 'CONTACT', 'phone': '202-444-2223', 'email': 'Chul.Kim@gunet.georgetown.edu'}, {'name': 'Chul Kim, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 38.89511, 'lon': -77.03637}}, {'facility': 'Dana-Farber Cancer Institute', 'status': 'RECRUITING', 'city': 'Boston', 'state': 'Massachusetts', 'zip': '02215', 'country': 'United States', 'contacts': [{'name': 'Start Your Patient Journey to Cancer Care and Support', 'role': 'CONTACT', 'phone': '877-442-3324'}], 'geoPoint': {'lat': 42.35843, 'lon': -71.05977}}, {'facility': 'South Texas Accelerated Research Therapeutics (START) Midwest', 'status': 'RECRUITING', 'city': 'Grand Rapids', 'state': 'Michigan', 'zip': '49546', 'country': 'United States', 'contacts': [{'name': 'Julie Burns', 'role': 'CONTACT', 'phone': '616-954-5559', 'email': 'julie.burns@startmidwest.com'}, {'name': 'Jade Blakeman', 'role': 'CONTACT', 'phone': '616-954-5551', 'email': 'jade.blakeman@startmidwest.com'}], 'geoPoint': {'lat': 42.96336, 'lon': -85.66809}}, {'facility': 'Masonic Cancer Center University of Minnesota', 'status': 'RECRUITING', 'city': 'Minneapolis', 'state': 'Minnesota', 'zip': '55455', 'country': 'United States', 'contacts': [{'name': 'Amit Kulkarni, MBBS', 'role': 'CONTACT', 'phone': '612-624-0123', 'email': 'kulkarni@umn.edu'}, {'name': 'Sara Crane', 'role': 'CONTACT', 'email': 'crane202@umn.edu'}], 'geoPoint': {'lat': 44.97997, 'lon': -93.26384}}, {'facility': 'Washington University', 'status': 'RECRUITING', 'city': 'Saint Louis', 'state': 'Missouri', 'zip': '63130', 'country': 'United States', 'contacts': [{'name': 'Medical Oncology Clinical Call Center', 'role': 'CONTACT', 'phone': '314-747-1171', 'email': 'MedicalOncologyClinicalCallCenter@dom.wustl.edu'}], 'geoPoint': {'lat': 38.62727, 'lon': -90.19789}}, {'facility': 'Memorial Sloan Kettering Cancer Center', 'status': 'RECRUITING', 'city': 'New York', 'state': 'New York', 'zip': '10065', 'country': 'United States', 'contacts': [{'name': 'Michael Offin, MD', 'role': 'CONTACT'}, {'role': 'CONTACT', 'phone': '646-888-8538'}], 'geoPoint': {'lat': 40.71427, 'lon': -74.00597}}, {'facility': 'NEXT Virginia', 'status': 'RECRUITING', 'city': 'Fairfax', 'state': 'Virginia', 'zip': '22031', 'country': 'United States', 'contacts': [{'name': 'Blake Patterson', 'role': 'CONTACT', 'phone': '703-783-4505', 'email': 'bpatterson@nextoncology.com'}], 'geoPoint': {'lat': 38.84622, 'lon': -77.30637}}, {'facility': 'Fred Hutchinson Cancer Research Center', 'status': 'RECRUITING', 'city': 'Seattle', 'state': 'Washington', 'zip': '98109', 'country': 'United States', 'contacts': [{'name': 'Rebecca Wood', 'role': 'CONTACT', 'phone': '206-606-6970', 'email': 'rwood1@seattlecca.org'}], 'geoPoint': {'lat': 47.60621, 'lon': -122.33207}}]}, 'ipdSharingStatementModule': {'ipdSharing': 'NO'}}, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-08-21'}, 'conditionBrowseModule': {'meshes': [{'id': 'D002277', 'term': 'Carcinoma'}, {'id': 'D009369', 'term': 'Neoplasms'}, {'id': 'D008175', 'term': 'Lung Neoplasms'}, {'id': 'D002289', 'term': 'Carcinoma, Non-Small-Cell Lung'}, {'id': 'D015179', 'term': 'Colorectal Neoplasms'}, {'id': 'D008545', 'term': 'Melanoma'}, {'id': 'D001932', 'term': 'Brain Neoplasms'}, {'id': 'D013964', 'term': 'Thyroid Neoplasms'}, {'id': 'D015614', 'term': 'Histiocytosis'}, {'id': 'D013959', 'term': 'Thyroid Diseases'}, {'id': 'D012008', 'term': 'Recurrence'}], 'ancestors': [{'id': 'D009375', 'term': 'Neoplasms, Glandular and Epithelial'}, {'id': 'D009370', 'term': 'Neoplasms by Histologic Type'}, {'id': 'D020969', 'term': 'Disease Attributes'}, {'id': 'D010335', 'term': 'Pathologic Processes'}, {'id': 'D012142', 'term': 'Respiratory Tract Neoplasms'}, {'id': 'D013899', 'term': 'Thoracic Neoplasms'}, {'id': 'D009371', 'term': 'Neoplasms by Site'}, {'id': 'D008171', 'term': 'Lung Diseases'}, {'id': 'D012140', 'term': 'Respiratory Tract Diseases'}, {'id': 'D002283', 'term': 'Carcinoma, Bronchogenic'}, {'id': 'D001984', 'term': 'Bronchial Neoplasms'}, {'id': 'D007414', 'term': 'Intestinal Neoplasms'}, {'id': 'D005770', 'term': 'Gastrointestinal Neoplasms'}, {'id': 'D004067', 'term': 'Digestive System Neoplasms'}, {'id': 'D004066', 'term': 'Digestive System Diseases'}, {'id': 'D005767', 'term': 'Gastrointestinal Diseases'}, {'id': 'D003108', 'term': 'Colonic Diseases'}, {'id': 'D007410', 'term': 'Intestinal Diseases'}, {'id': 'D012002', 'term': 'Rectal Diseases'}, {'id': 'D018358', 'term': 'Neuroendocrine Tumors'}, {'id': 'D017599', 'term': 'Neuroectodermal Tumors'}, {'id': 'D009373', 'term': 'Neoplasms, Germ Cell and Embryonal'}, {'id': 'D009380', 'term': 'Neoplasms, Nerve Tissue'}, {'id': 'D018326', 'term': 'Nevi and Melanomas'}, {'id': 'D012878', 'term': 'Skin Neoplasms'}, {'id': 'D012871', 'term': 'Skin Diseases'}, {'id': 'D004700', 'term': 'Endocrine System Diseases'}, {'id': 'D016543', 'term': 'Central Nervous System Neoplasms'}, {'id': 'D009423', 'term': 'Nervous System Neoplasms'}, {'id': 'D001927', 'term': 'Brain Diseases'}, {'id': 'D002493', 'term': 'Central Nervous System Diseases'}, {'id': 'D009422', 'term': 'Nervous System Diseases'}, {'id': 'D004701', 'term': 'Endocrine Gland Neoplasms'}, {'id': 'D006258', 'term': 'Head and Neck Neoplasms'}, {'id': 'D008206', 'term': 'Lymphatic Diseases'}], 'browseLeaves': [{'id': 'M5534', 'name': 'Carcinoma', 'asFound': 'Carcinoma', 'relevance': 'HIGH'}, {'id': 'M12307', 'name': 'Neoplasm Metastasis', 'relevance': 'LOW'}, {'id': 'M11172', 'name': 'Lung Neoplasms', 'asFound': 'Lung Cancer', 'relevance': 'HIGH'}, {'id': 'M5546', 'name': 'Carcinoma, Non-Small-Cell Lung', 'asFound': 'Lung Non-Small Cell Carcinoma', 'relevance': 'HIGH'}, {'id': 'M11528', 'name': 'Melanoma', 'asFound': 'Melanoma', 'relevance': 'HIGH'}, {'id': 'M14850', 'name': 'Recurrence', 'asFound': 'Recurrent', 'relevance': 'HIGH'}, {'id': 'M16718', 'name': 'Thyroid Diseases', 'asFound': 'Thyroid', 'relevance': 'HIGH'}, {'id': 'M16723', 'name': 'Thyroid Neoplasms', 'asFound': 'Thyroid Carcinoma', 'relevance': 'HIGH'}, {'id': 'M18216', 'name': 'Histiocytosis', 'asFound': 'Histiocytosis', 'relevance': 'HIGH'}, {'id': 'M17890', 'name': 'Colorectal Neoplasms', 'asFound': 'Colorectal Carcinoma', 'relevance': 'HIGH'}, {'id': 'M5209', 'name': 'Brain Neoplasms', 'asFound': 'Brain Metastases', 'relevance': 'HIGH'}, {'id': 'M12320', 'name': 'Neoplasms, Glandular and Epithelial', 'relevance': 'LOW'}, {'id': 'M12315', 'name': 'Neoplasms by Histologic Type', 'relevance': 'LOW'}, {'id': 'M22700', 'name': 'Disease Attributes', 'relevance': 'LOW'}, {'id': 'M14979', 'name': 'Respiratory Tract Neoplasms', 'relevance': 'LOW'}, {'id': 'M16658', 'name': 'Thoracic Neoplasms', 'relevance': 'LOW'}, {'id': 'M11168', 'name': 'Lung Diseases', 'relevance': 'LOW'}, {'id': 'M14977', 'name': 'Respiratory Tract Diseases', 'relevance': 'LOW'}, {'id': 'M5540', 'name': 'Carcinoma, Bronchogenic', 'relevance': 'LOW'}, {'id': 'M5260', 'name': 'Bronchial Neoplasms', 'relevance': 'LOW'}, {'id': 'M10448', 'name': 'Intestinal Neoplasms', 'relevance': 'LOW'}, {'id': 'M8886', 'name': 'Gastrointestinal Neoplasms', 'relevance': 'LOW'}, {'id': 'M7256', 'name': 'Digestive System Neoplasms', 'relevance': 'LOW'}, {'id': 'M8883', 'name': 'Gastrointestinal Diseases', 'relevance': 'LOW'}, {'id': 'M7255', 'name': 'Digestive System Diseases', 'relevance': 'LOW'}, {'id': 'M6336', 'name': 'Colonic Diseases', 'relevance': 'LOW'}, {'id': 'M10444', 'name': 'Intestinal Diseases', 'relevance': 'LOW'}, {'id': 'M14844', 'name': 'Rectal Diseases', 'relevance': 'LOW'}, {'id': 'M20495', 'name': 'Neuroendocrine Tumors', 'relevance': 'LOW'}, {'id': 'M20388', 'name': 'Neuroectodermal Tumors, Primitive', 'relevance': 'LOW'}, {'id': 'M19845', 'name': 'Neuroectodermal Tumors', 'relevance': 'LOW'}, {'id': 'M12318', 'name': 'Neoplasms, Germ Cell and Embryonal', 'relevance': 'LOW'}, {'id': 'M12325', 'name': 'Neoplasms, Nerve Tissue', 'relevance': 'LOW'}, {'id': 'M12446', 'name': 'Nevus', 'relevance': 'LOW'}, {'id': 'M12448', 'name': 'Nevus, Pigmented', 'relevance': 'LOW'}, {'id': 'M20470', 'name': 'Nevi and Melanomas', 'relevance': 'LOW'}, {'id': 'M15681', 'name': 'Skin Neoplasms', 'relevance': 'LOW'}, {'id': 'M15674', 'name': 'Skin Diseases', 'relevance': 'LOW'}, {'id': 'M7862', 'name': 'Endocrine System Diseases', 'relevance': 'LOW'}, {'id': 'M18937', 'name': 'Central Nervous System Neoplasms', 'relevance': 'LOW'}, {'id': 'M12367', 'name': 'Nervous System Neoplasms', 'relevance': 'LOW'}, {'id': 'M5204', 'name': 'Brain Diseases', 'relevance': 'LOW'}, {'id': 'M5742', 'name': 'Central Nervous System Diseases', 'relevance': 'LOW'}, {'id': 'M7863', 'name': 'Endocrine Gland Neoplasms', 'relevance': 'LOW'}, {'id': 'M9348', 'name': 'Head and Neck Neoplasms', 'relevance': 'LOW'}, {'id': 'M11203', 'name': 'Lymphatic Diseases', 'relevance': 'LOW'}, {'id': 'T1792', 'name': 'Dendritic Cell Tumor', 'asFound': 'Dendritic Cell Neoplasm', 'relevance': 'HIGH'}, {'id': 'T4091', 'name': 'Neuroendocrine Tumor', 'relevance': 'LOW'}, {'id': 'T4092', 'name': 'Neuroepithelioma', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'BC04', 'name': 'Neoplasms'}, {'abbrev': 'All', 'name': 'All Conditions'}, {'abbrev': 'BC23', 'name': 'Symptoms and General Pathology'}, {'abbrev': 'BC08', 'name': 'Respiratory Tract (Lung and Bronchial) Diseases'}, {'abbrev': 'BC17', 'name': 'Skin and Connective Tissue Diseases'}, {'abbrev': 'BC19', 'name': 'Gland and Hormone Related Diseases'}, {'abbrev': 'BC15', 'name': 'Blood and Lymph Conditions'}, {'abbrev': 'BC06', 'name': 'Digestive System Diseases'}, {'abbrev': 'BC10', 'name': 'Nervous System Diseases'}, {'abbrev': 'Rare', 'name': 'Rare Diseases'}]}, 'interventionBrowseModule': {'browseLeaves': [{'id': 'M11900', 'name': 'Mitogens', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'All', 'name': 'All Drugs and Chemicals'}]}}, 'hasResults': False}\n",
      "Keys for NCT05737706:\n",
      "dict_keys(['protocolSection', 'derivedSection', 'hasResults'])\n",
      "Content for NCT05737706:\n",
      "{'protocolSection': {'identificationModule': {'nctId': 'NCT05737706', 'orgStudyIdInfo': {'id': 'CA246-0005'}, 'secondaryIdInfos': [{'id': 'CA246-0005', 'type': 'OTHER', 'domain': 'Bristol-Myers Squibb Protocol ID'}, {'id': '1133-001', 'type': 'OTHER', 'domain': 'Mirati Therapeutics Protocol ID'}], 'organization': {'fullName': 'Mirati Therapeutics Inc.', 'class': 'INDUSTRY'}, 'briefTitle': 'Study of MRTX1133 in Patients With Advanced Solid Tumors Harboring a KRAS G12D Mutation', 'officialTitle': 'A Phase 1/2 Multiple Expansion Cohort Trial of MRTX1133 in Patients With Advanced Solid Tumors Harboring a KRAS G12D Mutation'}, 'statusModule': {'statusVerifiedDate': '2025-04', 'overallStatus': 'TERMINATED', 'whyStopped': 'Formulation challenges', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2023-03-06', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2025-03-10', 'type': 'ACTUAL'}, 'completionDateStruct': {'date': '2025-03-10', 'type': 'ACTUAL'}, 'studyFirstSubmitDate': '2023-02-10', 'studyFirstSubmitQcDate': '2023-02-10', 'studyFirstPostDateStruct': {'date': '2023-02-21', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2025-04-03', 'lastUpdatePostDateStruct': {'date': '2025-04-06', 'type': 'ACTUAL'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'}, 'leadSponsor': {'name': 'Mirati Therapeutics Inc.', 'class': 'INDUSTRY'}}, 'oversightModule': {'oversightHasDmc': True, 'isFdaRegulatedDrug': True, 'isFdaRegulatedDevice': False}, 'descriptionModule': {'briefSummary': 'A Phase 1/2 study of MRTX1133 in solid tumors harboring a KRAS G12D mutation.', 'detailedDescription': 'This first-in-human clinical trial will begin with an exploration of MRTX1133 dose and regimen. As potentially viable regimens are identified, Phase 1b expansion cohorts may be implemented to ensure collection of sufficient safety and PK information, and early evidence of clinical activity are available to recommend Phase 2 regimens. In Phase 2, separate cohorts of patients by histological diagnosis and/or baseline characteristics will be evaluated for the clinical activity and efficacy of MRTX1133.\\n\\nThis study was terminated prior to phase 2 initiating. Only phase 1 of the study was conducted.'}, 'conditionsModule': {'conditions': ['Solid Tumor', 'Advanced Solid Tumor', 'Non-small Cell Lung Cancer', 'Colo-rectal Cancer', 'Pancreatic Adenocarcinoma'], 'keywords': ['Non-Small Cell Lung Cancer', 'NSCLC', 'colorectal cancer', 'CRC', 'PDAC', 'KRAS', 'G12D', 'Solid Tumor', 'Advanced Solid Tumor', 'Malignant', 'Pancreatic Cancer', 'Pancreatic Adenocarcinoma']}, 'designModule': {'studyType': 'INTERVENTIONAL', 'phases': ['PHASE1'], 'designInfo': {'allocation': 'NON_RANDOMIZED', 'interventionModel': 'SEQUENTIAL', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 63, 'type': 'ACTUAL'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'Phase 1/1B', 'type': 'EXPERIMENTAL', 'description': 'Dose Escalation/Evaluation', 'interventionNames': ['Drug: MRTX1133']}, {'label': 'Phase 2', 'type': 'EXPERIMENTAL', 'description': 'MRTX1133 recommended Phase 2 dose administered to separate cohorts of patients with selected solid tumor malignancies with KRAS G12D mutation to include the following: NSCLC, PDAC, CRC, Other Solid Tumors', 'interventionNames': ['Drug: MRTX1133']}], 'interventions': [{'type': 'DRUG', 'name': 'MRTX1133', 'description': 'KRAS G12D Inhibitor', 'armGroupLabels': ['Phase 1/1B', 'Phase 2']}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Phase 1: Number of Patients who Experience Dose-Limiting Toxicity', 'timeFrame': '21 Days'}, {'measure': 'Phase 1/1b: Number of patients who experience a treatment-related adverse event', 'timeFrame': 'Up to 2 years'}, {'measure': 'Phase 2: Objective response rate (ORR)', 'timeFrame': '2 years'}, {'measure': 'Phase 2: Duration of response (DOR)', 'timeFrame': '2 years'}, {'measure': 'Phase 2: Progression free survival (PFS)', 'timeFrame': '2 years'}, {'measure': 'Phase 2: Overall survival (OS)', 'timeFrame': '2 years'}], 'secondaryOutcomes': [{'measure': 'Area under plasma concentration versus time curve (AUC)', 'timeFrame': 'up to 4 days'}, {'measure': 'Time to achieve maximal plasma concentration (Tmax)', 'timeFrame': 'up to 4 days'}, {'measure': 'Maximum observed plasma concentration (Cmax)', 'timeFrame': 'up to 4 days'}, {'measure': 'Terminal elimination half-life (t1/2)', 'timeFrame': 'up to 4 days'}, {'measure': 'Apparent total plasma clearance when dosed orally (CL/F)', 'timeFrame': 'up to 4 days'}, {'measure': 'Apparent volume of distribution when dosed orally (Vz/F)', 'timeFrame': 'up to 4 days'}]}, 'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\n\\n* Histologically confirmed diagnosis of a solid tumor malignancy harboring KRAS G12D mutation in tumor tissue or ctDNA.\\n* Unresectable or metastatic disease.\\n* Patients must have received standard therapies appropriate for their tumor type and stage; first-line treatment for PDAC for certain cohorts.\\n* Presence of tumor lesions to be evaluated per RECIST v1.1:\\n\\n  1. in the Phase 1 dose escalation cohorts, patients must have measurable or evaluable disease.\\n  2. in the Phase 1b and Phase 2 cohorts, patients must have measurable disease.\\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\\n* Adequate organ function.\\n* Age ≥ 18 years\\n\\nExclusion Criteria:\\n\\n* Active brain metastases or carcinomatous meningitis.\\n* Prior treatment with a KRAS G12D inhibitor (Phase 1b \\\\& Phase 2 only).\\n* History of significant hemoptysis or hemorrhage within 4 weeks of the first dose of study treatment.\\n* History of intestinal disease, inflammatory bowel disease, major gastric surgery, or other gastrointestinal conditions likely to alter absorption of study treatment or result in inability to swallow oral medications.\\n* History of malignant small bowel obstruction.\\n* Cardiac abnormalities.', 'healthyVolunteers': False, 'sex': 'ALL', 'minimumAge': '18 Years', 'stdAges': ['ADULT', 'OLDER_ADULT']}, 'contactsLocationsModule': {'overallOfficials': [{'name': 'Bristol-Myers Squibb', 'affiliation': 'Bristol-Myers Squibb', 'role': 'STUDY_DIRECTOR'}], 'locations': [{'facility': 'Local Institution - 311', 'city': 'Phoenix', 'state': 'Arizona', 'zip': '85054', 'country': 'United States', 'geoPoint': {'lat': 33.44838, 'lon': -112.07404}}, {'facility': 'Local Institution - 309', 'city': 'New Haven', 'state': 'Connecticut', 'zip': '06520 8028', 'country': 'United States', 'geoPoint': {'lat': 41.30815, 'lon': -72.92816}}, {'facility': 'Local Institution - 301', 'city': 'Lady Lake', 'state': 'Florida', 'zip': '32159 8987', 'country': 'United States', 'geoPoint': {'lat': 28.91749, 'lon': -81.92286}}, {'facility': 'Local Institution - 306', 'city': 'Baltimore', 'state': 'Maryland', 'zip': '21231', 'country': 'United States', 'geoPoint': {'lat': 39.29038, 'lon': -76.61219}}, {'facility': 'Local Institution - 308', 'city': 'Boston', 'state': 'Massachusetts', 'zip': '02114 3117', 'country': 'United States', 'geoPoint': {'lat': 42.35843, 'lon': -71.05977}}, {'facility': 'Local Institution - 310', 'city': 'Boston', 'state': 'Massachusetts', 'zip': '02215', 'country': 'United States', 'geoPoint': {'lat': 42.35843, 'lon': -71.05977}}, {'facility': 'Local Institution - 314', 'city': 'Grand Rapids', 'state': 'Michigan', 'zip': '49546', 'country': 'United States', 'geoPoint': {'lat': 42.96336, 'lon': -85.66809}}, {'facility': 'Local Institution - 312', 'city': 'New York', 'state': 'New York', 'zip': '10065 6800', 'country': 'United States', 'geoPoint': {'lat': 40.71427, 'lon': -74.00597}}, {'facility': 'Local Institution - 303', 'city': 'Nashville', 'state': 'Tennessee', 'zip': '37203', 'country': 'United States', 'geoPoint': {'lat': 36.16589, 'lon': -86.78444}}, {'facility': 'Local Institution - 302', 'city': 'Houston', 'state': 'Texas', 'zip': '77030', 'country': 'United States', 'geoPoint': {'lat': 29.76328, 'lon': -95.36327}}, {'facility': 'Local Institution - 304', 'city': 'San Antonio', 'state': 'Texas', 'zip': '78229 3307', 'country': 'United States', 'geoPoint': {'lat': 29.42412, 'lon': -98.49363}}, {'facility': 'Local Institution - 313', 'city': 'San Antonio', 'state': 'Texas', 'zip': '78229', 'country': 'United States', 'geoPoint': {'lat': 29.42412, 'lon': -98.49363}}, {'facility': 'Local Institution - 305', 'city': 'Fairfax', 'state': 'Virginia', 'zip': '22031', 'country': 'United States', 'geoPoint': {'lat': 38.84622, 'lon': -77.30637}}, {'facility': 'Local Institution - 307', 'city': 'Seattle', 'state': 'Washington', 'zip': '98109 1023', 'country': 'United States', 'geoPoint': {'lat': 47.60621, 'lon': -122.33207}}]}, 'referencesModule': {'seeAlsoLinks': [{'label': 'BMS Clinical Trial Information', 'url': 'https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html'}, {'label': 'BMS Clinical Trial Patient Recruiting', 'url': 'http://www.BMSClinicalTrials.com'}]}}, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-08-21'}, 'conditionBrowseModule': {'meshes': [{'id': 'D009369', 'term': 'Neoplasms'}, {'id': 'D002289', 'term': 'Carcinoma, Non-Small-Cell Lung'}, {'id': 'D000230', 'term': 'Adenocarcinoma'}], 'ancestors': [{'id': 'D008175', 'term': 'Lung Neoplasms'}, {'id': 'D012142', 'term': 'Respiratory Tract Neoplasms'}, {'id': 'D013899', 'term': 'Thoracic Neoplasms'}, {'id': 'D009371', 'term': 'Neoplasms by Site'}, {'id': 'D008171', 'term': 'Lung Diseases'}, {'id': 'D012140', 'term': 'Respiratory Tract Diseases'}, {'id': 'D002283', 'term': 'Carcinoma, Bronchogenic'}, {'id': 'D001984', 'term': 'Bronchial Neoplasms'}, {'id': 'D002277', 'term': 'Carcinoma'}, {'id': 'D009375', 'term': 'Neoplasms, Glandular and Epithelial'}, {'id': 'D009370', 'term': 'Neoplasms by Histologic Type'}], 'browseLeaves': [{'id': 'M11172', 'name': 'Lung Neoplasms', 'relevance': 'LOW'}, {'id': 'M5546', 'name': 'Carcinoma, Non-Small-Cell Lung', 'asFound': 'Non-small Cell Lung Cancer', 'relevance': 'HIGH'}, {'id': 'M13110', 'name': 'Pancreatic Neoplasms', 'relevance': 'LOW'}, {'id': 'M3585', 'name': 'Adenocarcinoma', 'asFound': 'Adenocarcinoma', 'relevance': 'HIGH'}, {'id': 'M5534', 'name': 'Carcinoma', 'relevance': 'LOW'}, {'id': 'M14979', 'name': 'Respiratory Tract Neoplasms', 'relevance': 'LOW'}, {'id': 'M16658', 'name': 'Thoracic Neoplasms', 'relevance': 'LOW'}, {'id': 'M11168', 'name': 'Lung Diseases', 'relevance': 'LOW'}, {'id': 'M14977', 'name': 'Respiratory Tract Diseases', 'relevance': 'LOW'}, {'id': 'M5540', 'name': 'Carcinoma, Bronchogenic', 'relevance': 'LOW'}, {'id': 'M5260', 'name': 'Bronchial Neoplasms', 'relevance': 'LOW'}, {'id': 'M12320', 'name': 'Neoplasms, Glandular and Epithelial', 'relevance': 'LOW'}, {'id': 'M12315', 'name': 'Neoplasms by Histologic Type', 'relevance': 'LOW'}, {'id': 'T4387', 'name': 'Pancreatic Cancer', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'BC04', 'name': 'Neoplasms'}, {'abbrev': 'BC08', 'name': 'Respiratory Tract (Lung and Bronchial) Diseases'}, {'abbrev': 'All', 'name': 'All Conditions'}, {'abbrev': 'BC06', 'name': 'Digestive System Diseases'}, {'abbrev': 'BC19', 'name': 'Gland and Hormone Related Diseases'}, {'abbrev': 'Rare', 'name': 'Rare Diseases'}]}}, 'hasResults': False}\n",
      "Keys for NCT05347797:\n",
      "dict_keys(['protocolSection', 'derivedSection', 'hasResults'])\n",
      "Content for NCT05347797:\n",
      "{'protocolSection': {'identificationModule': {'nctId': 'NCT05347797', 'orgStudyIdInfo': {'id': 'QMAN-18-0181-1-003'}, 'organization': {'fullName': 'QIAGEN Gaithersburg, Inc', 'class': 'INDUSTRY'}, 'briefTitle': 'Clinical Study Testing DNA Extracted From Tumour Tissue Biopsy Samples, Using the Therascreen® KRAS RGQ PCR Kit', 'officialTitle': 'Phase 3 Multicentre, Prospective, Interventional Clinical Study Testing DNA Extracted From Tumour Tissue Biopsy Samples, Using the Therascreen® KRAS RGQ PCR Kit, From Patients With Non-Small Cell Lung Cancer, Screened in Clinical Study (Protocol No. 20190009).'}, 'statusModule': {'statusVerifiedDate': '2024-10', 'overallStatus': 'COMPLETED', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2020-03-13', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2021-04-22', 'type': 'ACTUAL'}, 'completionDateStruct': {'date': '2021-04-22', 'type': 'ACTUAL'}, 'studyFirstSubmitDate': '2022-04-01', 'studyFirstSubmitQcDate': '2022-04-20', 'studyFirstPostDateStruct': {'date': '2022-04-26', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2024-11-01', 'lastUpdatePostDateStruct': {'date': '2024-11-04', 'type': 'ACTUAL'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'}, 'leadSponsor': {'name': 'QIAGEN Gaithersburg, Inc', 'class': 'INDUSTRY'}, 'collaborators': [{'name': 'Amgen', 'class': 'INDUSTRY'}]}, 'oversightModule': {'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'descriptionModule': {'briefSummary': 'An interventional, prospective study. It is estimated that up to 800 patient tissue samples (from approximately 650 patients enrolled at approximately 300 clinical trial sites), will be obtained as part of enrolment into Phase 3 of Clinical Study (Protocol No. 20190009), for testing using the therascreen® KRAS RGQ PCR Kit (KRAS Kit).', 'detailedDescription': 'This is an interventional, prospective clinical performance study protocol, for the testing of DNA extracted from tumour tissue biopsy samples (resected and core needle biopsy \\\\[CNB\\\\]/fine needle aspiration \\\\[FNA\\\\]) tumour tissue ) obtained from patients with Non-Small Cell Lung Cancer (NSCLC), using the KRAS Kit.\\n\\nUp to 800 patient tissue samples (from approximately 300 clinical trial sites), obtained in the Clinical Study (Protocol No. 20190009), will be tested using the KRAS Kit. The testing will be performed at the investigational device clinical testing sites, Q2 Solutions Laboratories in the four geographical locations: USA, Singapore, UK and China.\\n\\nThe primary objective of the Clinical Study (Protocol No. 20190009) is to evaluate tumour objective response rate (ORR) assessed by MODIFIED RECIST 1.1 criteria of AMG 510 as a monotherapy in patients using the Clinical Study Assay, KRAS Kit to assess whether to treat patients with KRAS G12Cmutated advanced tumours (NSCLC).\\n\\nThe clinical data from the study will be used to determine the drug-device efficacy to support future regulatory submissions for the device-drug combination.'}, 'conditionsModule': {'conditions': ['Non-small Cell Lung Cancer']}, 'designModule': {'studyType': 'INTERVENTIONAL', 'phases': ['NA'], 'designInfo': {'allocation': 'NA', 'interventionModel': 'SINGLE_GROUP', 'primaryPurpose': 'DIAGNOSTIC', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 495, 'type': 'ACTUAL'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'Clinical Performance Study Protocol for therascreen® KRAS RGQ PCR Kit', 'type': 'OTHER', 'description': 'The KRAS Kit is a real-time qualitative PCR assay used on the Rotor-Gene Q MDx instrument for the detection of somatic G12C mutations in the human KRAS oncogene using DNA extracted from formalin fixed paraffin-embedded (FFPE) Non-small Cell Lung Cancer (NSCLC) tissue. The KRAS Kit is intended to aid in the identification of cancer patients who may be eligible for treatment with AMG 510.', 'interventionNames': ['Diagnostic Test: therascreen® KRAS RGQ PCR Kit']}], 'interventions': [{'type': 'DIAGNOSTIC_TEST', 'name': 'therascreen® KRAS RGQ PCR Kit', 'description': 'To utilize a Clinical Study assay, the therascreen® KRAS RGQ PCR Kit, as a screening test in Phase 3 of Clinical Study (Protocol No. 20190009), in order to identify patients with NSCLC with KRAS G12C mutation positive tumours.', 'armGroupLabels': ['Clinical Performance Study Protocol for therascreen® KRAS RGQ PCR Kit']}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'therascreen® KRAS RGQ PCR Kit (KRAS Kit).', 'description': 'To utilize the Clinical Trial Assay, the (KRAS Kit), as a screening test in Phase 3 of Clinical Study (Protocol No. 20190009), in order to identify patients with NSCLC who have the KRAS G12C mutation.', 'timeFrame': '5 business days'}]}, 'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\n\\n* All patients who provided consent (by signing and dating the ICF for Protocol No. 20190009), may be included in the Clinical Performance Study.\\n\\nExclusion Criteria:\\n\\n* Patients whose tumour tissue biopsy samples are not Clinical Study Assay evaluable will be asked to provide further tumour tissue biopsy samples. Patients with samples identified for the study which have insufficient testing material will have their sample excluded, as will specimens which have undergone decalcification.', 'healthyVolunteers': False, 'sex': 'ALL', 'stdAges': ['CHILD', 'ADULT', 'OLDER_ADULT']}, 'contactsLocationsModule': {'locations': [{'facility': 'QIAGEN Gaithersburg, Inc', 'city': 'Manchester', 'zip': 'M130BH', 'country': 'United Kingdom', 'geoPoint': {'lat': 53.48095, 'lon': -2.23743}}]}, 'ipdSharingStatementModule': {'ipdSharing': 'NO'}}, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-08-21'}, 'conditionBrowseModule': {'meshes': [{'id': 'D008175', 'term': 'Lung Neoplasms'}, {'id': 'D002289', 'term': 'Carcinoma, Non-Small-Cell Lung'}], 'ancestors': [{'id': 'D012142', 'term': 'Respiratory Tract Neoplasms'}, {'id': 'D013899', 'term': 'Thoracic Neoplasms'}, {'id': 'D009371', 'term': 'Neoplasms by Site'}, {'id': 'D009369', 'term': 'Neoplasms'}, {'id': 'D008171', 'term': 'Lung Diseases'}, {'id': 'D012140', 'term': 'Respiratory Tract Diseases'}, {'id': 'D002283', 'term': 'Carcinoma, Bronchogenic'}, {'id': 'D001984', 'term': 'Bronchial Neoplasms'}], 'browseLeaves': [{'id': 'M11172', 'name': 'Lung Neoplasms', 'asFound': 'Lung Cancer', 'relevance': 'HIGH'}, {'id': 'M5546', 'name': 'Carcinoma, Non-Small-Cell Lung', 'asFound': 'Non-small Cell Lung Cancer', 'relevance': 'HIGH'}, {'id': 'M5534', 'name': 'Carcinoma', 'relevance': 'LOW'}, {'id': 'M14979', 'name': 'Respiratory Tract Neoplasms', 'relevance': 'LOW'}, {'id': 'M16658', 'name': 'Thoracic Neoplasms', 'relevance': 'LOW'}, {'id': 'M11168', 'name': 'Lung Diseases', 'relevance': 'LOW'}, {'id': 'M14977', 'name': 'Respiratory Tract Diseases', 'relevance': 'LOW'}, {'id': 'M5540', 'name': 'Carcinoma, Bronchogenic', 'relevance': 'LOW'}, {'id': 'M5260', 'name': 'Bronchial Neoplasms', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'BC04', 'name': 'Neoplasms'}, {'abbrev': 'BC08', 'name': 'Respiratory Tract (Lung and Bronchial) Diseases'}, {'abbrev': 'All', 'name': 'All Conditions'}]}, 'interventionBrowseModule': {'browseLeaves': [{'id': 'M8681', 'name': 'Formaldehyde', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'Infe', 'name': 'Anti-Infective Agents'}, {'abbrev': 'All', 'name': 'All Drugs and Chemicals'}]}}, 'hasResults': False}\n",
      "Keys for NCT06607185:\n",
      "dict_keys(['protocolSection', 'derivedSection', 'hasResults'])\n",
      "Content for NCT06607185:\n",
      "{'protocolSection': {'identificationModule': {'nctId': 'NCT06607185', 'orgStudyIdInfo': {'id': '27237'}, 'secondaryIdInfos': [{'id': 'J5Q-OX-JRDA', 'type': 'OTHER', 'domain': 'Eli Lilly and Company'}], 'organization': {'fullName': 'Eli Lilly and Company', 'class': 'INDUSTRY'}, 'briefTitle': 'A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors', 'officialTitle': 'A Phase 1a/1b Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors'}, 'statusModule': {'statusVerifiedDate': '2025-07', 'overallStatus': 'RECRUITING', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2024-10-21', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2030-01', 'type': 'ESTIMATED'}, 'completionDateStruct': {'date': '2030-01', 'type': 'ESTIMATED'}, 'studyFirstSubmitDate': '2024-09-19', 'studyFirstSubmitQcDate': '2024-09-19', 'studyFirstPostDateStruct': {'date': '2024-09-23', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2025-08-05', 'lastUpdatePostDateStruct': {'date': '2025-08-08', 'type': 'ACTUAL'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'}, 'leadSponsor': {'name': 'Eli Lilly and Company', 'class': 'INDUSTRY'}}, 'oversightModule': {'oversightHasDmc': False, 'isFdaRegulatedDrug': True, 'isFdaRegulatedDevice': False}, 'descriptionModule': {'briefSummary': 'The main purpose of the study is to assess whether the study drug, LY4066434, is safe and tolerable when administered to participants with locally advanced or metastatic solid tumors with certain KRAS mutations. LY4066434 will be given alone or in combination with other treatments. The study will have 2 parts: monotherapy dose escalation and dose optimization. The study is expected to last up to approximately 5 years.'}, 'conditionsModule': {'conditions': ['Pancreatic Ductal Adenocarcinoma', 'Non-small Cell Lung Cancer', 'Colorectal Cancer', 'Advanced Solid Tumor', 'Metastatic Solid Tumor'], 'keywords': ['KRAS', 'KRAS mutation', 'KRASG12C', 'KRASG12D', 'KRASG12V', 'KRASG12S', 'KRASG12A', 'KRASG13D', 'LY4066434', 'Targeted therapy', 'Lung cancer', 'Pancreas cancer', 'Colon cancer', 'Rectal cancer', 'Colorectal cancer', 'Ovarian cancer', 'Endometrial cancer', 'Cholangiocarcinoma', 'Esophageal cancer', 'KRAS-mutant tumor', 'PanKRAS', 'Pan KRAS']}, 'designModule': {'studyType': 'INTERVENTIONAL', 'phases': ['PHASE1'], 'designInfo': {'allocation': 'NON_RANDOMIZED', 'interventionModel': 'SEQUENTIAL', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 750, 'type': 'ESTIMATED'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'LY4066434 Monotherapy Dose Escalation', 'type': 'EXPERIMENTAL', 'description': 'Escalating doses of LY4066434 administered orally.', 'interventionNames': ['Drug: LY4066434.']}, {'label': 'LY4066434 Dose Optimization', 'type': 'EXPERIMENTAL', 'description': 'LY4066434 administered orally either alone or with another investigational agent.', 'interventionNames': ['Drug: LY4066434.', 'Drug: Cetuximab', 'Drug: Nab paclitaxel', 'Drug: Gemcitabine', 'Drug: Oxaliplatin', 'Drug: Leucovorin', 'Drug: Irinotecan', 'Drug: 5Fluorouracil', 'Drug: Carboplatin', 'Drug: Cisplatin', 'Drug: Pemetrexed', 'Drug: Pembrolizumab']}], 'interventions': [{'type': 'DRUG', 'name': 'LY4066434.', 'description': 'Administered orally.', 'armGroupLabels': ['LY4066434 Dose Optimization', 'LY4066434 Monotherapy Dose Escalation']}, {'type': 'DRUG', 'name': 'Cetuximab', 'description': 'Administered intravenously.', 'armGroupLabels': ['LY4066434 Dose Optimization']}, {'type': 'DRUG', 'name': 'Nab paclitaxel', 'description': 'Administered intravenously.', 'armGroupLabels': ['LY4066434 Dose Optimization']}, {'type': 'DRUG', 'name': 'Gemcitabine', 'description': 'Administered intravenously.', 'armGroupLabels': ['LY4066434 Dose Optimization']}, {'type': 'DRUG', 'name': 'Oxaliplatin', 'description': 'Administered intravenously.', 'armGroupLabels': ['LY4066434 Dose Optimization']}, {'type': 'DRUG', 'name': 'Leucovorin', 'description': 'Administered intravenously.', 'armGroupLabels': ['LY4066434 Dose Optimization'], 'otherNames': ['Folinic Acid']}, {'type': 'DRUG', 'name': 'Irinotecan', 'description': 'Administered intravenously.', 'armGroupLabels': ['LY4066434 Dose Optimization']}, {'type': 'DRUG', 'name': '5Fluorouracil', 'description': 'Administered intravenously.', 'armGroupLabels': ['LY4066434 Dose Optimization']}, {'type': 'DRUG', 'name': 'Carboplatin', 'description': 'Administered intravenously.', 'armGroupLabels': ['LY4066434 Dose Optimization']}, {'type': 'DRUG', 'name': 'Cisplatin', 'description': 'Administered intravenously.', 'armGroupLabels': ['LY4066434 Dose Optimization']}, {'type': 'DRUG', 'name': 'Pemetrexed', 'description': 'Administered intravenously.', 'armGroupLabels': ['LY4066434 Dose Optimization']}, {'type': 'DRUG', 'name': 'Pembrolizumab', 'description': 'Administered intravenously.', 'armGroupLabels': ['LY4066434 Dose Optimization']}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Number of Participants with Dose-limiting Toxicities (DLTs)', 'timeFrame': 'During the first cycle of LY4066434 treatment (up to 28 days)'}, {'measure': 'Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration', 'description': 'A summary of TEAEs, SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module.', 'timeFrame': 'Up to approximately 5 years'}], 'secondaryOutcomes': [{'measure': 'Overall Response Rate (ORR)', 'description': 'ORR as assessed by investigator per Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST v1.1)', 'timeFrame': 'Up to approximately 5 years'}, {'measure': 'Best Overall Response (BOR)', 'description': 'BOR as assessed by investigator per RECIST v1.1', 'timeFrame': 'Up to approximately 5 years'}, {'measure': 'Duration of Response (DOR)', 'description': 'DOR as assessed by investigator per RECIST v1.1', 'timeFrame': 'Up to approximately 5 years'}, {'measure': 'Disease Control Rate (DCR)', 'description': 'DCR as assessed by investigator per RECIST v1.1', 'timeFrame': 'Up to approximately 5 years'}, {'measure': 'Time to Response (TTR)', 'description': 'TTR as assessed by investigator per RECIST v1.1', 'timeFrame': 'Up to approximately 5 years'}, {'measure': 'Pharmacokinetics (PK): Maximum Observed Concentration (Cmax) of LY4066434 Alone', 'description': 'PK: Cmax of LY4066434', 'timeFrame': 'Predose through Day 168'}, {'measure': 'Pharmacokinetics (PK): Maximum Observed Concentration (Cmax) of LY4066434 in Combination With Other Agents', 'description': 'PK: Cmax of LY4066434', 'timeFrame': 'Predose through Day 168'}, {'measure': 'PK: Time to Maximum Concentration (Tmax) of LY4066434 Alone', 'description': 'PK: Tmax of LY4066434', 'timeFrame': 'Predose through Day 168'}, {'measure': 'PK: Time to Maximum Concentration (Tmax) of LY4066434 in Combination With Other Agents', 'description': 'PK: Tmax of LY4066434', 'timeFrame': 'Predose through Day 168'}, {'measure': 'PK: Area Under the Concentration Versus Time Curve (AUC) of LY4066434 Alone', 'description': 'PK: AUC of LY4066434', 'timeFrame': 'Predose through Day 168'}, {'measure': 'PK: Area Under the Concentration Versus Time Curve (AUC) of LY4066434 in Combination With Other Agents', 'description': 'PK: AUC of LY4066434', 'timeFrame': 'Predose through Day 168'}]}, 'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\n\\n* Have evidence of KRAS G12C, G12D, G12V, G12A, G12S, or G13D mutation in tumor tissue or circulating tumor DNA\\n* Histological or cytologically proven diagnosis of a locally advanced, unresectable, and/or metastatic solid tumor cancer\\n* Have measurable disease per RECIST 1.1\\n* Have an ECOG performance status of ≤1\\n* Must not be pregnant and/or planning to breastfeed during the trial or within 180 days of the last dose of trial intervention\\n* Must be able to swallow tablets\\n* Participants with asymptomatic or treated CNS disease may be eligible\\n\\nExclusion Criteria:\\n\\n* Have known active CNS metastases and/or carcinomatous meningitis\\n* Have any unresolved toxicities from prior therapy greater than NCI CTCAE Version 5.0 Grade 1 at the time of starting trial treatment, except for alopecia, hearing loss, peripheral neuropathy and ongoing endocrinopathies controlled on appropriate replacement therapy\\n* Have significant cardiovascular disease defined as unstable angina or acute coronary syndrome, history of myocardial infarction, known left ventricular ejection fraction or heart failure, uncontrolled or symptomatic arrhythmias.\\n* Have known active hepatitis B virus (HBV), hepatitis C virus (HCV) or untreated HIV infection\\n* Have other active malignancy unless in remission with life expectancy greater than 2 years.\\n* Have active uncontrolled systemic bacterial, viral, fungal, or parasitic infection\\n* Have history of non-infectious pneumonitis/interstitial lung disease that received steroids or has current clinically significant pneumonitis/interstitial lung disease', 'healthyVolunteers': False, 'sex': 'ALL', 'minimumAge': '18 Years', 'stdAges': ['ADULT', 'OLDER_ADULT']}, 'contactsLocationsModule': {'centralContacts': [{'name': 'There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or', 'role': 'CONTACT', 'phone': '13176154559', 'email': 'clinical_inquiry_hub@lilly.com'}], 'overallOfficials': [{'name': 'Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)', 'affiliation': 'Eli Lilly and Company', 'role': 'STUDY_DIRECTOR'}], 'locations': [{'facility': 'University of Alabama at Birmingham', 'status': 'NOT_YET_RECRUITING', 'city': 'Birmingham', 'state': 'Alabama', 'zip': '35233', 'country': 'United States', 'geoPoint': {'lat': 33.52066, 'lon': -86.80249}}, {'facility': 'Mayo Clinic', 'status': 'RECRUITING', 'city': 'Phoenix', 'state': 'Arizona', 'zip': '85054', 'country': 'United States', 'geoPoint': {'lat': 33.44838, 'lon': -112.07404}}, {'facility': 'City of Hope', 'status': 'RECRUITING', 'city': 'Duarte', 'state': 'California', 'zip': '91010', 'country': 'United States', 'geoPoint': {'lat': 34.13945, 'lon': -117.97729}}, {'facility': 'University of California, Los Angeles (UCLA)', 'status': 'RECRUITING', 'city': 'Los Angeles', 'state': 'California', 'zip': '90025', 'country': 'United States', 'geoPoint': {'lat': 34.05223, 'lon': -118.24368}}, {'facility': 'University of Colorado Denver', 'status': 'NOT_YET_RECRUITING', 'city': 'Denver', 'state': 'Colorado', 'zip': '80220', 'country': 'United States', 'geoPoint': {'lat': 39.73915, 'lon': -104.9847}}, {'facility': 'Yale University School of Medicine - Yale Cancer Center', 'status': 'RECRUITING', 'city': 'New Haven', 'state': 'Connecticut', 'zip': '06520-8028', 'country': 'United States', 'geoPoint': {'lat': 41.30815, 'lon': -72.92816}}, {'facility': 'The University of Chicago Medical Center (UCMC)', 'status': 'NOT_YET_RECRUITING', 'city': 'Chicago', 'state': 'Illinois', 'zip': '60637', 'country': 'United States', 'geoPoint': {'lat': 41.85003, 'lon': -87.65005}}, {'facility': 'Indiana University (IU)', 'status': 'RECRUITING', 'city': 'Indianapolis', 'state': 'Indiana', 'zip': '46202', 'country': 'United States', 'geoPoint': {'lat': 39.76838, 'lon': -86.15804}}, {'facility': 'Massachusetts General Hospital', 'status': 'RECRUITING', 'city': 'Boston', 'state': 'Massachusetts', 'zip': '02114', 'country': 'United States', 'geoPoint': {'lat': 42.35843, 'lon': -71.05977}}, {'facility': 'Dana-Farber Cancer Institute', 'status': 'RECRUITING', 'city': 'Boston', 'state': 'Massachusetts', 'zip': '02215', 'country': 'United States', 'geoPoint': {'lat': 42.35843, 'lon': -71.05977}}, {'facility': 'Henry Ford Health System', 'status': 'RECRUITING', 'city': 'Detriot', 'state': 'Michigan', 'zip': '48202', 'country': 'United States', 'geoPoint': {'lat': 42.33143, 'lon': -83.04575}}, {'facility': 'South Texas Accelerated Research Therapeutics (START) Midwest', 'status': 'RECRUITING', 'city': 'Grand Rapids', 'state': 'Michigan', 'zip': '49546', 'country': 'United States', 'geoPoint': {'lat': 42.96336, 'lon': -85.66809}}, {'facility': 'Mayo Clinic - Rochester', 'status': 'NOT_YET_RECRUITING', 'city': 'Rochester', 'state': 'Minnesota', 'zip': '55905', 'country': 'United States', 'geoPoint': {'lat': 44.02163, 'lon': -92.4699}}, {'facility': 'Columbia University', 'status': 'RECRUITING', 'city': 'New York', 'state': 'New York', 'zip': '10032', 'country': 'United States', 'geoPoint': {'lat': 40.71427, 'lon': -74.00597}}, {'facility': 'David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center', 'status': 'RECRUITING', 'city': 'New York', 'state': 'New York', 'zip': '10065', 'country': 'United States', 'geoPoint': {'lat': 40.71427, 'lon': -74.00597}}, {'facility': 'Duke University Medical Center', 'status': 'RECRUITING', 'city': 'Durham', 'state': 'North Carolina', 'zip': '27710', 'country': 'United States', 'geoPoint': {'lat': 35.99403, 'lon': -78.89862}}, {'facility': 'Cleveland Clinic', 'status': 'RECRUITING', 'city': 'Cleveland', 'state': 'Ohio', 'zip': '44195', 'country': 'United States', 'geoPoint': {'lat': 41.4995, 'lon': -81.69541}}, {'facility': 'University of Oklahoma - Health Sciences Center', 'status': 'NOT_YET_RECRUITING', 'city': 'Oklahoma City', 'state': 'Oklahoma', 'zip': '73104', 'country': 'United States', 'geoPoint': {'lat': 35.46756, 'lon': -97.51643}}, {'facility': 'University of Pittsburgh Medical Center', 'status': 'RECRUITING', 'city': 'Pittsburgh', 'state': 'Pennsylvania', 'zip': '15232', 'country': 'United States', 'geoPoint': {'lat': 40.44062, 'lon': -79.99589}}, {'facility': 'SCRI Oncology Partners', 'status': 'RECRUITING', 'city': 'Nashville', 'state': 'Tennessee', 'zip': '37203', 'country': 'United States', 'geoPoint': {'lat': 36.16589, 'lon': -86.78444}}, {'facility': 'University of Texas Southwestern', 'status': 'RECRUITING', 'city': 'Dallas', 'state': 'Texas', 'zip': '75244', 'country': 'United States', 'geoPoint': {'lat': 32.78306, 'lon': -96.80667}}, {'facility': 'MD Anderson Cancer Center', 'status': 'RECRUITING', 'city': 'Houston', 'state': 'Texas', 'zip': '77030', 'country': 'United States', 'geoPoint': {'lat': 29.76328, 'lon': -95.36327}}, {'facility': 'South Texas Accelerated Research Therapeutics (START)', 'status': 'RECRUITING', 'city': 'San Antonio', 'state': 'Texas', 'zip': '78229', 'country': 'United States', 'geoPoint': {'lat': 29.42412, 'lon': -98.49363}}, {'facility': 'Virginia Cancer Specialists', 'status': 'RECRUITING', 'city': 'Fairfax', 'state': 'Virginia', 'zip': '22031', 'country': 'United States', 'geoPoint': {'lat': 38.84622, 'lon': -77.30637}}, {'facility': 'Swedish Cancer Institute (SCI)', 'status': 'NOT_YET_RECRUITING', 'city': 'Seattle', 'state': 'Washington', 'zip': '98104', 'country': 'United States', 'geoPoint': {'lat': 47.60621, 'lon': -122.33207}}, {'facility': 'Universite Libre de Bruxelles (ULB) - Institut Jules Bordet', 'status': 'RECRUITING', 'city': 'Brussels', 'zip': '1070', 'country': 'Belgium', 'geoPoint': {'lat': 50.85045, 'lon': 4.34878}}, {'facility': 'Cliniques universitaires Saint-Luc', 'status': 'RECRUITING', 'city': 'Brussels', 'zip': '1200', 'country': 'Belgium', 'geoPoint': {'lat': 50.85045, 'lon': 4.34878}}, {'facility': 'University Hospital Gent', 'status': 'RECRUITING', 'city': 'Gent', 'zip': '9000', 'country': 'Belgium', 'geoPoint': {'lat': 51.05, 'lon': 3.71667}}, {'facility': 'Cancer Institute & Hospital, Chinese Academy of Medical Sciences', 'status': 'NOT_YET_RECRUITING', 'city': 'Beijing', 'zip': '100020', 'country': 'China', 'geoPoint': {'lat': 39.9075, 'lon': 116.39723}}, {'facility': 'The First Affiliated Hospital, College of Medicine, Zhejiang University', 'status': 'NOT_YET_RECRUITING', 'city': 'Hangzhou', 'zip': '310006', 'country': 'China', 'geoPoint': {'lat': 30.29365, 'lon': 120.16142}}, {'facility': 'Shandong Province Tumor Hospital', 'status': 'NOT_YET_RECRUITING', 'city': 'Jinan', 'zip': '250117', 'country': 'China', 'geoPoint': {'lat': 36.66833, 'lon': 116.99722}}, {'facility': 'Shanghai East Hospital, Tongji University', 'status': 'NOT_YET_RECRUITING', 'city': 'Shanghai', 'zip': '0200120', 'country': 'China', 'geoPoint': {'lat': 31.22222, 'lon': 121.45806}}, {'facility': 'Tianjin Medical University Cancer Institute & Hospital', 'status': 'NOT_YET_RECRUITING', 'city': 'Tianjin', 'zip': '300060', 'country': 'China', 'geoPoint': {'lat': 39.14222, 'lon': 117.17667}}, {'facility': 'Centre Leon Berard', 'status': 'NOT_YET_RECRUITING', 'city': 'Lyon', 'zip': '69008', 'country': 'France', 'geoPoint': {'lat': 45.74848, 'lon': 4.84669}}, {'facility': 'Institut Gustave Roussy', 'status': 'NOT_YET_RECRUITING', 'city': 'Villejuif cedex', 'zip': '94805', 'country': 'France', 'geoPoint': {'lat': 48.7939, 'lon': 2.35992}}, {'facility': 'Charite Universitaetsmedizin Berlin', 'status': 'NOT_YET_RECRUITING', 'city': 'Berlin', 'zip': '10117', 'country': 'Germany', 'geoPoint': {'lat': 52.52437, 'lon': 13.41053}}, {'facility': 'Krankenhaus Nordwest GmbH', 'status': 'NOT_YET_RECRUITING', 'city': 'Frankfurt', 'zip': '60488', 'country': 'Germany', 'geoPoint': {'lat': 50.11552, 'lon': 8.68417}}, {'facility': 'Asklepios Kliniken Hamburg GmbH - Asklepios Klinik Altona', 'status': 'NOT_YET_RECRUITING', 'city': 'Hamburg', 'zip': '22763', 'country': 'Germany', 'geoPoint': {'lat': 53.57532, 'lon': 10.01534}}, {'facility': 'SLK-Kliniken Heilbronn GmBH', 'status': 'RECRUITING', 'city': 'Heilbronn', 'zip': '74078', 'country': 'Germany', 'geoPoint': {'lat': 49.13995, 'lon': 9.22054}}, {'facility': 'Universitaetsklinikum Wuerzburg', 'status': 'NOT_YET_RECRUITING', 'city': 'Wuerzburg', 'zip': '97080', 'country': 'Germany', 'geoPoint': {'lat': 49.79391, 'lon': 9.95121}}, {'facility': 'Centro Ricerche Cliniche di Verona s.r.l.', 'status': 'NOT_YET_RECRUITING', 'city': 'Verona', 'zip': '37134', 'country': 'Italy', 'geoPoint': {'lat': 45.4299, 'lon': 10.98444}}, {'facility': 'National Cancer Center Hospital East', 'status': 'RECRUITING', 'city': 'Chiba', 'zip': '277-8577', 'country': 'Japan', 'geoPoint': {'lat': 35.6, 'lon': 140.11667}}, {'facility': 'Kyoto University Hospital', 'status': 'RECRUITING', 'city': 'Kyoto', 'zip': '606-8507', 'country': 'Japan', 'geoPoint': {'lat': 35.02107, 'lon': 135.75385}}, {'facility': 'Shizuoka Cancer Center', 'status': 'RECRUITING', 'city': 'Shizuoka', 'zip': '411-8777', 'country': 'Japan', 'geoPoint': {'lat': 34.98333, 'lon': 138.38333}}, {'facility': 'National Cancer Center Hospital', 'status': 'RECRUITING', 'city': 'Tokyo', 'zip': '104-0045', 'country': 'Japan', 'geoPoint': {'lat': 35.6895, 'lon': 139.69171}}, {'facility': 'Cancer Institute Hospital of JFCR', 'status': 'RECRUITING', 'city': 'Tokyo', 'zip': '135-8550', 'country': 'Japan', 'geoPoint': {'lat': 35.6895, 'lon': 139.69171}}, {'facility': 'Hospital del Mar', 'status': 'NOT_YET_RECRUITING', 'city': 'Barcelona', 'zip': '08003', 'country': 'Spain', 'geoPoint': {'lat': 41.38879, 'lon': 2.15899}}, {'facility': \"Hospital Universitario Vall d'Hebron\", 'status': 'NOT_YET_RECRUITING', 'city': 'Barcelona', 'zip': '08035', 'country': 'Spain', 'geoPoint': {'lat': 41.38879, 'lon': 2.15899}}, {'facility': \"Institut Catala d'Oncologia - L'Hospitalet\", 'status': 'NOT_YET_RECRUITING', 'city': 'Barcelona', 'zip': '08908', 'country': 'Spain', 'geoPoint': {'lat': 41.38879, 'lon': 2.15899}}, {'facility': 'Hospital General Universitario Gregorio Maranon', 'status': 'NOT_YET_RECRUITING', 'city': 'Madrid', 'zip': '28007', 'country': 'Spain', 'geoPoint': {'lat': 40.4165, 'lon': -3.70256}}, {'facility': 'Hospital Universitario Ramon y Cajal', 'status': 'NOT_YET_RECRUITING', 'city': 'Madrid', 'zip': '28034', 'country': 'Spain', 'geoPoint': {'lat': 40.4165, 'lon': -3.70256}}, {'facility': 'Hospital Universitario 12 de Octubre', 'status': 'RECRUITING', 'city': 'Madrid', 'zip': '28041', 'country': 'Spain', 'geoPoint': {'lat': 40.4165, 'lon': -3.70256}}, {'facility': 'Hospital Regional Universitario de Malaga', 'status': 'NOT_YET_RECRUITING', 'city': 'Malaga', 'zip': '29010', 'country': 'Spain', 'geoPoint': {'lat': 36.72016, 'lon': -4.42034}}, {'facility': 'National Taiwan University Hospital Hsin-Chu Branch', 'status': 'RECRUITING', 'city': 'Hsinchu', 'zip': '300195', 'country': 'Taiwan', 'geoPoint': {'lat': 24.80361, 'lon': 120.96861}}, {'facility': 'National Taiwan University Hospital', 'status': 'RECRUITING', 'city': 'Taipei', 'zip': '10002', 'country': 'Taiwan', 'geoPoint': {'lat': 25.04776, 'lon': 121.53185}}]}, 'referencesModule': {'seeAlsoLinks': [{'label': 'A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors', 'url': 'http://trials.lilly.com/en-US/trial/533775'}]}, 'ipdSharingStatementModule': {'ipdSharing': 'NO'}}, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-08-20'}, 'conditionBrowseModule': {'meshes': [{'id': 'D009369', 'term': 'Neoplasms'}, {'id': 'D015179', 'term': 'Colorectal Neoplasms'}], 'ancestors': [{'id': 'D009371', 'term': 'Neoplasms by Site'}, {'id': 'D007414', 'term': 'Intestinal Neoplasms'}, {'id': 'D005770', 'term': 'Gastrointestinal Neoplasms'}, {'id': 'D004067', 'term': 'Digestive System Neoplasms'}, {'id': 'D004066', 'term': 'Digestive System Diseases'}, {'id': 'D005767', 'term': 'Gastrointestinal Diseases'}, {'id': 'D003108', 'term': 'Colonic Diseases'}, {'id': 'D007410', 'term': 'Intestinal Diseases'}, {'id': 'D012002', 'term': 'Rectal Diseases'}], 'browseLeaves': [{'id': 'M13110', 'name': 'Pancreatic Neoplasms', 'relevance': 'LOW'}, {'id': 'M3585', 'name': 'Adenocarcinoma', 'relevance': 'LOW'}, {'id': 'M11172', 'name': 'Lung Neoplasms', 'relevance': 'LOW'}, {'id': 'M5546', 'name': 'Carcinoma, Non-Small-Cell Lung', 'relevance': 'LOW'}, {'id': 'M20426', 'name': 'Cholangiocarcinoma', 'relevance': 'LOW'}, {'id': 'M12974', 'name': 'Ovarian Neoplasms', 'relevance': 'LOW'}, {'id': 'M1704', 'name': 'Carcinoma, Ovarian Epithelial', 'relevance': 'LOW'}, {'id': 'M8088', 'name': 'Esophageal Neoplasms', 'relevance': 'LOW'}, {'id': 'M17890', 'name': 'Colorectal Neoplasms', 'asFound': 'Colorectal Cancer', 'relevance': 'HIGH'}, {'id': 'M10448', 'name': 'Intestinal Neoplasms', 'relevance': 'LOW'}, {'id': 'M8886', 'name': 'Gastrointestinal Neoplasms', 'relevance': 'LOW'}, {'id': 'M7256', 'name': 'Digestive System Neoplasms', 'relevance': 'LOW'}, {'id': 'M8883', 'name': 'Gastrointestinal Diseases', 'relevance': 'LOW'}, {'id': 'M7255', 'name': 'Digestive System Diseases', 'relevance': 'LOW'}, {'id': 'M6336', 'name': 'Colonic Diseases', 'relevance': 'LOW'}, {'id': 'M10444', 'name': 'Intestinal Diseases', 'relevance': 'LOW'}, {'id': 'M14844', 'name': 'Rectal Diseases', 'relevance': 'LOW'}, {'id': 'T2141', 'name': 'Esophageal Cancer', 'relevance': 'LOW'}, {'id': 'T4387', 'name': 'Pancreatic Cancer', 'relevance': 'LOW'}, {'id': 'T755', 'name': 'Bile Duct Cancer', 'relevance': 'LOW'}, {'id': 'T4352', 'name': 'Ovarian Cancer', 'relevance': 'LOW'}, {'id': 'T4354', 'name': 'Ovarian Epithelial Cancer', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'BC04', 'name': 'Neoplasms'}, {'abbrev': 'BC06', 'name': 'Digestive System Diseases'}, {'abbrev': 'BC19', 'name': 'Gland and Hormone Related Diseases'}, {'abbrev': 'All', 'name': 'All Conditions'}, {'abbrev': 'BC08', 'name': 'Respiratory Tract (Lung and Bronchial) Diseases'}, {'abbrev': 'BXS', 'name': 'Urinary Tract, Sexual Organs, and Pregnancy Conditions'}, {'abbrev': 'Rare', 'name': 'Rare Diseases'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'D002955', 'term': 'Leucovorin'}, {'id': 'D016190', 'term': 'Carboplatin'}, {'id': 'D000093542', 'term': 'Gemcitabine'}, {'id': 'C582435', 'term': 'Pembrolizumab'}, {'id': 'D000077150', 'term': 'Oxaliplatin'}, {'id': 'D005472', 'term': 'Fluorouracil'}, {'id': 'D000077146', 'term': 'Irinotecan'}, {'id': 'D000068437', 'term': 'Pemetrexed'}, {'id': 'D000068818', 'term': 'Cetuximab'}], 'ancestors': [{'id': 'D000970', 'term': 'Antineoplastic Agents'}, {'id': 'D045504', 'term': 'Molecular Mechanisms of Pharmacological Action'}, {'id': 'D000964', 'term': 'Antimetabolites, Antineoplastic'}, {'id': 'D000963', 'term': 'Antimetabolites'}, {'id': 'D000074322', 'term': 'Antineoplastic Agents, Immunological'}, {'id': 'D000082082', 'term': 'Immune Checkpoint Inhibitors'}, {'id': 'D007166', 'term': 'Immunosuppressive Agents'}, {'id': 'D007155', 'term': 'Immunologic Factors'}, {'id': 'D045505', 'term': 'Physiological Effects of Drugs'}, {'id': 'D059004', 'term': 'Topoisomerase I Inhibitors'}, {'id': 'D059003', 'term': 'Topoisomerase Inhibitors'}, {'id': 'D004791', 'term': 'Enzyme Inhibitors'}, {'id': 'D000931', 'term': 'Antidotes'}, {'id': 'D020011', 'term': 'Protective Agents'}, {'id': 'D014803', 'term': 'Vitamin B Complex'}, {'id': 'D014815', 'term': 'Vitamins'}, {'id': 'D018977', 'term': 'Micronutrients'}, {'id': 'D005493', 'term': 'Folic Acid Antagonists'}, {'id': 'D019384', 'term': 'Nucleic Acid Synthesis Inhibitors'}], 'browseLeaves': [{'id': 'M1674', 'name': 'Oxaliplatin', 'asFound': 'Individual', 'relevance': 'HIGH'}, {'id': 'M19537', 'name': 'Paclitaxel', 'relevance': 'LOW'}, {'id': 'M18650', 'name': 'Carboplatin', 'asFound': 'Total', 'relevance': 'HIGH'}, {'id': 'M264', 'name': 'Pemetrexed', 'asFound': 'Assigned', 'relevance': 'HIGH'}, {'id': 'M2985', 'name': 'Gemcitabine', 'asFound': 'Post-', 'relevance': 'HIGH'}, {'id': 'M349416', 'name': 'Pembrolizumab', 'asFound': 'Type', 'relevance': 'HIGH'}, {'id': 'M6182', 'name': 'Cisplatin', 'relevance': 'LOW'}, {'id': 'M1671', 'name': 'Irinotecan', 'asFound': 'Hospital', 'relevance': 'HIGH'}, {'id': 'M231', 'name': 'Albumin-Bound Paclitaxel', 'relevance': 'LOW'}, {'id': 'M8600', 'name': 'Fluorouracil', 'asFound': 'Only', 'relevance': 'HIGH'}, {'id': 'M6191', 'name': 'Leucovorin', 'asFound': 'Line', 'relevance': 'HIGH'}, {'id': 'M315', 'name': 'Cetuximab', 'asFound': 'Observational', 'relevance': 'HIGH'}, {'id': 'M13114', 'name': 'Pancreatin', 'relevance': 'LOW'}, {'id': 'M22554', 'name': 'Pancrelipase', 'relevance': 'LOW'}, {'id': 'M29233', 'name': 'Levoleucovorin', 'relevance': 'LOW'}, {'id': 'M8618', 'name': 'Folic Acid', 'relevance': 'LOW'}, {'id': 'M4281', 'name': 'Antimetabolites', 'relevance': 'LOW'}, {'id': 'M1346', 'name': 'Antineoplastic Agents, Immunological', 'relevance': 'LOW'}, {'id': 'M2342', 'name': 'Immune Checkpoint Inhibitors', 'relevance': 'LOW'}, {'id': 'M10212', 'name': 'Immunosuppressive Agents', 'relevance': 'LOW'}, {'id': 'M10201', 'name': 'Immunologic Factors', 'relevance': 'LOW'}, {'id': 'M29349', 'name': 'Topoisomerase I Inhibitors', 'relevance': 'LOW'}, {'id': 'M7951', 'name': 'Enzyme Inhibitors', 'relevance': 'LOW'}, {'id': 'M4250', 'name': 'Antidotes', 'relevance': 'LOW'}, {'id': 'M21869', 'name': 'Protective Agents', 'relevance': 'LOW'}, {'id': 'M17558', 'name': 'Vitamins', 'relevance': 'LOW'}, {'id': 'M17546', 'name': 'Vitamin B Complex', 'relevance': 'LOW'}, {'id': 'M21009', 'name': 'Micronutrients', 'relevance': 'LOW'}, {'id': 'M16885', 'name': 'Trace Elements', 'relevance': 'LOW'}, {'id': 'M8619', 'name': 'Folic Acid Antagonists', 'relevance': 'LOW'}, {'id': 'T447', 'name': 'Folinic Acid', 'asFound': 'Ropivacaine', 'relevance': 'HIGH'}, {'id': 'T475', 'name': 'Vitamin B9', 'relevance': 'LOW'}, {'id': 'T446', 'name': 'Folic Acid', 'relevance': 'LOW'}, {'id': 'T120', 'name': 'Cola', 'relevance': 'LOW'}, {'id': 'T448', 'name': 'Folate', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'ANeo', 'name': 'Antineoplastic Agents'}, {'abbrev': 'All', 'name': 'All Drugs and Chemicals'}, {'abbrev': 'Micro', 'name': 'Micronutrients'}, {'abbrev': 'Gast', 'name': 'Gastrointestinal Agents'}, {'abbrev': 'Hemat', 'name': 'Hematinics'}, {'abbrev': 'Vi', 'name': 'Vitamins'}, {'abbrev': 'HB', 'name': 'Herbal and Botanical'}]}}, 'hasResults': False}\n",
      "Keys for NCT06497556:\n",
      "dict_keys(['protocolSection', 'derivedSection', 'hasResults'])\n",
      "Content for NCT06497556:\n",
      "{'protocolSection': {'identificationModule': {'nctId': 'NCT06497556', 'orgStudyIdInfo': {'id': 'BO45217'}, 'secondaryIdInfos': [{'id': '2024-510908-37-00', 'type': 'OTHER', 'domain': 'EU CT Number'}], 'organization': {'fullName': 'Hoffmann-La Roche', 'class': 'INDUSTRY'}, 'briefTitle': 'A Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Participants With Previously Treated KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer', 'officialTitle': 'A Phase III, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Patients With Previously Treated KRAS G12C-Positive Advanced or Metastatic Non-Small Cell Lung Cancer', 'acronym': 'Krascendo 1'}, 'statusModule': {'statusVerifiedDate': '2025-08', 'overallStatus': 'RECRUITING', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2024-09-23', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2026-09-23', 'type': 'ESTIMATED'}, 'completionDateStruct': {'date': '2029-09-30', 'type': 'ESTIMATED'}, 'studyFirstSubmitDate': '2024-07-05', 'studyFirstSubmitQcDate': '2024-07-05', 'studyFirstPostDateStruct': {'date': '2024-07-11', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2025-08-01', 'lastUpdatePostDateStruct': {'date': '2025-08-03', 'type': 'ACTUAL'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'}, 'leadSponsor': {'name': 'Hoffmann-La Roche', 'class': 'INDUSTRY'}, 'collaborators': [{'name': 'Chugai Pharmaceutical', 'class': 'INDUSTRY'}]}, 'oversightModule': {'oversightHasDmc': True, 'isFdaRegulatedDrug': True, 'isFdaRegulatedDevice': False}, 'descriptionModule': {'briefSummary': 'The purpose of this study is to assess the safety and efficacy of divarasib compared to locally approved KRAS G12C inhibitors (sotorasib or adagrasib) in participants with KRAS G12C-positive (KRAS G12C +) advanced or metastatic non-small cell lung cancer (NSCLC).'}, 'conditionsModule': {'conditions': ['Non-Small Cell Lung Cancer', 'KRAS G12C Lung Cancer'], 'keywords': ['Advanced Non-Small Cell Lung Cancer', 'KRAS G12 Lung Cancer', 'Advanced Lung Cancer', 'Metastatic lung cancer', 'Divarasib', 'KRAS G12C Inhibitor', 'KRAS G12C Positive', 'KRAS Mutation', 'KRAS G12C Mutation', 'Lung Cancer Mutation']}, 'designModule': {'studyType': 'INTERVENTIONAL', 'phases': ['PHASE3'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 320, 'type': 'ESTIMATED'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'Divarasib', 'type': 'EXPERIMENTAL', 'description': 'Participants will receive divarasib orally, once daily (QD).', 'interventionNames': ['Drug: Divarasib']}, {'label': 'KRAS G12C inhibitor', 'type': 'ACTIVE_COMPARATOR', 'description': 'Participants will receive Sotorasib orally QD or adagrasib orally twice a day (BID)', 'interventionNames': ['Drug: Sotorasib', 'Drug: Adagrasib']}], 'interventions': [{'type': 'DRUG', 'name': 'Divarasib', 'description': 'Divarasib will be administered orally QD', 'armGroupLabels': ['Divarasib']}, {'type': 'DRUG', 'name': 'Sotorasib', 'description': 'Sotorasib will be administered orally QD', 'armGroupLabels': ['KRAS G12C inhibitor']}, {'type': 'DRUG', 'name': 'Adagrasib', 'description': 'Adagrasib will be administred orally BID', 'armGroupLabels': ['KRAS G12C inhibitor']}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Progression-Free Survival (PFS)', 'description': 'PFS is defined as the time from randomization to the first occurrence of disease progression, as determined by blinded independent central review (BICR) according to RECIST v1.1, or death from any cause (whichever occurs first)', 'timeFrame': 'Up to approximately 4 years'}], 'secondaryOutcomes': [{'measure': 'Overall Survival (OS)', 'description': 'OS is defined as the time from randomization to death from any cause', 'timeFrame': 'Up to approximately 4 years'}, {'measure': 'Objective Response', 'description': 'Objective response is defined as complete response (CR) or partial response (PR) as determined by BICR according to RECIST v1.1', 'timeFrame': 'Up to approximately 4 years'}, {'measure': 'Time to Confirmed Deterioration (TTCD) on the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) Dyspnea Item and Physical Functioning Scale', 'timeFrame': 'Baseline up to approximately 4 years'}, {'measure': 'TTCD on the EORTC Quality-of-Life Questionnaire-Supplemental Lung Cancer Module (QLQ-LC13) Cough Scale', 'timeFrame': 'Baseline up to approximately 4 years'}, {'measure': 'Duration of Response (DOR)', 'description': 'DOR is defined as the time from the first occurrence of a documented objective response to disease progression, as determined by BICR according to RECIST v1.1, or death from any cause (whichever occurs first)', 'timeFrame': 'Up to approximately 4 years'}, {'measure': 'Percentage of Participants with Adverse Events (AEs)', 'timeFrame': 'Up to approximately 4 years'}, {'measure': 'Number of Participants Reporting Presence, Frequency, Severity, and/or Degree of Interference with Daily Function of Symptomatic Treatment Toxicities Assessed by NCI Patient-Reported Outcomes Common Terminology Criteria for Adverse Events (PRO-CTCAE)', 'timeFrame': 'Up to approximately 4 years'}, {'measure': 'Change from Baseline in Diarrhea, Nausea, Vomiting, Anorexia, Alopecia, Dyspnea, Cough, Constipation, Myalgia, Headache, and Rash/Acne as Assessed Through use of the NCI PRO-CTCAE', 'timeFrame': 'Baseline up to approximately 4 years'}, {'measure': \"Frequency of Participants' Response of the Degree they are Troubled with Treatment Symptoms, as Assessed Through use of the single-item EORTC Item List (IL46)\", 'timeFrame': 'Up to approximately 4 years'}, {'measure': 'Change from Baseline in Cough, Chest Pain, Dyspnea, Physical and Role Functioning, and Global Health Status score/Quality of Life Score (GHS/QoL) at Each Timepoint as Assessed Through use of the EORTC QLQ-LC13 and QLQ-C30', 'timeFrame': 'Baseline up to approximately 4 years'}, {'measure': 'TTCD on the EORTC QLQ-C30 Role Functioning and GHS/QoL scales', 'timeFrame': 'Up to approximately 4 years'}, {'measure': 'TTCD on the Chest Pain Scale of the QLQ-LC13 Scales', 'timeFrame': 'Up to approximately 4 years'}]}, 'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\n\\n* Unequivocal histologically or cytologically confirmed diagnosis of metastatic or locally advanced NSCLC not amenable to treatment with surgical resection or combined chemoradiation\\n* Disease progression during or after treatment with at least one prior systemic therapy but no more than three lines of prior systemic therapy in the advanced or metastatic setting\\n* Measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1\\n* Documentation of the presence of a KRAS G12C mutation\\n* Availability of a representative formalin-fixed, paraffin-embedded (FFPE) tumor specimen in a paraffin block (preferred) or 10-15 (15 preferred) unstained, freshly cut, serial slides with an associated pathology report\\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\\n* Life expectancy of \\\\>= 12 weeks\\n\\nExclusion Criteria:\\n\\n* Known hypersensitivity to any of the components of divarasib, or sotorasib or adagrasib\\n* Malabsorption syndrome or other condition that would interfere with enteral absorption\\n* Known concomitant second oncogenic driver\\n* Mixed small-cell lung cancer or large cell neuroendocrine histology\\n* Known and untreated, or active central nervous system (CNS) metastases\\n* Leptomeningeal disease or carcinomatous meningitis\\n* Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures biweekly or more frequently\\n* Any infection that, in the opinion of the investigator, could impact patient safety, or treatment with therapeutic oral or IV antibiotics within 14 days prior to Day 1 of Cycle 1\\n* Prior treatment with any KRAS G12C inhibitor or pan-KRAS/RAS inhibitor\\n* More than 30 Gy of radiotherapy to the lung within 6 months of randomization\\n* Uncontrolled tumor-related pain\\n* Unresolved toxicities from prior anticancer therapy\\n* History of malignancy within 5 years prior to screening, with the exception of the cancer under investigation in this study and malignancies with a negligible risk of metastasis or death (e.g., 5-year OS rate \\\\>90%), such as adequately treated carcinoma in situ of the cervix, nonmelanoma skin carcinoma, localized prostate cancer, ductal carcinoma in situ, or Stage I uterine cancer', 'healthyVolunteers': False, 'sex': 'ALL', 'minimumAge': '18 Years', 'stdAges': ['ADULT', 'OLDER_ADULT']}, 'contactsLocationsModule': {'centralContacts': [{'name': 'Reference Study ID Number: BO45217 https://forpatients.roche.com/', 'role': 'CONTACT', 'phone': '888-662-6728 (U.S. and Canada)', 'email': 'global-roche-genentech-trials@gene.com'}], 'overallOfficials': [{'name': 'Clinical Trials', 'affiliation': 'Hoffmann-La Roche', 'role': 'STUDY_DIRECTOR'}], 'locations': [{'facility': 'Banner Health MD Anderson AZ', 'status': 'RECRUITING', 'city': 'Gilbert', 'state': 'Arizona', 'zip': '85234', 'country': 'United States', 'geoPoint': {'lat': 33.35283, 'lon': -111.78903}}, {'facility': 'Banner Health MD Anderson AZ', 'status': 'RECRUITING', 'city': 'Phoenix', 'state': 'Arizona', 'zip': '85006', 'country': 'United States', 'geoPoint': {'lat': 33.44838, 'lon': -112.07404}}, {'facility': 'University of Arkansas For Medical Sciences', 'status': 'RECRUITING', 'city': 'Little Rock', 'state': 'Arkansas', 'zip': '72205', 'country': 'United States', 'geoPoint': {'lat': 34.74648, 'lon': -92.28959}}, {'facility': 'Los Angeles Cancer Network', 'status': 'RECRUITING', 'city': 'Los Angeles', 'state': 'California', 'zip': '90017-4803', 'country': 'United States', 'geoPoint': {'lat': 34.05223, 'lon': -118.24368}}, {'facility': 'UCLA Hematology / Oncology Clinic', 'status': 'RECRUITING', 'city': 'Los Angeles', 'state': 'California', 'zip': '90095', 'country': 'United States', 'geoPoint': {'lat': 34.05223, 'lon': -118.24368}}, {'facility': 'Community Clinical Trials', 'status': 'RECRUITING', 'city': 'Orange', 'state': 'California', 'zip': '92868', 'country': 'United States', 'geoPoint': {'lat': 33.78779, 'lon': -117.85311}}, {'facility': 'Zuckerberg San Francisco General Hospital', 'status': 'RECRUITING', 'city': 'San Francisco', 'state': 'California', 'zip': '94110', 'country': 'United States', 'geoPoint': {'lat': 37.77493, 'lon': -122.41942}}, {'facility': 'University of California, San Francisco', 'status': 'RECRUITING', 'city': 'San Francisco', 'state': 'California', 'zip': '94158', 'country': 'United States', 'geoPoint': {'lat': 37.77493, 'lon': -122.41942}}, {'facility': 'UC Health Oncology Research', 'status': 'RECRUITING', 'city': 'Colorado Springs', 'state': 'Colorado', 'zip': '80909', 'country': 'United States', 'geoPoint': {'lat': 38.83388, 'lon': -104.82136}}, {'facility': 'Yale Cancer Center', 'status': 'RECRUITING', 'city': 'New Haven', 'state': 'Connecticut', 'zip': '06519', 'country': 'United States', 'geoPoint': {'lat': 41.30815, 'lon': -72.92816}}, {'facility': 'Bay Pines Foundation Inc', 'status': 'RECRUITING', 'city': 'Bay Pines', 'state': 'Florida', 'zip': '33744', 'country': 'United States', 'geoPoint': {'lat': 27.81419, 'lon': -82.77816}}, {'facility': 'Florida Cancer Specialists', 'status': 'RECRUITING', 'city': 'Fort Myers', 'state': 'Florida', 'zip': '33901', 'country': 'United States', 'geoPoint': {'lat': 26.62168, 'lon': -81.84059}}, {'facility': 'University of Miami', 'status': 'RECRUITING', 'city': 'Miami', 'state': 'Florida', 'zip': '33136', 'country': 'United States', 'geoPoint': {'lat': 25.77427, 'lon': -80.19366}}, {'facility': 'Cancer Specialists of North Florida', 'status': 'RECRUITING', 'city': 'Saint Augustine', 'state': 'Florida', 'zip': '32086', 'country': 'United States', 'geoPoint': {'lat': 29.89469, 'lon': -81.31452}}, {'facility': 'Florida Cancer Specialists.', 'status': 'RECRUITING', 'city': 'Saint Petersburg', 'state': 'Florida', 'zip': '33705', 'country': 'United States', 'geoPoint': {'lat': 27.77086, 'lon': -82.67927}}, {'facility': 'Florida Cancer Specialists', 'status': 'RECRUITING', 'city': 'West Palm Beach', 'state': 'Florida', 'zip': '33401', 'country': 'United States', 'geoPoint': {'lat': 26.71534, 'lon': -80.05337}}, {'facility': 'University Cancer & Blood Center, LLC', 'status': 'RECRUITING', 'city': 'Athens', 'state': 'Georgia', 'zip': '30607', 'country': 'United States', 'geoPoint': {'lat': 33.96095, 'lon': -83.37794}}, {'facility': 'Summit Cancer Care PC', 'status': 'RECRUITING', 'city': 'Savannah', 'state': 'Georgia', 'zip': '31405', 'country': 'United States', 'geoPoint': {'lat': 32.08354, 'lon': -81.09983}}, {'facility': 'Rush University Medical Center', 'status': 'RECRUITING', 'city': 'Chicago', 'state': 'Illinois', 'zip': '60612-3244', 'country': 'United States', 'geoPoint': {'lat': 41.85003, 'lon': -87.65005}}, {'facility': 'University of Chicago Medical Center', 'status': 'RECRUITING', 'city': 'Chicago', 'state': 'Illinois', 'zip': '60637', 'country': 'United States', 'geoPoint': {'lat': 41.85003, 'lon': -87.65005}}, {'facility': 'IU Health Ball Memorial Hospital', 'status': 'RECRUITING', 'city': 'Muncie', 'state': 'Indiana', 'zip': '47303', 'country': 'United States', 'geoPoint': {'lat': 40.19338, 'lon': -85.38636}}, {'facility': 'Mission Cancer + Blood - IMMC', 'status': 'RECRUITING', 'city': 'Waukee', 'state': 'Iowa', 'zip': '50263', 'country': 'United States', 'geoPoint': {'lat': 41.61166, 'lon': -93.88523}}, {'facility': 'Baptist Health Lexington', 'status': 'RECRUITING', 'city': 'Lexington', 'state': 'Kentucky', 'zip': '40503', 'country': 'United States', 'geoPoint': {'lat': 37.98869, 'lon': -84.47772}}, {'facility': 'Norton Cancer Institute- Poplar', 'status': 'RECRUITING', 'city': 'Louisville', 'state': 'Kentucky', 'zip': '40217', 'country': 'United States', 'geoPoint': {'lat': 38.25424, 'lon': -85.75941}}, {'facility': 'VA Shreveport Healthcare System', 'status': 'RECRUITING', 'city': 'Shreveport', 'state': 'Louisiana', 'zip': '71101', 'country': 'United States', 'geoPoint': {'lat': 32.52515, 'lon': -93.75018}}, {'facility': 'New England Cancer Specialists', 'status': 'RECRUITING', 'city': 'Scarborough', 'state': 'Maine', 'zip': '04074', 'country': 'United States', 'geoPoint': {'lat': 43.57814, 'lon': -70.32172}}, {'facility': 'Beth Israel Deaconess Medical Center', 'status': 'RECRUITING', 'city': 'Boston', 'state': 'Massachusetts', 'zip': '02215', 'country': 'United States', 'geoPoint': {'lat': 42.35843, 'lon': -71.05977}}, {'facility': 'Dana Farber Cancer Institute', 'status': 'RECRUITING', 'city': 'Boston', 'state': 'Massachusetts', 'zip': '02215', 'country': 'United States', 'geoPoint': {'lat': 42.35843, 'lon': -71.05977}}, {'facility': 'Dana Farber/Harvard Cancer Center (Foxborough)', 'status': 'RECRUITING', 'city': 'Foxboro', 'state': 'Massachusetts', 'zip': '02035', 'country': 'United States', 'geoPoint': {'lat': 42.06538, 'lon': -71.24783}}, {'facility': 'Dana-Farber Cancer Institute', 'status': 'RECRUITING', 'city': 'Methuen', 'state': 'Massachusetts', 'zip': '01844', 'country': 'United States', 'geoPoint': {'lat': 42.7262, 'lon': -71.19089}}, {'facility': 'University of Michigan', 'status': 'RECRUITING', 'city': 'Ann Arbor', 'state': 'Michigan', 'zip': '48109-0934', 'country': 'United States', 'geoPoint': {'lat': 42.27756, 'lon': -83.74088}}, {'facility': 'Henry Ford Health System;Clinical Trials Office', 'status': 'RECRUITING', 'city': 'Detroit', 'state': 'Michigan', 'zip': '48202', 'country': 'United States', 'geoPoint': {'lat': 42.33143, 'lon': -83.04575}}, {'facility': 'Cancer and Hematology Centers of Western Michigan', 'status': 'RECRUITING', 'city': 'Grand Rapids', 'state': 'Michigan', 'zip': '49503', 'country': 'United States', 'geoPoint': {'lat': 42.96336, 'lon': -85.66809}}, {'facility': 'Nebraska Methodist Estabrook Cancer Center', 'status': 'RECRUITING', 'city': 'Omaha', 'state': 'Nebraska', 'zip': '68114', 'country': 'United States', 'geoPoint': {'lat': 41.25626, 'lon': -95.94043}}, {'facility': 'Renown Regional Medical Center Hospital', 'status': 'RECRUITING', 'city': 'Reno', 'state': 'Nevada', 'zip': '89502-1576', 'country': 'United States', 'geoPoint': {'lat': 39.52963, 'lon': -119.8138}}, {'facility': 'New York Cancer & Blood Specialists', 'status': 'RECRUITING', 'city': 'Bronx', 'state': 'New York', 'zip': '10469', 'country': 'United States', 'geoPoint': {'lat': 40.84985, 'lon': -73.86641}}, {'facility': 'New York Cancer & Blood Specialists - New Hyde Park', 'status': 'RECRUITING', 'city': 'New Hyde Park', 'state': 'New York', 'zip': '11042-1116', 'country': 'United States', 'geoPoint': {'lat': 40.7351, 'lon': -73.68791}}, {'facility': 'New York Cancer and Blood Specialists-Central Park Hematology & Oncology', 'status': 'RECRUITING', 'city': 'New York', 'state': 'New York', 'zip': '10028', 'country': 'United States', 'geoPoint': {'lat': 40.71427, 'lon': -74.00597}}, {'facility': 'Mount SInai Medical Center', 'status': 'RECRUITING', 'city': 'New York', 'state': 'New York', 'zip': '10029', 'country': 'United States', 'geoPoint': {'lat': 40.71427, 'lon': -74.00597}}, {'facility': 'Columbia University Medical Center', 'status': 'RECRUITING', 'city': 'New York', 'state': 'New York', 'zip': '10032', 'country': 'United States', 'geoPoint': {'lat': 40.71427, 'lon': -74.00597}}, {'facility': 'North Shore Hematology Oncology Associates P.C. DBA New York Cancer and Blood Specialists', 'status': 'RECRUITING', 'city': 'Shirley', 'state': 'New York', 'zip': '11967', 'country': 'United States', 'geoPoint': {'lat': 40.80149, 'lon': -72.8676}}, {'facility': 'University of North Carolina At Chapel Hill', 'status': 'RECRUITING', 'city': 'Chapel Hill', 'state': 'North Carolina', 'zip': '27514', 'country': 'United States', 'geoPoint': {'lat': 35.9132, 'lon': -79.05584}}, {'facility': 'East Carolina University', 'status': 'RECRUITING', 'city': 'Greenville', 'state': 'North Carolina', 'zip': '27834', 'country': 'United States', 'geoPoint': {'lat': 35.61266, 'lon': -77.36635}}, {'facility': 'Firsthealth of The Carolinas', 'status': 'RECRUITING', 'city': 'Pinehurst', 'state': 'North Carolina', 'zip': '28374', 'country': 'United States', 'geoPoint': {'lat': 35.19543, 'lon': -79.46948}}, {'facility': 'Ohio State University Comprehensive Cancer Center', 'status': 'RECRUITING', 'city': 'Columbus', 'state': 'Ohio', 'zip': '43210', 'country': 'United States', 'geoPoint': {'lat': 39.96118, 'lon': -82.99879}}, {'facility': 'SCRI Mark H. Zangmeister Center', 'status': 'RECRUITING', 'city': 'Columbus', 'state': 'Ohio', 'zip': '43219', 'country': 'United States', 'geoPoint': {'lat': 39.96118, 'lon': -82.99879}}, {'facility': 'Taylor Cancer Research Center', 'status': 'RECRUITING', 'city': 'Maumee', 'state': 'Ohio', 'zip': '43537', 'country': 'United States', 'geoPoint': {'lat': 41.56283, 'lon': -83.65382}}, {'facility': 'Oncology Associates of Oregon, P.C', 'status': 'RECRUITING', 'city': 'Eugene', 'state': 'Oregon', 'zip': '97401', 'country': 'United States', 'geoPoint': {'lat': 44.05207, 'lon': -123.08675}}, {'facility': 'Oregon Health & Science University', 'status': 'RECRUITING', 'city': 'Portland', 'state': 'Oregon', 'zip': '97239', 'country': 'United States', 'geoPoint': {'lat': 45.52345, 'lon': -122.67621}}, {'facility': 'Fox Chase Cancer Center', 'status': 'RECRUITING', 'city': 'Philadelphia', 'state': 'Pennsylvania', 'zip': '19111', 'country': 'United States', 'geoPoint': {'lat': 39.95233, 'lon': -75.16379}}, {'facility': 'Allegheny Cancer Center', 'status': 'RECRUITING', 'city': 'Pittsburgh', 'state': 'Pennsylvania', 'zip': '15212', 'country': 'United States', 'geoPoint': {'lat': 40.44062, 'lon': -79.99589}}, {'facility': 'Gibbs Cancer Center & Research Institute', 'status': 'RECRUITING', 'city': 'Spartanburg', 'state': 'South Carolina', 'zip': '29303', 'country': 'United States', 'geoPoint': {'lat': 34.94957, 'lon': -81.93205}}, {'facility': 'Avera Cancer Institute', 'status': 'RECRUITING', 'city': 'Sioux Falls', 'state': 'South Dakota', 'zip': '57105', 'country': 'United States', 'geoPoint': {'lat': 43.54997, 'lon': -96.70033}}, {'facility': 'Tennessee Oncology, PLLC - Chattanooga', 'status': 'RECRUITING', 'city': 'Chattanooga', 'state': 'Tennessee', 'zip': '37404', 'country': 'United States', 'geoPoint': {'lat': 35.04563, 'lon': -85.30968}}, {'facility': 'Baptist Clinical Research Institute', 'status': 'RECRUITING', 'city': 'Memphis', 'state': 'Tennessee', 'zip': '38120', 'country': 'United States', 'geoPoint': {'lat': 35.14953, 'lon': -90.04898}}, {'facility': 'Tennessee Oncology', 'status': 'RECRUITING', 'city': 'Nashville', 'state': 'Tennessee', 'zip': '37203', 'country': 'United States', 'geoPoint': {'lat': 36.16589, 'lon': -86.78444}}, {'facility': 'JPS Health Network', 'status': 'RECRUITING', 'city': 'Fort Worth', 'state': 'Texas', 'zip': '76104', 'country': 'United States', 'geoPoint': {'lat': 32.72541, 'lon': -97.32085}}, {'facility': 'MD Anderson Cancer Center', 'status': 'RECRUITING', 'city': 'Houston', 'state': 'Texas', 'zip': '77030', 'country': 'United States', 'geoPoint': {'lat': 29.76328, 'lon': -95.36327}}, {'facility': 'Texas Oncology - Northeast Texas', 'status': 'RECRUITING', 'city': 'Longview', 'state': 'Texas', 'zip': '75601', 'country': 'United States', 'geoPoint': {'lat': 32.5007, 'lon': -94.74049}}, {'facility': 'Virginia Commonwealth University - Massey Cancer Center', 'status': 'RECRUITING', 'city': 'Richmond', 'state': 'Virginia', 'zip': '23298-0042', 'country': 'United States', 'geoPoint': {'lat': 37.55376, 'lon': -77.46026}}, {'facility': 'Hospital Britanico', 'status': 'ACTIVE_NOT_RECRUITING', 'city': 'Buenos Aires', 'zip': 'C1280AEB', 'country': 'Argentina', 'geoPoint': {'lat': -34.61315, 'lon': -58.37723}}, {'facility': 'Centro Oncologico Korben', 'status': 'ACTIVE_NOT_RECRUITING', 'city': 'Ciudad Autonoma Buenos Aires', 'zip': 'C1426AGE', 'country': 'Argentina', 'geoPoint': {'lat': -34.61315, 'lon': -58.37723}}, {'facility': 'Clinica Adventista Belgrano', 'status': 'WITHDRAWN', 'city': 'Ciudad Autonoma Buenos Aires', 'zip': 'C1430EGF', 'country': 'Argentina', 'geoPoint': {'lat': -34.61315, 'lon': -58.37723}}, {'facility': 'Sanatorio Parque S.A.', 'status': 'WITHDRAWN', 'city': 'Rosario', 'zip': 'S2000QGB', 'country': 'Argentina', 'geoPoint': {'lat': -32.94682, 'lon': -60.63932}}, {'facility': 'Kinghorn Cancer Centre', 'status': 'ACTIVE_NOT_RECRUITING', 'city': 'Darlinghurst', 'state': 'New South Wales', 'zip': '2010', 'country': 'Australia', 'geoPoint': {'lat': -33.87939, 'lon': 151.21925}}, {'facility': 'Liverpool Hospital', 'status': 'ACTIVE_NOT_RECRUITING', 'city': 'Liverpool', 'state': 'New South Wales', 'zip': '2170', 'country': 'Australia', 'geoPoint': {'lat': -33.90011, 'lon': 150.93328}}, {'facility': 'GenesisCare North Shore', 'status': 'ACTIVE_NOT_RECRUITING', 'city': 'St Leonards', 'state': 'New South Wales', 'zip': '2065', 'country': 'Australia', 'geoPoint': {'lat': -33.82344, 'lon': 151.19836}}, {'facility': 'Sunshine Coast University Hospital', 'status': 'ACTIVE_NOT_RECRUITING', 'city': 'Birtinya', 'state': 'Queensland', 'zip': '4575', 'country': 'Australia', 'geoPoint': {'lat': -26.74322, 'lon': 153.11913}}, {'facility': 'Lyell McEwin Hospital', 'status': 'ACTIVE_NOT_RECRUITING', 'city': 'Elizabeth Vale', 'state': 'South Australia', 'zip': '5112', 'country': 'Australia', 'geoPoint': {'lat': -34.74857, 'lon': 138.66819}}, {'facility': 'Peter Maccallum Cancer Centre', 'status': 'ACTIVE_NOT_RECRUITING', 'city': 'Melbourne', 'state': 'Victoria', 'zip': '3000', 'country': 'Australia', 'geoPoint': {'lat': -37.814, 'lon': 144.96332}}, {'facility': 'Klinik Penzing', 'status': 'WITHDRAWN', 'city': 'Wien', 'zip': '1140', 'country': 'Austria', 'geoPoint': {'lat': 48.20849, 'lon': 16.37208}}, {'facility': 'Institut für Lungenforschung Wien', 'status': 'RECRUITING', 'city': 'Wien', 'zip': '1160', 'country': 'Austria', 'geoPoint': {'lat': 48.20849, 'lon': 16.37208}}, {'facility': 'Krankenhaus Nord - Klinik Floridsdorf', 'status': 'ACTIVE_NOT_RECRUITING', 'city': 'Wien', 'zip': '1210', 'country': 'Austria', 'geoPoint': {'lat': 48.20849, 'lon': 16.37208}}, {'facility': 'AZORG Campus Aalst-Moorselbaan', 'status': 'ACTIVE_NOT_RECRUITING', 'city': 'Aalst', 'zip': '9300', 'country': 'Belgium', 'geoPoint': {'lat': 50.93604, 'lon': 4.0355}}, {'facility': 'UZ Brussel', 'status': 'ACTIVE_NOT_RECRUITING', 'city': 'Brussel', 'zip': '1090', 'country': 'Belgium', 'geoPoint': {'lat': 50.85045, 'lon': 4.34878}}, {'facility': 'Cliniques Universitaires St-Luc', 'status': 'ACTIVE_NOT_RECRUITING', 'city': 'Bruxelles', 'zip': '1200', 'country': 'Belgium', 'geoPoint': {'lat': 50.85045, 'lon': 4.34878}}, {'facility': 'UZ Antwerpen', 'status': 'ACTIVE_NOT_RECRUITING', 'city': 'Edegem', 'zip': '2650', 'country': 'Belgium', 'geoPoint': {'lat': 51.15662, 'lon': 4.44504}}, {'facility': 'Jessa Zkh (Campus Virga Jesse)', 'status': 'ACTIVE_NOT_RECRUITING', 'city': 'Hasselt', 'zip': '3500', 'country': 'Belgium', 'geoPoint': {'lat': 50.93106, 'lon': 5.33781}}, {'facility': 'CHU de Liège (Sart Tilman)', 'status': 'ACTIVE_NOT_RECRUITING', 'city': 'Liège', 'zip': '4000', 'country': 'Belgium', 'geoPoint': {'lat': 50.63373, 'lon': 5.56749}}, {'facility': 'CHU UCL Mont-Godinne', 'status': 'ACTIVE_NOT_RECRUITING', 'city': 'Mont-godinne', 'zip': '5530', 'country': 'Belgium'}, {'facility': 'AZ Delta (Campus Rumbeke)', 'status': 'ACTIVE_NOT_RECRUITING', 'city': 'Roeselare', 'zip': '8800', 'country': 'Belgium', 'geoPoint': {'lat': 50.94653, 'lon': 3.12269}}, {'facility': 'Vitaz', 'status': 'COMPLETED', 'city': 'Sint Niklaas', 'zip': '9100', 'country': 'Belgium', 'geoPoint': {'lat': 51.16509, 'lon': 4.1437}}, {'facility': 'ZAS Sint Augustinus Wilrijk', 'status': 'ACTIVE_NOT_RECRUITING', 'city': 'Wilrijk', 'zip': '2610', 'country': 'Belgium', 'geoPoint': {'lat': 51.16734, 'lon': 4.39513}}, {'facility': 'Hospital Sao Rafael - HSR', 'status': 'RECRUITING', 'city': 'Salvador', 'state': 'Bahia', 'zip': '41253-190', 'country': 'Brazil', 'geoPoint': {'lat': -12.97111, 'lon': -38.51083}}, {'facility': 'Hospital Brasilia', 'status': 'RECRUITING', 'city': 'Brasilia', 'state': 'Distrito Federal', 'zip': '71635580', 'country': 'Brazil', 'geoPoint': {'lat': -15.77972, 'lon': -47.92972}}, {'facility': 'Clinica Onconeo', 'status': 'RECRUITING', 'city': 'Campo Grande', 'state': 'Mato Grosso Do Sul', 'zip': '79002-061', 'country': 'Brazil', 'geoPoint': {'lat': -20.44278, 'lon': -54.64639}}, {'facility': 'Santa Casa de Misericordia de Porto Alegre', 'status': 'ACTIVE_NOT_RECRUITING', 'city': 'Porto Alegre', 'state': 'Rio Grande Do Sul', 'zip': '90020-090', 'country': 'Brazil', 'geoPoint': {'lat': -30.03306, 'lon': -51.23}}, {'facility': 'Hospital Nossa Senhora da Conceicao', 'status': 'ACTIVE_NOT_RECRUITING', 'city': 'Porto Alegre', 'state': 'Rio Grande Do Sul', 'zip': '90040-373', 'country': 'Brazil', 'geoPoint': {'lat': -30.03306, 'lon': -51.23}}, {'facility': 'Hospital Mae de Deus', 'status': 'ACTIVE_NOT_RECRUITING', 'city': 'Porto Alegre', 'state': 'Rio Grande Do Sul', 'zip': '90110-000', 'country': 'Brazil', 'geoPoint': {'lat': -30.03306, 'lon': -51.23}}, {'facility': 'Hospital de Cancer de Barretos', 'status': 'RECRUITING', 'city': 'Barretos', 'state': 'São Paulo', 'zip': '14784-400', 'country': 'Brazil', 'geoPoint': {'lat': -20.55722, 'lon': -48.56778}}, {'facility': 'Hospital de Base de Sao Jose do Rio Preto', 'status': 'RECRUITING', 'city': 'Sao Jose do Rio Preto', 'state': 'São Paulo', 'zip': '15090-000', 'country': 'Brazil', 'geoPoint': {'lat': -20.81972, 'lon': -49.37944}}, {'facility': 'Hospital Sírio-Libanês', 'status': 'RECRUITING', 'city': 'Sao Paulo', 'state': 'São Paulo', 'zip': '01308-050', 'country': 'Brazil', 'geoPoint': {'lat': -23.5475, 'lon': -46.63611}}, {'facility': 'Hospital Alemao Oswaldo Cruz', 'status': 'RECRUITING', 'city': 'Sao Paulo', 'state': 'São Paulo', 'zip': '01323-903', 'country': 'Brazil', 'geoPoint': {'lat': -23.5475, 'lon': -46.63611}}, {'facility': 'Oncoclinicas Rio de Janeiro S.A.', 'status': 'RECRUITING', 'city': 'Rio de Janeiro', 'zip': '22250-905', 'country': 'Brazil', 'geoPoint': {'lat': -22.90278, 'lon': -43.2075}}, {'facility': 'William Osler Health Centre - Brampton Civic Hospital', 'status': 'RECRUITING', 'city': 'Brampton', 'state': 'Ontario', 'zip': 'L6R 3J7', 'country': 'Canada', 'geoPoint': {'lat': 43.68341, 'lon': -79.76633}}, {'facility': 'Princess Margaret Cancer Center', 'status': 'RECRUITING', 'city': 'Toronto', 'state': 'Ontario', 'zip': 'M5G 2M9', 'country': 'Canada', 'geoPoint': {'lat': 43.70011, 'lon': -79.4163}}, {'facility': 'Jewish General Hospital', 'status': 'RECRUITING', 'city': 'Montreal', 'state': 'Quebec', 'zip': 'H3T 1E2', 'country': 'Canada', 'geoPoint': {'lat': 45.50884, 'lon': -73.58781}}, {'facility': 'Aarhus Universitetshospital', 'status': 'ACTIVE_NOT_RECRUITING', 'city': 'Aarhus N', 'zip': '8200', 'country': 'Denmark', 'geoPoint': {'lat': 56.15674, 'lon': 10.21076}}, {'facility': 'Herlev Hospital', 'status': 'ACTIVE_NOT_RECRUITING', 'city': 'Herlev', 'zip': '2730', 'country': 'Denmark', 'geoPoint': {'lat': 55.72366, 'lon': 12.43998}}, {'facility': 'Regionshospitalet Gødstrup', 'status': 'COMPLETED', 'city': 'Herning', 'zip': '7400', 'country': 'Denmark', 'geoPoint': {'lat': 56.13932, 'lon': 8.97378}}, {'facility': 'Helsinki University Central Hospital', 'status': 'ACTIVE_NOT_RECRUITING', 'city': 'Helsinki', 'zip': '00029', 'country': 'Finland', 'geoPoint': {'lat': 60.16952, 'lon': 24.93545}}, {'facility': 'Kuopio Uni Hospital', 'status': 'ACTIVE_NOT_RECRUITING', 'city': 'Kuopio', 'zip': '70211', 'country': 'Finland', 'geoPoint': {'lat': 62.89238, 'lon': 27.67703}}, {'facility': 'Turku Uni Central Hospital', 'status': 'RECRUITING', 'city': 'Turku', 'zip': '20520', 'country': 'Finland', 'geoPoint': {'lat': 60.45148, 'lon': 22.26869}}, {'facility': 'CHU Angers', 'status': 'RECRUITING', 'city': 'Angers', 'zip': '49933', 'country': 'France', 'geoPoint': {'lat': 47.46667, 'lon': -0.55}}, {'facility': 'CHRU Brest', 'status': 'RECRUITING', 'city': 'Brest', 'zip': '29200', 'country': 'France', 'geoPoint': {'lat': 48.3903, 'lon': -4.48628}}, {'facility': 'Chu Toulouse', 'status': 'RECRUITING', 'city': 'Bron', 'zip': '69500', 'country': 'France', 'geoPoint': {'lat': 45.73333, 'lon': 4.91667}}, {'facility': 'Hopital Louis Pradel', 'status': 'RECRUITING', 'city': 'Bron', 'zip': '69677', 'country': 'France', 'geoPoint': {'lat': 45.73333, 'lon': 4.91667}}, {'facility': 'CHRU Lille', 'status': 'RECRUITING', 'city': 'Lille', 'zip': '59037', 'country': 'France', 'geoPoint': {'lat': 50.63297, 'lon': 3.05858}}, {'facility': 'Centre Leon Berard', 'status': 'RECRUITING', 'city': 'Lyon', 'zip': '69373', 'country': 'France', 'geoPoint': {'lat': 45.74848, 'lon': 4.84669}}, {'facility': 'CHU Montpellier', 'status': 'RECRUITING', 'city': 'Montpellier', 'zip': '34295', 'country': 'France', 'geoPoint': {'lat': 43.61092, 'lon': 3.87723}}, {'facility': 'Centre Antoine Lacassagne Centre Régional de Lutte Contre Le Cancer', 'status': 'RECRUITING', 'city': 'Nice', 'zip': '06100', 'country': 'France', 'geoPoint': {'lat': 43.70313, 'lon': 7.26608}}, {'facility': 'Hopital Tenon', 'status': 'RECRUITING', 'city': 'Paris', 'zip': '75970', 'country': 'France', 'geoPoint': {'lat': 48.85341, 'lon': 2.3488}}, {'facility': 'CHU Bordeaux', 'status': 'RECRUITING', 'city': 'Pessac', 'zip': '33604', 'country': 'France', 'geoPoint': {'lat': 44.81011, 'lon': -0.64129}}, {'facility': 'CH de Saint Quentin', 'status': 'RECRUITING', 'city': 'Saint Quentin', 'zip': '2100', 'country': 'France', 'geoPoint': {'lat': 49.84889, 'lon': 3.28757}}, {'facility': 'Chru de Strasbourg', 'status': 'RECRUITING', 'city': 'Strasbourg', 'zip': '67091', 'country': 'France', 'geoPoint': {'lat': 48.58392, 'lon': 7.74553}}, {'facility': 'Hia Sainte Anne', 'status': 'RECRUITING', 'city': 'Toulon', 'zip': '83041', 'country': 'France', 'geoPoint': {'lat': 43.12442, 'lon': 5.92836}}, {'facility': 'Evangelische Lungenklinik Berlin', 'status': 'RECRUITING', 'city': 'Berlin', 'zip': '13125', 'country': 'Germany', 'geoPoint': {'lat': 52.52437, 'lon': 13.41053}}, {'facility': 'Charité Universitätsmedizin Berlin, Med Klinik Infekto und Pneumo', 'status': 'RECRUITING', 'city': 'Berlin', 'zip': '13353', 'country': 'Germany', 'geoPoint': {'lat': 52.52437, 'lon': 13.41053}}, {'facility': 'Helios Klinikum Emil von Behring GmbH', 'status': 'RECRUITING', 'city': 'Berlin', 'zip': '14165', 'country': 'Germany', 'geoPoint': {'lat': 52.52437, 'lon': 13.41053}}, {'facility': 'Klinikum Braunschweig', 'status': 'RECRUITING', 'city': 'Braunschweig', 'zip': '38114', 'country': 'Germany', 'geoPoint': {'lat': 52.26594, 'lon': 10.52673}}, {'facility': 'KEM/Evang. Kliniken Essen Mitte gGmbH', 'status': 'RECRUITING', 'city': 'Essen', 'zip': '45136', 'country': 'Germany', 'geoPoint': {'lat': 51.45657, 'lon': 7.01228}}, {'facility': 'Universitätsklinikum Essen', 'status': 'RECRUITING', 'city': 'Essen', 'zip': '45147', 'country': 'Germany', 'geoPoint': {'lat': 51.45657, 'lon': 7.01228}}, {'facility': 'Klinikum Esslingen', 'status': 'RECRUITING', 'city': 'Esslingen', 'zip': '73730', 'country': 'Germany', 'geoPoint': {'lat': 48.73961, 'lon': 9.30473}}, {'facility': 'Asklepios Fachkliniken GmbH', 'status': 'RECRUITING', 'city': 'Gauting', 'zip': '82131', 'country': 'Germany', 'geoPoint': {'lat': 48.06919, 'lon': 11.37703}}, {'facility': 'LungenClinic Großhansdorf GmbH', 'status': 'RECRUITING', 'city': 'Großhansdorf', 'zip': '22927', 'country': 'Germany', 'geoPoint': {'lat': 53.66667, 'lon': 10.28333}}, {'facility': 'Krankenhaus Martha-Maria Halle-Doelau gGmbH', 'status': 'RECRUITING', 'city': 'Halle', 'zip': '06120', 'country': 'Germany', 'geoPoint': {'lat': 51.48159, 'lon': 11.97948}}, {'facility': 'Thoraxklinik Heidelberg gGmbH', 'status': 'RECRUITING', 'city': 'Heidelberg', 'zip': '69126', 'country': 'Germany', 'geoPoint': {'lat': 49.40768, 'lon': 8.69079}}, {'facility': 'Lungenklinik Hemer', 'status': 'RECRUITING', 'city': 'Hemer', 'zip': '58675', 'country': 'Germany', 'geoPoint': {'lat': 51.38707, 'lon': 7.77019}}, {'facility': 'Universität Des Saarlandes', 'status': 'RECRUITING', 'city': 'Homburg', 'zip': '66421', 'country': 'Germany', 'geoPoint': {'lat': 49.32637, 'lon': 7.33867}}, {'facility': 'Lungenfachklinik Immenhausen', 'status': 'RECRUITING', 'city': 'Immenhausen', 'zip': '34376', 'country': 'Germany', 'geoPoint': {'lat': 51.42763, 'lon': 9.48017}}, {'facility': 'Uniklinik Schleswig-Holstein', 'status': 'RECRUITING', 'city': 'Kiel', 'zip': '24116', 'country': 'Germany', 'geoPoint': {'lat': 54.32133, 'lon': 10.13489}}, {'facility': 'Klinikum Koeln-Merheim', 'status': 'RECRUITING', 'city': 'Köln', 'zip': '51109', 'country': 'Germany', 'geoPoint': {'lat': 50.93333, 'lon': 6.95}}, {'facility': 'SLK Kliniken Heilbronn GmbH, Standort Fachklinik Löwenstein', 'status': 'RECRUITING', 'city': 'Löwenstein', 'zip': '74245', 'country': 'Germany', 'geoPoint': {'lat': 49.0954, 'lon': 9.38069}}, {'facility': 'Universitätsklinikum Schleswig-Holstein', 'status': 'RECRUITING', 'city': 'Lübeck', 'zip': '23538', 'country': 'Germany', 'geoPoint': {'lat': 53.86893, 'lon': 10.68729}}, {'facility': 'Universität Mannheim', 'status': 'RECRUITING', 'city': 'Mannheim', 'zip': '68167', 'country': 'Germany', 'geoPoint': {'lat': 49.4891, 'lon': 8.46694}}, {'facility': 'Klinikum Bogenhausen', 'status': 'RECRUITING', 'city': 'München', 'zip': '81925', 'country': 'Germany', 'geoPoint': {'lat': 48.13743, 'lon': 11.57549}}, {'facility': 'Universitätsklinikum Münster, Medizinische Klinik A, Translationale Onkologie', 'status': 'RECRUITING', 'city': 'Münster', 'zip': '48149', 'country': 'Germany', 'geoPoint': {'lat': 51.96236, 'lon': 7.62571}}, {'facility': 'Pius Hospital Oldenburg', 'status': 'ACTIVE_NOT_RECRUITING', 'city': 'Oldenburg', 'zip': '26121', 'country': 'Germany', 'geoPoint': {'lat': 53.14118, 'lon': 8.21467}}, {'facility': 'Universitätsklinikum Regensburg', 'status': 'RECRUITING', 'city': 'Regensburg', 'zip': '93053', 'country': 'Germany', 'geoPoint': {'lat': 49.01513, 'lon': 12.10161}}, {'facility': 'Klinikum Würzburg Mitte gGmbH', 'status': 'RECRUITING', 'city': 'Würzburg', 'zip': '97074', 'country': 'Germany', 'geoPoint': {'lat': 49.79391, 'lon': 9.95121}}, {'facility': 'Uoa Sotiria Hospital', 'status': 'ACTIVE_NOT_RECRUITING', 'city': 'Athens', 'zip': '115 27', 'country': 'Greece', 'geoPoint': {'lat': 37.97945, 'lon': 23.71622}}, {'facility': 'Errikos Dynan Hospital', 'status': 'ACTIVE_NOT_RECRUITING', 'city': 'Athens', 'zip': '11526', 'country': 'Greece', 'geoPoint': {'lat': 37.97945, 'lon': 23.71622}}, {'facility': 'Metropolitan Hospital Fourth Oncology Clinic', 'status': 'WITHDRAWN', 'city': 'Faliro', 'zip': '185 47', 'country': 'Greece'}, {'facility': 'University Hospital of Larissa', 'status': 'ACTIVE_NOT_RECRUITING', 'city': 'Larissa', 'zip': '411 10', 'country': 'Greece', 'geoPoint': {'lat': 39.63689, 'lon': 22.41761}}, {'facility': 'Theageneio Hospital', 'status': 'ACTIVE_NOT_RECRUITING', 'city': 'Thessaloniki', 'zip': '546 39', 'country': 'Greece', 'geoPoint': {'lat': 40.64361, 'lon': 22.93086}}, {'facility': 'Ag. Loukas Hospital', 'status': 'ACTIVE_NOT_RECRUITING', 'city': 'Thessaloniki', 'zip': '55236', 'country': 'Greece', 'geoPoint': {'lat': 40.64361, 'lon': 22.93086}}, {'facility': 'Hong Kong Integrated Oncology Centre', 'status': 'RECRUITING', 'city': 'Hong Kong', 'country': 'Hong Kong', 'geoPoint': {'lat': 22.27832, 'lon': 114.17469}}, {'facility': 'Queen Mary Hospital', 'status': 'ACTIVE_NOT_RECRUITING', 'city': 'Hong Kong', 'country': 'Hong Kong', 'geoPoint': {'lat': 22.27832, 'lon': 114.17469}}, {'facility': 'Tuen Mun Hospital', 'status': 'ACTIVE_NOT_RECRUITING', 'city': 'Hong Kong', 'country': 'Hong Kong', 'geoPoint': {'lat': 22.27832, 'lon': 114.17469}}, {'facility': 'Prince of Wales Hosp', 'status': 'ACTIVE_NOT_RECRUITING', 'city': 'Shatin', 'country': 'Hong Kong', 'geoPoint': {'lat': 22.38333, 'lon': 114.18333}}, {'facility': 'Az. Osp. Pugliese Ciaccio', 'status': 'RECRUITING', 'city': 'Catanzaro', 'state': 'Calabria', 'zip': '88100', 'country': 'Italy', 'geoPoint': {'lat': 38.88247, 'lon': 16.60086}}, {'facility': 'AZ.Osp S. Orsola ? Malpighi-Reparto di Oncologia Medica', 'status': 'RECRUITING', 'city': 'Bologna', 'state': 'Emilia-Romagna', 'zip': '40138', 'country': 'Italy', 'geoPoint': {'lat': 44.49381, 'lon': 11.33875}}, {'facility': 'A.O. Universitaria Di Parma', 'status': 'COMPLETED', 'city': 'Parma', 'state': 'Emilia-Romagna', 'zip': '43100', 'country': 'Italy', 'geoPoint': {'lat': 44.79935, 'lon': 10.32618}}, {'facility': 'AUSL della Romagna', 'status': 'RECRUITING', 'city': 'Ravenna', 'state': 'Emilia-Romagna', 'zip': '48121', 'country': 'Italy', 'geoPoint': {'lat': 44.41344, 'lon': 12.20121}}, {'facility': 'Azienda Sanitaria Universitaria Friuli Centrale ? PO Universitario Santa Maria della Misericordia', 'status': 'RECRUITING', 'city': 'Udine', 'state': 'Friuli-Venezia Giulia', 'zip': '33100', 'country': 'Italy', 'geoPoint': {'lat': 46.0693, 'lon': 13.23715}}, {'facility': 'IRCCS Istituto Regina Elena (IFO)', 'status': 'ACTIVE_NOT_RECRUITING', 'city': 'Roma', 'state': 'Lazio', 'zip': '00144', 'country': 'Italy', 'geoPoint': {'lat': 41.89193, 'lon': 12.51133}}, {'facility': 'Ospedale Policlinico San Martino', 'status': 'ACTIVE_NOT_RECRUITING', 'city': 'Genova', 'state': 'Liguria', 'zip': '16132', 'country': 'Italy', 'geoPoint': {'lat': 44.40478, 'lon': 8.94438}}, {'facility': 'Asst Papa Giovanni XXIII', 'status': 'RECRUITING', 'city': 'Bergamo', 'state': 'Lombardia', 'zip': '24100', 'country': 'Italy', 'geoPoint': {'lat': 45.69601, 'lon': 9.66721}}, {'facility': 'IRCCS Istituto Clinico Humanitas', 'status': 'RECRUITING', 'city': 'Rozzano (MI)', 'state': 'Lombardia', 'zip': '20089', 'country': 'Italy', 'geoPoint': {'lat': 45.38193, 'lon': 9.1559}}, {'facility': 'A.O.U. Maggiore della Carità', 'status': 'RECRUITING', 'city': 'Novara', 'state': 'Piemonte', 'zip': '28100', 'country': 'Italy', 'geoPoint': {'lat': 45.44694, 'lon': 8.62118}}, {'facility': 'Irccs Ist. Tumori Giovanni Paolo Ii', 'status': 'ACTIVE_NOT_RECRUITING', 'city': 'Bari', 'state': 'Puglia', 'zip': '70124', 'country': 'Italy', 'geoPoint': {'lat': 41.11148, 'lon': 16.8554}}, {'facility': 'Ospedale Civile SS Annunziata', 'status': 'ACTIVE_NOT_RECRUITING', 'city': 'Sassari', 'state': 'Sardegna', 'zip': '07100', 'country': 'Italy', 'geoPoint': {'lat': 40.72586, 'lon': 8.55552}}, {'facility': 'AO Ospedali Riuniti Villa Sofia-Cervello-Presidio Ospedaliero Cervello', 'status': 'ACTIVE_NOT_RECRUITING', 'city': 'Palermo', 'state': 'Sicilia', 'zip': '90146', 'country': 'Italy', 'geoPoint': {'lat': 38.13205, 'lon': 13.33561}}, {'facility': 'Azienda Ospedaliero-Universitaria Careggi', 'status': 'ACTIVE_NOT_RECRUITING', 'city': 'Firenze', 'state': 'Toscana', 'zip': '50139', 'country': 'Italy', 'geoPoint': {'lat': 43.77925, 'lon': 11.24626}}, {'facility': 'Azienda Ospedaliero Universitaria Pisana', 'status': 'ACTIVE_NOT_RECRUITING', 'city': 'Pisa', 'state': 'Toscana', 'zip': '56126', 'country': 'Italy', 'geoPoint': {'lat': 43.70853, 'lon': 10.4036}}, {'facility': 'IRCCS Istituto Oncologico Veneto (IOV)', 'status': 'ACTIVE_NOT_RECRUITING', 'city': 'Padova', 'state': 'Veneto', 'zip': '35128', 'country': 'Italy', 'geoPoint': {'lat': 45.40797, 'lon': 11.88586}}, {'facility': 'Shikoku Cancer Center', 'status': 'RECRUITING', 'city': 'Ehime', 'zip': '791-0280', 'country': 'Japan', 'geoPoint': {'lat': 33.63163, 'lon': 132.76886}}, {'facility': 'Kyushu University Hospital', 'status': 'RECRUITING', 'city': 'Fukuoka', 'zip': '812-8582', 'country': 'Japan', 'geoPoint': {'lat': 33.6, 'lon': 130.41667}}, {'facility': 'Hokkaido University Hospital', 'status': 'RECRUITING', 'city': 'Hokkaido', 'zip': '060-8648', 'country': 'Japan', 'geoPoint': {'lat': 43.41104, 'lon': 142.88878}}, {'facility': 'Sendai Kousei Hospital', 'status': 'RECRUITING', 'city': 'Miyagi', 'zip': '981-0914', 'country': 'Japan'}, {'facility': 'Niigata Cancer Center Hospital', 'status': 'RECRUITING', 'city': 'Niigata', 'zip': '951-8566', 'country': 'Japan', 'geoPoint': {'lat': 37.88637, 'lon': 139.00589}}, {'facility': 'Okayama University Hospital', 'status': 'RECRUITING', 'city': 'Okayama', 'zip': '700-8558', 'country': 'Japan', 'geoPoint': {'lat': 34.65, 'lon': 133.93333}}, {'facility': 'Kindai University Hospital', 'status': 'RECRUITING', 'city': 'Osaka', 'zip': '589-8511', 'country': 'Japan', 'geoPoint': {'lat': 34.69374, 'lon': 135.50218}}, {'facility': 'Shizuoka Cancer Center', 'status': 'RECRUITING', 'city': 'Shizuoka', 'zip': '411-8777', 'country': 'Japan', 'geoPoint': {'lat': 34.98333, 'lon': 138.38333}}, {'facility': 'National Cancer Center Hospital', 'status': 'RECRUITING', 'city': 'Tokyo', 'zip': '104-0045', 'country': 'Japan', 'geoPoint': {'lat': 35.6895, 'lon': 139.69171}}, {'facility': 'The Cancer Institute Hospital of JFCR', 'status': 'RECRUITING', 'city': 'Tokyo', 'zip': '135-8550', 'country': 'Japan', 'geoPoint': {'lat': 35.6895, 'lon': 139.69171}}, {'facility': 'Wakayama Medical University Hospital', 'status': 'RECRUITING', 'city': 'Wakayama', 'zip': '641-8510', 'country': 'Japan', 'geoPoint': {'lat': 34.23333, 'lon': 135.16667}}, {'facility': 'Pusan National University Hospital', 'status': 'ACTIVE_NOT_RECRUITING', 'city': 'Busan', 'zip': '602-739', 'country': 'Korea, Republic of', 'geoPoint': {'lat': 35.10278, 'lon': 129.04028}}, {'facility': 'Chungbuk National University Hospital', 'status': 'ACTIVE_NOT_RECRUITING', 'city': 'Cheongju-si', 'zip': '28644', 'country': 'Korea, Republic of', 'geoPoint': {'lat': 36.63722, 'lon': 127.48972}}, {'facility': 'Kyungpook National University Chilgok Hospital', 'status': 'ACTIVE_NOT_RECRUITING', 'city': 'Daegu', 'zip': '41404', 'country': 'Korea, Republic of', 'geoPoint': {'lat': 35.87028, 'lon': 128.59111}}, {'facility': 'Keimyung University Dongsan Medical Center', 'status': 'ACTIVE_NOT_RECRUITING', 'city': 'Daegu', 'zip': '41931', 'country': 'Korea, Republic of', 'geoPoint': {'lat': 35.87028, 'lon': 128.59111}}, {'facility': \"St. Vincent's Hospital\", 'status': 'ACTIVE_NOT_RECRUITING', 'city': 'Gyeonggi-do', 'zip': '16247', 'country': 'Korea, Republic of', 'geoPoint': {'lat': 37.58944, 'lon': 126.76917}}, {'facility': 'Pusan National University Yangsan Hospital', 'status': 'ACTIVE_NOT_RECRUITING', 'city': 'Gyeongsangnam-do', 'zip': '50612', 'country': 'Korea, Republic of'}, {'facility': 'Gachon University Gil Medical Center', 'status': 'ACTIVE_NOT_RECRUITING', 'city': 'Incheon', 'zip': '21565', 'country': 'Korea, Republic of', 'geoPoint': {'lat': 37.45646, 'lon': 126.70515}}, {'facility': 'Chonnam National University Hwasun Hospital', 'status': 'RECRUITING', 'city': 'Jeollanam-do', 'zip': '58128', 'country': 'Korea, Republic of'}, {'facility': 'Seoul National University Bundang Hospital', 'status': 'ACTIVE_NOT_RECRUITING', 'city': 'Seongnam-si', 'zip': '463-707', 'country': 'Korea, Republic of', 'geoPoint': {'lat': 37.43861, 'lon': 127.13778}}, {'facility': 'Korea University Anam Hospital', 'status': 'ACTIVE_NOT_RECRUITING', 'city': 'Seoul', 'zip': '02841', 'country': 'Korea, Republic of', 'geoPoint': {'lat': 37.566, 'lon': 126.9784}}, {'facility': 'Seoul National University Hospital', 'status': 'ACTIVE_NOT_RECRUITING', 'city': 'Seoul', 'zip': '03080', 'country': 'Korea, Republic of', 'geoPoint': {'lat': 37.566, 'lon': 126.9784}}, {'facility': 'Samsung Medical Center', 'status': 'ACTIVE_NOT_RECRUITING', 'city': 'Seoul', 'zip': '06351', 'country': 'Korea, Republic of', 'geoPoint': {'lat': 37.566, 'lon': 126.9784}}, {'facility': 'Korea University Guro Hospital', 'status': 'ACTIVE_NOT_RECRUITING', 'city': 'Seoul', 'zip': '08308', 'country': 'Korea, Republic of', 'geoPoint': {'lat': 37.566, 'lon': 126.9784}}, {'facility': 'Centro de Infusion E Investigacion Oncologia de Saltillo Sc', 'status': 'RECRUITING', 'city': 'Saltillo', 'state': 'Coahuila', 'zip': '25230', 'country': 'Mexico', 'geoPoint': {'lat': 25.42321, 'lon': -101.0053}}, {'facility': 'Hospital Civil de Guadalajara Fray Antonio Alcalde', 'status': 'RECRUITING', 'city': 'Guadalajara', 'state': 'Jalisco', 'zip': '44280', 'country': 'Mexico', 'geoPoint': {'lat': 20.66682, 'lon': -103.39182}}, {'facility': 'Clínica Integral Internacional de Oncología S de RL de CV', 'status': 'RECRUITING', 'city': 'Heroica Puebla de Zaragoza', 'state': 'Puebla', 'zip': '72530', 'country': 'Mexico', 'geoPoint': {'lat': 19.03793, 'lon': -98.20346}}, {'facility': 'PanAmerican Clinical Research, Querétaro', 'status': 'RECRUITING', 'city': 'Santiago de Querétaro', 'state': 'Queretaro', 'zip': '76100', 'country': 'Mexico', 'geoPoint': {'lat': 20.58806, 'lon': -100.38806}}, {'facility': 'ARKE Estudios Clínicos S.A. de C.V.', 'status': 'ACTIVE_NOT_RECRUITING', 'city': 'Ciudad de México', 'zip': '06700', 'country': 'Mexico', 'geoPoint': {'lat': 19.42847, 'lon': -99.12766}}, {'facility': 'Jeroen Bosch Ziekenhuis', 'status': 'ACTIVE_NOT_RECRUITING', 'city': \"'S Hertogenbosch\", 'zip': '5223 GZ', 'country': 'Netherlands', 'geoPoint': {'lat': 51.69917, 'lon': 5.30417}}, {'facility': 'Ziekenhuis Rijnstate', 'status': 'ACTIVE_NOT_RECRUITING', 'city': 'Arnhem', 'zip': '6815 AD', 'country': 'Netherlands', 'geoPoint': {'lat': 51.98, 'lon': 5.91111}}, {'facility': 'Amphia Ziekenhuis', 'status': 'RECRUITING', 'city': 'Breda', 'zip': '4818CK', 'country': 'Netherlands', 'geoPoint': {'lat': 51.58656, 'lon': 4.77596}}, {'facility': 'Ziekenhuis St. Jansdal', 'status': 'ACTIVE_NOT_RECRUITING', 'city': 'Harderwijk', 'zip': '3844 DG', 'country': 'Netherlands', 'geoPoint': {'lat': 52.34167, 'lon': 5.62083}}, {'facility': 'Medisch Centrum Haaglanden, locatie Antoniushove', 'status': 'RECRUITING', 'city': 'Leidschendam', 'zip': '2262 BA', 'country': 'Netherlands', 'geoPoint': {'lat': 52.08833, 'lon': 4.39444}}, {'facility': 'Isala', 'status': 'ACTIVE_NOT_RECRUITING', 'city': 'Zwolle', 'zip': '8025 AB', 'country': 'Netherlands', 'geoPoint': {'lat': 52.5125, 'lon': 6.09444}}, {'facility': 'Instytut \"Centrum Zdrowia Matki Polki\"', 'status': 'RECRUITING', 'city': '?ód?', 'zip': '93-338', 'country': 'Poland'}, {'facility': 'Kujawsko-Pomorskie Centrum Pulmonologii', 'status': 'RECRUITING', 'city': 'Bydgoszcz', 'zip': '85-326', 'country': 'Poland', 'geoPoint': {'lat': 53.1235, 'lon': 18.00762}}, {'facility': 'Uniwersyteckie Centrum Kliniczne, Klinika Onkologii i Radioterapii', 'status': 'RECRUITING', 'city': 'Gdansk', 'zip': '80-214', 'country': 'Poland', 'geoPoint': {'lat': 54.35205, 'lon': 18.64637}}, {'facility': 'Krakowski Szpital Specjalistyczny im sw. Jana Paw?a II', 'status': 'RECRUITING', 'city': 'Kraków', 'zip': '31-202', 'country': 'Poland', 'geoPoint': {'lat': 50.06143, 'lon': 19.93658}}, {'facility': 'Uniwersytecki Szpital Kliniczny nr 4 w Lublinie', 'status': 'RECRUITING', 'city': 'Lublin', 'zip': '20-954', 'country': 'Poland', 'geoPoint': {'lat': 51.25, 'lon': 22.56667}}, {'facility': 'Warminsko-Mazurskie Centrum Chorób P?uc w Olsztynie', 'status': 'RECRUITING', 'city': 'Olsztyn', 'zip': '10-357', 'country': 'Poland', 'geoPoint': {'lat': 53.77995, 'lon': 20.49416}}, {'facility': 'Wielkopolskie Centrum Pulmonologii i Torakochirurgii w Poznaniu', 'status': 'RECRUITING', 'city': 'Poznan', 'zip': '60-569', 'country': 'Poland', 'geoPoint': {'lat': 52.40692, 'lon': 16.92993}}, {'facility': 'Radomskie Centrum Onkologii', 'status': 'RECRUITING', 'city': 'Radom', 'zip': '26-600', 'country': 'Poland', 'geoPoint': {'lat': 51.40253, 'lon': 21.14714}}, {'facility': 'Instytut Gruzlicy I Chorob Pluc', 'status': 'RECRUITING', 'city': 'Warszawa', 'zip': '01-138', 'country': 'Poland', 'geoPoint': {'lat': 52.22977, 'lon': 21.01178}}, {'facility': 'Narod.Inst.Onkol. im. M.Sklodowskiej - Curie-Panst.Inst.Bad', 'status': 'RECRUITING', 'city': 'Warszawa', 'zip': '02-781', 'country': 'Poland', 'geoPoint': {'lat': 52.22977, 'lon': 21.01178}}, {'facility': 'Dolno?L?Skie Centrum Onkologii, Pulmonologii I Hematologii', 'status': 'RECRUITING', 'city': 'Wroc?aw', 'zip': '53-439', 'country': 'Poland'}, {'facility': 'Hospital de Braga', 'status': 'COMPLETED', 'city': 'Braga', 'zip': '4710-243', 'country': 'Portugal', 'geoPoint': {'lat': 41.55032, 'lon': -8.42005}}, {'facility': 'CHUC - Unidade de Pneumologia Oncológica', 'status': 'ACTIVE_NOT_RECRUITING', 'city': 'Coimbra', 'zip': '3000-075', 'country': 'Portugal', 'geoPoint': {'lat': 40.20564, 'lon': -8.41955}}, {'facility': 'Centro Clinico Champalimaud', 'status': 'ACTIVE_NOT_RECRUITING', 'city': 'Lisboa', 'zip': '1400-038', 'country': 'Portugal', 'geoPoint': {'lat': 38.71667, 'lon': -9.13333}}, {'facility': 'Centro Hospitalar do Porto ? Hospital de Santo António', 'status': 'ACTIVE_NOT_RECRUITING', 'city': 'Porto', 'zip': '4099-001', 'country': 'Portugal', 'geoPoint': {'lat': 41.14961, 'lon': -8.61099}}, {'facility': 'IPO do Porto', 'status': 'ACTIVE_NOT_RECRUITING', 'city': 'Porto', 'zip': '4200-072', 'country': 'Portugal', 'geoPoint': {'lat': 41.14961, 'lon': -8.61099}}, {'facility': 'National Cancer Centre', 'status': 'ACTIVE_NOT_RECRUITING', 'city': 'Singapore', 'zip': '168583', 'country': 'Singapore', 'geoPoint': {'lat': 1.28967, 'lon': 103.85007}}, {'facility': 'Curie Oncology (Farrer)', 'status': 'RECRUITING', 'city': 'Singapore', 'zip': '217562', 'country': 'Singapore', 'geoPoint': {'lat': 1.28967, 'lon': 103.85007}}, {'facility': 'Institut Catala d Oncologia Hospitalet', 'status': 'ACTIVE_NOT_RECRUITING', 'city': 'Hospitalet de Llobregat', 'state': 'Barcelona', 'zip': '08908', 'country': 'Spain', 'geoPoint': {'lat': 41.35967, 'lon': 2.10028}}, {'facility': 'Hospital Nuestra Senora de Valme', 'status': 'ACTIVE_NOT_RECRUITING', 'city': 'Seville', 'state': 'Sevilla', 'zip': '41014', 'country': 'Spain', 'geoPoint': {'lat': 37.38283, 'lon': -5.97317}}, {'facility': 'Hospital de la Santa Creu i Sant Pau', 'status': 'RECRUITING', 'city': 'Barcelona', 'zip': '08025', 'country': 'Spain', 'geoPoint': {'lat': 41.38879, 'lon': 2.15899}}, {'facility': 'Hospital Vall Hebron', 'status': 'RECRUITING', 'city': 'Barcelona', 'country': 'Spain', 'geoPoint': {'lat': 41.38879, 'lon': 2.15899}}, {'facility': 'Hospital General Universitario Gregorio Marañon', 'status': 'RECRUITING', 'city': 'Madrid', 'zip': '28007', 'country': 'Spain', 'geoPoint': {'lat': 40.4165, 'lon': -3.70256}}, {'facility': 'Hospital Universitario La Paz', 'status': 'RECRUITING', 'city': 'Madrid', 'zip': '280146', 'country': 'Spain', 'geoPoint': {'lat': 40.4165, 'lon': -3.70256}}, {'facility': 'Hospital Regional Universitario de Malaga', 'status': 'RECRUITING', 'city': 'Malaga', 'zip': '29010', 'country': 'Spain', 'geoPoint': {'lat': 36.72016, 'lon': -4.42034}}, {'facility': 'Hospital Universitario la Fe', 'status': 'RECRUITING', 'city': 'Valencia', 'zip': '46026', 'country': 'Spain', 'geoPoint': {'lat': 39.46975, 'lon': -0.37739}}, {'facility': 'Hospital Universitario Miguel Servet', 'status': 'RECRUITING', 'city': 'Zaragoza', 'zip': '50009', 'country': 'Spain', 'geoPoint': {'lat': 41.65606, 'lon': -0.87734}}, {'facility': 'Gävle Sjukhus', 'status': 'ACTIVE_NOT_RECRUITING', 'city': 'Gävle', 'zip': '80187', 'country': 'Sweden', 'geoPoint': {'lat': 60.67452, 'lon': 17.14174}}, {'facility': 'Hsin-Chu Branch of National Taiwan University Hospital', 'status': 'WITHDRAWN', 'city': 'Hsinchu City', 'zip': '300', 'country': 'Taiwan'}, {'facility': 'Kaohsiung Medical University Chung-Ho Memorial Hospital', 'status': 'ACTIVE_NOT_RECRUITING', 'city': 'Kaohsiung', 'zip': '807', 'country': 'Taiwan', 'geoPoint': {'lat': 22.61626, 'lon': 120.31333}}, {'facility': 'Chung Shan Medical University Hospital', 'status': 'ACTIVE_NOT_RECRUITING', 'city': 'Taichung', 'zip': '402306', 'country': 'Taiwan', 'geoPoint': {'lat': 24.1469, 'lon': 120.6839}}, {'facility': 'National Taiwan University Hospital', 'status': 'ACTIVE_NOT_RECRUITING', 'city': 'Taipei', 'zip': '00100', 'country': 'Taiwan', 'geoPoint': {'lat': 25.04776, 'lon': 121.53185}}, {'facility': 'Taipei Veterans General Hospital', 'status': 'ACTIVE_NOT_RECRUITING', 'city': 'Taipei', 'zip': '112', 'country': 'Taiwan', 'geoPoint': {'lat': 25.04776, 'lon': 121.53185}}, {'facility': 'Chang Gung Medical Foundation - Linkou', 'status': 'ACTIVE_NOT_RECRUITING', 'city': 'Taoyuan', 'zip': '333', 'country': 'Taiwan', 'geoPoint': {'lat': 24.95233, 'lon': 121.20193}}, {'facility': 'Vajira Hospital', 'status': 'ACTIVE_NOT_RECRUITING', 'city': 'Bangkok', 'zip': '10300', 'country': 'Thailand', 'geoPoint': {'lat': 13.75398, 'lon': 100.50144}}, {'facility': 'Siriraj Hospital - Chulabhorn Bone Marrow Transplant Centre', 'status': 'ACTIVE_NOT_RECRUITING', 'city': 'Bangkok', 'zip': '10700', 'country': 'Thailand', 'geoPoint': {'lat': 13.75398, 'lon': 100.50144}}, {'facility': 'Srinagarind Hospital', 'status': 'RECRUITING', 'city': 'Khon Kaen', 'zip': '40002', 'country': 'Thailand', 'geoPoint': {'lat': 16.44671, 'lon': 102.833}}, {'facility': 'Songklanagarind Hospital', 'status': 'ACTIVE_NOT_RECRUITING', 'city': 'Songkhla', 'zip': '90110', 'country': 'Thailand', 'geoPoint': {'lat': 7.19882, 'lon': 100.5951}}, {'facility': 'Blackpool Victoria Hospital', 'status': 'RECRUITING', 'city': 'Blackpool', 'zip': 'FY3 8NR', 'country': 'United Kingdom', 'geoPoint': {'lat': 53.81667, 'lon': -3.05}}, {'facility': \"Addenbrooke's Hospital\", 'status': 'ACTIVE_NOT_RECRUITING', 'city': 'Cambridge', 'zip': 'CB2 0QQ', 'country': 'United Kingdom', 'geoPoint': {'lat': 52.2, 'lon': 0.11667}}, {'facility': 'Velindre NHS Trust - Velindre Cancer Centre', 'status': 'WITHDRAWN', 'city': 'Cardiff', 'zip': 'CF14 2TL', 'country': 'United Kingdom', 'geoPoint': {'lat': 51.48, 'lon': -3.18}}, {'facility': 'Castle Hill Hospital', 'status': 'ACTIVE_NOT_RECRUITING', 'city': 'Cottingham', 'zip': 'HU16 5JQ', 'country': 'United Kingdom', 'geoPoint': {'lat': 52.50243, 'lon': -0.7554}}, {'facility': 'Beatson West of Scotland Cancer Centre', 'status': 'ACTIVE_NOT_RECRUITING', 'city': 'Glasgow', 'zip': 'G12 0YN', 'country': 'United Kingdom', 'geoPoint': {'lat': 55.86515, 'lon': -4.25763}}, {'facility': 'St James University Hospital', 'status': 'ACTIVE_NOT_RECRUITING', 'city': 'Leeds', 'zip': 'LS9 7TF', 'country': 'United Kingdom', 'geoPoint': {'lat': 53.79648, 'lon': -1.54785}}, {'facility': \"Guy's Hospital - Cancer Centre\", 'status': 'ACTIVE_NOT_RECRUITING', 'city': 'London', 'zip': 'SE1 9RT', 'country': 'United Kingdom', 'geoPoint': {'lat': 51.50853, 'lon': -0.12574}}, {'facility': 'Royal Marsden Hospital - London', 'status': 'ACTIVE_NOT_RECRUITING', 'city': 'London', 'zip': 'SW3 6JJ', 'country': 'United Kingdom', 'geoPoint': {'lat': 51.50853, 'lon': -0.12574}}, {'facility': 'The Christie NHS Foundation Trust', 'status': 'RECRUITING', 'city': 'Manchester', 'zip': 'M20 4BX', 'country': 'United Kingdom', 'geoPoint': {'lat': 53.48095, 'lon': -2.23743}}, {'facility': 'Nottingham City Hospital', 'status': 'ACTIVE_NOT_RECRUITING', 'city': 'Nottingham', 'zip': 'NG5 1PB', 'country': 'United Kingdom', 'geoPoint': {'lat': 52.9536, 'lon': -1.15047}}, {'facility': 'University Hospitals of North Midlands NHS Trust-Royal Stoke University Hospital', 'status': 'WITHDRAWN', 'city': 'Stoke-On-Trent', 'zip': 'ST4 6QG', 'country': 'United Kingdom', 'geoPoint': {'lat': 53.00415, 'lon': -2.18538}}, {'facility': 'Royal Marsden Hospital (Sutton)', 'status': 'ACTIVE_NOT_RECRUITING', 'city': 'Sutton', 'zip': 'SM2 5PT', 'country': 'United Kingdom', 'geoPoint': {'lat': 51.35, 'lon': -0.2}}, {'facility': 'Torbay Hospital', 'status': 'ACTIVE_NOT_RECRUITING', 'city': 'Torquay', 'zip': 'TQ27AA', 'country': 'United Kingdom', 'geoPoint': {'lat': 50.46198, 'lon': -3.5252}}]}, 'ipdSharingStatementModule': {'ipdSharing': 'YES', 'description': \"For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing\"}}, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-08-20'}, 'conditionBrowseModule': {'meshes': [{'id': 'D008175', 'term': 'Lung Neoplasms'}, {'id': 'D002289', 'term': 'Carcinoma, Non-Small-Cell Lung'}], 'ancestors': [{'id': 'D012142', 'term': 'Respiratory Tract Neoplasms'}, {'id': 'D013899', 'term': 'Thoracic Neoplasms'}, {'id': 'D009371', 'term': 'Neoplasms by Site'}, {'id': 'D009369', 'term': 'Neoplasms'}, {'id': 'D008171', 'term': 'Lung Diseases'}, {'id': 'D012140', 'term': 'Respiratory Tract Diseases'}, {'id': 'D002283', 'term': 'Carcinoma, Bronchogenic'}, {'id': 'D001984', 'term': 'Bronchial Neoplasms'}], 'browseLeaves': [{'id': 'M11172', 'name': 'Lung Neoplasms', 'asFound': 'Lung Cancer', 'relevance': 'HIGH'}, {'id': 'M5546', 'name': 'Carcinoma, Non-Small-Cell Lung', 'asFound': 'Non-small Cell Lung Cancer', 'relevance': 'HIGH'}, {'id': 'M5534', 'name': 'Carcinoma', 'relevance': 'LOW'}, {'id': 'M14979', 'name': 'Respiratory Tract Neoplasms', 'relevance': 'LOW'}, {'id': 'M16658', 'name': 'Thoracic Neoplasms', 'relevance': 'LOW'}, {'id': 'M11168', 'name': 'Lung Diseases', 'relevance': 'LOW'}, {'id': 'M14977', 'name': 'Respiratory Tract Diseases', 'relevance': 'LOW'}, {'id': 'M5540', 'name': 'Carcinoma, Bronchogenic', 'relevance': 'LOW'}, {'id': 'M5260', 'name': 'Bronchial Neoplasms', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'BC04', 'name': 'Neoplasms'}, {'abbrev': 'BC08', 'name': 'Respiratory Tract (Lung and Bronchial) Diseases'}, {'abbrev': 'All', 'name': 'All Conditions'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'C000706028', 'term': 'Sotorasib'}, {'id': 'C000718190', 'term': 'Adagrasib'}], 'ancestors': [{'id': 'D000082082', 'term': 'Immune Checkpoint Inhibitors'}, {'id': 'D045504', 'term': 'Molecular Mechanisms of Pharmacological Action'}, {'id': 'D000074322', 'term': 'Antineoplastic Agents, Immunological'}, {'id': 'D000970', 'term': 'Antineoplastic Agents'}], 'browseLeaves': [{'id': 'M96444', 'name': 'Sotorasib', 'asFound': 'SSC', 'relevance': 'HIGH'}, {'id': 'M288000', 'name': 'Adagrasib', 'asFound': 'Hazards', 'relevance': 'HIGH'}, {'id': 'M2342', 'name': 'Immune Checkpoint Inhibitors', 'relevance': 'LOW'}, {'id': 'M1346', 'name': 'Antineoplastic Agents, Immunological', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'ANeo', 'name': 'Antineoplastic Agents'}, {'abbrev': 'All', 'name': 'All Drugs and Chemicals'}]}}, 'hasResults': False}\n",
      "Keys for NCT05480865:\n",
      "dict_keys(['protocolSection', 'derivedSection', 'hasResults'])\n",
      "Content for NCT05480865:\n",
      "{'protocolSection': {'identificationModule': {'nctId': 'NCT05480865', 'orgStudyIdInfo': {'id': 'NAV-1003'}, 'organization': {'fullName': 'Navire Pharma Inc., a BridgeBio company', 'class': 'INDUSTRY'}, 'briefTitle': 'SHP2 Inhibitor BBP-398 in Combination With Sotorasib in Patients With Advanced Solid Tumors and a KRAS-G12C Mutation', 'officialTitle': 'A Phase 1 Study of the SHP2 Inhibitor BBP-398 (Formerly Known as IACS-15509) in Combination With the KRAS-G12C Inhibitor Sotorasib in Patients With Advanced Solid Tumors and a KRAS-G12C Mutation', 'acronym': 'Argonaut'}, 'statusModule': {'statusVerifiedDate': '2024-12', 'overallStatus': 'TERMINATED', 'whyStopped': 'Business Reasons', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2022-07-06', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2024-08-22', 'type': 'ACTUAL'}, 'completionDateStruct': {'date': '2024-08-22', 'type': 'ACTUAL'}, 'studyFirstSubmitDate': '2022-07-15', 'studyFirstSubmitQcDate': '2022-07-27', 'studyFirstPostDateStruct': {'date': '2022-07-29', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2024-12-09', 'lastUpdatePostDateStruct': {'date': '2024-12-12', 'type': 'ACTUAL'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'}, 'leadSponsor': {'name': 'Navire Pharma Inc., a BridgeBio company', 'class': 'INDUSTRY'}, 'collaborators': [{'name': 'Amgen', 'class': 'INDUSTRY'}]}, 'oversightModule': {'oversightHasDmc': False, 'isFdaRegulatedDrug': True, 'isFdaRegulatedDevice': False, 'isUsExport': True}, 'descriptionModule': {'briefSummary': 'This is a Phase 1 study of BBP-398, a SHP2 inhibitor, in combination with sotorasib, a KRAS-G12C inhibitor (KRAS-G12Ci), in patients with a KRAS-G12C mutation.\\n\\nThe study involves 2 parts: Phase 1a Dose Escalation and Phase 1b Dose Expansion/Optimization.', 'detailedDescription': 'The primary objectives for Phase 1a Dose Escalation are to evaluate safety and tolerability, and recommend a phase 1b dose (RP1bD) of the combination.\\n\\nThe primary objectives for Phase 1b Dose Expansion/Optimization are to evaluate safety and tolerability, and the antitumor activity (defined by the ORR assessed by the investigator according to RECIST v1.1) of BBP-398 when used in combination with sotorasib across two dose regimens in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with a KRAS-G12C mutation and who are KRAS-G12Ci naïve, and recommend a phase 2 dose (RP2D) of the combination.'}, 'conditionsModule': {'conditions': ['Solid Tumor, Adult', 'Metastatic Solid Tumor', 'Metastatic NSCLC', 'Non Small Cell Lung Cancer'], 'keywords': ['KRAS-G12C mutation', 'SHP2', 'MAPK-pathway alterations', 'NSCLC']}, 'designModule': {'studyType': 'INTERVENTIONAL', 'phases': ['PHASE1'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'SEQUENTIAL', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 28, 'type': 'ACTUAL'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'Dose Escalation: BBP-398 Level 1 and sotorasib', 'type': 'EXPERIMENTAL', 'description': 'BBP-398 dose Level 1 capsules administered once a day (QD) for a 28-day treatment cycle in combination with sotorasib tablets administered once a day (QD) for a 28-day treatment cycle', 'interventionNames': ['Drug: BBP-398', 'Drug: sotorasib']}, {'label': 'Dose Escalation: BBP-398 Level 2 and sotorasib', 'type': 'EXPERIMENTAL', 'description': 'BBP-398 dose Level 2 capsules administered once a day (QD) for a 28-day treatment cycle in combination with sotorasib tablets administered once a day (QD) for a 28-day treatment cycle', 'interventionNames': ['Drug: BBP-398', 'Drug: sotorasib']}, {'label': 'Dose Escalation: BBP-398 Level 3 and sotorasib', 'type': 'EXPERIMENTAL', 'description': 'BBP-398 dose Level 3 capsules administered once a day (QD) for a 28-day treatment cycle in combination with sotorasib tablets administered once a day (QD) for a 28-day treatment cycle', 'interventionNames': ['Drug: BBP-398', 'Drug: sotorasib']}, {'label': 'Dose Expansion/Optimization: BBP-398 Dose Regimen 1 and sotorasib', 'type': 'EXPERIMENTAL', 'description': 'BBP-398 Dose Regimen 1 capsules administered once a day (QD) for a 28-day treatment cycle in combination with sotorasib tablets administered once a day (QD) for a 28-day treatment cycle', 'interventionNames': ['Drug: BBP-398', 'Drug: sotorasib']}, {'label': 'Dose Expansion/Optimization: BBP-398 Dose Regimen 2 and sotorasib', 'type': 'EXPERIMENTAL', 'description': 'BBP-398 Dose Regimen 2 capsules administered once a day (QD) for a 28-day treatment cycle in combination with sotorasib tablets administered once a day (QD) for a 28-day treatment cycle', 'interventionNames': ['Drug: BBP-398', 'Drug: sotorasib']}], 'interventions': [{'type': 'DRUG', 'name': 'BBP-398', 'description': 'BBP-398 administered orally', 'armGroupLabels': ['Dose Escalation: BBP-398 Level 1 and sotorasib', 'Dose Escalation: BBP-398 Level 2 and sotorasib', 'Dose Escalation: BBP-398 Level 3 and sotorasib', 'Dose Expansion/Optimization: BBP-398 Dose Regimen 1 and sotorasib', 'Dose Expansion/Optimization: BBP-398 Dose Regimen 2 and sotorasib']}, {'type': 'DRUG', 'name': 'sotorasib', 'description': 'sotorasib administered orally', 'armGroupLabels': ['Dose Escalation: BBP-398 Level 1 and sotorasib', 'Dose Escalation: BBP-398 Level 2 and sotorasib', 'Dose Escalation: BBP-398 Level 3 and sotorasib', 'Dose Expansion/Optimization: BBP-398 Dose Regimen 1 and sotorasib', 'Dose Expansion/Optimization: BBP-398 Dose Regimen 2 and sotorasib']}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Phase 1a Dose Escalation Primary Objective: Incidence and Severity of Treatment-Emergent Adverse Events, Serious Adverse Events, and Dose Limiting Toxicities', 'description': 'Number of patients experiencing treatment-emergent adverse events, serious adverse events, including changes in lab parameters, vital signs and electrocardiogram changes; duration, and severity based on National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v5.0', 'timeFrame': 'Completion of 1 Cycle (28 days)'}, {'measure': 'Phase 1b Dose Expansion/Optimization Primary Objective: Incidence and Severity of Treatment-Emergent Adverse Events, and Serious Adverse Events', 'description': 'Number of patients experiencing treatment-emergent adverse events, serious adverse events, including changes in lab parameters, vital signs and electrocardiogram changes; duration, and severity based on National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v5.0', 'timeFrame': 'Completion of 1 Cycle (28 days)'}, {'measure': 'Phase 1b Dose Expansion/Optimization Primary Objective: Overall Response Rate (ORR)', 'description': 'Complete Response (CR) + Partial Response (PR) rates, defined by RECIST v1.1', 'timeFrame': '8 weeks'}], 'secondaryOutcomes': [{'measure': 'Phase 1a Dose Escalation Secondary Objectives: Overall Response Rate (ORR)', 'description': 'Complete Response (CR) + Partial Response (PR) rates, defined by RECIST v1.1', 'timeFrame': '8 weeks'}, {'measure': 'Duration of response', 'description': 'Defined by RECIST v1.1', 'timeFrame': '8 weeks'}, {'measure': 'Progression Free Survival (PFS)', 'description': 'Time from treatment start to progression of disease or death by any cause', 'timeFrame': '8 weeks'}, {'measure': 'Overall survival (OS)', 'description': 'Time from treatment start to death', 'timeFrame': '8 weeks'}, {'measure': 'Maximum Observed Plasma Concentration (Cmax) of BBP-398', 'description': 'Maximum plasma concentration of BBP-398 in combination with sotorasib', 'timeFrame': 'Cycle 2 Day 1'}, {'measure': 'Time to Cmax (Tmax) of BBP-398', 'description': 'Amount of time to reach Cmax of BBP-398 in combination with sotorasib', 'timeFrame': 'Cycle 2 Day 1'}, {'measure': 'Area under the plasma concentration-time curve (AUC) of BBP-398', 'description': 'Area under the plasma concentration versus time curve of BBP-398 in combination with sotorasib', 'timeFrame': 'Cycle 2 Day 1'}, {'measure': 'Half-life (T1/2) of BBP-398', 'description': 'Terminal half-life of BBP-398 in combination with sotorasib', 'timeFrame': 'Cycle 2 Day 1'}, {'measure': 'Observed Maximum Plasma Concentration (Cmax) of sotorasib', 'description': 'Maximum plasma concentration of sotorasib in combination with BBP-398', 'timeFrame': 'Cycle 2 Day 1'}, {'measure': 'Time to Cmax (Tmax) of sotorasib', 'description': 'Amount of time to reach Cmax of sotorasib in combination with BBP-398', 'timeFrame': 'Cycle 2 Day 1'}, {'measure': 'Area under the plasma concentration-time curve (AUC) over dosing interval of sotorasib', 'description': 'Area under the plasma concentration versus time curve of sotorasib in combination with BBP-398', 'timeFrame': 'Cycle 2 Day 1'}, {'measure': 'Half-life (T1/2) of sotorasib', 'description': 'Terminal half-life of sotorasib in combination with BBP-398', 'timeFrame': 'Cycle 2 Day 1'}, {'measure': 'Circulating and intratumoral target engagement biomarkers of BBP-398 activity in combination with sotorasib', 'description': 'Raw, normalized, and/or baseline adjusted analyte signal', 'timeFrame': '24 months'}]}, 'eligibilityModule': {'eligibilityCriteria': 'Key Inclusion Criteria:\\n\\n* Patients must have histologically documented, locally advanced and unresectable, or metastatic solid tumor with documentation of a KRAS-G12C mutation within 2 years prior to screening.\\n* Patients must have measurable disease by RECIST v1.1.\\n* Patients must have a minimum life expectancy of \\\\>12 weeks after start of study treatment.\\n* Patients must have progression or disease recurrence on or after all available standard of care therapies.\\n* Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-1.\\n* Patients must have adequate organ function.\\n\\nKey Exclusion Criteria:\\n\\n* Patients that have participated in an interventional clinical study within the last 4 weeks.\\n* Patients that have received radiotherapy or proton therapy with a limited field of radiation for palliation within 1 week of the start of study treatment, OR radiation to more than 30% of the bone marrow or with a wide field of radiation within 4 weeks of the start of study treatment.\\n* Patients with untreated and/or active CNS metastases.\\n* Patients that have a history of allogenic bone marrow transplant.', 'healthyVolunteers': False, 'sex': 'ALL', 'minimumAge': '18 Years', 'maximumAge': '99 Years', 'stdAges': ['ADULT', 'OLDER_ADULT']}, 'contactsLocationsModule': {'locations': [{'facility': 'Cancer Research SA', 'city': 'Adelaide', 'state': 'South Australia', 'zip': '5000', 'country': 'Australia', 'geoPoint': {'lat': -34.92866, 'lon': 138.59863}}, {'facility': 'Southern Oncology Clinical Research Unit', 'city': 'Adelaide', 'state': 'South Australia', 'zip': '5042', 'country': 'Australia', 'geoPoint': {'lat': -34.92866, 'lon': 138.59863}}, {'facility': 'Peninsula & South Eastern Haematology and Oncology Group', 'city': 'Frankston', 'state': 'Victoria', 'zip': '3199', 'country': 'Australia', 'geoPoint': {'lat': -38.14458, 'lon': 145.12291}}, {'facility': 'One Clinical Research', 'city': 'Perth', 'state': 'Western Australia', 'zip': '6009', 'country': 'Australia', 'geoPoint': {'lat': -31.95224, 'lon': 115.8614}}, {'facility': 'St John of God Subiaco Hospital', 'city': 'Subiaco', 'state': 'Western Australia', 'zip': '6008', 'country': 'Australia', 'geoPoint': {'lat': -31.9485, 'lon': 115.8268}}, {'facility': 'Orange Health Service', 'city': 'Orange', 'zip': 'NSW 2800', 'country': 'Australia', 'geoPoint': {'lat': -33.28397, 'lon': 149.10018}}, {'facility': 'Rigshospitalet', 'city': 'Copenhagen', 'zip': 'DK-2100', 'country': 'Denmark', 'geoPoint': {'lat': 55.67594, 'lon': 12.56553}}, {'facility': 'Institute Bergonie', 'city': 'Bordeaux', 'zip': '33076', 'country': 'France', 'geoPoint': {'lat': 44.84044, 'lon': -0.5805}}, {'facility': 'Centre Georges François Leclerc', 'city': 'Dijon', 'zip': '21079', 'country': 'France', 'geoPoint': {'lat': 47.31667, 'lon': 5.01667}}, {'facility': 'CHU Grenobles Aples', 'city': 'Grenoble', 'zip': '38043 CEDEX9', 'country': 'France', 'geoPoint': {'lat': 45.16667, 'lon': 5.71667}}, {'facility': 'Hopital Bichat-Claude Bernard', 'city': 'Paris', 'zip': '75018', 'country': 'France', 'geoPoint': {'lat': 48.85341, 'lon': 2.3488}}, {'facility': 'CHU de Rennes - Hôpital Pontchaillou', 'city': 'Rennes', 'zip': '35000', 'country': 'France', 'geoPoint': {'lat': 48.11198, 'lon': -1.67429}}, {'facility': \"St. Luke's Hospital S.A.\", 'city': 'Thessaloníki', 'zip': '55236', 'country': 'Greece', 'geoPoint': {'lat': 40.64361, 'lon': 22.93086}}, {'facility': 'Careggi University Hospital', 'city': 'Florence', 'state': 'Largo Brambilla', 'zip': '50134', 'country': 'Italy', 'geoPoint': {'lat': 43.77925, 'lon': 11.24626}}, {'facility': 'Spedali Civili - Brescia', 'city': 'Brescia', 'zip': '25123', 'country': 'Italy', 'geoPoint': {'lat': 45.53558, 'lon': 10.21472}}, {'facility': 'Istituto Nazionale Tumori (INT) \"Fondazione G. Pascale\"', 'city': 'Napoli', 'zip': '80131', 'country': 'Italy', 'geoPoint': {'lat': 40.85216, 'lon': 14.26811}}, {'facility': 'U.O.C Oncoematologia AOU \"Luigi Vanvitelli\"', 'city': 'Napoli', 'zip': '80131', 'country': 'Italy', 'geoPoint': {'lat': 40.85216, 'lon': 14.26811}}, {'facility': 'Het Nederlands Kanker Instituut - Antoni van Leewenhoek Ziekenhuis', 'city': 'Amsterdam', 'zip': '1066 CX', 'country': 'Netherlands', 'geoPoint': {'lat': 52.37403, 'lon': 4.88969}}, {'facility': 'Erasmus Medical Center', 'city': 'Rotterdam', 'zip': '3000 CA', 'country': 'Netherlands', 'geoPoint': {'lat': 51.9225, 'lon': 4.47917}}, {'facility': 'Quiron Salud Barcelona', 'city': 'Barcelona', 'zip': '08023', 'country': 'Spain', 'geoPoint': {'lat': 41.38879, 'lon': 2.15899}}, {'facility': \"Vall d'Heborn University Hospital - VHIO\", 'city': 'Barcelona', 'zip': '08035', 'country': 'Spain', 'geoPoint': {'lat': 41.38879, 'lon': 2.15899}}, {'facility': 'Clinica Universidad de Navarra', 'city': 'Madrid', 'zip': '28027', 'country': 'Spain', 'geoPoint': {'lat': 40.4165, 'lon': -3.70256}}, {'facility': 'Quiron Salud Madrid', 'city': 'Madrid', 'zip': '28223', 'country': 'Spain', 'geoPoint': {'lat': 40.4165, 'lon': -3.70256}}, {'facility': 'Virgen De La Victoria', 'city': 'Málaga', 'zip': '29010', 'country': 'Spain', 'geoPoint': {'lat': 36.72016, 'lon': -4.42034}}, {'facility': 'Hospital Universitario Virgen De La Macarena', 'city': 'Sevilla', 'country': 'Spain', 'geoPoint': {'lat': 37.38283, 'lon': -5.97317}}]}}, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-08-21'}, 'conditionBrowseModule': {'meshes': [{'id': 'D009369', 'term': 'Neoplasms'}], 'browseLeaves': [{'id': 'M11172', 'name': 'Lung Neoplasms', 'relevance': 'LOW'}, {'id': 'M5546', 'name': 'Carcinoma, Non-Small-Cell Lung', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'BC04', 'name': 'Neoplasms'}, {'abbrev': 'BC08', 'name': 'Respiratory Tract (Lung and Bronchial) Diseases'}, {'abbrev': 'All', 'name': 'All Conditions'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'C000706028', 'term': 'Sotorasib'}], 'ancestors': [{'id': 'D000082082', 'term': 'Immune Checkpoint Inhibitors'}, {'id': 'D045504', 'term': 'Molecular Mechanisms of Pharmacological Action'}, {'id': 'D000074322', 'term': 'Antineoplastic Agents, Immunological'}, {'id': 'D000970', 'term': 'Antineoplastic Agents'}], 'browseLeaves': [{'id': 'M96444', 'name': 'Sotorasib', 'asFound': 'Subgingival', 'relevance': 'HIGH'}, {'id': 'M2342', 'name': 'Immune Checkpoint Inhibitors', 'relevance': 'LOW'}, {'id': 'M1346', 'name': 'Antineoplastic Agents, Immunological', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'ANeo', 'name': 'Antineoplastic Agents'}, {'abbrev': 'All', 'name': 'All Drugs and Chemicals'}]}}, 'hasResults': False}\n",
      "Keys for NCT06599502:\n",
      "dict_keys(['protocolSection', 'derivedSection', 'hasResults'])\n",
      "Content for NCT06599502:\n",
      "{'protocolSection': {'identificationModule': {'nctId': 'NCT06599502', 'orgStudyIdInfo': {'id': 'D7080C00001'}, 'organization': {'fullName': 'AstraZeneca', 'class': 'INDUSTRY'}, 'briefTitle': 'A Phase I/IIa Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AZD0022 as Monotherapy and in Combination With Anti-cancer Agents in Adult Participants With Tumours Harbouring a KRASG12D Mutation', 'officialTitle': 'A Phase I/IIa, Open-label, Multi-centre Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of AZD0022 Monotherapy and in Combination With Anti-cancer Agents in Participants With Tumours Harbouring a KRASG12D Mutation (ALAFOSS-01)', 'acronym': 'ALAFOSS-01'}, 'statusModule': {'statusVerifiedDate': '2025-08', 'overallStatus': 'RECRUITING', 'startDateStruct': {'date': '2024-10-18', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2028-01-20', 'type': 'ESTIMATED'}, 'completionDateStruct': {'date': '2028-01-20', 'type': 'ESTIMATED'}, 'studyFirstSubmitDate': '2024-08-19', 'studyFirstSubmitQcDate': '2024-09-13', 'studyFirstPostDateStruct': {'date': '2024-09-19', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2025-08-13', 'lastUpdatePostDateStruct': {'date': '2025-08-17', 'type': 'ACTUAL'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'}, 'leadSponsor': {'name': 'AstraZeneca', 'class': 'INDUSTRY'}}, 'oversightModule': {'isFdaRegulatedDrug': True, 'isFdaRegulatedDevice': False}, 'descriptionModule': {'briefSummary': 'This is a first-in-human, modular, Phase I/IIa, open-label, multi-centre study to assess the safety, tolerability, PK, and preliminary efficacy of AZD0022 monotherapy in combination with other anti-cancer agents in participants with tumours harbouring a KRASG12D mutation.', 'detailedDescription': 'This first time in human, open-label, multi-centre study will administer AZD0022 orally to participants with tumours harbouring a KRASG12D mutation.\\n\\nThis study will have initially 2 modules.\\n\\n* Module 1: AZD0022 monotherapy\\n* Module 2: AZD0022 in combination with other anti-cancer agents (Cetuximab)\\n\\nEach Module has 3 parts. Dose Escalation (Part A), Dose Optimisation (Part B) and Potential Efficacy Expansion (Part C).'}, 'conditionsModule': {'conditions': ['Advanced Solid Tumours', 'Non-Small Cell Lung Cancer (NSCLC)', 'Pancreatic Ductal Adenocarcinoma (PDAC)', 'Colorectal Cancer (CRC)']}, 'designModule': {'studyType': 'INTERVENTIONAL', 'phases': ['PHASE1', 'PHASE2'], 'designInfo': {'allocation': 'NON_RANDOMIZED', 'interventionModel': 'SEQUENTIAL', 'interventionModelDescription': 'This protocol has a modular design, with the potential for future Modules or treatment to be added via protocol amendments. Participants will receive oral doses of AZD0022, either as monotherapy or in combination with other anti-cancer agents', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 430, 'type': 'ESTIMATED'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'Module 1 Part A. Dose Escalation', 'type': 'EXPERIMENTAL', 'description': 'AZD0022 monotherapy', 'interventionNames': ['Drug: AZD0022']}, {'label': 'Module 1 Part B. Dose Optimisation', 'type': 'EXPERIMENTAL', 'description': 'AZD0022 monotherapy', 'interventionNames': ['Drug: AZD0022']}, {'label': 'Module 1 Part C. Potential Efficacy Expansion', 'type': 'EXPERIMENTAL', 'description': 'AZD0022 monotherapy', 'interventionNames': ['Drug: AZD0022']}, {'label': 'Module 1 Part B. Food Effect Cohort', 'type': 'EXPERIMENTAL', 'description': 'AZD0022 monotherapy', 'interventionNames': ['Drug: AZD0022']}, {'label': 'Module 2 Part A. Dose Escalation', 'type': 'EXPERIMENTAL', 'description': 'AZD0022 in combination with Cetuximab', 'interventionNames': ['Drug: AZD0022', 'Drug: Cetuximab']}, {'label': 'Module 2 Part B. Dose Optimisation', 'type': 'EXPERIMENTAL', 'description': 'AZD0022 in combination with Cetuximab', 'interventionNames': ['Drug: AZD0022', 'Drug: Cetuximab']}, {'label': 'Module 2 Part C. Potential Efficacy Expansion', 'type': 'EXPERIMENTAL', 'description': 'AZD0022 in combination with Cetuximab', 'interventionNames': ['Drug: AZD0022', 'Drug: Cetuximab']}], 'interventions': [{'type': 'DRUG', 'name': 'AZD0022', 'description': 'AZD0022 is an oral KRASG12D inhibitor that blocks KRASG12D function in patients with this type of mutation.', 'armGroupLabels': ['Module 1 Part A. Dose Escalation', 'Module 1 Part B. Dose Optimisation', 'Module 1 Part B. Food Effect Cohort', 'Module 1 Part C. Potential Efficacy Expansion', 'Module 2 Part A. Dose Escalation', 'Module 2 Part B. Dose Optimisation', 'Module 2 Part C. Potential Efficacy Expansion']}, {'type': 'DRUG', 'name': 'Cetuximab', 'description': 'Cetuximab (Erbitux®) is a recombinant chimeric human/mouse Immunoglobulin G monoclonal antibody which binds to EGFR and competitively inhibits the binding of EGFR and other ligands', 'armGroupLabels': ['Module 2 Part A. Dose Escalation', 'Module 2 Part B. Dose Optimisation', 'Module 2 Part C. Potential Efficacy Expansion']}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Incidence of participants with Dose-Limiting Toxicity (DLT), Adverse events (AEs) and Serious Adverse Events (SAEs).', 'description': 'Determine if treatment with AZD0022 as a monotherapy and in combination with other anti-cancer agents is safe and tolerable through the assessment of DLTs, AEs, SAEs, and change from baseline in laboratory parameters, vital signs, and ECGs.\\n\\nPart A (Dose Escalation) and Part B (Dose Optimisation). DLTs only applicable for Part A.', 'timeFrame': 'From time of informed consent, through study completion to 30 days post last dose; an average of 2 years'}, {'measure': 'Number of patients who discontinue AZD0022 due to toxicity', 'description': 'To investigate the safety and tolerability of AZD0022 as a monotherapy and in combination with other anti-cancer agents in participants with advanced tumours harbouring a KRASG12D mutation\\n\\nPart A (Dose Escalation) and Part B (Dose Optimisation)', 'timeFrame': 'From time of informed consent to 30 days post last dose'}, {'measure': 'ORR (Objective Response Rate)', 'description': 'Evaluated according to RECIST v1.1 (Response Evaluation Criteria in Solid Tumours Version 1.1)\\n\\nPart C (Potential Efficacy Expansion)\\n\\nPercentage of participants with a confirmed Complete Response (CR) or Partial Response (PR)', 'timeFrame': 'Time from first dose of AZD002 through study completion; approximate duration of 2 years'}], 'secondaryOutcomes': [{'measure': 'CR rate (Complete Response)', 'description': 'To assess the preliminary anti-tumour activity of AZD0022 as a monotherapy and in combination with other anti-cancer agents\\n\\nRadiological response evaluated according to RECIST v1.1 (Response Evaluation Criteria in Solid Tumours Version 1.1)\\n\\nPart A (Dose Escalation), Part B (Dose Optimisation) and Part C (Potential Efficacy Expansion)\\n\\nPercentage of participants with a confirmed Complete Response (CR)', 'timeFrame': 'From first dose (non-randomised study parts) or from randomisation (randomised) through study completion; approximate duration of 2 years'}, {'measure': 'DoR (Duration of Response)', 'description': 'To assess the preliminary anti-tumour activity of AZD0022 as a monotherapy and in combination with other anti-cancer agents\\n\\nRadiological response evaluated according to RECIST v1.1 (Response Evaluation Criteria in Solid Tumours Version 1.1)\\n\\nPart A (Dose Escalation), Part B (Dose Optimisation) and Part C (Potential Efficacy Expansion).\\n\\nTime from the date of first documented evidence of CR or PR until date of first documented disease progression or death.', 'timeFrame': 'From the date of first response until date of disease progression (RECIST 1.1) or death in the absence of disease progression; approximate duration of 2 years.'}, {'measure': 'DCR (Disease Control Rate)', 'description': 'To assess the preliminary anti-tumour activity of AZD0022 as a monotherapy and in combination with other anti-cancer agents\\n\\nRadiological response evaluated according to RECIST v1.1 (Response Evaluation Criteria in Solid Tumours Version 1.1)\\n\\nPart A (Dose Escalation), Part B (Dose Optimisation) and Part C (Potential Efficacy Expansion).\\n\\nPercentage of participants who have a confirmed CR, PR, or Stable Disease (SD) for at least 11 weeks after start of treatment.', 'timeFrame': 'From first dose (non-randomised study parts) or from randomisation (randomised) until progression. For each patient, this is expected to be at 12 weeks'}, {'measure': 'DRR (Durable Response Rate)', 'description': 'To assess the preliminary anti-tumour activity of AZD0022 as a monotherapy and in combination with other anti-cancer agents\\n\\nRadiological response evaluated according to RECIST v1.1 (Response Evaluation Criteria in Solid Tumours Version 1.1)\\n\\nPart A (Dose Escalation), Part B (Dose Optimisation) and Part C (Potential Efficacy Expansion).\\n\\nPercentage of participants who have a confirmed response (CR/PR) with a duration of at least 3 months.', 'timeFrame': 'From first documented response up until progression, or the last evaluable assessment in the absence of progression; approximate duration of 2 years.'}, {'measure': 'TTR (Time to Response)', 'description': 'To assess the preliminary anti-tumour activity of AZD0022 as a monotherapy and in combination with other anti-cancer agents\\n\\nRadiological response evaluated according to RECIST v1.1 (Response Evaluation Criteria in Solid Tumours Version 1.1)\\n\\nPart A (Dose Escalation), Part B (Dose Optimisation) and Part C (Potential Efficacy Expansion)\\n\\nTime from first dose/randomisation date until date of first documented evidence of CR or PR per RECIST v1.1', 'timeFrame': 'From first dose (non-randomised study parts) or from randomisation (randomised study parts) until the date of documented objective response; approximate duration of 2 years.'}, {'measure': 'PFS (Progression Free Survival)', 'description': 'To assess the preliminary anti-tumour activity of AZD0022 as a monotherapy and in combination with other anti-cancer agents\\n\\nRadiological response evaluated according to RECIST v1.1 (Response Evaluation Criteria in Solid Tumours Version 1.1)\\n\\nPart A (Dose Escalation), Part B (Dose Optimisation) and Part C (Potential Efficacy Expansion).\\n\\nTime from first dose/randomisation date until date of first documented disease progression or death.', 'timeFrame': \"'From first dose (non-randomised study parts) or from randomisation (randomised study parts) to progressive disease or death in the absence of disease progression; approximate duration of 2 years\"}, {'measure': 'Change in tumour size', 'description': 'To assess the preliminary anti-tumour activity of AZD0022 as a monotherapy and in combination with other anti-cancer agents\\n\\nRadiological response evaluated according to RECIST v1.1 (Response Evaluation Criteria in Solid Tumours Version 1.1)\\n\\nPart A (Dose Escalation), Part B (Dose Optimisation) and Part C (Potential Efficacy Expansion)\\n\\nPercentage change in tumor size from baseline per RECIST v1.1', 'timeFrame': 'From the first dose of study intervention (non-randomised study parts) or from randomisation (randomised), at predefined intervals throughout the administration of AZD0022; approximate duration of 2 years.'}, {'measure': 'OS (Overall Survival)', 'description': 'To assess the preliminary anti-tumour activity of AZD0022 as a monotherapy and in combination with other anti-cancer agents\\n\\nPart A (Dose Escalation), Part B (Dose Optimisation) and Part C (Potential Efficacy Expansion).\\n\\nTime from first dose/randomisation date until death due to any case.', 'timeFrame': 'From first dose of study intervention (non-randomised study parts) or from randomisation (randomised study parts) to death; approximate duration of 2 years.'}, {'measure': 'Complete Molecular Response (cMR).', 'description': 'To assess the molecular response rate via ctDNA on treatment with AZD0022 as a monotherapy and in combination with other anti-cancer agents\\n\\nPart A (Dose Escalation), Part B (Dose Optimisation) and Part C (Potential Efficacy Expansion).', 'timeFrame': 'From the first dose of study intervention (non-randomised study parts) or from randomisation (randomised study parts), at predefined intervals throughout the administration of AZD0022; approximate duration of 2 years.'}, {'measure': 'Pharmacokinetics of AZD0022: Maximum plasma concentration of the study drug (Cmax)', 'description': 'Maximum observed plasma concentration of the study drug\\n\\nPart A (Dose Escalation) and Part B (Dose Optimisation)', 'timeFrame': 'From the first dose of study intervention (non-randomised study parts) or from randomisation (randomised study parts), at predefined intervals throughout the administration of AZD0022; approximate duration of 2 years.'}, {'measure': 'Pharmacokinetics of AZD0022: Time to maximum plasma concentration of the study drug (T-max)', 'description': 'Time to maximum observed plasma concentration of the study drug\\n\\nPart A (Dose Escalation) and Part B (Dose Optimisation)', 'timeFrame': 'From the first dose of study intervention (non-randomised study parts) or from randomisation (randomised study parts), at predefined intervals throughout the administration of AZD0022; approximate duration of 2 years.'}, {'measure': 'Pharmacokinetics of AZD0022: AuClast (Area Under the Plasma Contentration-Time Curve to the Last Measurable Plasma Concentration)', 'description': 'A pharmacokinetic measurement of the volume of plasma from which the study drug is completely removed per unit time.\\n\\nPart A (Dose Escalation) and Part B (Dose Optimisation)', 'timeFrame': 'From the first dose of study intervention (non-randomised study parts) or from randomisation (randomised study parts), at predefined intervals throughout the administration of AZD0022 until Cycle 3 Day 1.'}, {'measure': 'Pharmacokinetics of AZD0022: Terminal elimination half-life (t 1/2)', 'description': 'Terminal elimination half life.\\n\\nPart A (Dose Escalation) and Part B (Dose Optimisation)', 'timeFrame': 'From the first dose of study intervention (non-randomised study parts) or from randomisation (randomised study parts), at predefined intervals throughout the administration of AZD0022 until Cycle 3 Day 1.'}, {'measure': 'Incidence of participants with Adverse events (AEs) and Serious Adverse Events (SAEs).', 'description': 'Determine if treatment with AZD0022 as a monotherapy and in combination with other anticancer agents is safe and tolerable through the assessment of AEs, SAEs, and change from baseline in laboratory parameters, vital signs, and ECGs.\\n\\nPart C (Potential Efficacy Expansion).', 'timeFrame': 'From time of informed consent, through study completion to 30 days post last dose; an average of 2 years'}, {'measure': 'Number of patients who discontinue AZD0022 due to toxicity', 'description': 'To further assess the safety and tolerability of AZD0022 as a monotherapy and in combination with other anti-cancer agents\\n\\nPart C (Potential Efficacy Expansion).', 'timeFrame': 'From time of informed consent, through study completion to 30 days post last dose; an average of 2 years'}, {'measure': 'TDT (Time to Discontinuation of Treatment)', 'description': 'To estimate the anti-tumour activity of AZD0022 as a monotherapy and in combination with other anti-cancer agents.\\n\\nPart C (Potential Efficacy Expansion)\\n\\nTime from first dose/randomisation date until discontinuation of treatment or death due to any case.', 'timeFrame': 'From first dose until discontinuation of treatment for any reason; approximate duration of 2 years.'}, {'measure': 'TFST (Time to First Subsequent Anti-Cancer)', 'description': 'To estimate the anti-tumour activity of AZD0022 as a monotherapy and in combination with other anti-cancer agents.\\n\\nPart C (Potential Efficacy Expansion).\\n\\nTime from first dose/randomisation date until start of first subsequent anti-cancer therapy after discontinuation of study treatment, or death due to any cause.', 'timeFrame': 'From date of first dose until start date of the first subsequent anti-cancer therapy after discontinuation of study treatment, or death; approximate duration of 2 years.'}, {'measure': 'Change in phospho-ERK', 'description': 'To assess KRAS pathway inhibition on treatment with AZD0022 as monotherapy\\n\\nModule 1 Part A (Dose Escalation), Module 1 Part B (Dose Optimisation) and Module 1 Part C (Potential Efficacy Expansion)\\\\*\\n\\nModule 2 Part A (Dose Escalation), Module 2 Part B (Dose Optimisation) and Module 2 Part C (Potential efficacy expansion)\\\\*\\n\\n\\\\*Potential Efficacy Expansion at Sponsor discretion based on emerging data.', 'timeFrame': 'From baseline, at predefined intervals throughout the administration of AZD0022; approximate duration of 2 years.'}, {'measure': 'Geometric mean and 90% CI for the ratio of fed:fasted in AUClast and Cmax for food-effect cohort.', 'description': 'To characterise the effect of food on AZD0022 as monotherapy\\n\\nModule 1 Food-effect only', 'timeFrame': 'From first dose, at predefined intervals throughout the administration of AZD0022; approximate duration of 2 years.'}, {'measure': 'PFS (Progression Free Survival) by BICR', 'description': 'To assess anti-tumour activity of AZD0022 as monotherapy and in combination with other anti-cancer agents\\n\\nRadiological response evaluated according to RECIST v1.1 (Response Evaluation Criteria in Solid Tumours Version 1.1)\\n\\nModule 1 Part B (Dose Optimisation) and Module 1 Part C (Potential Efficacy Expansion)\\n\\nModule 2 Part B (Dose Optimisation) and Part C (Potential Efficacy Expansion)', 'timeFrame': 'From first dose (non-randomised study parts) or from randomisation (randomised study parts) to progressive disease or death in the absence of disease progression; approximate duration of 2 years'}, {'measure': 'ORR (Objective Response Rate) by BICR', 'description': 'To assess anti-tumour activity of AZD0022 as monotherapy and in combination with other anti-cancer agents\\n\\nRadiological response evaluated according to RECIST v1.1 (Response Evaluation Criteria in Solid Tumours Version 1.1)\\n\\nModule 1 Part B (Dose Optimisation) and Module 1 Part C (Potential Efficacy Expansion)\\n\\nModule 2 Part B (Dose Optimisation) and Part C (Potential Efficacy Expansion)', 'timeFrame': 'From first dose (non-randomised study parts) or from randomisation (randomised) through study completion; approximate duration of 2 years'}, {'measure': 'DoR (Duration of Rate) by BICR', 'description': 'To assess anti-tumour activity of AZD0022 as monotherapy and in combination with other anti-cancer agents\\n\\nRadiological response evaluated according to RECIST v1.1 (Response Evaluation Criteria in Solid Tumours Version 1.1)\\n\\nModule 1 Part B (Dose Optimisation) and Module 1 Part C (Potential Efficacy Expansion)\\n\\nModule 2 Part B (Dose Optimisation) and Part C (Potential Efficacy Expansion)', 'timeFrame': 'From the date of first response until date of disease progression (RECIST 1.1) or death in the absence of disease progression; approximate duration of 2 years.'}, {'measure': 'ORR (Objective Response Rate) by Investigator', 'description': 'To assess anti-tumour activity of AZD0022 as monotherapy and in combination with other anti-cancer agents\\n\\nRadiological response evaluated according to RECIST v1.1 (Response Evaluation Criteria in Solid Tumours Version 1.1)\\n\\nModule 1 Part A (Dose Escalation) and Module 1 Part B (Dose Optimisation)\\n\\nModule 2 Part A (Dose Escalation) and Module 2 Part B (Dose Optimisation)', 'timeFrame': 'From first dose (non-randomised study parts) or from randomisation (randomised) through study completion; approximate duration of 2 years'}]}, 'eligibilityModule': {'eligibilityCriteria': 'Key Inclusion Criteria:\\n\\nFor whole study:\\n\\n1. Participant must be ≥ 18 years or the legal age of consent in the jurisdiction in which the study is taking place at the time of signing the ICF.\\n2. Participants must have a histologically or cytologically confirmed metastatic or locally advanced tumour. Further details on tumour types are specified in Module-specific inclusion criteria.\\n3. Participants must have received and progressed on, are refractory or are intolerant to standard therapy for the specific tumour type, or as per Module-specific criteria. Participants with contraindications to, or who refuse SoC therapy may be considered, provided that it is documented and the participant has been informed about all available therapeutic options.\\n4. Documented KRASG12D mutation in tissue or liquid biopsy.\\n5. Provision of a FFPE tumour sample.\\n6. Participants must have at least one measurable target lesion per RECIST v1.1.\\n7. Adequate organ and marrow function as defined in study protocol.\\n\\nModule 1 Key Inclusion Criteria\\n\\n1. Type of tumours with a KRASG12D mutation:\\n\\n   1. For NSCLC: Patients must have NSCLC that is not amenable to curative treatment and should have progressed on at least one prior line of SoC treatment for metastatic NSCLC (including but not limited to platinum-based chemotherapy, immunotherapy, targeted therapy or first line SoC combinations); prior experimental treatments are allowed.\\n   2. For CRC: Patients must have CRC that is not amenable to curative treatment and should have progressed on at least 2 prior lines of SoC treatment for metastatic CRC; prior experimental treatments are allowed.\\n   3. For PDAC: Patients must have PDAC that is not amenable to curative treatment and should have progressed at least one prior line of SoC treatment for metastatic PDAC (including but not limited to FOLFIRINOX, gemcitabine plus abraxane and gemcitabine monotherapy); prior experimental treatments are allowed.\\n   4. For patients enrolled in Part C (NSCLC and PDAC): at least one but no more than 2 lines of prior treatment in metastatic settings; prior experimental treatments are allowed.\\n2. Progression or recurrence of the disease within 6 months of completing neo/adjuvant treatment (ie, chemotherapy, immunotherapy, chemoradiotherapy, etc) will be considered as a first line of treatment.\\n3. For Part B food-effect cohort, participants must be able to eat a standard high-fat meal and must be able to fast for at least 10 hours.\\n\\nModule 2 Inclusion Criteria\\n\\n1. For Part A (M2A, dose escalation) participants must have pathologically documented locally advanced or metastatic CRC with a KRASG12D mutation.\\n2. For Part B (M2B, dose optimisation) participants must have pathologically documented locally advanced or metastatic, PDAC or CRC with a KRASG12D mutation.\\n3. For Part C (M2C, potential efficacy expansion) participants must have pathologically documented locally advanced or metastatic CRC with a KRASG12D mutation.\\n\\n4(a) For CRC: Patients must have CRC that is not amenable to curative treatment and should have progressed on at least 2 prior lines of SoC treatment for metastatic CRC; prior treatment are allowed.\\n\\n(b) For PDAC: Patients must have PDAC that is not amenable to curative treatment and should have progressed at least one prior line of SoC treatment for metastatic PDAC (including but not limited to FOLFIRINOX, gemcitabine plus abraxane and gemcitabine monotherapy); prior experimental treatment are allowed.\\n\\n(c) For patients enrolled in Part C (M2C), at least 2 but no more than 3 lines of prior treatment in metastatic setting; prior experimental treatment are allowed.\\n\\n5. Progression or recurrence of the disease within 6 months of completing neo/adjuvant treatment (ie, chemotherapy, immunotherapy, and chemoradiotherapy) will be considered as a first line of treatment.\\n\\nExclusion Criteria:\\n\\nFor whole study:\\n\\n1. Any significant laboratory finding or any severe and uncontrolled medical condition.\\n2. Any evidence of clinically significant current or prior ILD (eg, required IV steroids or high supplemental oxygen) or where a new suspected ILD cannot be ruled out by imaging at screening.\\n3. Spinal cord compression, leptomeningeal disease, or active brain metastases. Asymptomatic brain metastases are allowed\\n4. History of allogenic organ transplantation.\\n5. Participants with any of the following cardiac criteria:\\n\\n   * Mean resting QTcF \\\\> 470 milliseconds on screening\\n   * Any factors that increase the risk of QT prolongation\\n   * Any clinically important abnormalities in rhythm, conduction or morphology of resting ECG (eg, complete left bundle branch block, second- or third-degree atrioventricular block), and clinically significant sinus node dysfunction not treated with pacemaker.\\n   * Bradycardia defined as a heart rate less than 60 beats per minute and/or hypotension defined as a blood pressure reading lower than 90 mm Hg for the top number (systolic) or 60 mm Hg for the bottom number (diastolic).\\n   * Baseline LVEF below the institutional lower limit of normal or \\\\< 50%, whichever is lower.\\n   * Symptomatic heart failure (as defined by New York Heart Association class ≥ 2).\\n   * Acute coronary syndrome/acute myocardial infarction, unstable angina pectoris, coronary intervention procedure with percutaneous coronary intervention, or coronary artery bypass grafting within 6 months before C1D1.\\n6. Prior exposure to any direct small molecule KRAS inhibitor.\\n7. Herbal preparations/medications are not allowed during treatment with study drug.\\n8. Any concomitant medications that are known strong inhibitors or inducers of CYP3A4/5, or sensitive CYP3A4/5 substrates or CYP3A4/5 substrates with a narrow therapeutic range. This also applies to moderate inhibitors and moderate inducers of CYP3A4/5 during Parts A and B of Modules 1 and 2.\\n9. Receipt of a cytotoxic or non-cytotoxic drug: 21 days or 5 half-lives, whichever is shorter, before the first dose of study intervention. Biological therapy including immune-oncology and monoclonal antibodies 28 days or 5 half-lives.\\n10. Less than or equal to 4 weeks for radiation therapy given with curative intent or ≤ 2 weeks for limited field radiation for palliation prior to the first dose of study treatment', 'healthyVolunteers': False, 'sex': 'ALL', 'minimumAge': '18 Years', 'stdAges': ['ADULT', 'OLDER_ADULT']}, 'contactsLocationsModule': {'centralContacts': [{'name': 'AstraZeneca Clinical Study Information Center', 'role': 'CONTACT', 'phone': '1-877-240-9479', 'email': 'information.center@astrazeneca.com'}], 'locations': [{'facility': 'Research Site', 'status': 'RECRUITING', 'city': 'Duarte', 'state': 'California', 'zip': '91010', 'country': 'United States', 'geoPoint': {'lat': 34.13945, 'lon': -117.97729}}, {'facility': 'Research Site', 'status': 'NOT_YET_RECRUITING', 'city': 'Los Angeles', 'state': 'California', 'zip': '90095', 'country': 'United States', 'geoPoint': {'lat': 34.05223, 'lon': -118.24368}}, {'facility': 'Research Site', 'status': 'RECRUITING', 'city': 'Stanford', 'state': 'California', 'zip': '94305-5847', 'country': 'United States', 'geoPoint': {'lat': 37.42411, 'lon': -122.16608}}, {'facility': 'Research Site', 'status': 'NOT_YET_RECRUITING', 'city': 'Aurora', 'state': 'Colorado', 'zip': '80045', 'country': 'United States', 'geoPoint': {'lat': 39.72943, 'lon': -104.83192}}, {'facility': 'Research Site', 'status': 'RECRUITING', 'city': 'New York', 'state': 'New York', 'zip': '10016', 'country': 'United States', 'geoPoint': {'lat': 40.71427, 'lon': -74.00597}}, {'facility': 'Research Site', 'status': 'NOT_YET_RECRUITING', 'city': 'New York', 'state': 'New York', 'zip': '10021', 'country': 'United States', 'geoPoint': {'lat': 40.71427, 'lon': -74.00597}}, {'facility': 'Research Site', 'status': 'NOT_YET_RECRUITING', 'city': 'Pittsburgh', 'state': 'Pennsylvania', 'zip': '15232', 'country': 'United States', 'geoPoint': {'lat': 40.44062, 'lon': -79.99589}}, {'facility': 'Research Site', 'status': 'RECRUITING', 'city': 'Nashville', 'state': 'Tennessee', 'zip': '37203', 'country': 'United States', 'geoPoint': {'lat': 36.16589, 'lon': -86.78444}}, {'facility': 'Research Site', 'status': 'RECRUITING', 'city': 'San Antonio', 'state': 'Texas', 'zip': '78229', 'country': 'United States', 'geoPoint': {'lat': 29.42412, 'lon': -98.49363}}, {'facility': 'Research Site', 'status': 'RECRUITING', 'city': 'Fairfax', 'state': 'Virginia', 'zip': '22031', 'country': 'United States', 'geoPoint': {'lat': 38.84622, 'lon': -77.30637}}, {'facility': 'Research Site', 'status': 'RECRUITING', 'city': 'Melbourne', 'zip': '3000', 'country': 'Australia', 'geoPoint': {'lat': -37.814, 'lon': 144.96332}}, {'facility': 'Research Site', 'status': 'RECRUITING', 'city': 'Edegem', 'zip': '2650', 'country': 'Belgium', 'geoPoint': {'lat': 51.15662, 'lon': 4.44504}}, {'facility': 'Research Site', 'status': 'RECRUITING', 'city': 'Leuven', 'zip': '3000', 'country': 'Belgium', 'geoPoint': {'lat': 50.87959, 'lon': 4.70093}}, {'facility': 'Research Site', 'status': 'RECRUITING', 'city': 'Edmonton', 'state': 'Alberta', 'zip': 'T6G 1Z2', 'country': 'Canada', 'geoPoint': {'lat': 53.55014, 'lon': -113.46871}}, {'facility': 'Research Site', 'status': 'RECRUITING', 'city': 'Toronto', 'state': 'Ontario', 'zip': 'M5G 1X5', 'country': 'Canada', 'geoPoint': {'lat': 43.70011, 'lon': -79.4163}}, {'facility': 'Research Site', 'status': 'RECRUITING', 'city': 'Montréal', 'state': 'Quebec', 'zip': 'H3A 1A1', 'country': 'Canada', 'geoPoint': {'lat': 45.50884, 'lon': -73.58781}}, {'facility': 'Research Site', 'status': 'NOT_YET_RECRUITING', 'city': 'Beijing', 'zip': '100142', 'country': 'China', 'geoPoint': {'lat': 39.9075, 'lon': 116.39723}}, {'facility': 'Research Site', 'status': 'NOT_YET_RECRUITING', 'city': 'Chengdu', 'zip': '610041', 'country': 'China', 'geoPoint': {'lat': 30.66667, 'lon': 104.06667}}, {'facility': 'Research Site', 'status': 'NOT_YET_RECRUITING', 'city': 'Zhengzhou', 'zip': '450008', 'country': 'China', 'geoPoint': {'lat': 34.75778, 'lon': 113.64861}}, {'facility': 'Research Site', 'status': 'NOT_YET_RECRUITING', 'city': 'Hong Kong', 'zip': '999077', 'country': 'Hong Kong', 'geoPoint': {'lat': 22.27832, 'lon': 114.17469}}, {'facility': 'Research Site', 'status': 'RECRUITING', 'city': 'Milano', 'zip': '20132', 'country': 'Italy', 'geoPoint': {'lat': 45.46427, 'lon': 9.18951}}, {'facility': 'Research Site', 'status': 'NOT_YET_RECRUITING', 'city': 'Napoli', 'zip': '80131', 'country': 'Italy', 'geoPoint': {'lat': 40.85216, 'lon': 14.26811}}, {'facility': 'Research Site', 'status': 'NOT_YET_RECRUITING', 'city': 'Verona', 'zip': '37134', 'country': 'Italy', 'geoPoint': {'lat': 45.4299, 'lon': 10.98444}}, {'facility': 'Research Site', 'status': 'RECRUITING', 'city': 'Kashiwa', 'zip': '227-8577', 'country': 'Japan', 'geoPoint': {'lat': 35.86224, 'lon': 139.97732}}, {'facility': 'Research Site', 'status': 'RECRUITING', 'city': 'Tokyo', 'zip': '104-0045', 'country': 'Japan', 'geoPoint': {'lat': 35.6895, 'lon': 139.69171}}, {'facility': 'Research Site', 'status': 'RECRUITING', 'city': 'Seoul', 'zip': '03080', 'country': 'Korea, Republic of', 'geoPoint': {'lat': 37.566, 'lon': 126.9784}}, {'facility': 'Research Site', 'status': 'RECRUITING', 'city': 'Seoul', 'zip': '06351', 'country': 'Korea, Republic of', 'geoPoint': {'lat': 37.566, 'lon': 126.9784}}, {'facility': 'Research Site', 'status': 'RECRUITING', 'city': 'Seoul', 'zip': '120-752', 'country': 'Korea, Republic of', 'geoPoint': {'lat': 37.566, 'lon': 126.9784}}, {'facility': 'Research Site', 'status': 'RECRUITING', 'city': 'Seoul', 'zip': '5505', 'country': 'Korea, Republic of', 'geoPoint': {'lat': 37.566, 'lon': 126.9784}}, {'facility': 'Research Site', 'status': 'NOT_YET_RECRUITING', 'city': 'Amsterdam', 'zip': '1066CX', 'country': 'Netherlands', 'geoPoint': {'lat': 52.37403, 'lon': 4.88969}}, {'facility': 'Research Site', 'status': 'RECRUITING', 'city': 'Gdańsk', 'zip': '80-214', 'country': 'Poland', 'geoPoint': {'lat': 54.35205, 'lon': 18.64637}}, {'facility': 'Research Site', 'status': 'RECRUITING', 'city': 'Łódź', 'zip': '93-513', 'country': 'Poland', 'geoPoint': {'lat': 51.75, 'lon': 19.46667}}, {'facility': 'Research Site', 'status': 'RECRUITING', 'city': 'Barcelona', 'zip': '08035', 'country': 'Spain', 'geoPoint': {'lat': 41.38879, 'lon': 2.15899}}, {'facility': 'Research Site', 'status': 'RECRUITING', 'city': \"L'Hospitalet de Llobregat\", 'zip': '08908', 'country': 'Spain', 'geoPoint': {'lat': 41.35967, 'lon': 2.10028}}, {'facility': 'Research Site', 'status': 'RECRUITING', 'city': 'Madrid', 'zip': '28007', 'country': 'Spain', 'geoPoint': {'lat': 40.4165, 'lon': -3.70256}}, {'facility': 'Research Site', 'status': 'RECRUITING', 'city': 'Madrid', 'zip': '28027', 'country': 'Spain', 'geoPoint': {'lat': 40.4165, 'lon': -3.70256}}, {'facility': 'Research Site', 'status': 'RECRUITING', 'city': 'Valencia', 'zip': '46026', 'country': 'Spain', 'geoPoint': {'lat': 39.46975, 'lon': -0.37739}}, {'facility': 'Research Site', 'status': 'NOT_YET_RECRUITING', 'city': 'Bangkok', 'zip': '10400', 'country': 'Thailand', 'geoPoint': {'lat': 13.75398, 'lon': 100.50144}}, {'facility': 'Research Site', 'status': 'NOT_YET_RECRUITING', 'city': 'Bangkok', 'zip': '10700', 'country': 'Thailand', 'geoPoint': {'lat': 13.75398, 'lon': 100.50144}}, {'facility': 'Research Site', 'status': 'NOT_YET_RECRUITING', 'city': 'Ankara', 'zip': '06800', 'country': 'Turkey', 'geoPoint': {'lat': 39.91987, 'lon': 32.85427}}, {'facility': 'Research Site', 'status': 'NOT_YET_RECRUITING', 'city': 'Istanbul', 'zip': '34718', 'country': 'Turkey', 'geoPoint': {'lat': 41.01384, 'lon': 28.94966}}, {'facility': 'Research Site', 'status': 'NOT_YET_RECRUITING', 'city': 'Cambridge', 'zip': 'CB2 0QQ', 'country': 'United Kingdom', 'geoPoint': {'lat': 52.2, 'lon': 0.11667}}, {'facility': 'Research Site', 'status': 'NOT_YET_RECRUITING', 'city': 'Manchester', 'zip': 'M20 4BX', 'country': 'United Kingdom', 'geoPoint': {'lat': 53.48095, 'lon': -2.23743}}, {'facility': 'Research Site', 'status': 'NOT_YET_RECRUITING', 'city': 'Newcastle-Upon-Tyne', 'zip': 'NE7 7DN', 'country': 'United Kingdom', 'geoPoint': {'lat': 54.97328, 'lon': -1.61396}}]}, 'ipdSharingStatementModule': {'ipdSharing': 'YES', 'description': 'Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment:\\n\\nhttps://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.', 'timeFrame': 'AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA PhRMA Data Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure', 'accessCriteria': 'When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.', 'url': 'https://vivli.org/'}}, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-08-20'}, 'conditionBrowseModule': {'meshes': [{'id': 'D000230', 'term': 'Adenocarcinoma'}], 'ancestors': [{'id': 'D009369', 'term': 'Neoplasms'}, {'id': 'D002277', 'term': 'Carcinoma'}, {'id': 'D009375', 'term': 'Neoplasms, Glandular and Epithelial'}, {'id': 'D009370', 'term': 'Neoplasms by Histologic Type'}], 'browseLeaves': [{'id': 'M3585', 'name': 'Adenocarcinoma', 'asFound': 'Adenocarcinoma', 'relevance': 'HIGH'}, {'id': 'M11172', 'name': 'Lung Neoplasms', 'relevance': 'LOW'}, {'id': 'M5546', 'name': 'Carcinoma, Non-Small-Cell Lung', 'relevance': 'LOW'}, {'id': 'M5534', 'name': 'Carcinoma', 'relevance': 'LOW'}, {'id': 'M12320', 'name': 'Neoplasms, Glandular and Epithelial', 'relevance': 'LOW'}, {'id': 'M12315', 'name': 'Neoplasms by Histologic Type', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'BC04', 'name': 'Neoplasms'}, {'abbrev': 'All', 'name': 'All Conditions'}, {'abbrev': 'BC08', 'name': 'Respiratory Tract (Lung and Bronchial) Diseases'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'D000068818', 'term': 'Cetuximab'}], 'ancestors': [{'id': 'D000074322', 'term': 'Antineoplastic Agents, Immunological'}, {'id': 'D000970', 'term': 'Antineoplastic Agents'}], 'browseLeaves': [{'id': 'M4225', 'name': 'Antibodies', 'relevance': 'LOW'}, {'id': 'M4230', 'name': 'Antibodies, Monoclonal', 'relevance': 'LOW'}, {'id': 'M10184', 'name': 'Immunoglobulins', 'relevance': 'LOW'}, {'id': 'M315', 'name': 'Cetuximab', 'asFound': 'Observational', 'relevance': 'HIGH'}, {'id': 'M10122', 'name': 'Immunoglobulin G', 'relevance': 'LOW'}, {'id': 'M19117', 'name': 'Immunoglobulins, Intravenous', 'relevance': 'LOW'}, {'id': 'M1346', 'name': 'Antineoplastic Agents, Immunological', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'All', 'name': 'All Drugs and Chemicals'}, {'abbrev': 'ANeo', 'name': 'Antineoplastic Agents'}]}}, 'hasResults': False}\n",
      "Keys for NCT04912687:\n",
      "dict_keys(['protocolSection', 'derivedSection', 'hasResults'])\n",
      "Content for NCT04912687:\n",
      "{'protocolSection': {'identificationModule': {'nctId': 'NCT04912687', 'orgStudyIdInfo': {'id': 'IB 2021-02'}, 'secondaryIdInfos': [{'id': '2021-A00685-36', 'type': 'OTHER', 'domain': 'ANSM IDRCB Number'}], 'organization': {'fullName': 'Institut Bergonié', 'class': 'OTHER'}, 'briefTitle': 'Implementing Circulating Tumor DNA Analysis at Initial Diagnosis to Improve Management of Advanced NSCLC Patients', 'officialTitle': 'Implementing Circulating Tumor DNA Analysis at Initial Diagnosis to Improve Management of Advanced Non-small Cell Lung Cancer Patients (NSCLC)', 'acronym': 'CIRCULAR'}, 'statusModule': {'statusVerifiedDate': '2025-08', 'overallStatus': 'RECRUITING', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2022-01-01', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2026-08-01', 'type': 'ESTIMATED'}, 'completionDateStruct': {'date': '2027-08-01', 'type': 'ESTIMATED'}, 'studyFirstSubmitDate': '2021-05-28', 'studyFirstSubmitQcDate': '2021-05-28', 'studyFirstPostDateStruct': {'date': '2021-06-03', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2025-08-11', 'lastUpdatePostDateStruct': {'date': '2025-08-13', 'type': 'ACTUAL'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'}, 'leadSponsor': {'name': 'Institut Bergonié', 'class': 'OTHER'}, 'collaborators': [{'name': 'AstraZeneca', 'class': 'INDUSTRY'}]}, 'oversightModule': {'oversightHasDmc': False, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'descriptionModule': {'briefSummary': 'Multicenter prospective cohort study aiming to evaluate the detection rate of EGFR gene mutation in patients with advanced NSCLC in a real-word clinical setting, based on liquid biopsy and tissue analyses.', 'detailedDescription': 'This a multicenter prospective cohort study. This study will be proposed to newly diagnosed advanced NSCLC patients. For included patients, archived paraffin embedded tumor tissue will be used for sequencing ; and blood sample will be collected for research purpose (plasma DNA collection and sequencing).\\n\\nBoth tissue and liquid biopsy samples will follow usual processes and will be sent to the Molecular Pathology laboratory of the Investigation center.'}, 'conditionsModule': {'conditions': ['Non Small Cell Lung Cancer', 'Advanced Solid Tumor'], 'keywords': ['non-small cell lung cancer', 'EGFR detection', 'liquid biopsy']}, 'designModule': {'studyType': 'INTERVENTIONAL', 'phases': ['NA'], 'designInfo': {'allocation': 'NA', 'interventionModel': 'SINGLE_GROUP', 'interventionModelDescription': 'This is a multicentric prospective cohort in which newly diagnosed advanced NSCLC patients will be included. For all patients, both tumor and liquid biopsy samples will be used for sequencing and detection of EGFR gene mutation', 'primaryPurpose': 'SCREENING', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 580, 'type': 'ESTIMATED'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'All patients', 'type': 'EXPERIMENTAL', 'description': 'For all patients, blood sample will be collected at inclusion (liquid biopsy) for sequencing.\\n\\nAs per standard management, for all of these patients, EGFR gene mutation will be also analyzed on archived tumor sample.', 'interventionNames': ['Diagnostic Test: EGFR gene mutation analysis on liquid biopsy']}], 'interventions': [{'type': 'DIAGNOSTIC_TEST', 'name': 'EGFR gene mutation analysis on liquid biopsy', 'description': 'Blood samples will be collected at inclusion for plasma DNA collection and analysis.', 'armGroupLabels': ['All patients']}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'To assess the detection rate of patients with an EGFR actionable alteration when using the combination of two diagnostic procedures which include liquid biopsy analysis (by droplet digital PCR or allele specific PCR) and tissue analysis', 'description': 'Resuls of each EGFR diagnostic procedure will be categorized as EGFR positive in case of the presence of an EGFR actionnable alteration ; as EGFR negative in case of the absence of an EGFR actionnable alteration ; or nor interpretable. A patient will be considered to have an EGFR actionable alteration if the mutation has been detected on the sequencing of tumor tissue OR if it has been detected on the liquid biopsy procedure', 'timeFrame': 'within 3 weeks after signature of informed consent'}], 'secondaryOutcomes': [{'measure': 'The detection rate of patients with an EGFR actionable alteration based on the use of liquid biopsy analysis only', 'description': 'A patient will be considered to have an EGFR actionable alteration (EGFR+) detected by the liquid biopsy analysis if an EGFR actionable alteration is identified based on the liquid biopsy analysis', 'timeFrame': 'within 3 weeks after signature of informed consent'}, {'measure': 'The detection rate of patients with an EGFR actionable alteration based on tissue analysis only', 'description': 'A patient will be considered to have an EGFR actionable alteration (EGFR+) detected by tissue analysis if an EGFR actionable alteration is identified based on the sequencing of tumor tissue', 'timeFrame': 'within 3 weeks after signature of informed consent'}, {'measure': 'The concordance and discordance rates between the two procedures', 'description': 'Concordance is defined whenever results of both techniques are identical (i.e. EGFR+ for both techniques or EGFR- for both techniques). Discordance is defined whenever results of both techniques are different.', 'timeFrame': 'within 3 weeks after signature of informed consent'}, {'measure': 'The failure rate for each procedure and reasons of failure (insufficient DNA quantity, poor DNA quality, insufficient tissue quantity, poor tissue quality, analytical failure)', 'description': '•\\n\\nFailure of a procedure (sequencing of tumor tissue or liquid biopsy) is defined whenever the procedure fails to provide an interpretable result (Reasons for failure will be collected, i.e. insufficient DNA quantity, poor DNA quality, insufficient DNA/tissue quantity, poor DNA/tissue quality, analytical failure)', 'timeFrame': 'within 3 weeks after signature of informed consent'}, {'measure': 'Delay to obtain sequencing results', 'description': 'The delay between the date of the signature of the informed consent and the date of availability of the results for each procedure', 'timeFrame': 'within 3 weeks after signature of informed consent'}, {'measure': 'Delay for treatment initiation', 'description': 'The delay between the date of sample collection and the date of treatment initiation', 'timeFrame': 'within 3 months after signature of informed consent'}]}, 'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\n\\n1. Male or female patients aged ≥ 18 years at time of proposal study,\\n2. Histologically confirmed non-small cell lung carcinoma,\\n3. No previous treatment for NSCLC,\\n4. Indication to EGFR status determination following HAS recommendation,\\n5. Voluntary signed and dated written informed consent prior to any study specific procedure\\n6. Patients with a social security in compliance with the French Law.\\n\\nExclusion Criteria:\\n\\n1. Treatment for advanced NSCLC started before liquid biopsy sampling.\\n2. Involvement in the planning and/or conduct of the study (applies to both Investigator staff and/or staff at the study site).', 'healthyVolunteers': False, 'sex': 'ALL', 'minimumAge': '18 Years', 'stdAges': ['ADULT', 'OLDER_ADULT']}, 'contactsLocationsModule': {'centralContacts': [{'name': 'Isabelle SOUBEYRAN, MD, PhD', 'role': 'CONTACT', 'phone': '(0)5.56.33.33.33', 'email': 'i.soubeyran@bordeaux.unicancer.fr'}, {'name': 'Simone MATHOULIN-PELISSIER, MD, PhD', 'role': 'CONTACT', 'phone': '(0)5.56.33.33.33', 'email': 's.mathoulin@bordeaux.unicancer.fr'}], 'locations': [{'facility': \"Institut de Cancérologie de l'Ouest - Site Paul Papin\", 'status': 'NOT_YET_RECRUITING', 'city': 'Angers', 'zip': '49000', 'country': 'France', 'contacts': [{'name': 'Alain MOREL, Pr', 'role': 'CONTACT', 'email': 'alain.morel@ico.unicancer.fr'}], 'geoPoint': {'lat': 47.46667, 'lon': -0.55}}, {'facility': 'Institut Bergonie', 'status': 'RECRUITING', 'city': 'Bordeaux', 'zip': '33076', 'country': 'France', 'contacts': [{'name': 'Sophie COUSIN, Dr', 'role': 'CONTACT', 'email': 's.cousin@bordeaux.unicancer.fr'}], 'geoPoint': {'lat': 44.84044, 'lon': -0.5805}}, {'facility': 'CHRU Lille', 'status': 'NOT_YET_RECRUITING', 'city': 'Lille', 'zip': '59037', 'country': 'France', 'contacts': [{'name': 'Alexis CORTOT, Pr', 'role': 'CONTACT', 'email': 'alexis.cortot@chru-lille.fr'}], 'geoPoint': {'lat': 50.63297, 'lon': 3.05858}}, {'facility': 'Hospices Civils de Lyon', 'status': 'RECRUITING', 'city': 'Lyon', 'zip': '69002', 'country': 'France', 'contacts': [{'name': 'Sébastien COURAUD, Pr', 'role': 'CONTACT', 'email': 'sebastien.couraud@chu-lyon.fr'}], 'geoPoint': {'lat': 45.74848, 'lon': 4.84669}}, {'facility': 'CHU Nice-Hopital de Cimiel', 'status': 'RECRUITING', 'city': 'Nice', 'zip': '06000', 'country': 'France', 'contacts': [{'name': 'Paul HOFMAN, Pr', 'role': 'CONTACT', 'email': 'hofman.p@chu-nice.fr'}], 'geoPoint': {'lat': 43.70313, 'lon': 7.26608}}, {'facility': 'Institut Curie', 'status': 'NOT_YET_RECRUITING', 'city': 'Paris', 'zip': '75248', 'country': 'France', 'contacts': [{'name': 'Catherine DANIEL, Dr', 'role': 'CONTACT', 'email': 'catherine.daniel@curie.fr'}], 'geoPoint': {'lat': 48.85341, 'lon': 2.3488}}, {'facility': 'CHU Poitiers', 'status': 'NOT_YET_RECRUITING', 'city': 'Poitiers', 'zip': '86021', 'country': 'France', 'contacts': [{'name': 'Clotilde DELDYCKE, Dr', 'role': 'CONTACT', 'email': 'clotilde.deldycke@chu-poitiers.fr'}], 'geoPoint': {'lat': 46.58333, 'lon': 0.33333}}, {'facility': 'CHU de Rennes - Hopital Pontchaillou', 'status': 'RECRUITING', 'city': 'Rennes', 'zip': '35033', 'country': 'France', 'contacts': [{'name': 'Hervé LENA, Dr', 'role': 'CONTACT', 'email': 'herve.lena@chu-rennes.fr'}], 'geoPoint': {'lat': 48.11198, 'lon': -1.67429}}, {'facility': 'CHU Strasbourg', 'status': 'RECRUITING', 'city': 'Strasbourg', 'zip': '67091', 'country': 'France', 'contacts': [{'name': 'Michèle BEAU-FALLER, Pr', 'role': 'CONTACT', 'email': 'michele.beau@chru-strasbourg.fr'}], 'geoPoint': {'lat': 48.58392, 'lon': 7.74553}}]}, 'ipdSharingStatementModule': {'ipdSharing': 'NO'}}, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-08-21'}, 'conditionBrowseModule': {'meshes': [{'id': 'D008175', 'term': 'Lung Neoplasms'}, {'id': 'D002289', 'term': 'Carcinoma, Non-Small-Cell Lung'}], 'ancestors': [{'id': 'D012142', 'term': 'Respiratory Tract Neoplasms'}, {'id': 'D013899', 'term': 'Thoracic Neoplasms'}, {'id': 'D009371', 'term': 'Neoplasms by Site'}, {'id': 'D009369', 'term': 'Neoplasms'}, {'id': 'D008171', 'term': 'Lung Diseases'}, {'id': 'D012140', 'term': 'Respiratory Tract Diseases'}, {'id': 'D002283', 'term': 'Carcinoma, Bronchogenic'}, {'id': 'D001984', 'term': 'Bronchial Neoplasms'}], 'browseLeaves': [{'id': 'M11172', 'name': 'Lung Neoplasms', 'asFound': 'Lung Cancer', 'relevance': 'HIGH'}, {'id': 'M5546', 'name': 'Carcinoma, Non-Small-Cell Lung', 'asFound': 'Non-small Cell Lung Cancer', 'relevance': 'HIGH'}, {'id': 'M5534', 'name': 'Carcinoma', 'relevance': 'LOW'}, {'id': 'M14979', 'name': 'Respiratory Tract Neoplasms', 'relevance': 'LOW'}, {'id': 'M16658', 'name': 'Thoracic Neoplasms', 'relevance': 'LOW'}, {'id': 'M11168', 'name': 'Lung Diseases', 'relevance': 'LOW'}, {'id': 'M14977', 'name': 'Respiratory Tract Diseases', 'relevance': 'LOW'}, {'id': 'M5540', 'name': 'Carcinoma, Bronchogenic', 'relevance': 'LOW'}, {'id': 'M5260', 'name': 'Bronchial Neoplasms', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'BC04', 'name': 'Neoplasms'}, {'abbrev': 'BC08', 'name': 'Respiratory Tract (Lung and Bronchial) Diseases'}, {'abbrev': 'All', 'name': 'All Conditions'}]}}, 'hasResults': False}\n",
      "Keys for NCT06595498:\n",
      "dict_keys(['protocolSection', 'derivedSection', 'hasResults'])\n",
      "Content for NCT06595498:\n",
      "{'protocolSection': {'identificationModule': {'nctId': 'NCT06595498', 'orgStudyIdInfo': {'id': 'RARE study'}, 'organization': {'fullName': 'Istituto Oncologico Veneto IRCCS', 'class': 'OTHER'}, 'briefTitle': 'Next Generation Sequencing Method for the Detection of EGFR Gene Mutations in the Plasma of Patients with Lung Cancer', 'officialTitle': 'Evaluation of an Ultrasensitive Next Generation Sequencing Method for the Detection of EGFR Gene Mutations in the Plasma of Patients with Lung Cancer'}, 'statusModule': {'statusVerifiedDate': '2024-09', 'overallStatus': 'RECRUITING', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2024-07-01', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2025-07-01', 'type': 'ESTIMATED'}, 'completionDateStruct': {'date': '2025-07-01', 'type': 'ESTIMATED'}, 'studyFirstSubmitDate': '2024-08-07', 'studyFirstSubmitQcDate': '2024-09-11', 'studyFirstPostDateStruct': {'date': '2024-09-19', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2024-09-11', 'lastUpdatePostDateStruct': {'date': '2024-09-19', 'type': 'ACTUAL'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'}, 'leadSponsor': {'name': 'Istituto Oncologico Veneto IRCCS', 'class': 'OTHER'}}, 'oversightModule': {'oversightHasDmc': False, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False, 'isUsExport': False}, 'descriptionModule': {'briefSummary': 'The study aims to evaluate the Plasma-SeqSensei™ Solid Cancer IVD Kit NGS diagnostic test (Sysmex) before its introduction into routine diagnostics. This is a test for research of EGFR mutations in cfDNA that needs to be evaluated in a patient population with lung adenocarcinoma already characterized for EGFR mutations by a molecular test of reference. The proposed study does not present any risk to participants.'}, 'conditionsModule': {'conditions': ['Carcinoma, Non-small Cell Lung Cancer (NSCLC)'], 'keywords': ['lung cancer', 'non-small cell lung cancer', 'EGFR mutation', 'Next Generation Sequencing', 'plasma']}, 'designModule': {'studyType': 'INTERVENTIONAL', 'phases': ['NA'], 'designInfo': {'allocation': 'NON_RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'DIAGNOSTIC', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 118, 'type': 'ESTIMATED'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'SeqSensei™ Solid Cancer IVD Kit (Sysmex)', 'type': 'EXPERIMENTAL', 'interventionNames': ['Diagnostic Test: Plasma- SeqSensei™ Solid Cancer IVD Kit (Sysmex)']}, {'label': 'cobas® EGFR Mutation Test v2 (Roche)', 'type': 'ACTIVE_COMPARATOR', 'interventionNames': ['Diagnostic Test: cobas® EGFR Mutation Test v2 (Roche)']}], 'interventions': [{'type': 'DIAGNOSTIC_TEST', 'name': 'Plasma- SeqSensei™ Solid Cancer IVD Kit (Sysmex)', 'description': \"The patients' blood has already been collected in Streck tubes for circulating DNA and the plasma has been stored at -80°C as per the procedure for the routine diagnostic test cobas EGFR Mutation Test v2. No further blood sampling will be required from patients. Circulating DNA/RNA will be extracted from 2-5 ml of plasma. The extracted cfDNA will be quantified. The libraries will be prepared using the NGS Plasma-SeqSensei™ Solid Cancer IVD Kit (Sysmex) and will be evaluated at the Tapestation (Agilent) to verify their quality and quantity using D1000 Screentapes. The libraries consisting of approximately 16 samples each will then be sequenced on an Illumina NextSeq 500 sequencer using the Illumina NextSeq 500/550 Mid Output Kit v2.5 (150 Cycles). Data analysis will be performed using Plasma-SeqSensei™ IVD Software (Sysmex).\", 'armGroupLabels': ['SeqSensei™ Solid Cancer IVD Kit (Sysmex)']}, {'type': 'DIAGNOSTIC_TEST', 'name': 'cobas® EGFR Mutation Test v2 (Roche)', 'description': \"The patients' blood has already been collected in Streck tubes for circulating DNA and the plasma has been stored at -80°C as per the procedure for the routine diagnostic test cobas EGFR Mutation Test v2. No further blood sampling will be required from patients. Circulating DNA/RNA will be extracted from 2-5 ml of plasma. The extracted cfDNA will be quantified. The libraries will be prepared using the cobas® EGFR Mutation Test v2 (Roche) and will be evaluated at the Tapestation (Agilent) to verify their quality and quantity using D1000 Screentapes. The libraries consisting of approximately 16 samples each will then be sequenced on an Illumina NextSeq 500 sequencer using the Illumina NextSeq 500/550 Mid Output Kit v2.5 (150 Cycles).\", 'armGroupLabels': ['cobas® EGFR Mutation Test v2 (Roche)']}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Primary Outcome', 'description': 'Evaluate the capability of the NGS test Plasma-SeqSensei™ Solid Cancer IVD Kit (Sysmex) in detecting a greater number of EGFR mutations compared to the diagnostic test routine cobas® EGFR Mutation Test v2 (Roche)', 'timeFrame': 'Through study completion, an average of 1 year'}], 'secondaryOutcomes': [{'measure': 'Secondary Outcome', 'description': 'Check if the NGS Plasma-SeqSensei™ Solid Cancer IVD Kit (Sysmex) is comparable to conventional test (cobas® EGFR MutationTest v2 (Roche)) in the detection of the mutational status of EGFR', 'timeFrame': 'Through study completion, an average of 1 year'}]}, 'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\n\\n* Males or Females aged at least 18 years;\\n* Patients with advanced or metastatic non-small cell lung cancer at diagnosis or progression who have previously had the cobas® EGFR Mutation Test v2 (Roche) performed on a liquid biopsy with a valid result (positive or negative);\\n* Availability of 6 mL of plasma.\\n\\nExclusion Criteria:\\n\\n* Plasma not available in sufficient quantities to perform both tests;\\n* Cobas test with invalid result.', 'healthyVolunteers': False, 'sex': 'ALL', 'minimumAge': '18 Years', 'stdAges': ['ADULT', 'OLDER_ADULT']}, 'contactsLocationsModule': {'centralContacts': [{'name': 'Stefano Indraccolo, Prof', 'role': 'CONTACT', 'phone': '049 8215875', 'email': 'stefano.indraccolo@iov.veneto.it'}, {'name': 'GianLuca De Salvo, MD', 'role': 'CONTACT', 'phone': '0498215704', 'email': 'clinical.trial@iov.veneto.it'}], 'locations': [{'facility': 'Istituto Oncologico Veneto', 'status': 'RECRUITING', 'city': 'Padova', 'zip': '35128', 'country': 'Italy', 'contacts': [{'name': 'Stefano Indraccolo, Prof', 'role': 'CONTACT', 'phone': '049 8215875', 'email': 'stefano.indraccolo@iov.veneto.it'}], 'geoPoint': {'lat': 45.40797, 'lon': 11.88586}}]}, 'ipdSharingStatementModule': {'ipdSharing': 'NO'}}, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-08-21'}, 'conditionBrowseModule': {'meshes': [{'id': 'D008175', 'term': 'Lung Neoplasms'}, {'id': 'D002289', 'term': 'Carcinoma, Non-Small-Cell Lung'}], 'ancestors': [{'id': 'D012142', 'term': 'Respiratory Tract Neoplasms'}, {'id': 'D013899', 'term': 'Thoracic Neoplasms'}, {'id': 'D009371', 'term': 'Neoplasms by Site'}, {'id': 'D009369', 'term': 'Neoplasms'}, {'id': 'D008171', 'term': 'Lung Diseases'}, {'id': 'D012140', 'term': 'Respiratory Tract Diseases'}, {'id': 'D002283', 'term': 'Carcinoma, Bronchogenic'}, {'id': 'D001984', 'term': 'Bronchial Neoplasms'}], 'browseLeaves': [{'id': 'M5534', 'name': 'Carcinoma', 'relevance': 'LOW'}, {'id': 'M11172', 'name': 'Lung Neoplasms', 'asFound': 'Lung Cancer', 'relevance': 'HIGH'}, {'id': 'M5546', 'name': 'Carcinoma, Non-Small-Cell Lung', 'asFound': 'Carcinoma, Non-Small-Cell Lung', 'relevance': 'HIGH'}, {'id': 'M14979', 'name': 'Respiratory Tract Neoplasms', 'relevance': 'LOW'}, {'id': 'M16658', 'name': 'Thoracic Neoplasms', 'relevance': 'LOW'}, {'id': 'M11168', 'name': 'Lung Diseases', 'relevance': 'LOW'}, {'id': 'M14977', 'name': 'Respiratory Tract Diseases', 'relevance': 'LOW'}, {'id': 'M5540', 'name': 'Carcinoma, Bronchogenic', 'relevance': 'LOW'}, {'id': 'M5260', 'name': 'Bronchial Neoplasms', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'BC04', 'name': 'Neoplasms'}, {'abbrev': 'All', 'name': 'All Conditions'}, {'abbrev': 'BC08', 'name': 'Respiratory Tract (Lung and Bronchial) Diseases'}]}}, 'hasResults': False}\n",
      "Keys for NCT02769286:\n",
      "dict_keys(['protocolSection', 'derivedSection', 'hasResults'])\n",
      "Content for NCT02769286:\n",
      "{'protocolSection': {'identificationModule': {'nctId': 'NCT02769286', 'orgStudyIdInfo': {'id': 'ESR-15-11075'}, 'organization': {'fullName': 'Chonnam National University Hospital', 'class': 'OTHER'}, 'briefTitle': 'Osimertinib in First and Second Line Treatment of NSCLC Harboring EGFR Mutations From Circulating Tumor DNA', 'officialTitle': 'Phase II Trial of AZD9291 in First Line Treatment of Lung Cancer Harboring Activating EGFR Mutation From Circulating Tumor DNA and Second Line Treatment After Acquired Resistance With T790M Mutation Detected From Circulating Tumor DNA', 'acronym': 'LiquidLung-O'}, 'statusModule': {'statusVerifiedDate': '2021-08', 'overallStatus': 'COMPLETED', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2016-08', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2018-12', 'type': 'ACTUAL'}, 'completionDateStruct': {'date': '2020-05', 'type': 'ACTUAL'}, 'studyFirstSubmitDate': '2016-05-09', 'studyFirstSubmitQcDate': '2016-05-10', 'studyFirstPostDateStruct': {'date': '2016-05-11', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2021-08-01', 'lastUpdatePostDateStruct': {'date': '2021-08-03', 'type': 'ACTUAL'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'PRINCIPAL_INVESTIGATOR', 'investigatorFullName': 'Young-Chul Kim', 'investigatorTitle': 'Professor', 'investigatorAffiliation': 'Chonnam National University Hospital'}, 'leadSponsor': {'name': 'Chonnam National University Hospital', 'class': 'OTHER'}}, 'oversightModule': {'oversightHasDmc': False}, 'descriptionModule': {'briefSummary': 'Treatment efficacy of osimertinib will be assessed in patients with lung cancer harboring activating epidermal growth factor receptor (EGFR) mutations (cohort 1) and those harboring T790M (cohort 2) which were detected from circulating tumor DNA', 'detailedDescription': 'This is a phase II, open-label, single centre study of AZD9291 administered orally in patients with advanced lung cancer with activating mutations of EGFR gene with or without T790M which were detected from circulating tumor DNA. EGFR-TKI naïve patients with activating EGFR mutation will be enrolled in cohort 1. Patients with acquired resistance to prior EGFR tyrosine kinase inhibitor (TKI) due to T790M mutation is going to be enrolled in cohort 2.'}, 'conditionsModule': {'conditions': ['Lung Neoplasms', 'EGFR Gene Mutations']}, 'designModule': {'studyType': 'INTERVENTIONAL', 'phases': ['PHASE2'], 'designInfo': {'allocation': 'NON_RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 38, 'type': 'ACTUAL'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'Osimertinib in cohort 1', 'type': 'EXPERIMENTAL', 'description': 'Treatment efficacy of osimertinib will be assessed in patients with lung cancer harboring EGFR mutations which were detected from circulating tumor DNA', 'interventionNames': ['Drug: Osimertinib']}, {'label': 'Osimertinib in cohort 2', 'type': 'EXPERIMENTAL', 'description': 'Treatment efficacy of osimertinib will be assessed in patients with lung cancer harboring T790M which were detected from circulating tumor DNA', 'interventionNames': ['Drug: Osimertinib']}], 'interventions': [{'type': 'DRUG', 'name': 'Osimertinib', 'description': 'Treatment efficacy of osimertinib will be assessed in patients with lung cancer harboring EGFR mutations (cohort 1) and those harboring T790M (cohort 2) which were detected from circulating tumor DNA', 'armGroupLabels': ['Osimertinib in cohort 1', 'Osimertinib in cohort 2'], 'otherNames': ['AZD9291']}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Response rate', 'description': 'RECIST v1.1', 'timeFrame': '2 months'}], 'secondaryOutcomes': [{'measure': 'Sensitivity of testing methods', 'description': 'Percentage of positive cases among cases tested with Mutyper or Cobas', 'timeFrame': '2 weeks'}, {'measure': 'Progression free survival', 'timeFrame': '2 years'}, {'measure': 'Duration of response', 'timeFrame': '2 years'}, {'measure': 'Number of participants with treatment-related adverse events as assessed by CTCAE v4.0', 'timeFrame': '2 years'}]}, 'eligibilityModule': {'eligibilityCriteria': \"Inclusion Criteria:\\n\\n\\\\< Cohort 1 \\\\>\\n\\n1. Provision of informed consent prior to any study specific procedures\\n2. Patients (male/female) must be \\\\> 18 years of age.\\n3. Locally advanced or metastatic non-small cell lung cancer, not amenable to curative surgery or radiotherapy with or without pathologic diagnosis\\n4. No prior exposure to EGFR TKI (multiple lines of prior cytotoxic chemotherapy are permitted.)\\n5. Activating EGFR mutation (G719X, exon 19 deletion, L858R, L861Q) detected from circulating tumor DNA either by PANA mutyper® or Cobas® EGFR mutation test.\\n6. Activating EGFR mutation (G719X, exon 19 deletion, L858R, L861Q) detected from tumor tissue or cytology specimen.\\n7. World Health Organization (WHO) performance status 0-2.\\n8. Patients must have a life expectancy ≥ 12 weeks.\\n9. Females should be using adequate contraceptive measures, should not be breast feeding and must have a negative pregnancy test prior to start of dosing if of child-bearing potential or must have evidence of non-child-bearing potential by fulfilling one of the following criteria at screening:\\n\\n   * Post-menopausal defined as aged more than 50 years and amenorrheic for at least 12 months following cessation of all exogenous hormonal treatments\\n   * Women under 50 years old would be consider postmenopausal if they have been amenorrheic for 12 months or more following cessation of exogenous hormonal treatments and with luteinizing hormone (LH) and follicle stimulating hormone (FSH) levels in the post-menopausal range for the institution\\n   * Documentation of irreversible surgical sterilisation by hysterectomy, bilateral oophorectomy or bilateral salpingectomy but not tubal ligation\\n10. Male patients should be willing to use barrier contraception.\\n11. Patient is willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations including follow up.\\n12. At least one lesion, not previously irradiated, that can be accurately measured at baseline as ≥ 10 mm in the longest diameter (except lymph nodes which must have short axis ≥ 15 mm) with computed tomography (CT)\\n\\n\\\\< Cohort 2 \\\\>\\n\\n1. Provision of informed consent prior to any study specific procedures\\n2. Patients (male/female) must be \\\\> 18 years of age.\\n3. Locally advanced or metastatic non-small cell lung cancer, not amenable to curative surgery or radiotherapy with or without pathologic diagnosis\\n4. Progression after prior exposure to gefitinib, erlotinib, afatinib or dacomitinib. Multiple lines of prior cytotoxic chemotherapy are permitted and there is no specified order of treatment.\\n5. Patients must fulfil one of the following:\\n\\n   5.1) Activating EGFR mutation (G719X, exon 19 deletion, L858R, L861Q) from tumor tissue or cytology or circulating tumor DNA 5.2) Must have experienced clinical benefit from prior EGFR-TKI, according to the Jackman criteria (Jackman 2010) followed by systemic objective progression (RECIST) while on continuous treatment with EGFR-TKI\\n6. T790M mutation detected from circulating tumor DNA either by PANA mutyper® or Cobas® EGFR mutation test.\\n7. World Health Organization (WHO) performance status 0-2.\\n8. Patients must have a life expectancy ≥ 12 weeks.\\n9. Females should be using adequate contraceptive measures, should not be breast feeding and must have a negative pregnancy test prior to start of dosing if of child-bearing potential or must have evidence of non-child-bearing potential by fulfilling one of the following criteria at screening:\\n\\n   * Post-menopausal defined as aged more than 50 years and amenorrheic for at least 12 months following cessation of all exogenous hormonal treatments\\n   * Women under 50 years old would be consider postmenopausal if they have been amenorrheic for 12 months or more following cessation of exogenous hormonal treatments and with LH and FSH levels in the post-menopausal range for the institution\\n   * Documentation of irreversible surgical sterilisation by hysterectomy, bilateral oophorectomy or bilateral salpingectomy but not tubal ligation\\n10. Male patients should be willing to use barrier contraception.\\n11. Patient is willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations including follow up.\\n12. At least one lesion, not previously irradiated, that can be accurately measured at baseline as ≥ 10 mm in the longest diameter (except lymph nodes which must have short axis ≥ 15 mm) with computed tomography (CT)\\n\\nExclusion Criteria:\\n\\n1. Previous treatment with AZD9291, or other 3rd generation EGFR TKI\\n2. Treatment with an investigational drug within five half-lives of the compound\\n3. Patients currently receiving (or unable to stop use prior to receiving the first dose of study treatment) medications or herbal supplements known to be potent inhibitors of CYP3A4 (at least 1 week prior) and potent inducers of CYP3A4 (at least 3 week prior) (Appendix A). All patients must try to avoid concomitant use of any medications, herbal supplements and/or ingestion of foods with known inducer/inhibitory effects on CYP3A4.\\n4. Any unresolved toxicities from prior therapy greater than Common Terminology Criteria for Adverse Events (CTCAE) grade 1 at the time of starting study treatment with the exception of alopecia and grade 2, prior platinum-therapy related neuropathy.\\n5. Any evidence of severe or uncontrolled systemic diseases, including uncontrolled hypertension and active bleeding diatheses, which in the investigator's opinion makes it undesirable for the patient to participate in the trial or which would jeopardise compliance with the protocol, or active infection including hepatitis B, hepatitis C and human immunodeficiency virus (HIV). Screening for chronic conditions is not required.\\n6. Patients with symptomatic central nervous system (CNS) metastases who are neurologically unstable\\n7. Past medical history of interstitial lung disease (ILD), drug-induced ILD, radiation pneumonitis requiring steroid treatment, or any evidence of clinically active ILD\\n8. Inadequate bone marrow reserve or organ function as demonstrated by any of the following laboratory values:\\n\\n   Absolute neutrophil count \\\\<1.5 x 109/L Platelet count \\\\<100 x 109/L Haemoglobin \\\\<90 g/L Alanine aminotransferase \\\\>2.5 times the upper limit of normal (ULN) if no demonstrable liver metastases or \\\\>5 times ULN in the presence of liver metastases Aspartate aminotransferase \\\\>2.5 times ULN if no demonstrable liver metastases or \\\\>5 times ULN in the presence of liver metastases Total bilirubin \\\\>1.5 times ULN if no liver metastases or \\\\>3 times ULN in the presence of documented Gilbert's Syndrome (unconjugated hyperbilirubinaemia) or liver metastases Creatinine \\\\>1.5 times ULN concurrent with creatinine clearance \\\\<50 ml/min (measured or calculated by Cockcroft and Gault equation); confirmation of creatinine clearance is only required when creatinine is \\\\>1.5 times ULN.\\n9. Any of the following cardiac criteria:\\n\\n   1. Mean resting corrected QT interval (QTc using Fredericia's formula) \\\\> 470 msec\\n   2. Any clinically important abnormalities in rhythm, conduction or morphology of resting ECG (e.g., complete left bundle branch block, third degree heart block, second degree heart block)\\n   3. Any factors that increase the risk of QTc prolongation or risk of arrhythmic events such as heart failure, hypokalemia, congenital long QT syndrome, family history of long QT syndrome or unexplained sudden death under 40 years of age in first degree relatives or any concomitant medication known to prolong the QT interval\\n10. Refractory nausea and vomiting, chronic gastrointestinal diseases, inability to swallow the formulated product or previous significant bowel resection that would preclude adequate absorption of AZD9291\\n11. History of hypersensitivity to AZD9291 (or drugs with a similar chemical structure or class to AZD9291) or any excipients of these agents\\n12. Males and females of reproductive potential who are not using an effective method of birth control and females who are pregnant or breastfeeding or have a positive (urine or serum) pregnancy test prior to study entry\\n13. Judgment by the Investigator that the patient should not participate in the study if the patient is unlikely to comply with study procedures, restrictions and requirements\\n14. Previous allogeneic bone marrow transplant.\\n15. Non-leukocyte depleted whole blood transfusion within 120 days of the date of the genetic sample collection.\", 'healthyVolunteers': False, 'sex': 'ALL', 'minimumAge': '19 Years', 'stdAges': ['ADULT', 'OLDER_ADULT']}, 'contactsLocationsModule': {'overallOfficials': [{'name': 'Young-Chul Kim, MD, PhD', 'affiliation': 'Chonnam National University Hospital', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'locations': [{'facility': 'Chonnam National University Hwasun Hospital', 'city': 'Hwasun', 'state': 'Jeonnam', 'zip': '58128', 'country': 'Korea, Republic of', 'geoPoint': {'lat': 35.06125, 'lon': 126.98746}}]}, 'referencesModule': {'references': [{'pmid': '25923549', 'type': 'BACKGROUND', 'citation': 'Janne PA, Yang JC, Kim DW, Planchard D, Ohe Y, Ramalingam SS, Ahn MJ, Kim SW, Su WC, Horn L, Haggstrom D, Felip E, Kim JH, Frewer P, Cantarini M, Brown KH, Dickinson PA, Ghiorghiu S, Ranson M. AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. N Engl J Med. 2015 Apr 30;372(18):1689-99. doi: 10.1056/NEJMoa1411817.'}, {'pmid': '23816960', 'type': 'BACKGROUND', 'citation': \"Sequist LV, Yang JC, Yamamoto N, O'Byrne K, Hirsh V, Mok T, Geater SL, Orlov S, Tsai CM, Boyer M, Su WC, Bennouna J, Kato T, Gorbunova V, Lee KH, Shah R, Massey D, Zazulina V, Shahidi M, Schuler M. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol. 2013 Sep 20;31(27):3327-34. doi: 10.1200/JCO.2012.44.2806. Epub 2013 Jul 1.\"}, {'pmid': '19949011', 'type': 'BACKGROUND', 'citation': 'Jackman D, Pao W, Riely GJ, Engelman JA, Kris MG, Janne PA, Lynch T, Johnson BE, Miller VA. Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. J Clin Oncol. 2010 Jan 10;28(2):357-60. doi: 10.1200/JCO.2009.24.7049. Epub 2009 Nov 30.'}]}, 'ipdSharingStatementModule': {'ipdSharing': 'NO'}}, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-08-21'}, 'conditionBrowseModule': {'meshes': [{'id': 'D008175', 'term': 'Lung Neoplasms'}], 'ancestors': [{'id': 'D012142', 'term': 'Respiratory Tract Neoplasms'}, {'id': 'D013899', 'term': 'Thoracic Neoplasms'}, {'id': 'D009371', 'term': 'Neoplasms by Site'}, {'id': 'D009369', 'term': 'Neoplasms'}, {'id': 'D008171', 'term': 'Lung Diseases'}, {'id': 'D012140', 'term': 'Respiratory Tract Diseases'}], 'browseLeaves': [{'id': 'M11172', 'name': 'Lung Neoplasms', 'asFound': 'Lung Neoplasms', 'relevance': 'HIGH'}, {'id': 'M14979', 'name': 'Respiratory Tract Neoplasms', 'relevance': 'LOW'}, {'id': 'M16658', 'name': 'Thoracic Neoplasms', 'relevance': 'LOW'}, {'id': 'M11168', 'name': 'Lung Diseases', 'relevance': 'LOW'}, {'id': 'M14977', 'name': 'Respiratory Tract Diseases', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'BC04', 'name': 'Neoplasms'}, {'abbrev': 'BC08', 'name': 'Respiratory Tract (Lung and Bronchial) Diseases'}, {'abbrev': 'All', 'name': 'All Conditions'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'C000596361', 'term': 'Osimertinib'}], 'ancestors': [{'id': 'D000092004', 'term': 'Tyrosine Kinase Inhibitors'}, {'id': 'D047428', 'term': 'Protein Kinase Inhibitors'}, {'id': 'D004791', 'term': 'Enzyme Inhibitors'}, {'id': 'D045504', 'term': 'Molecular Mechanisms of Pharmacological Action'}, {'id': 'D000970', 'term': 'Antineoplastic Agents'}], 'browseLeaves': [{'id': 'M145673', 'name': 'Osimertinib', 'asFound': 'Oxygenation', 'relevance': 'HIGH'}, {'id': 'M2889', 'name': 'Tyrosine Kinase Inhibitors', 'relevance': 'LOW'}, {'id': 'M25820', 'name': 'Protein Kinase Inhibitors', 'relevance': 'LOW'}, {'id': 'M7951', 'name': 'Enzyme Inhibitors', 'relevance': 'LOW'}, {'id': 'T22', 'name': 'Tyrosine', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'ANeo', 'name': 'Antineoplastic Agents'}, {'abbrev': 'All', 'name': 'All Drugs and Chemicals'}, {'abbrev': 'AA', 'name': 'Amino Acids'}]}}, 'hasResults': False}\n",
      "Keys for NCT04552613:\n",
      "dict_keys(['protocolSection', 'derivedSection', 'hasResults'])\n",
      "Content for NCT04552613:\n",
      "{'protocolSection': {'identificationModule': {'nctId': 'NCT04552613', 'orgStudyIdInfo': {'id': 'K2020109'}, 'organization': {'fullName': 'The Fourth Affiliated Hospital of Zhejiang University School of Medicine', 'class': 'OTHER'}, 'briefTitle': 'Efficacy of Targeted Therapy Combined Chemotherapy in Advanced EGFR Positive NSCLC Patients', 'officialTitle': 'Efficacy of Targeted Therapy Combined Chemotherapy in Advanced EGFR Positive NSCLC Patients With Concurrent Driver Gene Mutations'}, 'statusModule': {'statusVerifiedDate': '2024-01', 'overallStatus': 'COMPLETED', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2020-11-23', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2023-09-24', 'type': 'ACTUAL'}, 'completionDateStruct': {'date': '2023-09-24', 'type': 'ACTUAL'}, 'studyFirstSubmitDate': '2020-09-13', 'studyFirstSubmitQcDate': '2020-09-16', 'studyFirstPostDateStruct': {'date': '2020-09-17', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2024-01-11', 'lastUpdatePostDateStruct': {'date': '2024-01-16', 'type': 'ACTUAL'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'}, 'leadSponsor': {'name': 'The Fourth Affiliated Hospital of Zhejiang University School of Medicine', 'class': 'OTHER'}}, 'oversightModule': {'oversightHasDmc': True, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'descriptionModule': {'briefSummary': 'This study is a randomized, multicenter clinical study ，which is designed to compare the efficacy of the safety and efficacy of treatment every 6 weeks in EGFR positive (Non-small cell lung cancer, NSCLC) with concurrent Driver gene mutations，who used EGFR-TKI with or without combined chemotherapy，estimated with stable efficacy (CR, PR, and SD) .In this study, subjects will be randomly assigned to the following two groups according to a 1:1 ratio:(A) Standard programme group, EGFR-TKI targeted therapy; (B) controlled programme group, EGFR-TKI targeted therapy combined chemotherapy(pemetrexed plus carboplatin for 4 cycles )', 'detailedDescription': \"This study is a randomized, multicenter clinical study aimed at EGFR positive non-small-cell lung cancer (NSCLC) subjects with concurrent Driver gene mutations who have not previously received systematic treatment. After comparing EGFR-TKI alone or EGFR-TKI combined with chemotherapy for 4 cycles, after the efficacy evaluation was stable (CR, PR, and SD), the safety and clinical efficacy of maintenance therapy every 6 weeks were compared. The eligible subjects in this study will be randomly assigned into the following two groups according to the 1: 1 ratio: (A) Standard programme group, EGFR-TKI targeted therapy; (B) controlled programme group, EGFR-TKI targeted therapy combined chemotherapy (pemetrexed plus carboplatin for 4 cycles ) During the course of the trial treatment, if the subject develops disease (the first PD), the researcher will decide whether to continue the medication according to the patient's situation and communicate with the patient, as follows: After the first PD of the subject, the researcher decides whether to continue the treatment with the original regimen according to the disease state of the subject. At least 4 weeks later, the tumor is evaluated again. If the tumor progresses again (the second PD), the subject's study treatment ends and the follow-up period is entered; if there is no progress, the original regimen is continued.\\n\\nThe primary end point was descriptive analysis of progression-free survival and Objective response rate.The secondary end point of this study was to compare the incidence of treatment-related grade 3-5 adverse events between the standard group and the controlled group. Using RECIST 1.1 as the evaluation standard, the independent imaging evaluation committee (IRRC) conducted the evaluation. For the first time to evaluate PD, regardless of whether they continue to study treatment after progression, the date of the first PD evaluated by IRRC will be used for all statistical analysis containing progress information.\"}, 'conditionsModule': {'conditions': ['Non-small-lung-cell Cancer', 'NSCLC', 'EGFR Gene Mutation']}, 'designModule': {'studyType': 'INTERVENTIONAL', 'phases': ['NA'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 114, 'type': 'ACTUAL'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'Standard programme group', 'type': 'EXPERIMENTAL', 'description': 'EGFR-TKI targeted therapy', 'interventionNames': ['Drug: EGFR-TKI']}, {'label': 'controlled programme group', 'type': 'ACTIVE_COMPARATOR', 'description': 'EGFR-TKI targeted therapy combined chemotherapy(pemetrexed plus carboplatin for 4 cycles )', 'interventionNames': ['Drug: EGFR-TKI combined with chemotherapy (pemetrexed plus carboplatin)']}], 'interventions': [{'type': 'DRUG', 'name': 'EGFR-TKI', 'description': '(A) Standard programme group, EGFR-TKI targeted therapy;', 'armGroupLabels': ['Standard programme group']}, {'type': 'DRUG', 'name': 'EGFR-TKI combined with chemotherapy (pemetrexed plus carboplatin)', 'description': '(B) controlled programme group, EGFR-TKI targeted therapy combined chemotherapy(pemetrexed plus carboplatin for 4 cycles )', 'armGroupLabels': ['controlled programme group']}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'progression-free survival', 'description': 'Patients with oncological diseases have a period of time from the start of treatment to the observation of disease progression or death due to any cause', 'timeFrame': 'three years'}, {'measure': 'objective response rate', 'description': 'Refers to the proportion of patients whose tumor shrinkage reaches a certain amount and remains for a certain period of time, including CR + PR cases', 'timeFrame': 'three years'}], 'secondaryOutcomes': [{'measure': 'overall survival', 'description': 'The time from randomization to death due to any cause. For subjects who have been lost to follow-up before death, the time of the last follow-up is usually calculated as the time of death.', 'timeFrame': 'three years'}]}, 'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\n\\n1. Volunteer for clinical research, fully understand, inform and sign informed consent forms (Informed Consent Form, ICF), willing to follow and be able to complete all trial procedures.\\n2. 18 to 80 years old (with critical values) when signing ICF.\\n3. Histopathology or hemology diagnostics of phase IIIB or IV (AJCC Version 8) NSCLC that cannot be surgicalor-able or radiotherapy.\\n4. Patients have never received systemic treatment throughout the body for phase IIIB or IV NSCLC(Neoadjuvant or adjuvant chemotherapy is excluded).\\n5. Known EGFR sensitivity mutations with concurrent other Driver gene mutations, such as T790M，TP53，RB1，PTEN，CDKN，PIK3A，DDR, KRAS and so on.\\n6. The end of non-systematic anti-tumor therapy is not only 2 weeks from the end of the study drug, and the treatment-related AE is restored to CTCAE 4.03 to level 1 (except for level 2 hair loss).\\n7. Within 4 weeks prior to randomization, at least one measurable target lesions assessed by irRC in accordance with RECIST 1.1 requirements.\\n8. The ECOG PS score for 7 days prior to the first drug use of the study drug was 0 or 1.\\n9. The expected lifetime is more than 12 weeks.\\n10. The main organ function sits well, i.e. meets the following criteria (no blood transfusion, albumin, recombinant human platelet production or Colony-stimulating factor (CSF) treatment within 14 days prior to the first drug use in this study):\\n\\n(1). Absolute neutrophil count \\\\>15.0 x 10\\\\^9/L; (2). Platelet count ≥ 100 x 10\\\\^9/L; (3). Hemoglobins ≥ 90 g/L; (4). Total bilirubin ≤.5 x ULN (except Gilbert syndrome, total bilirubin ≤ 3.0 mg/dL); (5). AST (SGOT) ≤ 2.5 x ULN, for patients with liver metastasis, ≤5.0 x ULN; (6). ALT (SGPT) is 2.5 x ULN, for patients with liver metastasis, ≤5.0 x ULN; (7). Clotting function: activated part of the clotting enzyme time (APTT) ≤ 1.5 x ULN, clotting enzyme raw time (PT) or international standardized ratio (INR) ≤1.5 x ULN; (8). Creatinine ≤1.5xULN, or creatinine clearance ≥60 mL/min (Cockcroft-Gault method).\\n\\n11. Female patients must meet one of the following:\\n\\n1. . Menopause (defined as having no menstruation for at least 1 year and no other reason for confirmation other than menopause);\\n2. . Sterilization performed (removal of the ovaries and/or uterus);\\n3. . Fertility, but must meet: Serum pregnancy tests must be negative within 7 days of randomization and agree to use 1% annual failure rate of contraception or to maintain abstinence (avoiding heterosexual intercourse) (at least 120 days after the signing of an informed consent form to the last time the drug was administered) (1% annual failure rate of contraceptive methods including bilateral tubal ligation, male sterilization, correct use of ovulation-suppressing hormones, release of intrauterine and intrauterine devices) and intrauterine devices.\\n\\n12. Male patients must meet the requirement to consent to abstinence (avoiding heterosexual intercourse) or to take contraception, provided that when the partner is a woman of childbearing age or who is pregnant, male patients must maintain abstinence or use condom contraception to prevent exposure to the embryo during treatment and for at least 150 days after the end of administration of the drug. Regular abstinence (e.g. calendar days, ovulation periods, basic body temperature or late-stage contraception) and in vitro ejaculation are substandard methods of contraception.\\n\\nExclusion Criteria:\\n\\n1. Received any of the following treatments: received systemic anti-tumor therapy (except neoadjuvant or adjuvant chemotherapy) previously; Within 4 weeks before the first administration of the drug, more than 30% of the bone marrow was treated with radiotherapy or a large area of radiation was carried out (except palliative radiotherapy for the purpose of relieving pain in non-target lesions only ); Other anti-tumor therapies, including molecular targeted therapies (EGFR TKI, angiogenesis inhibitors, etc.), immunotherapy (such as cellular immunotherapy anti-PD-1 or PD-L1), other experimental drug therapies, etc.\\n2. Major surgery was performed within 4 weeks before the first administration of the study drug.\\n3. Patients were taking (or cannot stop taking) certain medications or herbal supplements that are known to be a strong inducer of cytopigment P450 (CYP450) 3A4 within 1 week prior to the first administration of the study drug.\\n4. Patients with dysphagia or possible absorption disorders as determined by the researcher.\\n5. Within 5 years or at the same time, there are other active malignancies. Cured limited tumors, such as skin base cell carcinoma, skin squamous carcinoma, superficial bladder cancer, prostate in situ cancer, cervical in situ cancer, etc. can be included in the group.\\n6. Patients with brain metastasis, the following could except:the largest diameter of brain metastasis lesions is less than 2 cm and no obvious symptoms; brain metastatic lesions have control, and stability more than 4 weeks.\\n7. Resting electrocardiogram (ECG) in rhythm, conduction and morphologically abnormal clinical significance, such as complete left bundle branch block, Ⅱ degrees above heart block, PR interval period \\\\> 250 milliseconds, etc.; myocardial infarction occurred within 6 months; presence of risk factors for prolonged QT interval or increased arrhythmia, such as heart failure, moderate or severe hypokalemia, diagnosed or suspected congenital long QT syndrome, a family history of long QT syndrome, or a history of sudden death under the age of 40 in a first-degree relative; mean QT interval (QTcF) after 3 Fridericia adjustments of electrocardiogram: \\\\> 450ms for males and \\\\> 470ms for females.\\n8. Pregnant or lactating women.\\n9. Hepatitis B virus infection (HBsAg positive, HBV-DNA \\\\>1000cps/ml and AST or ALT\\\\>2.0xULN), hepatitis C virus infection or HIV infection which is not controlled or in active.\\n10. Other uncontrolled concomitant diseases include, but are not limited to infectious or active infections.\\n11. A history of epilepsy, mental illness, or other social factors that limit adherence to the program.\\n12. The researcher considers it inappropriate to participate in this study.', 'healthyVolunteers': False, 'sex': 'ALL', 'minimumAge': '18 Years', 'maximumAge': '80 Years', 'stdAges': ['ADULT', 'OLDER_ADULT']}, 'contactsLocationsModule': {'overallOfficials': [{'name': 'Kai Wang, PhD', 'affiliation': 'The Fourth Affiliated Hospital of Zhejiang University', 'role': 'STUDY_CHAIR'}], 'locations': [{'facility': 'China, Zhejiang', 'city': 'Hangzhou', 'state': 'Zhejiang', 'zip': '310000', 'country': 'China', 'geoPoint': {'lat': 30.29365, 'lon': 120.16142}}]}, 'ipdSharingStatementModule': {'ipdSharing': 'NO'}}, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-08-21'}, 'conditionBrowseModule': {'meshes': [{'id': 'D002289', 'term': 'Carcinoma, Non-Small-Cell Lung'}], 'ancestors': [{'id': 'D002283', 'term': 'Carcinoma, Bronchogenic'}, {'id': 'D001984', 'term': 'Bronchial Neoplasms'}, {'id': 'D008175', 'term': 'Lung Neoplasms'}, {'id': 'D012142', 'term': 'Respiratory Tract Neoplasms'}, {'id': 'D013899', 'term': 'Thoracic Neoplasms'}, {'id': 'D009371', 'term': 'Neoplasms by Site'}, {'id': 'D009369', 'term': 'Neoplasms'}, {'id': 'D008171', 'term': 'Lung Diseases'}, {'id': 'D012140', 'term': 'Respiratory Tract Diseases'}], 'browseLeaves': [{'id': 'M5534', 'name': 'Carcinoma', 'relevance': 'LOW'}, {'id': 'M5546', 'name': 'Carcinoma, Non-Small-Cell Lung', 'asFound': 'NSCLC', 'relevance': 'HIGH'}, {'id': 'M5540', 'name': 'Carcinoma, Bronchogenic', 'relevance': 'LOW'}, {'id': 'M5260', 'name': 'Bronchial Neoplasms', 'relevance': 'LOW'}, {'id': 'M11172', 'name': 'Lung Neoplasms', 'relevance': 'LOW'}, {'id': 'M14979', 'name': 'Respiratory Tract Neoplasms', 'relevance': 'LOW'}, {'id': 'M16658', 'name': 'Thoracic Neoplasms', 'relevance': 'LOW'}, {'id': 'M11168', 'name': 'Lung Diseases', 'relevance': 'LOW'}, {'id': 'M14977', 'name': 'Respiratory Tract Diseases', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'BC04', 'name': 'Neoplasms'}, {'abbrev': 'All', 'name': 'All Conditions'}, {'abbrev': 'BC08', 'name': 'Respiratory Tract (Lung and Bronchial) Diseases'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'D016190', 'term': 'Carboplatin'}, {'id': 'D000068437', 'term': 'Pemetrexed'}], 'ancestors': [{'id': 'D000970', 'term': 'Antineoplastic Agents'}, {'id': 'D004791', 'term': 'Enzyme Inhibitors'}, {'id': 'D045504', 'term': 'Molecular Mechanisms of Pharmacological Action'}, {'id': 'D005493', 'term': 'Folic Acid Antagonists'}, {'id': 'D019384', 'term': 'Nucleic Acid Synthesis Inhibitors'}], 'browseLeaves': [{'id': 'M18650', 'name': 'Carboplatin', 'asFound': 'Total', 'relevance': 'HIGH'}, {'id': 'M264', 'name': 'Pemetrexed', 'asFound': 'Assigned', 'relevance': 'HIGH'}, {'id': 'M7951', 'name': 'Enzyme Inhibitors', 'relevance': 'LOW'}, {'id': 'M8618', 'name': 'Folic Acid', 'relevance': 'LOW'}, {'id': 'M17546', 'name': 'Vitamin B Complex', 'relevance': 'LOW'}, {'id': 'M8619', 'name': 'Folic Acid Antagonists', 'relevance': 'LOW'}, {'id': 'T447', 'name': 'Folinic Acid', 'relevance': 'LOW'}, {'id': 'T475', 'name': 'Vitamin B9', 'relevance': 'LOW'}, {'id': 'T446', 'name': 'Folic Acid', 'relevance': 'LOW'}, {'id': 'T448', 'name': 'Folate', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'ANeo', 'name': 'Antineoplastic Agents'}, {'abbrev': 'All', 'name': 'All Drugs and Chemicals'}, {'abbrev': 'Micro', 'name': 'Micronutrients'}, {'abbrev': 'Hemat', 'name': 'Hematinics'}, {'abbrev': 'Vi', 'name': 'Vitamins'}]}}, 'hasResults': False}\n",
      "Keys for NCT06071013:\n",
      "dict_keys(['protocolSection', 'derivedSection', 'hasResults'])\n",
      "Content for NCT06071013:\n",
      "{'protocolSection': {'identificationModule': {'nctId': 'NCT06071013', 'orgStudyIdInfo': {'id': 'CMUH112-REC2-121'}, 'organization': {'fullName': 'China Medical University Hospital', 'class': 'OTHER'}, 'briefTitle': 'Nintedanib Plus EGFR TKI In EGFR-mutated Non-small Cell Lung Cancer Patients', 'officialTitle': 'A Phase I/Phase II Study of Nintedanib Plus EGFR TKI In EGFR-mutated Non-small Cell Lung Cancer Patients'}, 'statusModule': {'statusVerifiedDate': '2025-01', 'overallStatus': 'RECRUITING', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2024-02-23', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2026-08-27', 'type': 'ESTIMATED'}, 'completionDateStruct': {'date': '2026-08-27', 'type': 'ESTIMATED'}, 'studyFirstSubmitDate': '2023-09-25', 'studyFirstSubmitQcDate': '2023-10-02', 'studyFirstPostDateStruct': {'date': '2023-10-06', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2025-01-20', 'lastUpdatePostDateStruct': {'date': '2025-01-23', 'type': 'ACTUAL'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'}, 'leadSponsor': {'name': 'China Medical University Hospital', 'class': 'OTHER'}, 'collaborators': [{'name': 'China Medical University, Taiwan', 'class': 'OTHER'}]}, 'oversightModule': {'oversightHasDmc': True, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False, 'isUsExport': False}, 'descriptionModule': {'briefSummary': 'The purpose of this study is to evaluate the efficacy and safety of Nintedanib with EGFR-TKI in participants with advanced EGFR-TKI-resistant non-small cell lung cancer', 'detailedDescription': \"The efficacy of the regimen is evaluated by participants' progression-free survival and overall survival.\\n\\nNintedanib is a medication that blocks endothelial cells in tumor microenvironments and is effective in delaying tumor progression. Nintedanib is also a drug approved for idiopathic pulmonary fibrosis in the clinic.\\n\\nThe participants will take 1 nintedanib tablet after a meal twice per day with a twelve-hour interval. EGFR TKI-gefitinib, erlotinib, afatinib, or osimertinib will be taken 1 tablet once per day during each treatment cycle. The treatment cycle in this study is 30 days.\\n\\nIn this study, the participants will have a physical exam in 6 weeks and 12 weeks after the initiation of the treatment. In the 6 weeks of the study, the participants will have blood tests and a CT scan. About 5cc of blood will be collected each time. In addition, the participant's tumor will be measured by a CT scan every 12 weeks.\\n\\nIf the participants develop any unacceptable symptoms or changes in liver function tests, the participants' treatment may be delayed and/or the dose decreased until the symptoms are disappeared. It may even be necessary to stop your treatment. The doctor will inform the participant of any changes in the participants' treatment schedule or in the doses of medication after he/she evaluates the participants in the clinic.\\n\\nAfter treatment ends, the participants will have a follow-up visit at the clinic. At this visit, the participants will have a complete physical exam, including blood (about 5cc) tests and CT scan to measure the size of the tumors.\\n\\nThis is an investigational study. Up to 20 participants will take part in this study.\"}, 'conditionsModule': {'conditions': ['Non-small Cell Lung Cancer', 'EGFR Gene Mutation', 'EGFR-TKI Resistant Mutation'], 'keywords': ['nPKC delta', 'Angiogenesis', 'EGFR TKI drug resistant']}, 'designModule': {'studyType': 'INTERVENTIONAL', 'phases': ['PHASE1', 'PHASE2'], 'designInfo': {'allocation': 'NA', 'interventionModel': 'SINGLE_GROUP', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 20, 'type': 'ESTIMATED'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'Nintedanib + gefitinib/erlotinib/afatinib/osimertinib', 'type': 'EXPERIMENTAL', 'description': 'Nintedanib will administered orally twice per day Gefitinib will administered orally once daily Erlotinib will administered orally once daily Afatinib will administered orally once daily Osimertinib will administered orally once daily', 'interventionNames': ['Drug: Nintedanib, gefitinib, erlotinib, afatinib, osimertinib']}], 'interventions': [{'type': 'DRUG', 'name': 'Nintedanib, gefitinib, erlotinib, afatinib, osimertinib', 'description': 'Nintedanib is a multiple tyrosine kinase inhibitor that can bind competitively to the ATP-binding pocket of these receptors and block intracellular signaling, which is critical for the proliferation and migration.\\n\\nGefitinib, erlotinib and afatinib are the first- and second- generation of EGFR tyrosine kinase inhibitors that reversibly and irreversibly inhibit the binding of ATP to the phosphate-binding loop of ATP binding site in the kinase domain of EGFR, leading to the inhibition of cell proliferation and induction of apoptosis of cancer cells.', 'armGroupLabels': ['Nintedanib + gefitinib/erlotinib/afatinib/osimertinib']}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'The toxicity of combinate nintedanib and EGFR TKI', 'timeFrame': 'Assessed every 6 weeks of chest CT scan until PD.'}, {'measure': 'Patient objective response rate', 'timeFrame': 'Assessed every 6 weeks of chest CT scan'}], 'secondaryOutcomes': [{'measure': 'Overall survival', 'timeFrame': 'Assessed every 12 weeks thereafter up to end of study at approximately 2 years'}]}, 'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\n\\n1. Participants between 20 to 70 years old, are pathologically confirmed advanced (stage III and IV) non-small cell lung cancer.\\n2. Positive EGFR mutations are diagenesis.\\n3. Participants with histologically/cytologically confirmed locally advanced or metastatic adenocarcinoma subtype NSCLC after the failure of first-line EGFR tyrosine kinase inhibitors- gefitinib, erlotinib, afatinib, or osimertinib.\\n4. Participants must have adequate hepatic, renal, and bone marrow function\\n\\nExclusion Criteria:\\n\\n1. Participants previously received first-line EGFR tyrosine kinase inhibitor with serious side effects.\\n2. Participants have known hypertension, and chronic liver and gastrointestinal disease.\\n3. Participants have known brain metastasis.\\n4. Female participants who are pregnant or breast-feeding\\n5. Participants have a known diagnosis of negative nPKCδ expression by immunohistochemistry (IHC).', 'healthyVolunteers': False, 'sex': 'ALL', 'minimumAge': '20 Years', 'maximumAge': '70 Years', 'stdAges': ['ADULT', 'OLDER_ADULT']}, 'contactsLocationsModule': {'centralContacts': [{'name': 'Chih-Yen Tu', 'role': 'CONTACT', 'phone': '+886-975-681-007', 'email': 'chesttu@gmail.com'}], 'overallOfficials': [{'name': 'Pulmonary Medicine', 'affiliation': 'China Medical University Hospital', 'role': 'STUDY_DIRECTOR'}], 'locations': [{'facility': 'China Medical University Hospital', 'status': 'RECRUITING', 'city': 'Taichung', 'country': 'Taiwan', 'geoPoint': {'lat': 24.1469, 'lon': 120.6839}}]}}, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-08-21'}, 'conditionBrowseModule': {'meshes': [{'id': 'D008175', 'term': 'Lung Neoplasms'}, {'id': 'D002289', 'term': 'Carcinoma, Non-Small-Cell Lung'}], 'ancestors': [{'id': 'D012142', 'term': 'Respiratory Tract Neoplasms'}, {'id': 'D013899', 'term': 'Thoracic Neoplasms'}, {'id': 'D009371', 'term': 'Neoplasms by Site'}, {'id': 'D009369', 'term': 'Neoplasms'}, {'id': 'D008171', 'term': 'Lung Diseases'}, {'id': 'D012140', 'term': 'Respiratory Tract Diseases'}, {'id': 'D002283', 'term': 'Carcinoma, Bronchogenic'}, {'id': 'D001984', 'term': 'Bronchial Neoplasms'}], 'browseLeaves': [{'id': 'M11172', 'name': 'Lung Neoplasms', 'asFound': 'Lung Cancer', 'relevance': 'HIGH'}, {'id': 'M5546', 'name': 'Carcinoma, Non-Small-Cell Lung', 'asFound': 'Non-small Cell Lung Cancer', 'relevance': 'HIGH'}, {'id': 'M5534', 'name': 'Carcinoma', 'relevance': 'LOW'}, {'id': 'M14979', 'name': 'Respiratory Tract Neoplasms', 'relevance': 'LOW'}, {'id': 'M16658', 'name': 'Thoracic Neoplasms', 'relevance': 'LOW'}, {'id': 'M11168', 'name': 'Lung Diseases', 'relevance': 'LOW'}, {'id': 'M14977', 'name': 'Respiratory Tract Diseases', 'relevance': 'LOW'}, {'id': 'M5540', 'name': 'Carcinoma, Bronchogenic', 'relevance': 'LOW'}, {'id': 'M5260', 'name': 'Bronchial Neoplasms', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'BC04', 'name': 'Neoplasms'}, {'abbrev': 'BC08', 'name': 'Respiratory Tract (Lung and Bronchial) Diseases'}, {'abbrev': 'All', 'name': 'All Conditions'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'D000069347', 'term': 'Erlotinib Hydrochloride'}, {'id': 'D000077156', 'term': 'Gefitinib'}, {'id': 'C000596361', 'term': 'Osimertinib'}, {'id': 'D000077716', 'term': 'Afatinib'}, {'id': 'C530716', 'term': 'Nintedanib'}], 'ancestors': [{'id': 'D000092004', 'term': 'Tyrosine Kinase Inhibitors'}, {'id': 'D047428', 'term': 'Protein Kinase Inhibitors'}, {'id': 'D004791', 'term': 'Enzyme Inhibitors'}, {'id': 'D045504', 'term': 'Molecular Mechanisms of Pharmacological Action'}, {'id': 'D000970', 'term': 'Antineoplastic Agents'}], 'browseLeaves': [{'id': 'M272925', 'name': 'Nintedanib', 'asFound': 'Subgroup', 'relevance': 'HIGH'}, {'id': 'M145673', 'name': 'Osimertinib', 'asFound': 'Oxygenation', 'relevance': 'HIGH'}, {'id': 'M2889', 'name': 'Tyrosine Kinase Inhibitors', 'relevance': 'LOW'}, {'id': 'M1882', 'name': 'Afatinib', 'asFound': 'Create', 'relevance': 'HIGH'}, {'id': 'M398', 'name': 'Erlotinib Hydrochloride', 'asFound': '600', 'relevance': 'HIGH'}, {'id': 'M1679', 'name': 'Gefitinib', 'asFound': 'pH', 'relevance': 'HIGH'}, {'id': 'M25820', 'name': 'Protein Kinase Inhibitors', 'relevance': 'LOW'}, {'id': 'M7951', 'name': 'Enzyme Inhibitors', 'relevance': 'LOW'}, {'id': 'T22', 'name': 'Tyrosine', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'ANeo', 'name': 'Antineoplastic Agents'}, {'abbrev': 'All', 'name': 'All Drugs and Chemicals'}, {'abbrev': 'AA', 'name': 'Amino Acids'}]}}, 'hasResults': False}\n",
      "Keys for NCT03755102:\n",
      "dict_keys(['protocolSection', 'derivedSection', 'hasResults'])\n",
      "Content for NCT03755102:\n",
      "{'protocolSection': {'identificationModule': {'nctId': 'NCT03755102', 'orgStudyIdInfo': {'id': '18-341'}, 'organization': {'fullName': 'Memorial Sloan Kettering Cancer Center', 'class': 'OTHER'}, 'briefTitle': 'A Pilot Study of Dacomitinib With or Without Osimertinib for Patients With Metastatic EGFR Mutant Lung Cancers With Disease Progression on Osimertinib.', 'officialTitle': 'A Pilot Study of Dacomitinib With or Without Osimertinib for Patients With Metastatic EGFR Mutant Lung Cancers With Disease Progressionon Osimertinib.'}, 'statusModule': {'statusVerifiedDate': '2022-11', 'overallStatus': 'COMPLETED', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2018-11-21', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2023-07-07', 'type': 'ACTUAL'}, 'completionDateStruct': {'date': '2023-07-07', 'type': 'ACTUAL'}, 'studyFirstSubmitDate': '2018-11-26', 'studyFirstSubmitQcDate': '2018-11-26', 'studyFirstPostDateStruct': {'date': '2018-11-27', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2025-05-12', 'lastUpdatePostDateStruct': {'date': '2025-05-15', 'type': 'ACTUAL'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'}, 'leadSponsor': {'name': 'Memorial Sloan Kettering Cancer Center', 'class': 'OTHER'}}, 'oversightModule': {'oversightHasDmc': True, 'isFdaRegulatedDrug': True, 'isFdaRegulatedDevice': False}, 'descriptionModule': {'briefSummary': 'The purpose of this study is to assess whether dacomitinib after osimertinib is effective in participants with metastatic EGR-mutant lung cancers.'}, 'conditionsModule': {'conditions': ['EGFR Gene Mutation', 'Lung Cancer', 'Lung Cancer Metastatic'], 'keywords': ['EGFR C797S', 'EGFR mutant lung cancer', 'dacomitinib', 'osimertinib', '18-341', 'Memorial Sloan Kettering Cancer Center']}, 'designModule': {'studyType': 'INTERVENTIONAL', 'phases': ['EARLY_PHASE1'], 'designInfo': {'allocation': 'NON_RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 17, 'type': 'ACTUAL'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'Cohort 1: Participants treated with dacomitinib alone', 'type': 'EXPERIMENTAL', 'description': 'Participants in this cohort have a somatic activating mutation in EGFR in a tumor biopsy or plasma cfDNA liquid biopsy.', 'interventionNames': ['Drug: Dacomitinib']}, {'label': 'Cohort 2: Participants treated with dacomitinib in combination with osimertinib', 'type': 'EXPERIMENTAL', 'description': 'Participants in this cohort have a secondary acquired EGFR mutation in addition to the sensitizing mutation', 'interventionNames': ['Drug: Dacomitinib', 'Drug: Osimertinib']}], 'interventions': [{'type': 'DRUG', 'name': 'Dacomitinib', 'description': 'Cohort 1 Dacomitinib Dosing:\\n\\nDose level 1: Dacomitinib 45mg daily Dose level -1: Dacomitinib 30mg daily Dose level -2: Dacomitinib 15mg daily\\n\\nCohort 2 Dacomitinib Dosing:\\n\\nDose level 1: Dacomitinib 30 mg daily Dose level -1: Dacomitinib 15 mg daily', 'armGroupLabels': ['Cohort 1: Participants treated with dacomitinib alone', 'Cohort 2: Participants treated with dacomitinib in combination with osimertinib']}, {'type': 'DRUG', 'name': 'Osimertinib', 'description': 'In cohort 2, participants will begin on dacomitinib orally daily in combination with Osimertinib\\n\\nDose level Osimertinib Dosing:\\n\\nDose level 1: Osimertinib 80 mg daily Dose level -1: Osimertinib 40 mg daily', 'armGroupLabels': ['Cohort 2: Participants treated with dacomitinib in combination with osimertinib']}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Overall Response Rate', 'description': 'Overall response rate (partial and complete responses) of dacomitinib in participants with EGFR-mutant lung cancers and disease progression on osimertinib', 'timeFrame': '1 year'}], 'secondaryOutcomes': [{'measure': 'Progression-free survival', 'timeFrame': '1 year'}, {'measure': 'Overall survival', 'timeFrame': '1 year'}]}, 'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\n\\n* Written informed consent\\n* Advanced biopsy-proven metastatic non-small cell lung cancer\\n* Somatic activating mutation in EGFR in a tumor biopsy or plasma cfDNA liquid biopsy\\n* Prior treatment with osimertinib with response followed by disease progression\\n* No prior first or second generation EGFR inhibitor treatment (gefitinib, afatinib, erlotinib)\\n* Archival tissue available from a tumor biopsy done after disease progression on osimertinib or willing to undergo a tumor biopsy or liquid biopsy after disease progression on osimertinib prior to study initiation\\n* Measurable (RECIST 1.1) indicator lesion not previously irradiated\\n* Karnofsky performance status (KPS) \\\\>/= 70%\\n* Age \\\\>/= 18 years old\\n* Ability to swallow oral medication\\n* Adequate organ function\\n\\n  * AST, ALT \\\\</= 3 x ULN\\n  * Total bilirubin \\\\</= 1.5x ULN\\n  * Creatinine \\\\</= 1.5x ULN OR calculated creatinine clearance \\\\>/= 60ml/min\\n  * Absolute neutrophil count (ANC) \\\\>/= 1000 cells/mm3\\n  * Hemoglobin\\\\>/=8.0 g/dL\\n  * Platelets \\\\>/=75,000/mm3\\n\\nExclusion Criteria:\\n\\n* Pregnant or lactating women\\n* Any radiotherapy within 1 week of starting treatment on protocol.\\n* Any major surgery within 1 weeks of starting treatment on protocol.\\n* Any evidence of active clinically significant interstitial lung disease\\n* Continue to have unresolved \\\\> grade 1 toxicity from any previous treatment Treatment\\n* Patients with a known mechanism of resistance to osimertinib that will clearly not respond to dacomitinib therapy (i.e. known MET amplification, ALK fusion, RET fusion).\\n* Symptomatic brain metastases or leptomeningeal disease requiring escalating doses of steroids', 'healthyVolunteers': False, 'sex': 'ALL', 'minimumAge': '18 Years', 'stdAges': ['ADULT', 'OLDER_ADULT']}, 'contactsLocationsModule': {'overallOfficials': [{'name': 'Helen Yu, MD', 'affiliation': 'Memorial Sloan Kettering Cancer Center', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'locations': [{'facility': 'Memorial Sloan Kettering Basking Ridge', 'city': 'Basking Ridge', 'state': 'New Jersey', 'zip': '07920', 'country': 'United States', 'geoPoint': {'lat': 40.70621, 'lon': -74.54932}}, {'facility': 'Memorial Sloan Kettering Monmouth', 'city': 'Middletown', 'state': 'New Jersey', 'zip': '07748', 'country': 'United States', 'geoPoint': {'lat': 40.39652, 'lon': -74.09211}}, {'facility': 'Memorial Sloan Kettering Bergen', 'city': 'Montvale', 'state': 'New Jersey', 'zip': '07645', 'country': 'United States', 'geoPoint': {'lat': 41.04676, 'lon': -74.02292}}, {'facility': 'Memorial Sloan Kettering Commack', 'city': 'Commack', 'state': 'New York', 'zip': '11725', 'country': 'United States', 'geoPoint': {'lat': 40.84288, 'lon': -73.29289}}, {'facility': 'Memorial Sloan Kettering Westchester', 'city': 'Harrison', 'state': 'New York', 'zip': '10604', 'country': 'United States', 'geoPoint': {'lat': 40.96899, 'lon': -73.71263}}, {'facility': 'Memorial Sloan Kettering Cancer Center', 'city': 'New York', 'state': 'New York', 'zip': '10065', 'country': 'United States', 'geoPoint': {'lat': 40.71427, 'lon': -74.00597}}, {'facility': 'Memorial Sloan Kettering Rockville Centre', 'city': 'Rockville Centre', 'state': 'New York', 'zip': '11570', 'country': 'United States', 'geoPoint': {'lat': 40.65871, 'lon': -73.64124}}, {'facility': 'Memorial Sloan Kettering Nassau', 'city': 'Uniondale', 'state': 'New York', 'zip': '11553', 'country': 'United States', 'geoPoint': {'lat': 40.70038, 'lon': -73.59291}}]}, 'referencesModule': {'seeAlsoLinks': [{'label': 'Memorial Sloan Kettering Cancer Center', 'url': 'http://www.mskcc.org'}]}, 'ipdSharingStatementModule': {'ipdSharing': 'YES', 'description': 'Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made beginning 12 months after publication and for up to 36 months post publication. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.'}}, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-08-21'}, 'conditionBrowseModule': {'meshes': [{'id': 'D008175', 'term': 'Lung Neoplasms'}], 'ancestors': [{'id': 'D012142', 'term': 'Respiratory Tract Neoplasms'}, {'id': 'D013899', 'term': 'Thoracic Neoplasms'}, {'id': 'D009371', 'term': 'Neoplasms by Site'}, {'id': 'D009369', 'term': 'Neoplasms'}, {'id': 'D008171', 'term': 'Lung Diseases'}, {'id': 'D012140', 'term': 'Respiratory Tract Diseases'}], 'browseLeaves': [{'id': 'M11172', 'name': 'Lung Neoplasms', 'asFound': 'Lung Cancer', 'relevance': 'HIGH'}, {'id': 'M20559', 'name': 'Disease Progression', 'relevance': 'LOW'}, {'id': 'M14979', 'name': 'Respiratory Tract Neoplasms', 'relevance': 'LOW'}, {'id': 'M16658', 'name': 'Thoracic Neoplasms', 'relevance': 'LOW'}, {'id': 'M11168', 'name': 'Lung Diseases', 'relevance': 'LOW'}, {'id': 'M14977', 'name': 'Respiratory Tract Diseases', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'BC04', 'name': 'Neoplasms'}, {'abbrev': 'BC08', 'name': 'Respiratory Tract (Lung and Bronchial) Diseases'}, {'abbrev': 'All', 'name': 'All Conditions'}, {'abbrev': 'BC23', 'name': 'Symptoms and General Pathology'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'C000596361', 'term': 'Osimertinib'}, {'id': 'C525726', 'term': 'Dacomitinib'}], 'ancestors': [{'id': 'D000092004', 'term': 'Tyrosine Kinase Inhibitors'}, {'id': 'D047428', 'term': 'Protein Kinase Inhibitors'}, {'id': 'D004791', 'term': 'Enzyme Inhibitors'}, {'id': 'D045504', 'term': 'Molecular Mechanisms of Pharmacological Action'}, {'id': 'D000970', 'term': 'Antineoplastic Agents'}], 'browseLeaves': [{'id': 'M145673', 'name': 'Osimertinib', 'asFound': 'Oxygenation', 'relevance': 'HIGH'}, {'id': 'M81036', 'name': 'Dacomitinib', 'asFound': 'Bone Density', 'relevance': 'HIGH'}, {'id': 'M2889', 'name': 'Tyrosine Kinase Inhibitors', 'relevance': 'LOW'}, {'id': 'M25820', 'name': 'Protein Kinase Inhibitors', 'relevance': 'LOW'}, {'id': 'M7951', 'name': 'Enzyme Inhibitors', 'relevance': 'LOW'}, {'id': 'T22', 'name': 'Tyrosine', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'ANeo', 'name': 'Antineoplastic Agents'}, {'abbrev': 'All', 'name': 'All Drugs and Chemicals'}, {'abbrev': 'AA', 'name': 'Amino Acids'}]}}, 'hasResults': False}\n",
      "Keys for NCT05166616:\n",
      "dict_keys(['protocolSection', 'derivedSection', 'hasResults'])\n",
      "Content for NCT05166616:\n",
      "{'protocolSection': {'identificationModule': {'nctId': 'NCT05166616', 'orgStudyIdInfo': {'id': '20609'}, 'secondaryIdInfos': [{'id': 'NCI-2021-12558', 'type': 'REGISTRY', 'domain': 'CTRP (Clinical Trial Reporting Program)'}, {'id': '20609', 'type': 'OTHER', 'domain': 'City of Hope Medical Center'}, {'id': 'P30CA033572', 'type': 'NIH', 'link': 'https://reporter.nih.gov/quickSearch/P30CA033572'}], 'organization': {'fullName': 'City of Hope Medical Center', 'class': 'OTHER'}, 'briefTitle': 'Minnelide and Osimertinib for the Treatment of Advanced EGFR Mutated Non-Small Cell Lung Cancer', 'officialTitle': 'A Phase 1b Open-Label, Dose-Escalation, Safety, and Pharmacodynamic Study of Minnelide™ Capsules Given in Combination With Osimertinib in Patients With EGFR Mutated NSCLC'}, 'statusModule': {'statusVerifiedDate': '2025-02', 'overallStatus': 'RECRUITING', 'startDateStruct': {'date': '2022-03-07', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2027-10-28', 'type': 'ESTIMATED'}, 'completionDateStruct': {'date': '2027-10-28', 'type': 'ESTIMATED'}, 'studyFirstSubmitDate': '2021-11-29', 'studyFirstSubmitQcDate': '2021-12-08', 'studyFirstPostDateStruct': {'date': '2021-12-22', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2025-02-20', 'lastUpdatePostDateStruct': {'date': '2025-02-24', 'type': 'ACTUAL'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'}, 'leadSponsor': {'name': 'City of Hope Medical Center', 'class': 'OTHER'}, 'collaborators': [{'name': 'National Cancer Institute (NCI)', 'class': 'NIH'}]}, 'oversightModule': {'oversightHasDmc': True, 'isFdaRegulatedDrug': True, 'isFdaRegulatedDevice': False, 'isUsExport': False}, 'descriptionModule': {'briefSummary': 'This phase Ib trial tests the side effects and best dose of minnelide when given together with osimertinib for the treatment of non-small cell lung cancer that has spread to other places in the body (advanced) and has a change (mutation) in a gene called EGFR. Minnelide is a biologically inactive compound that can be broken down in the body to produce a drug that rapidly releases the active compound triptolide when exposed to phosphatases in the bloodstream. Sometimes, mutations in the EGFR gene cause EGFR proteins to be made in higher than normal amounts on some types of cancer cells. This causes cancer cells to divide more rapidly. Osimertinib may stop the growth of tumor cells by blocking EGFR that is needed for cell growth in this type of cancer. Minnelide and osimertinib may work better in treating patients with EGFR mutant advanced non-small cell lung cancer.', 'detailedDescription': 'PRIMARY OBJECTIVES:\\n\\nI. To determine the maximum tolerated dose (MTD) and the dose limiting toxicities (DLT) of triptolide analog (minnelide) capsules when given in combination with osimertinib.\\n\\nII. To establish the dose of minnelide capsules recommended for future phase II studies when given in combination with full dose osimertinib (recommended phase II dose \\\\[RP2D\\\\]).\\n\\nSECONDARY OBJECTIVES:\\n\\nI. To observe patients for any evidence of antitumor activity of minnelide capsules by objective radiographic assessment when in combination with osimertinib.\\n\\nII. To determine pharmacodynamic effects of minnelide capsules on heat shock protein (HSP)72 levels when given in combination with osimertinib.\\n\\nEXPLORATORY OBJECTIVES:\\n\\nI. Measure HSP levels, pre/post and during therapy as predictive biomarker. II. Determine levels of minnelide in the blood, and its effect. III. Determine the cell free deoxyribonucleic acid (DNA) in blood as biomarker. IV. Evaluate the microbiome pre-, during-, and post-therapy as potentiator of therapeutic response.\\n\\nV. Determine the exosomes as biomarker.\\n\\nOUTLINE: This is a dose-escalation study of minnelide.\\n\\nPatients receive minnelide orally (PO) once daily (QD) on days 1-21 and osimertinib PO QD on days 1-28. Cycles repeat every 28 days for 6 months in the absence of disease progression or unacceptable toxicity.\\n\\nAfter completion of study treatment, patients are followed up at 30 days and then every 3 months for 2 years.'}, 'conditionsModule': {'conditions': ['Advanced Lung Non-Small Cell Carcinoma', 'Locally Advanced Lung Non-Small Cell Carcinoma', 'Stage III Lung Cancer AJCC v8', 'Stage IIIA Lung Cancer AJCC v8', 'Stage IIIB Lung Cancer AJCC v8', 'Stage IIIC Lung Cancer AJCC v8', 'Stage IV Lung Cancer AJCC v8', 'Stage IVA Lung Cancer AJCC v8', 'Stage IVB Lung Cancer AJCC v8', 'Unresectable Lung Non-Small Cell Carcinoma']}, 'designModule': {'studyType': 'INTERVENTIONAL', 'phases': ['PHASE1'], 'designInfo': {'allocation': 'NA', 'interventionModel': 'SINGLE_GROUP', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 30, 'type': 'ESTIMATED'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'Treatment (minnelide, osimertinib)', 'type': 'EXPERIMENTAL', 'description': 'Patients receive minnelide PO QD on days 1-21 and osimertinib PO QD on days 1-28. Cycles repeat every 28 days for 6 months in the absence of disease progression or unacceptable toxicity.', 'interventionNames': ['Procedure: Biopsy', 'Drug: Osimertinib', 'Drug: Triptolide Analog']}], 'interventions': [{'type': 'PROCEDURE', 'name': 'Biopsy', 'description': 'Correlative studies', 'armGroupLabels': ['Treatment (minnelide, osimertinib)'], 'otherNames': ['BIOPSY_TYPE', 'Bx']}, {'type': 'DRUG', 'name': 'Osimertinib', 'description': 'Given PO', 'armGroupLabels': ['Treatment (minnelide, osimertinib)'], 'otherNames': ['AZD-9291', 'AZD9291', 'Mereletinib', 'Tagrisso']}, {'type': 'DRUG', 'name': 'Triptolide Analog', 'description': 'Given PO', 'armGroupLabels': ['Treatment (minnelide, osimertinib)'], 'otherNames': ['Minnelide']}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Maximum tolerated dose (MTD) of osimertinib and minnelide', 'timeFrame': 'Up to 28 days'}, {'measure': 'Recommended phase II dose (RP2D) of minnelide and osimertinib', 'timeFrame': 'Up to 28 days'}], 'secondaryOutcomes': [{'measure': 'Pharmacodynamic effects of minnelide on heat shock protein (HSP)72 expression', 'description': 'To analyze the pharmacodynamic effects of Minnelide on HSP72 protein levels in serum collected at specific timepoints before and after treatment.', 'timeFrame': 'Up to 2 years'}, {'measure': 'Objective response rate', 'description': 'Assessed per Response Evaluation Criteria in Solid Tumors (RECIST) version (v) 1.1.', 'timeFrame': 'Up to 2 years'}, {'measure': 'Duration of overall response', 'timeFrame': 'Up to 2 years'}, {'measure': 'Evidence of anti-tumor activity of minnelide when in combination with osimertinib', 'description': 'Assessed by objective radiographic assessment.', 'timeFrame': 'Up to 2 years'}, {'measure': 'Incidence of adverse events', 'description': 'Assessed per Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.', 'timeFrame': 'Up to 2 years'}, {'measure': 'Progression-free survival (PFS)', 'description': 'Assessed per RECIST v 1.1. Median PFS will be determined using the Kaplan-Meier method.', 'timeFrame': 'Up to 2 years'}, {'measure': 'Overall survival', 'description': 'Assessed per RECIST v 1.1.', 'timeFrame': 'From the date of study enrollment to the date of death from any cause, assessed up to 2 years'}], 'otherOutcomes': [{'measure': 'HSP levels pre and post therapy', 'timeFrame': 'Baseline and up to 2 years'}, {'measure': 'Levels of minnelide in the blood', 'timeFrame': 'Up to 2 years'}, {'measure': 'Cell free deoxyribonucleic acid (DNA) in blood', 'timeFrame': 'Up to 2 years'}, {'measure': 'Evaluation of the microbiome', 'description': 'To evaluate the microbiome through amplicon sequencing of DNA extracted from fecal material collected by patients at baseline, restaging (2 cycles/8 weeks), and post-therapy (after disease progression/treatment discontinuation).', 'timeFrame': 'Up to 2 years'}, {'measure': 'Determination of the exosomes', 'description': 'To determine potential biomarkers through whole exome sequencing of tumor specimen. In brief, whole exome sequencing using a structured exome design will be performed on paired tumor/normal samples.\\n\\nThis assay enables identification of mutations within exons as well as detection of structural variants including copy number variants and translocation breakpoints.', 'timeFrame': 'Up to 2 years'}]}, 'eligibilityModule': {'eligibilityCriteria': \"Inclusion Criteria:\\n\\n* Documented informed consent of the participant and/or legally authorized representative\\n\\n  * Assent, when appropriate, will be obtained per institutional guidelines\\n* Agreement to two research biopsies\\n\\n  * If tumor is unbiopsiable or not safely biopsied, exceptions may be granted with study principal investigator (PI) approval\\n* Age: \\\\>= 18 years\\n* Karnofsky performance \\\\>= 70%\\n* Histologically confirmed advanced non-small cell lung cancer (NSCLC). Patients with locally advanced NSCLC must not be candidates for surgical resection, radiation, or chemoradiation with curative intent\\n* The tumor harbors 1 of the 2 common epidermal growth factor receptor (EGFR) mutations known to be associated with epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKI) sensitivity (Ex19del or L858R), either alone or in combination with other epidermal growth factor receptor (EGFR) mutations, which may include T790M\\n* Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1\\n* Tumor progression after receiving standard/approved osimertinib\\n* Fully recovered from the acute toxic effects (except alopecia) to =\\\\< grade 1 to prior anti-cancer therapy. Grade 2 neuropathy is allowed\\n* Absolute neutrophil count (ANC) \\\\>= 1,500/mm\\\\^3 (within 14 days prior to day 1 of protocol therapy)\\n\\n  * NOTE: Growth factor is not permitted within 14 days of ANC assessment\\n* Platelets \\\\>= 100,000/mm\\\\^3 (within 14 days prior to day 1 of protocol therapy)\\n\\n  * NOTE: Platelet transfusions are not permitted within 14 days of platelet assessment\\n* Hemoglobin \\\\>= 9 g/dL (within 14 days prior to day 1 of protocol therapy)\\n* Total bilirubin =\\\\< 1.5 X ULN (unless has Gilbert's disease). Total bilirubin \\\\< 3 x ULN in the presence of documented Gilbert's disease (within 14 days prior to day 1 of protocol therapy)\\n* Aspartate aminotransferase (AST) =\\\\< 2.5 x upper limit of normal (ULN) (if liver metastases are present, then =\\\\< 5 x ULN is allowed) (within 14 days prior to day 1 of protocol therapy)\\n* Alanine aminotransferase (ALT) =\\\\< 2.5 x ULN if liver metastases are present, then =\\\\< 5 x ULN is allowed) (within 14 days prior to day 1 of protocol therapy)\\n* Alkaline phosphatase =\\\\< 2.5 x ULN if liver metastases are present, then =\\\\< 5 x ULN is allowed) (within 14 days prior to day 1 of protocol therapy)\\n* Serum creatinine within normal limits, OR creatinine clearance of \\\\>= 60 mL/min per 24 hour urine test for patients with creatinine levels above ULN (within 14 days prior to day 1 of protocol therapy)\\n\\n  * Creatinine clearance (CrCl, by Cockcroft-Gault) is utilized for all patients to allow for evaluation of the effect of CrCl on the minnelide/triptolide exposures\\n* If not receiving anticoagulants: International normalized ratio (INR) OR prothrombin time (PT) =\\\\< 1.5 x ULN (within 14 days prior to day 1 of protocol therapy)\\n\\n  * If on anticoagulant therapy: PT must be within therapeutic range of intended use of anticoagulants\\n* If not receiving anticoagulants: Activated partial thromboplastin time (aPTT) =\\\\< 1.5 x ULN (within 14 days prior to day 1 of protocol therapy)\\n\\n  * If on anticoagulant therapy: aPTT must be within therapeutic range of intended use of anticoagulants\\n* Albumin \\\\>= 3.0 /dL (within 14 days prior to day 1 of protocol therapy)\\n* Urinalysis - no clinically significant abnormalities (within 14 days prior to day 1 of protocol therapy)\\n* QT corrected (QTc) =\\\\< 470 ms (using the Bazett's formula)\\n\\n  * Note: To be performed within 28 days prior to Day 1 of protocol therapy.\\n* Women of childbearing potential (WOCBP): negative urine or serum pregnancy test (within 14 days prior to day 1 of protocol therapy)\\n\\n  * If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required\\n* Agreement by females and males of childbearing potential to use an effective method of birth control or abstain from heterosexual activity for the course of the study through at least 6 weeks after the last dose of protocol therapy. Contraception must be continued following discontinuation of the study drugs for at least five half-lives of both study drugs\\n\\n  * Childbearing potential defined as not being surgically sterilized (men and women) or have not been free from menses for \\\\> 1 year (women only)\\n  * Female patients of childbearing potential must:\\n\\n    * Agree to practice 1 highly effective method of non-hormonal contraception and one additional effective (barrier) method at the same time, from the time of signing the informed consent through 180 days after the last dose of study drug, or\\n    * Agree to practice true abstinence, when is in line with the preferred and usual lifestyle of the subject. (Periodic abstinence \\\\[e.g. calendar, ovulation, symptothermal, postovulation methods\\\\], withdrawal, spermicides only, and lactational amenorrhea are not acceptable methods of contraception. Female and male condoms should not be used together.)\\n    * Agree not to donate eggs (ova) during the course of this study or 180 days after receiving their last dose of study drug. Agree not to breast-feed for the duration of treatment through 6 months post treatment.\\n  * Male patients of childbearing potential must:\\n\\n    * Agree to practice effective barrier contraception during the entire study treatment period and through 180 days after the last dose of study drug, or\\n    * Agree to practice true abstinence, when this is in line with the preferred and usual lifestyle of the subject. (Periodic abstinence \\\\[e.g. calendar, ovulation, symptothermal, postovulation methods for the female partner\\\\] and withdrawal are not acceptable methods of contraception. Female and male condoms should not be used together.)\\n    * Agree not to donate sperm during the course of this study or within 180 days after receiving their last dose of study drug.\\n* Patients must be able to swallow and retain oral medications\\n* Previously tolerant of osimertinib at 80 mg QD\\n\\nExclusion Criteria:\\n\\n* Treatment with radiation therapy, surgery, chemotherapy, or investigational therapy within 21 days prior to day 1 of protocol therapy (6 weeks for nitrosoureas or Mitomycin C). Exceptions to this exclusion are brain radiation and osimertinib\\n* Biological therapy, immunotherapy within 21 days prior to day 1 of protocol therapy\\n* Strong CYP3A4 inducers/ inhibitors within 14 days prior to day 1 of protocol therapy\\n* Patients receiving class 1A or class III antiarrhythmic agents within 14 days prior to Day 1 of protocol therapy\\n* Herbal and alternative (eg. turmeric, cannabidiol, ginseng) medications within 7 days prior to Day 1 of protocol therapy\\n* Clarithromycin, loperamide, ondansetron within 7 days prior to day 1 of protocol therapy\\n* History of allergic reactions attributed to compounds of similar chemical or biologic composition to study agent\\n* Active diarrhea\\n* Clinically significant uncontrolled illness\\n* Known history of immunodeficiency virus (HIV) or hepatitis B or hepatitis C infection\\n* Prior malignancy other than carcinoma in situ of the cervix, or nonmelanoma skin cancer, unless that prior malignancy was diagnosed and definitively treated 5 or more years prior to study entry with no subsequent evidence of recurrence. Patients with a history of low grade (Gleason score =\\\\< 6 = Gleason Group 1) localized prostate cancer will be eligible even if diagnosed less than 5 years prior to study entry\\n* Females only: Pregnant or breastfeeding\\n* Any malabsorption condition\\n* Any other condition that would, in the Investigator's judgment, contraindicate the patient's participation in the clinical study due to safety concerns with clinical study procedures.\\n* New York Heart Association Class III or IV, cardiac disease, myocardial infarction within the past 6 months, unstable arrhythmia, or evidence of ischemia on electrocardiogram (ECG)\\n* Clinical evidence of central nervous system (CNS) metastases or leptomeningeal carcinomatosis, except for individuals who have previously-treated CNS metastases, are asymptomatic, and have had no requirement for steroid medication for 1 week prior to the first dose of study drug and have completed radiation 2 weeks prior to the first dose of study drug\\n* Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic therapy\\n* Diagnosis of congenital long QT syndrome\\n* Prospective participants who, in the opinion of the investigator, may not be able to comply with all study procedures (including compliance issues related to feasibility/logistics)\", 'healthyVolunteers': False, 'sex': 'ALL', 'minimumAge': '18 Years', 'stdAges': ['ADULT', 'OLDER_ADULT']}, 'contactsLocationsModule': {'overallOfficials': [{'name': 'Erminia Massarelli', 'affiliation': 'City of Hope Medical Center', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'locations': [{'facility': 'City of Hope Medical Center', 'status': 'RECRUITING', 'city': 'Duarte', 'state': 'California', 'zip': '91010', 'country': 'United States', 'contacts': [{'name': 'Erminia Massarelli', 'role': 'CONTACT', 'phone': '626-218-3712', 'email': 'emassarelli@coh.org'}, {'name': 'Erminia Massarelli', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 34.13945, 'lon': -117.97729}}]}}, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-08-21'}, 'conditionBrowseModule': {'meshes': [{'id': 'D002277', 'term': 'Carcinoma'}, {'id': 'D008175', 'term': 'Lung Neoplasms'}, {'id': 'D002289', 'term': 'Carcinoma, Non-Small-Cell Lung'}], 'ancestors': [{'id': 'D009375', 'term': 'Neoplasms, Glandular and Epithelial'}, {'id': 'D009370', 'term': 'Neoplasms by Histologic Type'}, {'id': 'D009369', 'term': 'Neoplasms'}, {'id': 'D012142', 'term': 'Respiratory Tract Neoplasms'}, {'id': 'D013899', 'term': 'Thoracic Neoplasms'}, {'id': 'D009371', 'term': 'Neoplasms by Site'}, {'id': 'D008171', 'term': 'Lung Diseases'}, {'id': 'D012140', 'term': 'Respiratory Tract Diseases'}, {'id': 'D002283', 'term': 'Carcinoma, Bronchogenic'}, {'id': 'D001984', 'term': 'Bronchial Neoplasms'}], 'browseLeaves': [{'id': 'M5534', 'name': 'Carcinoma', 'asFound': 'Carcinoma', 'relevance': 'HIGH'}, {'id': 'M11172', 'name': 'Lung Neoplasms', 'asFound': 'Lung Cancer', 'relevance': 'HIGH'}, {'id': 'M5546', 'name': 'Carcinoma, Non-Small-Cell Lung', 'asFound': 'Lung Non-Small Cell Carcinoma', 'relevance': 'HIGH'}, {'id': 'M12320', 'name': 'Neoplasms, Glandular and Epithelial', 'relevance': 'LOW'}, {'id': 'M12315', 'name': 'Neoplasms by Histologic Type', 'relevance': 'LOW'}, {'id': 'M14979', 'name': 'Respiratory Tract Neoplasms', 'relevance': 'LOW'}, {'id': 'M16658', 'name': 'Thoracic Neoplasms', 'relevance': 'LOW'}, {'id': 'M11168', 'name': 'Lung Diseases', 'relevance': 'LOW'}, {'id': 'M14977', 'name': 'Respiratory Tract Diseases', 'relevance': 'LOW'}, {'id': 'M5540', 'name': 'Carcinoma, Bronchogenic', 'relevance': 'LOW'}, {'id': 'M5260', 'name': 'Bronchial Neoplasms', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'BC04', 'name': 'Neoplasms'}, {'abbrev': 'All', 'name': 'All Conditions'}, {'abbrev': 'BC08', 'name': 'Respiratory Tract (Lung and Bronchial) Diseases'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'C000596361', 'term': 'Osimertinib'}, {'id': 'C001899', 'term': 'Triptolide'}], 'ancestors': [{'id': 'D000092004', 'term': 'Tyrosine Kinase Inhibitors'}, {'id': 'D047428', 'term': 'Protein Kinase Inhibitors'}, {'id': 'D004791', 'term': 'Enzyme Inhibitors'}, {'id': 'D045504', 'term': 'Molecular Mechanisms of Pharmacological Action'}, {'id': 'D000970', 'term': 'Antineoplastic Agents'}, {'id': 'D018906', 'term': 'Antineoplastic Agents, Alkylating'}, {'id': 'D000477', 'term': 'Alkylating Agents'}, {'id': 'D000988', 'term': 'Antispermatogenic Agents'}, {'id': 'D045505', 'term': 'Physiological Effects of Drugs'}, {'id': 'D003272', 'term': 'Contraceptive Agents, Male'}, {'id': 'D003270', 'term': 'Contraceptive Agents'}, {'id': 'D012102', 'term': 'Reproductive Control Agents'}, {'id': 'D007166', 'term': 'Immunosuppressive Agents'}, {'id': 'D007155', 'term': 'Immunologic Factors'}], 'browseLeaves': [{'id': 'M145673', 'name': 'Osimertinib', 'asFound': 'ATG', 'relevance': 'HIGH'}, {'id': 'M271827', 'name': 'Triptolide', 'asFound': 'Fixed partial denture', 'relevance': 'HIGH'}, {'id': 'M2889', 'name': 'Tyrosine Kinase Inhibitors', 'relevance': 'LOW'}, {'id': 'M25820', 'name': 'Protein Kinase Inhibitors', 'relevance': 'LOW'}, {'id': 'M7951', 'name': 'Enzyme Inhibitors', 'relevance': 'LOW'}, {'id': 'M20942', 'name': 'Antineoplastic Agents, Alkylating', 'relevance': 'LOW'}, {'id': 'M3820', 'name': 'Alkylating Agents', 'relevance': 'LOW'}, {'id': 'M6494', 'name': 'Contraceptive Agents', 'relevance': 'LOW'}, {'id': 'M6496', 'name': 'Contraceptive Agents, Male', 'relevance': 'LOW'}, {'id': 'M10212', 'name': 'Immunosuppressive Agents', 'relevance': 'LOW'}, {'id': 'M10201', 'name': 'Immunologic Factors', 'relevance': 'LOW'}, {'id': 'T22', 'name': 'Tyrosine', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'ANeo', 'name': 'Antineoplastic Agents'}, {'abbrev': 'All', 'name': 'All Drugs and Chemicals'}, {'abbrev': 'Repr', 'name': 'Reproductive Control Agents'}, {'abbrev': 'AA', 'name': 'Amino Acids'}]}}, 'hasResults': False}\n",
      "Keys for NCT02926768:\n",
      "dict_keys(['protocolSection', 'derivedSection', 'hasResults'])\n",
      "Content for NCT02926768:\n",
      "{'protocolSection': {'identificationModule': {'nctId': 'NCT02926768', 'orgStudyIdInfo': {'id': 'CK-101-101'}, 'organization': {'fullName': 'Checkpoint Therapeutics, Inc.', 'class': 'INDUSTRY'}, 'briefTitle': 'Phase I/II Study of CK-101 in NSCLC Patients and Other Advanced Solid Tumors', 'officialTitle': 'A Phase I/II, Open-Label, Safety, Pharmacokinetic and Efficacy Study of Ascending Doses of Oral CK-101 in Patients With Advanced Solid Tumors'}, 'statusModule': {'statusVerifiedDate': '2022-07', 'overallStatus': 'COMPLETED', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2016-09', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2020-09', 'type': 'ACTUAL'}, 'completionDateStruct': {'date': '2022-06', 'type': 'ACTUAL'}, 'studyFirstSubmitDate': '2016-09-29', 'studyFirstSubmitQcDate': '2016-10-05', 'studyFirstPostDateStruct': {'date': '2016-10-06', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2022-07-25', 'lastUpdatePostDateStruct': {'date': '2022-07-26', 'type': 'ACTUAL'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'}, 'leadSponsor': {'name': 'Checkpoint Therapeutics, Inc.', 'class': 'INDUSTRY'}}, 'oversightModule': {'oversightHasDmc': False}, 'descriptionModule': {'briefSummary': 'CK-101 is a novel, potent, small molecule tyrosine kinase inhibitor (TKI) that selectively targets mutant forms of the epidermal growth factor receptor (EGFR) while sparing wild-type (WT) EGFR. The purpose of the study is to evaluate the pharmacokinetic (PK) and safety profile of oral CK-101; to determine the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of oral CK-101; to assess the safety and efficacy of CK-101 in treatment-naive NSCLC patients known to have activating EGFR mutations and previously treated NSCLC patients known to have the T790M EGFR mutation.', 'detailedDescription': 'This is a first-in-human, two-part, open-label, safety, pharmacokinetic, and efficacy study of oral CK-101 administered daily in ascending doses in patients with advanced solid tumor cancer, followed by a Phase 2 portion at the recommended Phase 2 dose (RP2D) in previously treated non-small cell lung cancer (NSCLC) patients who have documented evidence of EGFR T790M mutation and have failed treatment with a first-line EGFR inhibitor.'}, 'conditionsModule': {'conditions': ['Lung Neoplasms', 'Carcinoma, Non-Small-Cell Lung', 'Lung Diseases', 'Adenocarcinoma'], 'keywords': ['Cancer', 'Non Small Cell Lung Cancer', 'EGFR sensitivity mutation', 'T790M', 'NSCLC', 'epidermal growth factor receptor', 'EGFR', 'EGFR inhibitor']}, 'designModule': {'studyType': 'INTERVENTIONAL', 'phases': ['PHASE1'], 'designInfo': {'allocation': 'NA', 'interventionModel': 'SINGLE_GROUP', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 136, 'type': 'ACTUAL'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'Daily dose of CK-101', 'type': 'EXPERIMENTAL', 'description': 'Daily oral dose of CK-101', 'interventionNames': ['Drug: CK-101']}], 'interventions': [{'type': 'DRUG', 'name': 'CK-101', 'description': 'Phase 1: CK-101 will be administered in escalating dosages in a period of 21-day cycles\\n\\nPhase 2: CK-101 will be administered daily', 'armGroupLabels': ['Daily dose of CK-101']}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Phase I: Incidence of dose-limiting toxicities (DLTs)', 'timeFrame': 'From baseline (first dose) to 28 days after last dose, expected average 6 months'}, {'measure': 'Phase II: Objective response rate (ORR): Defined as the rate of complete responses [CR] or partial responses [PR] per RECIST Version 1.1 as assessed by an independent central review', 'timeFrame': 'From baseline (first dose) until disease progression or withdrawal from study, expected average 10 months'}], 'secondaryOutcomes': [{'measure': 'Phase II: Evaluation of tumor response based on disease control rate as assessed by RECIST 1.1', 'timeFrame': 'From baseline (first dose) until disease progression or withdrawal from study, expected average 10 months'}, {'measure': 'Phase II: Evaluation of tumor response based on duration of response as assessed by RECIST 1.1', 'timeFrame': 'From baseline (first dose) until disease progression or withdrawal from study, expected average 10 months'}, {'measure': 'Phase II: Evaluation of tumor response based on tumor shrinkage as assessed by RECIST 1.1', 'timeFrame': 'From baseline (first dose) until disease progression or withdrawal from study, expected average 10 months'}, {'measure': 'Phase II: Evaluation of tumor response based on progression free survival as assessed by RECIST 1.1', 'timeFrame': 'From baseline (first dose) until disease progression or withdrawal from study, expected average 10 months'}, {'measure': 'Phase I: Change from baseline in QT/QTc interval', 'timeFrame': 'Cycle 1 Day 1 until disease progression or withdrawal from study, expected average 10 months'}, {'measure': 'Phase I: Plasma concentrations of CK-101 following dosing with CK-101 as assessed by area under the curve', 'timeFrame': 'Days 1, 8 and 15 of Cycle 1 and Day 1 of Cycle 2'}, {'measure': 'Phase I: Plasma concentrations of CK-101 following dosing with CK-101 as assessed by maximum concentration', 'timeFrame': 'Days 1, 8 and 15 of Cycle 1 and Day 1 of Cycle 2'}, {'measure': 'Phase I: Plasma concentrations of CK-101 following dosing with CK-101 as assessed by elimination half-life', 'timeFrame': 'Days 1, 8 and 15 of Cycle 1 and Day 1 of Cycle 2'}]}, 'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\n\\n* Measureable disease according to RECIST Version 1.1\\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\\n* Minimum age of 18 years\\n* Adequate hematological, hepatic and renal function\\n* Written consent on an Institutional Review Board-approved informed consent form prior to any study-specific evaluation\\n* Histologically or cytologically confirmed diagnosis of one of the following:\\n\\n  1. Metastatic or unresectable locally advanced NSCLC with documented evidence that the tumor harbors one of the two common EGFR mutations known to be associated with EGFR tyrosine kinase inhibitor (TKI) sensitivity (exon 19 deletion, L858R), either alone or in combination with other EGFR mutations, determined by PCR-based testing of the tumor tissue or plasma sample, and without prior exposure to an EGFR-TKI therapy; OR\\n  2. Metastatic or unresectable locally advanced NSCLC:\\n\\n     1. with documented evidence that the tumor harbors an EGFR mutation known to be associated with EGFR TKI sensitivity (including G719X, exon 19 deletion, L858R, L861Q); and\\n     2. with evidence of radiological disease progression while on a previous continuous treatment with a first-generation EGFR TKI. In addition, other lines of therapy may have been given. All patients must have evidence of radiological disease progression on or following the last treatment administered; and\\n     3. with documented evidence of EGFR T790M mutation determined by PCR-based testing of the tumor tissue or plasma sample following disease progression on most recent treatment regimen (irrespective of whether this is EGFR TKI or chemotherapy).\\n\\nExclusion Criteria:\\n\\n* Active second malignancy or other prior malignancy treated with chemotherapy less than or equal to 6 months prior to treatment with CK-101\\n* History of, or evidence of clinically active, interstitial lung disease\\n* Brain metastases unless asymptomatic, stable and not requiring steroids for at least 2 weeks\\n* Treatment with prohibited medications\\n* Any toxicity related to prior treatment must have resolved to Grade 1 or less, with the exception of alopecia and Grade 2, prior platinum-therapy related neuropathy\\n* Certain cardiac abnormalities or history\\n* Non-study related surgical procedures less than or equal to 14 days prior to CK-101 administration\\n* Females who are pregnant or breastfeeding.\\n* Refusal to use adequate contraception for fertile patients (females and males)\\n* Presence of any serious or unstable concomitant systemic disorder incompatible with the clinical study\\n* Refractory nausea and vomiting, chronic gastrointestinal diseases, inability to swallow the formulated product or previous significant bowel resection', 'healthyVolunteers': False, 'sex': 'ALL', 'minimumAge': '18 Years', 'stdAges': ['ADULT', 'OLDER_ADULT']}, 'contactsLocationsModule': {'locations': [{'facility': 'Research Site', 'city': 'Sarasota', 'state': 'Florida', 'zip': '34232', 'country': 'United States', 'geoPoint': {'lat': 27.33643, 'lon': -82.53065}}, {'facility': 'Research Site', 'city': 'Saint Louis', 'state': 'Missouri', 'zip': '63110', 'country': 'United States', 'geoPoint': {'lat': 38.62727, 'lon': -90.19789}}, {'facility': 'Research Site', 'city': 'Hackensack', 'state': 'New Jersey', 'zip': '07601', 'country': 'United States', 'geoPoint': {'lat': 40.88593, 'lon': -74.04347}}, {'facility': 'Research Site', 'city': 'Nashville', 'state': 'Tennessee', 'zip': '37203', 'country': 'United States', 'geoPoint': {'lat': 36.16589, 'lon': -86.78444}}, {'facility': 'Research Site', 'city': 'Greenslopes', 'state': 'Queensland', 'zip': '4120', 'country': 'Australia', 'geoPoint': {'lat': -27.50815, 'lon': 153.04951}}, {'facility': 'Research Site', 'city': 'Grafton', 'state': 'Auckland', 'zip': '1010', 'country': 'New Zealand', 'geoPoint': {'lat': -36.86029, 'lon': 174.76566}}, {'facility': 'Research Site', 'city': 'Christchurch', 'zip': '8011', 'country': 'New Zealand', 'geoPoint': {'lat': -43.53333, 'lon': 172.63333}}, {'facility': 'Research Site', 'city': 'Wellington', 'zip': '6021', 'country': 'New Zealand', 'geoPoint': {'lat': -41.28664, 'lon': 174.77557}}, {'facility': 'Research Site', 'city': 'Bydgoszcz', 'state': 'Kujawsko-Pomorskie', 'zip': '85-231', 'country': 'Poland', 'geoPoint': {'lat': 53.1235, 'lon': 18.00762}}, {'facility': 'Research Site', 'city': 'Bydgoszcz', 'state': 'Kujawsko-Pomorskie', 'zip': '85-796', 'country': 'Poland', 'geoPoint': {'lat': 53.1235, 'lon': 18.00762}}, {'facility': 'Research Site', 'city': 'Lublin', 'state': 'Lubelskie', 'zip': '20-064', 'country': 'Poland', 'geoPoint': {'lat': 51.25, 'lon': 22.56667}}, {'facility': 'Research Site', 'city': 'Białystok', 'state': 'Podlaskie', 'zip': '15-044', 'country': 'Poland', 'geoPoint': {'lat': 53.13333, 'lon': 23.16433}}, {'facility': 'Research Site', 'city': 'Poznań', 'state': 'Wielkopolskie', 'zip': '60-693', 'country': 'Poland', 'geoPoint': {'lat': 52.40692, 'lon': 16.92993}}, {'facility': 'Research Site', 'city': 'Szczecin', 'state': 'Zachodniopomorskie', 'zip': '70-784', 'country': 'Poland', 'geoPoint': {'lat': 53.42894, 'lon': 14.55302}}, {'facility': 'Research Site, Pathumwan', 'city': 'Bangkok', 'zip': '10330', 'country': 'Thailand', 'geoPoint': {'lat': 13.75398, 'lon': 100.50144}}, {'facility': 'Research Site, Ratchathewi District', 'city': 'Bangkok', 'zip': '10400', 'country': 'Thailand', 'geoPoint': {'lat': 13.75398, 'lon': 100.50144}}, {'facility': 'Research Site, Bangkok Noi District', 'city': 'Bangkok', 'zip': '10700', 'country': 'Thailand', 'geoPoint': {'lat': 13.75398, 'lon': 100.50144}}, {'facility': 'Research Site, Muang District', 'city': 'Chiang Mai', 'zip': '50200', 'country': 'Thailand', 'geoPoint': {'lat': 18.79038, 'lon': 98.98468}}, {'facility': 'Research Site', 'city': 'Khon Kaen', 'zip': '40002', 'country': 'Thailand', 'geoPoint': {'lat': 16.44671, 'lon': 102.833}}, {'facility': 'Research Site, Muang', 'city': 'Phitsanulok', 'zip': '65000', 'country': 'Thailand', 'geoPoint': {'lat': 16.82481, 'lon': 100.25858}}]}}, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-08-21'}, 'conditionBrowseModule': {'meshes': [{'id': 'D002289', 'term': 'Carcinoma, Non-Small-Cell Lung'}, {'id': 'D008175', 'term': 'Lung Neoplasms'}, {'id': 'D008171', 'term': 'Lung Diseases'}], 'ancestors': [{'id': 'D009369', 'term': 'Neoplasms'}, {'id': 'D012140', 'term': 'Respiratory Tract Diseases'}, {'id': 'D002283', 'term': 'Carcinoma, Bronchogenic'}, {'id': 'D001984', 'term': 'Bronchial Neoplasms'}, {'id': 'D012142', 'term': 'Respiratory Tract Neoplasms'}, {'id': 'D013899', 'term': 'Thoracic Neoplasms'}, {'id': 'D009371', 'term': 'Neoplasms by Site'}], 'browseLeaves': [{'id': 'M11168', 'name': 'Lung Diseases', 'asFound': 'Lung Disease', 'relevance': 'HIGH'}, {'id': 'M5534', 'name': 'Carcinoma', 'relevance': 'LOW'}, {'id': 'M11172', 'name': 'Lung Neoplasms', 'asFound': 'Lung Neoplasms', 'relevance': 'HIGH'}, {'id': 'M5546', 'name': 'Carcinoma, Non-Small-Cell Lung', 'asFound': 'Carcinoma, Non-Small-Cell Lung', 'relevance': 'HIGH'}, {'id': 'M10018', 'name': 'Hypersensitivity', 'relevance': 'LOW'}, {'id': 'M3585', 'name': 'Adenocarcinoma', 'relevance': 'LOW'}, {'id': 'M14977', 'name': 'Respiratory Tract Diseases', 'relevance': 'LOW'}, {'id': 'M5540', 'name': 'Carcinoma, Bronchogenic', 'relevance': 'LOW'}, {'id': 'M5260', 'name': 'Bronchial Neoplasms', 'relevance': 'LOW'}, {'id': 'M14979', 'name': 'Respiratory Tract Neoplasms', 'relevance': 'LOW'}, {'id': 'M16658', 'name': 'Thoracic Neoplasms', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'BC08', 'name': 'Respiratory Tract (Lung and Bronchial) Diseases'}, {'abbrev': 'All', 'name': 'All Conditions'}, {'abbrev': 'BC04', 'name': 'Neoplasms'}, {'abbrev': 'BC20', 'name': 'Immune System Diseases'}]}, 'interventionBrowseModule': {'browseLeaves': [{'id': 'M11900', 'name': 'Mitogens', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'All', 'name': 'All Drugs and Chemicals'}]}}, 'hasResults': False}\n",
      "Keys for NCT02504346:\n",
      "dict_keys(['protocolSection', 'derivedSection', 'hasResults'])\n",
      "Content for NCT02504346:\n",
      "{'protocolSection': {'identificationModule': {'nctId': 'NCT02504346', 'orgStudyIdInfo': {'id': '2015/10301'}, 'organization': {'fullName': 'Oslo University Hospital', 'class': 'OTHER'}, 'briefTitle': 'AZD9291, an Irreversible EGFR-TKI, in Relapsed EGFR-mutated Non-small Cell Lung Cancer Patients Previously Treated With an EGFR-TKI, Coupled to Extensive Translational Studies', 'officialTitle': 'AZD9291, an Irreversible EGFR-TKI, in Relapsed EGFR-mutated Non-small Cell Lung Cancer Patients Previously Treated With an EGFR-TKI, Coupled to Extensive Translational Studies', 'acronym': 'TREM'}, 'statusModule': {'statusVerifiedDate': '2023-03', 'overallStatus': 'UNKNOWN', 'lastKnownStatus': 'ACTIVE_NOT_RECRUITING', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2015-08', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2023-06-01', 'type': 'ESTIMATED'}, 'completionDateStruct': {'date': '2023-06', 'type': 'ESTIMATED'}, 'studyFirstSubmitDate': '2015-07-20', 'studyFirstSubmitQcDate': '2015-07-20', 'studyFirstPostDateStruct': {'date': '2015-07-21', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2023-03-27', 'lastUpdatePostDateStruct': {'date': '2023-03-28', 'type': 'ACTUAL'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'PRINCIPAL_INVESTIGATOR', 'investigatorFullName': 'Odd Terje Brustugun', 'investigatorTitle': 'Senior consultant', 'investigatorAffiliation': 'Oslo University Hospital'}, 'leadSponsor': {'name': 'Oslo University Hospital', 'class': 'OTHER'}, 'collaborators': [{'name': 'AstraZeneca', 'class': 'INDUSTRY'}]}, 'oversightModule': {'oversightHasDmc': False}, 'descriptionModule': {'briefSummary': 'Phase II, single-arm study to assess the safety and efficacy of AZD9291 (80 mg, orally, once daily) in second-line (or later) patients with EGFR mutation-positive, locally advanced or metastatic NSCLC, who have progressed following treatment with an approved epidermal growth factor tyrosine kinase inhibitor agent.', 'detailedDescription': 'This is a phase II, single-arm study to assess the safety and efficacy of AZD9291 (80 mg, orally, once daily) in second-line (or later) patients with EGFR mutation-positive, locally advanced or metastatic NSCLC, who have progressed following treatment with an approved epidermal growth factor tyrosine kinase inhibitor agent.\\n\\nIf feasible, subjects will have to provide a biopsy sample for molecular testing following confirmed disease progression on the most recent treatment regimen. A second biopsy will be sampled at progression on AZD9291, if feasible. Liquid biopsies will be sampled throughout the treatment period.\\n\\nSubjects should continue on study treatment until RECIST 1.1-defined progression or until a treatment discontinuation criterion is met. There is no maximum duration of treatment as subjects may continue to receive investigational product beyond RECIST 1.1 defined progression as long as they are continuing to show clinical benefit, as judged by the investigator.'}, 'conditionsModule': {'conditions': ['Lung Cancer', 'Targeted Therapy']}, 'designModule': {'studyType': 'INTERVENTIONAL', 'phases': ['PHASE2'], 'designInfo': {'allocation': 'NA', 'interventionModel': 'SINGLE_GROUP', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 200, 'type': 'ESTIMATED'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'Treatment', 'type': 'EXPERIMENTAL', 'description': 'Non-randomized trial, all patients receive therapy - singel-arm', 'interventionNames': ['Drug: AZD9291']}], 'interventions': [{'type': 'DRUG', 'name': 'AZD9291', 'armGroupLabels': ['Treatment']}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Objective response rate', 'description': 'Measured by RECIST 1.1', 'timeFrame': '12 weeks'}]}, 'eligibilityModule': {'eligibilityCriteria': \"Inclusion Criteria:\\n\\n1. Provision of signed and dated, written informed consent.\\n2. Age \\\\> 18 years.\\n3. Histologically or cytologically documented locally advanced or metastatic NSCLC not amenable to curative surgery or radiotherapy.\\n4. Radiological disease progression following at least one prior EGFR TKI.\\n5. Documented EGFR mutation known to be associated with EGFR TKI sensitivity (also including T790M).\\n6. ECOG status 0-2 and a minimum life expectancy of 12 weeks.\\n7. At least one lesion, not previously irradiated and not chosen for biopsy during the study screening period, that can be accurately measured at baseline according to RECIST 1.1.\\n8. Females should be using adequate contraceptive measures, should not be breast feeding and must have a negative pregnancy test prior to start of dosing if of child-bearing potential or must have evidence of non-child-bearing potential by fulfilling one of the following criteria at screening:\\n\\n   * Post-menopausal defined as aged more than 50 years and amenorrhoeic for at least 12 months following cessation of all exogenous hormonal treatments\\n   * Women under 50 years old would be considered postmenopausal if they have been amenorrheic for 12 months or more following cessation of exogenous hormonal treatments and with Luteinizing Hormone (LH) and Follicle-Stimulating Hormone (FSH) levels in the post-menopausal range for the institution\\n   * Documentation of irreversible surgical sterilisation by hysterectomy, bilateral oophorectomy or bilateral salpingectomy but not tubal ligation.\\n9. Male subjects must be willing to use barrier contraception.\\n\\n   -\\n\\nExclusion Criteria:\\n\\n* 1. Treatment with an EGFR-TKI within 8 days or approximately 5x half-life, whichever is the longer, of the first dose of study treatment.\\n\\n  2. Treatment with cytotoxic chemotherapy, investigational agents or other anticancer drugs from a previous treatment regimen or clinical study within 14 days or approximately 5x half-life, whichever is the longer, of the first dose of study treatment.\\n\\n  3. Previous treatment with AZD9291, or another EGFR TKI with similar profile, e.g. CO-1686 4. Major surgery within 4 weeks of inclusion 5. Radiotherapy treatment to more than 30% of the bone marrow or with a wide field of radiation within 4 weeks of inclusion 6. Subjects currently receiving (or unable to stop using) potent inhibitors or inducers of CYP3A4 7. Any unresolved toxicities from prior therapy greater than CTCAE grade 1 (with the exception of alopecia grade 2) at the time of starting study treatment.\\n\\n  8. Spinal cord compression or brain metastases unless asymptomatic and on stable steroid dosage for at least 2 weeks prior to start of study treatment.\\n\\n  9. Any evidence of severe or uncontrolled systemic diseases which in the investigator's opinion makes it undesirable for the subject to participate in the trial or which would jeopardise compliance with the protocol, or active infection including hepatitis B, hepatitis C and human immunodeficiency virus (HIV). Screening for chronic conditions is not required.\\n\\n  10. Gastrointestinal conditions incompatible with swallowing or precluding absorption of AZD9291.\\n\\n  11. Exclude based on any of the following cardiac criteria:\\n* Mean resting corrected QT interval (QTc using Fredericia's formula) \\\\> 470 msec\\n* Any clinically important abnormalities in rhythm, conduction or morphology of resting ECG (e.g., complete left bundle branch block, third degree heart block, second degree heart block)\\n* Any factors that increase the risk of QTc prolongation or risk of arrhythmic events such as heart failure, hypokalemia, congenital long QT syndrome, family history of long QT syndrome or unexplained sudden death under 40 years of age in first degree relatives or any concomitant medication known to prolong the QT interval 12. Current or previous significant interstitial lung disease or radiation pneumonitis 13. Absolute neutrophil count \\\\< 1.5 x 109/L 14. Platelet count \\\\< 100 x 109/L 15. Haemoglobin \\\\< 80 g/L 16. Alanine aminotransferase (ALT) \\\\> 2.5 times the upper limit of normal (ULN) if no demonstrable liver metastases or \\\\> 5 times ULN in the presence of liver metastases 17. Aspartate aminotransferase (AST) \\\\> 2.5 times ULN if no demonstrable liver metastases or \\\\> 5 times ULN in the presence of liver metastases 18. Total bilirubin \\\\> 1.5 times ULN if no liver metastases or \\\\> 3 times ULN in the presence of documented Gilbert's Syndrome (unconjugated hyperbilirubinaemia) or liver metastases 19. Creatinine \\\\>1.5 times ULN concurrent with creatinine clearance \\\\< 50 ml/min (measured or calculated by Cockcroft and Gault equation), 20. History of hypersensitivity of AZD9291 (or drugs with a similar chemical structure or class.\\n\\n  21. Women who are pregnant or breast-feeding, or have a positive (urine or serum) pregnancy test prior to study entry 22. Judgment by the investigator that the subject should not participate in the study if the subject is unlikely to comply with study procedures, restrictions and requirements.\", 'healthyVolunteers': False, 'sex': 'ALL', 'minimumAge': '18 Years', 'stdAges': ['ADULT', 'OLDER_ADULT']}, 'contactsLocationsModule': {'locations': [{'facility': 'Herlev Hospital', 'city': 'Copenhagen', 'country': 'Denmark', 'geoPoint': {'lat': 55.67594, 'lon': 12.56553}}, {'facility': 'Oulu University Hospital', 'city': 'Oulu', 'country': 'Finland', 'geoPoint': {'lat': 65.01236, 'lon': 25.46816}}, {'facility': 'National Cancer Institute', 'city': 'Vilnius', 'country': 'Lithuania', 'geoPoint': {'lat': 54.68916, 'lon': 25.2798}}, {'facility': 'Drammen Hospital - Vestre Viken HF', 'city': 'Drammen', 'zip': 'N-3004', 'country': 'Norway', 'geoPoint': {'lat': 59.74389, 'lon': 10.20449}}, {'facility': 'Norwegian Radium Hospital', 'city': 'Oslo', 'zip': 'N-0309', 'country': 'Norway', 'geoPoint': {'lat': 59.91273, 'lon': 10.74609}}, {'facility': 'St Olavs hospital', 'city': 'Trondheim', 'zip': 'N-7008', 'country': 'Norway', 'geoPoint': {'lat': 63.43049, 'lon': 10.39506}}, {'facility': 'Karolinska University Hospital', 'city': 'Stockholm', 'country': 'Sweden', 'geoPoint': {'lat': 59.33258, 'lon': 18.0649}}]}, 'referencesModule': {'references': [{'pmid': '32200138', 'type': 'DERIVED', 'citation': 'Eide IJZ, Helland A, Ekman S, Mellemgaard A, Hansen KH, Cicenas S, Koivunen J, Gronberg BH, Brustugun OT. Osimertinib in T790M-positive and -negative patients with EGFR-mutated advanced non-small cell lung cancer (the TREM-study). Lung Cancer. 2020 May;143:27-35. doi: 10.1016/j.lungcan.2020.03.009. Epub 2020 Mar 12.'}]}}, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-08-21'}, 'conditionBrowseModule': {'meshes': [{'id': 'D008175', 'term': 'Lung Neoplasms'}], 'ancestors': [{'id': 'D012142', 'term': 'Respiratory Tract Neoplasms'}, {'id': 'D013899', 'term': 'Thoracic Neoplasms'}, {'id': 'D009371', 'term': 'Neoplasms by Site'}, {'id': 'D009369', 'term': 'Neoplasms'}, {'id': 'D008171', 'term': 'Lung Diseases'}, {'id': 'D012140', 'term': 'Respiratory Tract Diseases'}], 'browseLeaves': [{'id': 'M11172', 'name': 'Lung Neoplasms', 'asFound': 'Lung Cancer', 'relevance': 'HIGH'}, {'id': 'M5546', 'name': 'Carcinoma, Non-Small-Cell Lung', 'relevance': 'LOW'}, {'id': 'M14979', 'name': 'Respiratory Tract Neoplasms', 'relevance': 'LOW'}, {'id': 'M16658', 'name': 'Thoracic Neoplasms', 'relevance': 'LOW'}, {'id': 'M11168', 'name': 'Lung Diseases', 'relevance': 'LOW'}, {'id': 'M14977', 'name': 'Respiratory Tract Diseases', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'BC04', 'name': 'Neoplasms'}, {'abbrev': 'BC08', 'name': 'Respiratory Tract (Lung and Bronchial) Diseases'}, {'abbrev': 'All', 'name': 'All Conditions'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'C000596361', 'term': 'Osimertinib'}], 'ancestors': [{'id': 'D000092004', 'term': 'Tyrosine Kinase Inhibitors'}, {'id': 'D047428', 'term': 'Protein Kinase Inhibitors'}, {'id': 'D004791', 'term': 'Enzyme Inhibitors'}, {'id': 'D045504', 'term': 'Molecular Mechanisms of Pharmacological Action'}, {'id': 'D000970', 'term': 'Antineoplastic Agents'}], 'browseLeaves': [{'id': 'M145673', 'name': 'Osimertinib', 'asFound': 'ATG', 'relevance': 'HIGH'}, {'id': 'M2889', 'name': 'Tyrosine Kinase Inhibitors', 'relevance': 'LOW'}, {'id': 'M25820', 'name': 'Protein Kinase Inhibitors', 'relevance': 'LOW'}, {'id': 'M7951', 'name': 'Enzyme Inhibitors', 'relevance': 'LOW'}, {'id': 'T22', 'name': 'Tyrosine', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'ANeo', 'name': 'Antineoplastic Agents'}, {'abbrev': 'All', 'name': 'All Drugs and Chemicals'}, {'abbrev': 'AA', 'name': 'Amino Acids'}]}}, 'hasResults': False}\n",
      "Keys for NCT06924398:\n",
      "dict_keys(['protocolSection', 'derivedSection', 'hasResults'])\n",
      "Content for NCT06924398:\n",
      "{'protocolSection': {'identificationModule': {'nctId': 'NCT06924398', 'orgStudyIdInfo': {'id': 'B2025-011-01'}, 'organization': {'fullName': 'Sun Yat-sen University', 'class': 'OTHER'}, 'briefTitle': 'Postoperative EGFR-TKI Therapy forContralateral Pulmonary Nodules in Patients With EGFR-Mutant NSCLC（ARMOR2501）', 'officialTitle': 'Postoperative EGFR-TKI Therapy for High-Risk Synchronous Resectable Contralateral Pulmonary Nodules in Patients With EGFR-Mutant Non-Small Cell Lung Cancer（ARMOR2501）', 'acronym': 'ARMOR2501'}, 'statusModule': {'statusVerifiedDate': '2025-06', 'overallStatus': 'RECRUITING', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2025-04-20', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2025-12-01', 'type': 'ESTIMATED'}, 'completionDateStruct': {'date': '2025-12-31', 'type': 'ESTIMATED'}, 'studyFirstSubmitDate': '2025-04-06', 'studyFirstSubmitQcDate': '2025-04-06', 'studyFirstPostDateStruct': {'date': '2025-04-11', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2025-06-08', 'lastUpdatePostDateStruct': {'date': '2025-06-10', 'type': 'ACTUAL'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'PRINCIPAL_INVESTIGATOR', 'investigatorFullName': 'Yang Hong', 'investigatorTitle': 'Prof', 'investigatorAffiliation': 'Sun Yat-sen University'}, 'leadSponsor': {'name': 'Sun Yat-sen University', 'class': 'OTHER'}}, 'oversightModule': {'oversightHasDmc': False, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False, 'isUsExport': False}, 'descriptionModule': {'briefSummary': \"Background Synchronous multifocal primary lung cancer (sMPLC) presents a therapeutic challenge, particularly for bilateral lesions. While surgical resection is standard for unilateral sMPLC, bilateral surgery carries high perioperative risks. This study evaluates postoperative adjuvant therapy with almonertinib, a third-generation EGFR-TKI, to reduce secondary surgery rates by targeting residual contralateral lesions in EGFR-mutant NSCLC patients.\\n\\nObjective\\n\\n* Primary: Assess the secondary surgery rate within one year after three months of almonertinib therapy.\\n* Secondary: Evaluate tumor response (ORR, EGFR-TKI response rate), survival outcomes (DFS, OS), treatment safety, and surgical feasibility post-therapy.\\n\\nStudy Design\\n\\n* Phase: Single-arm, open-label, phase II trial.\\n* Population: 32 patients with bilateral sMPLC (EGFR exon 19 deletion/L858R mutations) after unilateral resection.\\n* Intervention: Oral almonertinib (110 mg/day) for three months, initiated 4-10 weeks post-surgery.\\n* Endpoints:\\n\\n  * Primary: Proportion requiring secondary surgery due to lesion persistence/progression.\\n  * Secondary: ORR (RECIST 1.1), DFS, OS, adverse events (CTCAE v5.0), and safety of delayed surgery.\\n* Inclusion Criteria:\\n\\n  * sMPLC diagnosis (MM/ACCP criteria), T1-2N0M0 primary lesion, residual contralateral nodules (≥8 mm, confirmed malignant).\\n  * ECOG 0-1, age 18-75 years, compliance with follow-up.\\n* Exclusion Criteria: Metastasis, severe organ dysfunction, prior malignancies (5 years), or concurrent QT-prolonging drugs.\\n\\nStatistical Analysis\\n\\n* Sample size calculated (α=0.05, power=0.95) to detect a reduction in secondary surgery rate from 100% (baseline) to 90%, accounting for 10% dropout.\\n* Survival analysis via Kaplan-Meier curves and Cox regression; descriptive statistics for response rates.\\n\\nSafety Monitoring\\n\\n• Adverse events graded by CTCAE v5.0, including interstitial lung disease (ILD), cardiac toxicity, and laboratory abnormalities. Dose adjustments (55 mg) or discontinuation mandated for grade ≥3 events.\\n\\nEthics and Compliance\\n\\n* Conducted per Good Clinical Practice (GCP) and Declaration of Helsinki.\\n* Informed consent required; independent review committee (IRC) evaluates imaging outcomes.\\n\\nExpected Outcomes\\n\\n* Almonertinib may reduce secondary surgery rates by suppressing residual lesions, supported by prior efficacy in NSCLC (median PFS: 19.3 months in AENEAS trial).\\n* Results will inform postoperative management strategies for bilateral sMPLC. Timeline Enrollment and preliminary efficacy analysis to conclude by December 2025. Conclusion ARMOR2501 aims to validate almonertinib's role in minimizing repeat surgeries for EGFR-mutant sMPLC, balancing efficacy and safety. Successful outcomes could establish a novel adjuvant paradigm for high-risk patients.\", 'detailedDescription': \"1. Background Lung cancer is the most prevalent and deadliest malignancy worldwide. It is estimated that 0.2%-20% of lung cancer patients have synchronous multiple primary lung cancer (sMPLC) at the time of diagnosis, with most lesions appearing as multiple bilateral ground-glass opacities (GGOs) on imaging1。In clinical practice, the surgical resection strategy for sMPLC depends on factors such as the number, anatomical location, and size of the lesions, while also considering the patient's age and lung function. This approach is often influenced by the surgeon's subjective judgment.2 For unilateral sMPLC, complete eradication can be achieved through a single surgery. However, for bilateral sMPLC, simultaneous bilateral surgery carries a high risk of perioperative complications, especially for elderly patients or those with poor lung function, making it difficult to tolerate.3Conversely, staged surgery exposes patients to the trauma of a second operation and additional perioperative and anesthesia-related risks.4-6If the contralateral lesion left untreated after initial surgery is malignant, the patient faces a high risk of disease progression. Therefore, effective postoperative treatment is necessary to prevent recurrence or progression while minimizing the trauma and financial burden associated with a second surgery.7However, there is currently no established standard therapy for residual contralateral operable lesions after initial surgery.\\n\\n   The epidermal growth factor receptor (EGFR) is a protein tyrosine kinase receptor located on chromosome 7p13-q22, spanning 200 kb and composed of 28 exons encoding 1,186 amino acids. The glycoprotein has a molecular weight of approximately 170 kDa and is widely distributed in all tissue cells except mature skeletal muscle cells, mesodermal tissues, and hematopoietic tissues. The EGFR family consists of four structurally similar receptor molecules: ErbB1 (EGFR), ErbB2 (HER2), ErbB3 (HER3), and ErbB4 (HER4), all of which belong to the receptor tyrosine kinase (RTK) family. They contain an extracellular ligand-binding domain, a transmembrane domain, and an intracellular tyrosine kinase domain, with the intracellular region being highly homologous to the erbB oncogene product.\\n\\n   Aberrant EGFR activation mechanisms include receptor amplification, ligand overexpression, activating mutations, and the loss of negative regulatory pathways, with EGFR mutation activation being the primary driver of tumor cell abnormal biological behavior. Anti-tumor agents targeting EGFR include small-molecule EGFR kinase inhibitors and anti-EGFR antibodies. Small-molecule EGFR tyrosine kinase inhibitors (TKIs) competitively bind to the ATP-binding site within the EGFR kinase domain, inhibiting kinase activity and blocking signal transduction pathways related to cancer cell proliferation and metastasis.\\n\\n   In sMPLC, a high proportion of patients harbor EGFR mutations.8,9 According to the National Comprehensive Cancer Network (NCCN) guidelines, adjuvant therapy with EGFR-TKIs is recommended for patients with EGFR-mutant IB-IIIA non-small cell lung cancer (NSCLC). 10However, the efficacy of EGFR-TKIs for residual contralateral operable lesions following surgical resection of an EGFR-mutant tumor remains unclear. A retrospective study showed that in EGFR-mutant sMPLC patients, EGFR-TKI therapy led to a reduction in the diameter of some residual GGOs, with an objective response rate of approximately 15%.7 However, this retrospective study did not specify the location, size, or nature of the residual GGOs, nor did it confirm whether they received standardized anti-inflammatory treatment. In a small-scale exploratory study conducted by our research team on early-stage sMPLC patients with bilateral operable lesions, the largest lesion was subjected to genetic testing following complete surgical resection of one lung. If EGFR L858R or exon 19 deletion mutations were detected, the patients received EGFR-TKI therapy for three months, followed by chest CT re-evaluation. A total of 12 patients were included in the analysis, of whom 3 exhibited significant regression of contralateral operable lesions, yielding a response rate of 25%.\\n\\n   Based on previous literature and our preliminary research findings, we propose a prospective study enrolling early-stage sMPLC patients with bilateral operable lesions. After surgical resection of one side and confirmation of EGFR mutation positivity, third-generation EGFR-TKI therapy will be administered for residual contralateral operable lesions. This study aims to validate the efficacy and safety of EGFR-TKI treatment for EGFR-mutant sMPLC residual lesions, providing a foundation for future postoperative adjuvant treatment strategies in bilateral sMPLC patients.\\n2. Objective 2.1 Primary To explore the secondary surgery rate within one year after three months of EGFR-TKI treatment for contralateral residual lesions in patients with bilateral sMPLC with EGFR mutations who have undergone unilateral surgery.\\n\\n2.2 Secondary\\n\\n1. To evaluate the response of contralateral operable lesions to EGFR-TKI treatment.\\n2. To assess the objective response rate (ORR) of contralateral residual lesions treated with EGFR-TKI.\\n3. To investigate the correlation between EGFR-TKI treatment and disease-free survival (DFS) as well as overall survival (OS).\\n4. To evaluate the safety of EGFR-TKI treatment in patients.\\n5. To assess disease progression in contralateral lesions during EGFR-TKI treatment.\\n6. To evaluate the safety of secondary surgery after EGFR-TKI treatment, including perioperative complication rates and surgical difficulty.\\n\\n3. Study Design 3.1 Sample Size This study calculated the sample size based on the estimated secondary surgery rate in the target population. According to existing literature and clinical experience, the current secondary surgery rate in the target population is 100%. Following EGFR-TKI treatment, the secondary surgery rate is projected to decrease to 90%. Using an exact probability one-sided test (α=0.05) with a statistical power of 0.95, the required sample size was determined to be 29 patients. To account for a potential 10% dropout rate, a total of 32 patients will be enrolled in the study.\\n\\n3.2 Intervention This study plans to prospectively enroll 32 patients with bilateral sMPLC, each presenting with operable lesions. In accordance with international guidelines, one side of the lesion will undergo curative surgical resection, and enrollment will only be permitted upon confirmation of an EGFR-sensitive mutation through genetic testing. Prior to formal enrollment, participants must be completely free from perioperative complications or must have recovered from any postoperative complications.\\n\\nEnrolled patients will undergo a baseline follow-up within 4 to 10 weeks postoperatively and will commence a three-month regimen of EGFR-TKI treatment on the same day. Additionally, a CT imaging follow-up will be conducted at the third month following baseline evaluation. If a patient experiences intolerable treatment-related adverse effects, EGFR-TKI therapy will be discontinued.\\n\\nIf residual lesions persist after three months of EGFR-TKI treatment, a multidisciplinary team (MDT) will convene to collectively determine the necessity of surgical intervention.\\n\\n3.3 Study Endpoints Primary Endpoints： Secondary Surgery Rate: The proportion of enrolled patients who, following the completion of a three-month EGFR-TKI treatment regimen, undergo surgical resection of residual lesions due to either disease progression or the persistence of lesions.\\n\\nSecondary Endpoints：\\n\\n1. EGFR-TKI Response Rate: The proportion of patients exhibiting a measurable reduction in the diameter of any residual lesion on CT imaging, as determined by an independent review committee (IRC) during follow-up radiological assessments.\\n2. Objective Response Rate (ORR): Defined as the proportion of patients achieving a significant reduction in tumor burden, encompassing cases of complete response (CR) and partial response (PR), as per standardized oncological criteria.\\n3. Overall Survival (OS): Defined as the duration from the date of patient enrollment to all-cause mortality.\\n4. Disease-Free Survival (DFS): Defined as the interval from patient enrollment to the first confirmed occurrence of disease recurrence, progression, or mortality.\\n5. Treatment-Related Adverse Events: The incidence and severity of adverse events associated with EGFR-TKI therapy, classified according to the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.\\n6. Disease Progression Rate During Treatment: Defined as the proportion of patients experiencing disease progression in contralateral operable lesions while undergoing EGFR-TKI therapy, relative to the total study cohort.\\n\\nTumor response and disease progression will be evaluated in accordance with RECIST 1.1 criteria by study investigators. For patients who remain alive and free of disease recurrence at the time of data analysis, the date of their most recent radiological assessment will be used as the censoring time point.\\n\\n4. Study population 4.1 Inclusion Criteria\\n\\nDisease-Related Inclusion Criteria:\\n\\n1. Patients diagnosed with sMPLC (according to MM/ACCP clinical criteria). Preoperative chest CT (1mm slice thickness) reveals multiple bilateral lesions, all meeting surgical criteria \\\\[≥8mm (pure ground-glass nodules (GGNs) must be \\\\>1cm) and unchanged after standard anti-inflammatory treatment\\\\].\\n2. Patients received standard anti-inflammatory treatment before surgery.\\n3. The primary lesion in the operated lung is staged as T1-2N0M0.\\n4. Patients have undergone surgical resection of one side of the lung, with pathology confirming adenocarcinoma and an EGFR-sensitive mutation (exon 19 deletion or exon 21 L858R point mutation).\\n5. After unilateral resection, the contralateral lung must have at least one suspected malignant residual nodule \\\\[≥8mm (pure GGNs must be \\\\>1cm) and \\\\<3cm, unchanged after standard anti-inflammatory treatment\\\\], which must be confirmed as malignant by a qualified radiologist and thoracic surgeon.\\n6. ECOG performance status (PS) score of 0-1.\\n\\nGeneral Inclusion Criteria:\\n\\n1. Patients voluntarily participate in the study and sign written informed consent.\\n2. Patients demonstrate good compliance.\\n3. Patients are capable of oral medication.\\n4. Patients aged between 18 and 75 years.\\n5. Patients who can tolerate postoperative EGFR-TKI adjuvant therapy, with an ECOG performance status of 0-1 and an expected survival of more than three months.\\n\\n4.2 Exclusion Criteria\\n\\n1. Patients with lymph node metastasis or distant metastasis.\\n2. Patients with severe heart, lung, liver, or kidney dysfunction who cannot tolerate surgery.\\n3. Patients with a history of other malignancies within five years (except effectively controlled basal cell carcinoma, cervical carcinoma in situ, ductal carcinoma in situ of the breast, papillary thyroid carcinoma, and superficial bladder tumors).\\n4. Patients taking medications known to prolong the QTc interval or induce ventricular tachycardia who need to continue such medications during the study period.\\n5. Patients with a history of interstitial lung disease (ILD) or drug-induced ILD.\\n6. Patients with severe gastrointestinal dysfunction, diseases, or clinical symptoms that may affect drug intake, transport, or absorption.\\n7. Patients with active hepatitis B, hepatitis C, or HIV infections.\\n8. Pregnant or lactating women or women of childbearing potential who have not taken contraceptive measures.\\n9. Patients with uncontrolled neurological or psychiatric disorders or mental illnesses.\\n10. Patients participating in other clinical trials or expected to receive other anti-tumor treatments during this trial.\\n11. Other conditions deemed unsuitable for the study by the investigators 4.3 Recruitment\\n\\nConsiderations:\\n\\n* Outpatients from the Department of Thoracic Surgery at Sun Yat-sen University Cancer Center;\\n* Recruitment through physician referral, where eligible patients are introduced to the study during routine clinical consultations;\\n* The cost of EGFR-TKI treatment during the study will be fully covered, with no financial burden on the patients.\\n\\n4.4 Criteria for Discontinuation of Treatment/Withdrawal from the Study 4.4.1 Discontinuation of Study Treatment Subjects may discontinue treatment at any time and for any reason. Additionally, investigators may determine whether to discontinue treatment if any adverse event occurs. Furthermore, treatment may be terminated if the subject is deemed unsuitable for continued therapy, violates the study protocol, or if discontinuation is required for administrative and/or safety reasons.\\n\\nSubjects must discontinue treatment under any of the following circumstances but may continue to be monitored within the study:\\n\\nThe subject or the subject's legal representative requests to discontinue treatment.\\n\\nAn adverse event occurs that, according to the study protocol, necessitates treatment discontinuation.\\n\\nThe subject develops a new malignancy requiring active treatment. A comorbid condition arises that precludes further treatment. The investigator decides to withdraw the subject from the study. The subject's serum pregnancy test returns a positive result. The subject demonstrates poor compliance. The investigator determines that, based on the subject's disease status or personal circumstances, continued administration of the investigational drug would expose the subject to unnecessary risk.\\n\\nCompletion of the protocol-specified treatment. 4.4.2 Withdrawal from the Study For patients who withdraw from the study, the investigator must inquire about the reason for withdrawal and whether any adverse events (AEs) have occurred. If feasible, the investigator should conduct follow-up visits and assessments for withdrawn patients. The reason for withdrawal and the date of discontinuation (i.e., the date of the last dose of the study drug) must be documented in the Case Report Form (CRF). Patients should return all remaining study medications.\\n\\nAt the time of withdrawal, if there are newly developed or aggravated Grade 3 or 4 laboratory abnormalities according to the Common Terminology Criteria for Adverse Events (CTCAE), the patient must undergo further examinations. The results should be recorded in the relevant section of the CRF until the laboratory values return to Grade 1 or 2, unless the abnormalities are deemed irreversible due to the underlying disease. For such cases, the investigator must document their assessment in both the CRF and the patient's medical record.\\n\\nAll ongoing study-related toxicities and serious adverse events (SAEs) at the time of study discontinuation must be followed up until resolution, unless the investigator determines that resolution is unlikely due to the patient's underlying disease.\\n\\nAfter study treatment discontinuation, the investigator must monitor all pre-existing or newly occurring AEs within 30 days of the last dose of the study drug. Any new AEs and SAEs occurring within this period must be reported, with SAEs requiring notification to the sponsor within 24 hours. Follow-up must continue until the resolution of the adverse event as described above.\\n\\nIf a patient dies during the study or within 28 days after study completion, the investigator must document the cause of death in detail in the SAE report form and submit it within 24 hours.\\n\\n5. Follow-up Enrolled patients will undergo a baseline follow-up at 4 weeks postoperatively (no later than 10 weeks) and initiate a 3-month course of EGFR-TKI treatment on the same day. Additionally, patients will undergo a CT imaging follow-up at the third month after baseline evaluation. If a patient experiences intolerable treatment-related adverse reactions, EGFR-TKI therapy will be discontinued. If residual lesions persist after three months, a multidisciplinary team (MDT) will convene to determine whether surgical intervention is warranted.\\n\\nAll patients receiving postoperative EGFR-TKI treatment will be followed up for five years postoperatively. The follow-up schedule for the first year is as follows:\\n\\n* Follow-up every three months, including assessments of general health status, symptoms and signs, routine blood tests, routine biochemical tests, contrast-enhanced chest CT scans, and abdominal ultrasound (covering liver, gallbladder, spleen, pancreas, bilateral kidneys, and bilateral adrenal glands).\\n* Safety monitoring visits every 4-6 weeks during treatment, including assessments of general health status, symptoms and signs, routine blood tests, and routine biochemical tests.\\n* Cranial MRI and bone scans will be performed based on clinical indications at the discretion of the investigator.\\n\\nThe follow-up schedule for years 2-3 is as follows:\\n\\n* Follow-up every six months, including assessments of general health status, symptoms and signs, routine blood tests, routine biochemical tests, contrast-enhanced chest CT scans, and abdominal ultrasound (covering liver, gallbladder, spleen, pancreas, bilateral kidneys, and bilateral adrenal glands).\\n* Cranial MRI and bone scans will be conducted as clinically indicated by the investigator.\\n\\nThe follow-up schedule for years 3-5 is as follows:\\n\\n* Follow-up every 12 months, including assessments of general health status, symptoms and signs, routine blood tests, routine biochemical tests, contrast-enhanced chest CT scans, and abdominal ultrasound (covering liver, gallbladder, spleen, pancreas, bilateral kidneys, and bilateral adrenal glands).\\n* Cranial MRI and bone scans will be performed based on clinical necessity as determined by the investigator.\"}, 'conditionsModule': {'conditions': ['Lung Cancer (NSCLC)'], 'keywords': ['Lung Cancer']}, 'designModule': {'studyType': 'INTERVENTIONAL', 'phases': ['PHASE2'], 'designInfo': {'allocation': 'NA', 'interventionModel': 'SINGLE_GROUP', 'interventionModelDescription': 'A total of 32 patients with bilateral operable sMPLC will be prospectively enrolled. After unilateral tumor resection and confirmation of EGFR mutation positivity, they will be included in the study.\\n\\nBefore formal enrollment, participants must be completely free from perioperative complications or have recovered from any complications. Enrolled patients will undergo baseline follow-up within 4 to 10 weeks postoperatively and start a three-month EGFR-TKI treatment on the same day. Patients will receive a CT follow-up at the end of the three-month treatment period. If they experience intolerable treatment-related adverse effects, EGFR-TKI treatment will be discontinued.\\n\\nIf the lesion persists after three months, a multidisciplinary team will determine whether to proceed with surgical treatment.', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 32, 'type': 'ESTIMATED'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'Study arm', 'type': 'EXPERIMENTAL', 'description': 'A total of 32 patients with bilateral operable sMPLC will be prospectively enrolled. After unilateral tumor resection and confirmation of EGFR mutation positivity, they will be included in the study.\\n\\nBefore formal enrollment, participants must be completely free from perioperative complications or have recovered from any complications. Enrolled patients will undergo baseline follow-up within 4 to 10 weeks postoperatively and start a three-month EGFR-TKI treatment on the same day. Patients will receive a CT follow-up at the end of the three-month treatment period. If they experience intolerable treatment-related adverse effects, EGFR-TKI treatment will be discontinued.\\n\\nIf the lesion persists after three months, a multidisciplinary team will determine whether to proceed with surgical treatment.', 'interventionNames': ['Drug: Postoperative EGFR-TKI Therapy']}], 'interventions': [{'type': 'DRUG', 'name': 'Postoperative EGFR-TKI Therapy', 'description': 'A total of 32 patients with bilateral operable sMPLC will be prospectively enrolled. After unilateral tumor resection and confirmation of EGFR mutation positivity, they will be included in the study.\\n\\nBefore formal enrollment, participants must be completely free from perioperative complications or have recovered from any complications. Enrolled patients will undergo baseline follow-up within 4 to 10 weeks postoperatively and start a three-month EGFR-TKI treatment on the same day. Patients will receive a CT follow-up at the end of the three-month treatment period. If they experience intolerable treatment-related adverse effects, EGFR-TKI treatment will be discontinued.\\n\\nIf the lesion persists after three months, a multidisciplinary team will determine whether to proceed with surgical treatment.', 'armGroupLabels': ['Study arm']}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Secondary Surgery Rate', 'description': 'The proportion of enrolled patients who, following the completion of a three-month EGFR-TKI treatment regimen, undergo surgical resection of residual lesions due to either disease progression or the persistence of lesions.', 'timeFrame': 'From enrollment to end of the completion of a three-month EGFR-TKI treatment regimen'}], 'secondaryOutcomes': [{'measure': 'EGFR-TKI Response Rate', 'description': 'The proportion of patients exhibiting a measurable reduction in the diameter of any residual lesion on CT imaging, as determined by an independent review committee (IRC) during follow-up radiological assessments.', 'timeFrame': 'From enrollment to end of the completion of a three-month EGFR-TKI treatment regimen'}, {'measure': 'Objective Response Rate (ORR)', 'description': 'Defined as the proportion of patients achieving a significant reduction in tumor burden, encompassing cases of complete response (CR) and partial response (PR), as per standardized oncological criteria.', 'timeFrame': 'From enrollment to end of the completion of a three-month EGFR-TKI treatment regimen'}, {'measure': 'Overall Survival (OS)', 'description': 'Defined as the duration from the date of patient enrollment to all-cause mortality.', 'timeFrame': 'Defined as the duration from the date of patient enrollment to all-cause mortality.'}, {'measure': 'Disease-Free Survival (DFS)', 'description': 'Defined as the interval from patient enrollment to the first confirmed occurrence of disease recurrence, progression, or mortality.', 'timeFrame': 'Defined as the interval from patient enrollment to the first confirmed occurrence of disease recurrence, progression, or mortality.'}, {'measure': 'Treatment-Related Adverse Events:', 'description': 'The incidence and severity of adverse events associated with EGFR-TKI therapy, classified according to the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.', 'timeFrame': 'From enrollment to the completion of adjuvant therapy'}]}, 'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\n\\n* 1）Patients diagnosed with sMPLC (according to MM/ACCP clinical criteria). Preoperative chest CT (1mm slice thickness) reveals multiple bilateral lesions, all meeting surgical criteria \\\\[≥8mm (pure ground-glass nodules (GGNs) must be \\\\>1cm) and unchanged after standard anti-inflammatory treatment\\\\].\\n\\n  2）Patients received standard anti-inflammatory treatment before surgery.\\n\\n  3）The primary lesion in the operated lung is staged as T1-2N0M0.\\n\\n  4）Patients have undergone surgical resection of one side of the lung, with pathology confirming adenocarcinoma and an EGFR-sensitive mutation (exon 19 deletion or exon 21 L858R point mutation).\\n\\n  5）After unilateral resection, the contralateral lung must have at least one suspected malignant residual nodule \\\\[≥8mm (pure GGNs must be \\\\>1cm) and \\\\<3cm, unchanged after standard anti-inflammatory treatment\\\\], which must be confirmed as malignant by a qualified radiologist and thoracic surgeon.\\n\\n  6）ECOG performance status (PS) score of 0-1.\\n\\nExclusion Criteria:\\n\\n* 1）Patients with lymph node metastasis or distant metastasis.\\n\\n  2）Patients with severe heart, lung, liver, or kidney dysfunction who cannot tolerate surgery.\\n\\n  3）Patients with a history of other malignancies within five years (except effectively controlled basal cell carcinoma, cervical carcinoma in situ, ductal carcinoma in situ of the breast, papillary thyroid carcinoma, and superficial bladder tumors).\\n\\n  4）Patients taking medications known to prolong the QTc interval or induce ventricular tachycardia who need to continue such medications during the study period.\\n\\n  5）Patients with a history of interstitial lung disease (ILD) or drug-induced ILD.\\n\\n  6）Patients with severe gastrointestinal dysfunction, diseases, or clinical symptoms that may affect drug intake, transport, or absorption.\\n\\n  7）Patients with active hepatitis B, hepatitis C, or HIV infections.\\n\\n  8）Pregnant or lactating women or women of childbearing potential who have not taken contraceptive measures.\\n\\n  9）Patients with uncontrolled neurological or psychiatric disorders or mental illnesses.\\n\\n  10）Patients participating in other clinical trials or expected to receive other anti-tumor treatments during this trial.\\n\\n  11）Other conditions deemed unsuitable for the study by the investigators', 'healthyVolunteers': False, 'sex': 'ALL', 'minimumAge': '18 Years', 'maximumAge': '75 Years', 'stdAges': ['ADULT', 'OLDER_ADULT']}, 'contactsLocationsModule': {'centralContacts': [{'name': 'Hong Yang, PhD', 'role': 'CONTACT', 'phone': '86 13560405144', 'email': 'yanghong@sysucc.org.cn'}, {'name': 'Zhichao Li, MD', 'role': 'CONTACT', 'phone': '+8615626140781', 'email': 'lizc1@sysucc.org.cn'}], 'overallOfficials': [{'name': 'Hong Yang, PhD', 'affiliation': 'Sun Yat-sen University', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'locations': [{'facility': 'Sun Yat-sen University Cancer Center', 'status': 'RECRUITING', 'city': 'Guangzhou', 'state': 'Guangdong', 'zip': '510060', 'country': 'China', 'contacts': [{'name': 'Hong Yang, M.D., PH.D.', 'role': 'CONTACT', 'phone': '00+86+02087343258', 'email': 'yanghong@sysucc.org.cn'}, {'name': 'Jiyang Chen, Bachelor', 'role': 'CONTACT', 'email': 'chenjy1@sysucc.org.cn'}, {'name': 'Hong Yang, M.D., PH.D.', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 23.11667, 'lon': 113.25}}]}, 'referencesModule': {'references': [{'pmid': '38364701', 'type': 'BACKGROUND', 'citation': 'Yang Z, Zhou B, Guo W, Peng Y, Tian H, Xu J, Wang S, Chen X, Hu B, Liu C, Wang Z, Li C, Gao S, He J. Genomic characteristics and immune landscape of super multiple primary lung cancer. EBioMedicine. 2024 Mar;101:105019. doi: 10.1016/j.ebiom.2024.105019. Epub 2024 Feb 15.'}, {'pmid': '33611336', 'type': 'BACKGROUND', 'citation': 'Cheng B, Li C, Zhao Y, Li J, Xiong S, Liang H, Liu Z, Zeng W, Liang W, He J. The impact of postoperative EGFR-TKIs treatment on residual GGO lesions after resection for lung cancer. Signal Transduct Target Ther. 2021 Feb 21;6(1):73. doi: 10.1038/s41392-020-00452-9. No abstract available.'}, {'pmid': '7677489', 'type': 'BACKGROUND', 'citation': 'Ginsberg RJ, Rubinstein LV. Randomized trial of lobectomy versus limited resection for T1 N0 non-small cell lung cancer. Lung Cancer Study Group. Ann Thorac Surg. 1995 Sep;60(3):615-22; discussion 622-3. doi: 10.1016/0003-4975(95)00537-u.'}, {'pmid': '38745149', 'type': 'BACKGROUND', 'citation': 'Feng G, Jia Y, Zhao G, Meng F, Wang T. Risk factors for postoperative pulmonary complications in elderly patients undergoing video-assisted thoracoscopic surgery lobectomy under general anesthesia: a retrospective study. BMC Surg. 2024 May 14;24(1):153. doi: 10.1186/s12893-024-02444-w.'}, {'pmid': '23746675', 'type': 'BACKGROUND', 'citation': 'Griffioen GH, Lagerwaard FJ, Haasbeek CJ, Smit EF, Slotman BJ, Senan S. Treatment of multiple primary lung cancers using stereotactic radiotherapy, either with or without surgery. Radiother Oncol. 2013 Jun;107(3):403-8. doi: 10.1016/j.radonc.2013.04.026. Epub 2013 Jun 6.'}, {'pmid': '25617985', 'type': 'BACKGROUND', 'citation': 'Jiang L, He J, Shi X, Shen J, Liang W, Yang C, He J. Prognosis of synchronous and metachronous multiple primary lung cancers: systematic review and meta-analysis. Lung Cancer. 2015 Mar;87(3):303-10. doi: 10.1016/j.lungcan.2014.12.013. Epub 2015 Jan 14.'}]}, 'ipdSharingStatementModule': {'ipdSharing': 'NO'}}, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-08-21'}, 'conditionBrowseModule': {'meshes': [{'id': 'D008175', 'term': 'Lung Neoplasms'}, {'id': 'D055613', 'term': 'Multiple Pulmonary Nodules'}], 'ancestors': [{'id': 'D012142', 'term': 'Respiratory Tract Neoplasms'}, {'id': 'D013899', 'term': 'Thoracic Neoplasms'}, {'id': 'D009371', 'term': 'Neoplasms by Site'}, {'id': 'D009369', 'term': 'Neoplasms'}, {'id': 'D008171', 'term': 'Lung Diseases'}, {'id': 'D012140', 'term': 'Respiratory Tract Diseases'}], 'browseLeaves': [{'id': 'M11172', 'name': 'Lung Neoplasms', 'asFound': 'Lung Cancer', 'relevance': 'HIGH'}, {'id': 'M5546', 'name': 'Carcinoma, Non-Small-Cell Lung', 'relevance': 'LOW'}, {'id': 'M28260', 'name': 'Multiple Pulmonary Nodules', 'asFound': 'Pulmonary Nodules', 'relevance': 'HIGH'}, {'id': 'M14979', 'name': 'Respiratory Tract Neoplasms', 'relevance': 'LOW'}, {'id': 'M16658', 'name': 'Thoracic Neoplasms', 'relevance': 'LOW'}, {'id': 'M11168', 'name': 'Lung Diseases', 'relevance': 'LOW'}, {'id': 'M14977', 'name': 'Respiratory Tract Diseases', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'BC04', 'name': 'Neoplasms'}, {'abbrev': 'BC08', 'name': 'Respiratory Tract (Lung and Bronchial) Diseases'}, {'abbrev': 'All', 'name': 'All Conditions'}]}}, 'hasResults': False}\n",
      "Keys for NCT06043817:\n",
      "dict_keys(['protocolSection', 'derivedSection', 'hasResults'])\n",
      "Content for NCT06043817:\n",
      "{'protocolSection': {'identificationModule': {'nctId': 'NCT06043817', 'orgStudyIdInfo': {'id': 'STX-721-101'}, 'organization': {'fullName': 'Antares Therapeutics, Inc', 'class': 'INDUSTRY'}, 'briefTitle': 'First-In-Human Study of STX-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations', 'officialTitle': 'First-In-Human Study of STX-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations'}, 'statusModule': {'statusVerifiedDate': '2025-08', 'overallStatus': 'RECRUITING', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2023-09-26', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2027-06-01', 'type': 'ESTIMATED'}, 'completionDateStruct': {'date': '2028-06-01', 'type': 'ESTIMATED'}, 'studyFirstSubmitDate': '2023-09-01', 'studyFirstSubmitQcDate': '2023-09-18', 'studyFirstPostDateStruct': {'date': '2023-09-21', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2025-08-01', 'lastUpdatePostDateStruct': {'date': '2025-08-06', 'type': 'ACTUAL'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'}, 'leadSponsor': {'name': 'Antares Therapeutics, Inc', 'class': 'INDUSTRY'}}, 'oversightModule': {'isFdaRegulatedDrug': True, 'isFdaRegulatedDevice': False}, 'descriptionModule': {'briefSummary': 'Study STX-721-101 is an open label, Phase 1/2 study evaluating the safety, tolerability, pharmacokinetic (PK) exposure, and preliminary antitumor activity of STX-721 in participants with non-small cell lung cancer (NSCLC) carrying EGFR/HER2 exon 20 insertion (ex20ins) mutations.'}, 'conditionsModule': {'conditions': ['Non-Small Cell Lung Cancer', 'NSCLC', 'EGFR/HER2 Exon 20 Insertion Mutation']}, 'designModule': {'studyType': 'INTERVENTIONAL', 'phases': ['PHASE1', 'PHASE2'], 'designInfo': {'allocation': 'NON_RANDOMIZED', 'interventionModel': 'SEQUENTIAL', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 185, 'type': 'ESTIMATED'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'Part 1: Dose Escalation', 'type': 'EXPERIMENTAL', 'interventionNames': ['Drug: STX-721 (Escalated)']}, {'label': 'Part 2: RP2D Selection', 'type': 'EXPERIMENTAL', 'interventionNames': ['Drug: STX-721 (3 dose levels)']}, {'label': 'Part 3: Dose Expansion', 'type': 'EXPERIMENTAL', 'interventionNames': ['Drug: STX-721 (RP2D)']}], 'interventions': [{'type': 'DRUG', 'name': 'STX-721 (Escalated)', 'description': 'STX-721 dose will be escalated per cBLRM-design.', 'armGroupLabels': ['Part 1: Dose Escalation']}, {'type': 'DRUG', 'name': 'STX-721 (3 dose levels)', 'description': 'Participants will receive STX-721 at one of two dose levels.', 'armGroupLabels': ['Part 2: RP2D Selection']}, {'type': 'DRUG', 'name': 'STX-721 (RP2D)', 'description': 'Participants will receive the RP2D of STX-721.', 'armGroupLabels': ['Part 3: Dose Expansion']}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Part 1 Dose Escalation (MTD): Dose Escalation - Number of participants who experience at least 1 DLT during the first 28 days of treatment', 'timeFrame': '28 days'}, {'measure': 'Part 1 Dose Escalation (OBD): Dose Escalation - Number of participants who experience at least 1 DLT during the first 28 days of treatment', 'timeFrame': '28 days'}, {'measure': 'Part 2 RP2D Selection: C(max) of STX-721', 'timeFrame': '1 year'}, {'measure': 'Part 2 RP2D Selection: AUC(0-inf) of STX-721', 'timeFrame': '1 year'}, {'measure': 'Part 2 RP2D Selection: AUC(0-t) of STX-721', 'timeFrame': '1 year'}, {'measure': 'Part 2 RP2D Selection: AUC(0-τ) of STX-721', 'timeFrame': '1 year'}, {'measure': 'Part 2 RP2D Selection: Number of participants with confirmed objective response rate (ORR) defined as the percentage of participants with partial response (PR) or complete response (CR) based on RECIST v1.1 per investigator assessment.', 'timeFrame': '1 year'}, {'measure': 'Part 3 Dose Expansion: Number of participants with confirmed ORR defined as the percentage of participants with PR or complete response CR based on RECIST v1.1 per investigator assessment.', 'timeFrame': '1 year'}]}, 'eligibilityModule': {'eligibilityCriteria': \"Key Inclusion Criteria:\\n\\n1. Has histologically- or cytologically confirmed diagnosis of NSCLC Stage IIIB/C or IV not eligible for curative intent surgery or chemoradiation\\n2. Part 1: Tumor tissue EGFR or HER2 exon 20 insertion mutations confirmed by qualified local laboratories. Parts 2 and 3: EGFR exon 20 insertion mutations confirmed by qualified local laboratories\\n3. Part 1: Has received all approved therapies for advanced or metastatic NSCLC or is ineligible. Part 2 and Part 3: Has received at least 1, but not more than 2, prior lines of treatment for advanced or metastatic NSCLC, 1 of which must be platinum-based chemotherapy unless contraindicated\\n4. Has documented tumor progression (based on radiological imaging)\\n5. Has new or recent tumor biopsy (collected at screening, if feasible) or archival tumor specimen collected in the past 10 years available for genomic profiling\\n6. Has at least one measurable tumor lesion per RECIST v1.1\\n7. Is ≥18 years of age at the time of signing the ICF\\n8. Has Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1\\n\\nKey Exclusion Criteria:\\n\\n1. Has a tumor that is known to harbor EGFR ex20ins p.H773_V774insH variant, or any EGFR kinase domain activating mutation concurrent with either a T790M and/or C797S resistance mutations\\n2. Has history (within ≤2 years before screening) of solid tumor or hematological malignancy that is histologically distinct from NSCLC\\n3. Has symptomatic brain or spinal metastases\\n4. Has toxicities from previous anticancer therapies that have not resolved to baseline levels or to CTCAE Grade ≤1, except for alopecia and peripheral neuropathy\\n5. Has any condition for which, in the opinion of the investigator, participation would not be in the best interest of the participant (e.g., could compromise the participant's well-being) or would prevent, limit, or confound the protocol-specified assessments\", 'healthyVolunteers': False, 'sex': 'ALL', 'minimumAge': '18 Years', 'stdAges': ['ADULT', 'OLDER_ADULT']}, 'contactsLocationsModule': {'centralContacts': [{'name': 'For questions concerning enrollment', 'role': 'CONTACT', 'phone': 'Please email:', 'email': 'clinicaltrials@antaresrx.com'}], 'locations': [{'facility': 'City of Hope', 'status': 'RECRUITING', 'city': 'Duarte', 'state': 'California', 'zip': '91010', 'country': 'United States', 'geoPoint': {'lat': 34.13945, 'lon': -117.97729}}, {'facility': 'City of Hope', 'status': 'RECRUITING', 'city': 'Huntington Beach', 'state': 'California', 'zip': '92648', 'country': 'United States', 'geoPoint': {'lat': 33.6603, 'lon': -117.99923}}, {'facility': 'City of Hope', 'status': 'RECRUITING', 'city': 'Irvine', 'state': 'California', 'zip': '92618', 'country': 'United States', 'geoPoint': {'lat': 33.66946, 'lon': -117.82311}}, {'facility': 'Levine Cancer Institute - Charlotte', 'status': 'RECRUITING', 'city': 'Charlotte', 'state': 'North Carolina', 'zip': '28204-2990', 'country': 'United States', 'geoPoint': {'lat': 35.22709, 'lon': -80.84313}}, {'facility': 'Thomas Jefferson University Research Facility', 'status': 'RECRUITING', 'city': 'Philadelphia', 'state': 'Pennsylvania', 'zip': '19107', 'country': 'United States', 'geoPoint': {'lat': 39.95233, 'lon': -75.16379}}, {'facility': 'SCRI Oncology Partners - PPDS', 'status': 'RECRUITING', 'city': 'Nashville', 'state': 'Tennessee', 'zip': '37203', 'country': 'United States', 'geoPoint': {'lat': 36.16589, 'lon': -86.78444}}, {'facility': 'University of Utah - Huntsman Cancer Institute - PPDS', 'status': 'RECRUITING', 'city': 'Salt Lake City', 'state': 'Utah', 'zip': '84112-5550', 'country': 'United States', 'geoPoint': {'lat': 40.76078, 'lon': -111.89105}}, {'facility': 'NEXT Virginia', 'status': 'RECRUITING', 'city': 'Fairfax', 'state': 'Virginia', 'zip': '22031-2171', 'country': 'United States', 'geoPoint': {'lat': 38.84622, 'lon': -77.30637}}, {'facility': \"EDOG Institut de Cancerologie de l'Ouest - PPDS\", 'status': 'RECRUITING', 'city': 'Saint-Herblain', 'state': 'Loire-Atlantique', 'zip': '44115', 'country': 'France', 'geoPoint': {'lat': 47.21765, 'lon': -1.64841}}, {'facility': 'Institut Claudius Regaud - PPDS', 'status': 'RECRUITING', 'city': 'Toulouse', 'zip': '31059', 'country': 'France', 'geoPoint': {'lat': 43.60426, 'lon': 1.44367}}, {'facility': 'Gustave Roussy', 'status': 'RECRUITING', 'city': 'Villejuif', 'zip': '94800', 'country': 'France', 'geoPoint': {'lat': 48.7939, 'lon': 2.35992}}, {'facility': 'Charité - Universitätsmedizin Berlin (CBF) - Hindenburgdamm 30', 'status': 'RECRUITING', 'city': 'Berlin', 'zip': '12203', 'country': 'Germany', 'geoPoint': {'lat': 52.52437, 'lon': 13.41053}}, {'facility': 'Universitätsklinikum Carl Gustav Carus an der TU Dresden', 'status': 'RECRUITING', 'city': 'Dresden', 'zip': '01307', 'country': 'Germany', 'geoPoint': {'lat': 51.05089, 'lon': 13.73832}}, {'facility': 'Chungbuk National University Hospital', 'status': 'RECRUITING', 'city': 'Cheongju-si', 'zip': '28644', 'country': 'Korea, Republic of', 'geoPoint': {'lat': 36.63722, 'lon': 127.48972}}, {'facility': 'Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis', 'status': 'RECRUITING', 'city': 'Amsterdam', 'zip': '1066', 'country': 'Netherlands', 'geoPoint': {'lat': 52.37403, 'lon': 4.88969}}, {'facility': 'Hospital Regional Universitario de Malaga - Hospital General', 'status': 'RECRUITING', 'city': 'Málaga', 'state': 'Malaga', 'zip': '29010', 'country': 'Spain', 'geoPoint': {'lat': 36.72016, 'lon': -4.42034}}, {'facility': 'Instituto de Investigacion Oncologica Vall dHebron (VHIO) - EPON', 'status': 'RECRUITING', 'city': 'Barcelona', 'zip': '8035', 'country': 'Spain', 'geoPoint': {'lat': 41.38879, 'lon': 2.15899}}, {'facility': 'Hospital Universitario Ramon y Cajal', 'status': 'RECRUITING', 'city': 'Madrid', 'zip': '28034', 'country': 'Spain', 'geoPoint': {'lat': 40.4165, 'lon': -3.70256}}, {'facility': 'Hospital Universitario Virgen del Rocio', 'status': 'RECRUITING', 'city': 'Sevilla', 'zip': '41013', 'country': 'Spain', 'geoPoint': {'lat': 37.38283, 'lon': -5.97317}}, {'facility': 'National Taiwan University Hospital', 'status': 'RECRUITING', 'city': 'Taipei City', 'zip': '10002', 'country': 'Taiwan', 'geoPoint': {'lat': 25.04776, 'lon': 121.53185}}, {'facility': 'Taipei Veterans General Hospital', 'status': 'RECRUITING', 'city': 'Taipei', 'zip': '11217', 'country': 'Taiwan', 'geoPoint': {'lat': 25.04776, 'lon': 121.53185}}]}}, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-08-21'}, 'conditionBrowseModule': {'meshes': [{'id': 'D008175', 'term': 'Lung Neoplasms'}, {'id': 'D002289', 'term': 'Carcinoma, Non-Small-Cell Lung'}], 'ancestors': [{'id': 'D012142', 'term': 'Respiratory Tract Neoplasms'}, {'id': 'D013899', 'term': 'Thoracic Neoplasms'}, {'id': 'D009371', 'term': 'Neoplasms by Site'}, {'id': 'D009369', 'term': 'Neoplasms'}, {'id': 'D008171', 'term': 'Lung Diseases'}, {'id': 'D012140', 'term': 'Respiratory Tract Diseases'}, {'id': 'D002283', 'term': 'Carcinoma, Bronchogenic'}, {'id': 'D001984', 'term': 'Bronchial Neoplasms'}], 'browseLeaves': [{'id': 'M11172', 'name': 'Lung Neoplasms', 'asFound': 'Lung Cancer', 'relevance': 'HIGH'}, {'id': 'M5546', 'name': 'Carcinoma, Non-Small-Cell Lung', 'asFound': 'Non-small Cell Lung Cancer', 'relevance': 'HIGH'}, {'id': 'M5534', 'name': 'Carcinoma', 'relevance': 'LOW'}, {'id': 'M14979', 'name': 'Respiratory Tract Neoplasms', 'relevance': 'LOW'}, {'id': 'M16658', 'name': 'Thoracic Neoplasms', 'relevance': 'LOW'}, {'id': 'M11168', 'name': 'Lung Diseases', 'relevance': 'LOW'}, {'id': 'M14977', 'name': 'Respiratory Tract Diseases', 'relevance': 'LOW'}, {'id': 'M5540', 'name': 'Carcinoma, Bronchogenic', 'relevance': 'LOW'}, {'id': 'M5260', 'name': 'Bronchial Neoplasms', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'BC04', 'name': 'Neoplasms'}, {'abbrev': 'BC08', 'name': 'Respiratory Tract (Lung and Bronchial) Diseases'}, {'abbrev': 'All', 'name': 'All Conditions'}]}}, 'hasResults': False}\n",
      "Keys for NCT04084717:\n",
      "dict_keys(['protocolSection', 'derivedSection', 'hasResults'])\n",
      "Content for NCT04084717:\n",
      "{'protocolSection': {'identificationModule': {'nctId': 'NCT04084717', 'orgStudyIdInfo': {'id': '18-5607'}, 'secondaryIdInfos': [{'id': 'CROME / WI235747', 'type': 'OTHER', 'domain': 'Princess Margaret Cancer Centre'}], 'organization': {'fullName': 'University Health Network, Toronto', 'class': 'OTHER'}, 'briefTitle': 'Study of Crizotinib for ROS1 and MET Activated Lung Cancer', 'officialTitle': 'Phase II Study of Crizotinib for ROS1 and MET Activated Lung Cancer (CROME)'}, 'statusModule': {'statusVerifiedDate': '2024-07', 'overallStatus': 'RECRUITING', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2019-12-03', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2024-12', 'type': 'ESTIMATED'}, 'completionDateStruct': {'date': '2025-06', 'type': 'ESTIMATED'}, 'studyFirstSubmitDate': '2019-09-08', 'studyFirstSubmitQcDate': '2019-09-08', 'studyFirstPostDateStruct': {'date': '2019-09-10', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2024-07-15', 'lastUpdatePostDateStruct': {'date': '2024-07-16', 'type': 'ACTUAL'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'}, 'leadSponsor': {'name': 'University Health Network, Toronto', 'class': 'OTHER'}, 'collaborators': [{'name': 'Pfizer', 'class': 'INDUSTRY'}]}, 'oversightModule': {'oversightHasDmc': True, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'descriptionModule': {'briefSummary': 'This is a phase 2 study of a drug called crizotinib in people with metastatic (the cancer has spread to other parts of the body) non-small cell lung cancer with a mutation (change) in genes called ROS1 or MET. The purpose of this study is to look at how effective crizotinib is at treating ROS1 or MET mutated non-small cell lung cancer.\\n\\nCrizotinib, also called XALKORI, is a chemotherapy drug that is currently approved for the treatment of ALK- or ROS1- positive advanced non-small cell lung cancer.', 'detailedDescription': 'The study consists of a screening period, study drug period, end of study drug visit and follow-up period.\\n\\nDuring the screening period, participants will be asked to have tests and procedures done to make sure that they are eligible to continue in the study. Screening may take several visits. Participants found to be eligible to continue in the study, will then enter the study drug period where they will take the study drug and have tests and procedures done about once a week for safety and for research purposes.\\n\\nParticipants who stop the study drug completely for any reason, will be asked to return to the clinic for an end of study drug visit about 28 days after their last dose of study drug to have tests and procedures done for safety and for research purposes. Participants that are experiencing any side effects during this time, will be closely followed by their study Doctor until the side effects have resolved or stabilized.\\n\\nParticipants who discontinue study drug for any reason other than disease progression, will be asked to have radiological imaging every 8 weeks to follow up on the status of their disease, until disease progression or the start a new treatment for their cancer.\\n\\nAfter their final visit, the study nurse will call participants approximately every 3 months to check on the status of their health.'}, 'conditionsModule': {'conditions': ['Non-squamous Non-small-cell Lung Cancer', 'Stage IV Non-small Cell Lung Cancer', 'ROS1 Gene Rearrangement', 'MET Activating Mutation', 'MET Amplification']}, 'designModule': {'studyType': 'INTERVENTIONAL', 'phases': ['PHASE2'], 'designInfo': {'allocation': 'NON_RANDOMIZED', 'interventionModel': 'PARALLEL', 'interventionModelDescription': 'Participants will be assigned to one of the following:\\n\\nCohort 1 - ROS1 rearrangement Cohort 2 - MET-activating mutation (exon 14) Cohort 3 - MET-amplification', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 50, 'type': 'ESTIMATED'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'ROS1 Rearrangement', 'type': 'EXPERIMENTAL', 'description': 'Patients with stage IV or incurable non-squamous non-small cell lung cancer with a documented ROS1 rearrangement will be assigned to this arm.', 'interventionNames': ['Drug: Crizotinib']}, {'label': 'MET-activating Mutation (exon 14)', 'type': 'EXPERIMENTAL', 'description': 'Patients with stage IV or incurable non-squamous non-small cell lung cancer with a documented MET-activating mutation (exon 14) will be assigned to this arm.', 'interventionNames': ['Drug: Crizotinib']}, {'label': 'MET-amplification', 'type': 'EXPERIMENTAL', 'description': 'Patients with stage IV or incurable non-squamous non-small cell lung cancer with a documented MET-amplification will be assigned to this arm.', 'interventionNames': ['Drug: Crizotinib']}], 'interventions': [{'type': 'DRUG', 'name': 'Crizotinib', 'description': 'Crizotinib is an orally administered, chemotherapy drug that works by blocking ALK, MET and ROS1 receptor tyrosine kinases from working.\\n\\nParticipants will receive crizotinib, orally (by mouth), at a dose of 250 mg, twice per day, every day of each 28 day cycle.', 'armGroupLabels': ['MET-activating Mutation (exon 14)', 'MET-amplification', 'ROS1 Rearrangement'], 'otherNames': ['XALKORI']}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Response Rate', 'description': 'Via RECIST 1.1', 'timeFrame': '5 years'}, {'measure': 'Progression-free survival', 'description': 'Via RECIST 1.1', 'timeFrame': '5 years'}, {'measure': 'Average Time-to-treatment Failure', 'description': 'Time from randomization to treatment discontinuation for any reason', 'timeFrame': '5 years'}, {'measure': 'Edmonton Symptom Assessment Scale (ESAS) Score', 'description': 'Patient related symptom improvement evaluated by ESAS', 'timeFrame': '5 years'}, {'measure': 'EQ5D-5L Questionnaire Score', 'description': 'Patient preference/health related utility evaluated by EQ5D-5L Questionnaire', 'timeFrame': '5 years'}, {'measure': 'Overall survival', 'description': 'Number of days from the date of randomization to the date of death', 'timeFrame': '2 years'}]}, 'eligibilityModule': {'eligibilityCriteria': \"Inclusion Criteria:\\n\\n* Histologically or cytologically confirmed diagnosis of stage IV or incurable non-squamous non-small cell lung cancer with a documented ROS1 rearrangement (cohort 1) or MET-activating mutation (exon 14) (cohort 2) or MET-amplification (cohort 3) tested in either plasma or tissue, as applicable\\n* 18 years of age or older.\\n* Measurable disease as per RECIST v1.1.\\n* Adequate hematologic and organ function within 7 days of the proposed start date of treatment and adequate cardiac function within 28 days of the proposed start date of treatment\\n* Life expectancy \\\\>12 weeks.\\n* Have the ability to understand and the willingness to sign a written informed consent document\\n* Eastern Cooperative Oncology Group (ECOG) performance status ≤2\\n* No contraindication to Crizotinib therapy\\n* Able to swallow and retain oral medication and does not have any clinically significant gastrointestinal abnormalities that may alter absorption such as malabsorption syndrome or major resection of the stomach or bowels.\\n* No pregnant\\n* Agree to use methods (as agreed upon by the study doctor and participant) before the study and for at least 120 days after the last dose of study drug to prevent pregnancy\\n\\nExclusion Criteria:\\n\\n* Symptomatic untreated brain metastases.\\n* Had chemotherapy (including investigational cytotoxic chemotherapy), biologic agents (e.g. targeted therapy or antibodies) within 4 weeks or radiotherapy within 2 weeks prior to the proposed first dose of study treatment.\\n* Adverse events attributed to prior anti-cancer therapy \\\\> Grade 1 if clinically relevant.\\n* Receiving medications or substances known to be strong inhibitors or inducers of CYP3A4.\\n* Any known intolerance to agents structurally similar to crizotinib.\\n* Congenital long QT syndrome or persistent corrected QT interval by Fredericia formula (QTcF) ≥ 500 msec.\\n* Any other condition that would, in the Investigator's judgment, contraindicate the patient's participation in the clinical study due to safety concerns or compliance with clinical study procedures, e.g., infection/inflammation, intestinal obstruction, unable to swallow medication, social/ psychological issues\", 'healthyVolunteers': False, 'sex': 'ALL', 'minimumAge': '18 Years', 'stdAges': ['ADULT', 'OLDER_ADULT']}, 'contactsLocationsModule': {'centralContacts': [{'name': 'Natasha Leighl, M.D.', 'role': 'CONTACT', 'phone': '416-946-4645', 'email': 'natasha.leighl@uhn.ca'}], 'overallOfficials': [{'name': 'Natasha Leighl, M.D.', 'affiliation': 'Princess Margaret Cancer Centre', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'locations': [{'facility': 'Princess Margaret Cancer Centre', 'status': 'RECRUITING', 'city': 'Toronto', 'state': 'Ontario', 'zip': 'M5G 1Z5', 'country': 'Canada', 'contacts': [{'name': 'Natasha Leighl', 'role': 'CONTACT', 'phone': '416-946-4645', 'email': 'natasha.leighl@uhn.ca'}, {'name': 'Natasha Leighil, M.D.', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 43.70011, 'lon': -79.4163}}]}}, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-08-21'}, 'conditionBrowseModule': {'meshes': [{'id': 'D008175', 'term': 'Lung Neoplasms'}, {'id': 'D002289', 'term': 'Carcinoma, Non-Small-Cell Lung'}], 'ancestors': [{'id': 'D012142', 'term': 'Respiratory Tract Neoplasms'}, {'id': 'D013899', 'term': 'Thoracic Neoplasms'}, {'id': 'D009371', 'term': 'Neoplasms by Site'}, {'id': 'D009369', 'term': 'Neoplasms'}, {'id': 'D008171', 'term': 'Lung Diseases'}, {'id': 'D012140', 'term': 'Respiratory Tract Diseases'}, {'id': 'D002283', 'term': 'Carcinoma, Bronchogenic'}, {'id': 'D001984', 'term': 'Bronchial Neoplasms'}], 'browseLeaves': [{'id': 'M11172', 'name': 'Lung Neoplasms', 'asFound': 'Lung Cancer', 'relevance': 'HIGH'}, {'id': 'M5546', 'name': 'Carcinoma, Non-Small-Cell Lung', 'asFound': 'Non-small Cell Lung Cancer', 'relevance': 'HIGH'}, {'id': 'M5534', 'name': 'Carcinoma', 'relevance': 'LOW'}, {'id': 'M14979', 'name': 'Respiratory Tract Neoplasms', 'relevance': 'LOW'}, {'id': 'M16658', 'name': 'Thoracic Neoplasms', 'relevance': 'LOW'}, {'id': 'M11168', 'name': 'Lung Diseases', 'relevance': 'LOW'}, {'id': 'M14977', 'name': 'Respiratory Tract Diseases', 'relevance': 'LOW'}, {'id': 'M5540', 'name': 'Carcinoma, Bronchogenic', 'relevance': 'LOW'}, {'id': 'M5260', 'name': 'Bronchial Neoplasms', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'BC04', 'name': 'Neoplasms'}, {'abbrev': 'BC08', 'name': 'Respiratory Tract (Lung and Bronchial) Diseases'}, {'abbrev': 'All', 'name': 'All Conditions'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'D000077547', 'term': 'Crizotinib'}], 'ancestors': [{'id': 'D000092004', 'term': 'Tyrosine Kinase Inhibitors'}, {'id': 'D047428', 'term': 'Protein Kinase Inhibitors'}, {'id': 'D004791', 'term': 'Enzyme Inhibitors'}, {'id': 'D045504', 'term': 'Molecular Mechanisms of Pharmacological Action'}, {'id': 'D000970', 'term': 'Antineoplastic Agents'}], 'browseLeaves': [{'id': 'M1825', 'name': 'Crizotinib', 'asFound': 'Instability', 'relevance': 'HIGH'}, {'id': 'M2889', 'name': 'Tyrosine Kinase Inhibitors', 'relevance': 'LOW'}, {'id': 'M25820', 'name': 'Protein Kinase Inhibitors', 'relevance': 'LOW'}, {'id': 'M7951', 'name': 'Enzyme Inhibitors', 'relevance': 'LOW'}, {'id': 'T22', 'name': 'Tyrosine', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'ANeo', 'name': 'Antineoplastic Agents'}, {'abbrev': 'All', 'name': 'All Drugs and Chemicals'}, {'abbrev': 'AA', 'name': 'Amino Acids'}]}}, 'hasResults': False}\n",
      "Keys for NCT05845671:\n",
      "dict_keys(['protocolSection', 'derivedSection', 'hasResults'])\n",
      "Content for NCT05845671:\n",
      "{'protocolSection': {'identificationModule': {'nctId': 'NCT05845671', 'orgStudyIdInfo': {'id': '22-1450.cc'}, 'secondaryIdInfos': [{'id': '61186372LUC2005', 'type': 'OTHER', 'domain': 'Janssen Scientific Affairs, LLC'}], 'organization': {'fullName': 'University of Colorado, Denver', 'class': 'OTHER'}, 'briefTitle': 'Amivantamab With Tyrosine Kinase Inhibitors (TKI) for Advanced NSCLC With ALK, ROS1, or RET Alterations', 'officialTitle': 'A Phase 1 / 2, Open Label, Study of Amivantamab (JNJ-61186372) Among Participants With Advanced NSCLC Harboring ALK, ROS1, and RET Gene Fusions in Combination With Tyrosine Kinase Inhibitors'}, 'statusModule': {'statusVerifiedDate': '2025-06', 'overallStatus': 'RECRUITING', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2023-07-17', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2027-01', 'type': 'ESTIMATED'}, 'completionDateStruct': {'date': '2028-01', 'type': 'ESTIMATED'}, 'studyFirstSubmitDate': '2023-04-25', 'studyFirstSubmitQcDate': '2023-04-25', 'studyFirstPostDateStruct': {'date': '2023-05-06', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2025-06-23', 'lastUpdatePostDateStruct': {'date': '2025-06-27', 'type': 'ACTUAL'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'}, 'leadSponsor': {'name': 'University of Colorado, Denver', 'class': 'OTHER'}, 'collaborators': [{'name': 'Janssen Research & Development, LLC', 'class': 'INDUSTRY'}]}, 'oversightModule': {'oversightHasDmc': True, 'isFdaRegulatedDrug': True, 'isFdaRegulatedDevice': False}, 'descriptionModule': {'briefSummary': 'Although non-small cell lung cancer (NSCLC) patients with anaplastic lymphoma kinase (ALK), c-ros oncogene 1(ROS1), and ret proto-oncogene (RET) gene fusions initially respond well to tyrosine kinase inhibitor (TKI) therapies, acquired resistance is inevitable. In many of these cases, increased activation of the erythroblastic leukemia viral oncogene homologue (ERBB) or cMet pathways appears to be a bypass signaling mechanism that allows these cancer cells to circumvent the selective pressure from TKIs. Recent data have suggested that these pathways compensate for each other in situations where one pathway is inhibited, leading to \"kinase switch\" drug resistance. Thus, the expected inhibition of both pathways via treatment with the amivantamab and combination TKI combination may improve overall efficacy by limiting the compensatory pathway activation.'}, 'conditionsModule': {'conditions': ['Lung Cancer', 'Non Small Cell Lung Cancer'], 'keywords': ['ALK', 'ROS1', 'RET']}, 'designModule': {'studyType': 'INTERVENTIONAL', 'phases': ['PHASE1', 'PHASE2'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'SEQUENTIAL', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 12, 'type': 'ESTIMATED'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'Dose Finding (Safety Lead-In) Cohort (<80 kg)', 'type': 'EXPERIMENTAL', 'description': 'To estimate the maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) in adult participants with advanced NSCLC with ALK, ROS1, and RET gene fusions.', 'interventionNames': ['Drug: Amivantamab 1050mg']}, {'label': 'Dose Finding (Safety Lead-In) Cohort (≥80 kg)', 'type': 'EXPERIMENTAL', 'description': 'To estimate the maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) in adult participants with advanced NSCLC with ALK, ROS1, and RET gene fusions.', 'interventionNames': ['Drug: Amivantamab 1400mg']}, {'label': 'Dose Expansion Cohort (<80 kg)', 'type': 'EXPERIMENTAL', 'description': 'To estimate the objective response rate (ORR) of amivantamab in combination with common TKIs used in ALK, ROS1, and RET advanced NSCLC progressing on TKIs.', 'interventionNames': ['Drug: Amivantamab (to be determined)']}, {'label': 'Dose Expansion Cohort (≥80 kg)', 'type': 'EXPERIMENTAL', 'description': 'To estimate the objective response rate (ORR) of amivantamab in combination with common TKIs used in ALK, ROS1, and RET advanced NSCLC progressing on TKIs.', 'interventionNames': ['Drug: Amivantamab (to be determined)']}], 'interventions': [{'type': 'DRUG', 'name': 'Amivantamab 1050mg', 'description': 'Amivantamab is a bispecific antibody that binds to the extracellular domains of EGFR and MET.\\n\\nIn in vitro and in vivo studies amivantamab was able to disrupt EGFR and MET signaling functions through blocking ligand binding and, in exon 20 insertion mutation models, degradation of EGFR and MET. The presence of EGFR and MET on the surface of tumor cells also allows for targeting of these cells for destruction by immune effector cells, such as natural killer cells and macrophages, through antibody-dependent cellular cytotoxicity (ADCC) and trogocytosis mechanisms, respectively.', 'armGroupLabels': ['Dose Finding (Safety Lead-In) Cohort (<80 kg)'], 'otherNames': ['JNJ-61186372']}, {'type': 'DRUG', 'name': 'Amivantamab 1400mg', 'description': 'Amivantamab is a bispecific antibody that binds to the extracellular domains of EGFR and MET.\\n\\nIn in vitro and in vivo studies amivantamab was able to disrupt EGFR and MET signaling functions through blocking ligand binding and, in exon 20 insertion mutation models, degradation of EGFR and MET. The presence of EGFR and MET on the surface of tumor cells also allows for targeting of these cells for destruction by immune effector cells, such as natural killer cells and macrophages, through antibody-dependent cellular cytotoxicity (ADCC) and trogocytosis mechanisms, respectively.', 'armGroupLabels': ['Dose Finding (Safety Lead-In) Cohort (≥80 kg)'], 'otherNames': ['JNJ-61186372']}, {'type': 'DRUG', 'name': 'Amivantamab (to be determined)', 'description': 'Amivantamab is a bispecific antibody that binds to the extracellular domains of EGFR and MET.\\n\\nIn in vitro and in vivo studies amivantamab was able to disrupt EGFR and MET signaling functions through blocking ligand binding and, in exon 20 insertion mutation models, degradation of EGFR and MET. The presence of EGFR and MET on the surface of tumor cells also allows for targeting of these cells for destruction by immune effector cells, such as natural killer cells and macrophages, through antibody-dependent cellular cytotoxicity (ADCC) and trogocytosis mechanisms, respectively.\\n\\nDose will be determine after the Safety Lead-In', 'armGroupLabels': ['Dose Expansion Cohort (<80 kg)'], 'otherNames': ['JNJ-61186372']}, {'type': 'DRUG', 'name': 'Amivantamab (to be determined)', 'description': 'Amivantamab is a bispecific antibody that binds to the extracellular domains of EGFR and MET.\\n\\nIn in vitro and in vivo studies amivantamab was able to disrupt EGFR and MET signaling functions through blocking ligand binding and, in exon 20 insertion mutation models, degradation of EGFR and MET. The presence of EGFR and MET on the surface of tumor cells also allows for targeting of these cells for destruction by immune effector cells, such as natural killer cells and macrophages, through antibody-dependent cellular cytotoxicity (ADCC) and trogocytosis mechanisms, respectively.\\n\\nDose will be determine after the Safety Lead-In', 'armGroupLabels': ['Dose Expansion Cohort (≥80 kg)'], 'otherNames': ['JNJ-61186372']}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Determine the MTD in adult participants with advanced NSCLC', 'description': 'The MTD is defined as the dose combination with a DLT rate closest to the target DLT rate of 22%. An unevaluable patient is one who fails to complete dosing in C1 unless due to drug-related toxicities. The starting dose level will be dose level 0.', 'timeFrame': '18 months'}, {'measure': 'Determine the recommended phase 2 dose in adult participants with advanced NSCLC', 'timeFrame': '20 months'}, {'measure': 'Estimate the objective response rate (ORR) of amivantamab in combination with common TKIs used in ALK, ROS1, and RET advanced NSCLC progressing on TKIs', 'description': 'To estimate the objective response rate (ORR) of amivantamab in combination with common TKIs used in ALK, ROS1, and RET advanced NSCLC progressing on TKIs. This will be done per investigator and independent central review via RECIST 1.1. and RANO guidelines (for patients with brain metastases)', 'timeFrame': '40 months'}], 'secondaryOutcomes': [{'measure': 'Collect treatment-related adverse events (TRAEs)', 'description': 'All graded AEs (using CTCAE 5.0 criteria)', 'timeFrame': '40 months'}, {'measure': 'Collect treatment-emergent adverse events', 'description': 'All graded AEs (using CTCAE 5.0 criteria)', 'timeFrame': '40 months'}, {'measure': 'To evaluate the overall progression free survival (PFS) in patients treated with amivantamab in combination with concurrent TKI in patients with advanced NSCLC with ALK, ROS1, and RET gene fusions', 'timeFrame': '40 months'}, {'measure': 'To evaluate the intracranial progression free survival (PFS) in patients treated with amivantamab in combination with concurrent TKI in patients with advanced NSCLC with ALK, ROS1, and RET gene fusions', 'timeFrame': '40 months'}, {'measure': 'To evaluate the extracranial progression free survival (PFS) in patients treated with amivantamab in combination with concurrent TKI in patients with advanced NSCLC with ALK, ROS1, and RET gene fusions', 'timeFrame': '40 months'}, {'measure': 'To evaluate the overall disease control rate (DCR) among patients treated with amivantamab in combination with concurrent TKI in patients with advanced NSCLC with ALK, ROS1, and RET gene fusions.', 'timeFrame': '40 months'}, {'measure': 'To evaluate the intracranial disease control rate (DCR) among patients treated with amivantamab in combination with concurrent TKI in patients with advanced NSCLC with ALK, ROS1, and RET gene fusions.', 'timeFrame': '40 months'}, {'measure': 'To evaluate the extracranial disease control rate (DCR) among patients treated with amivantamab in combination with concurrent TKI in patients with advanced NSCLC with ALK, ROS1, and RET gene fusions.', 'timeFrame': '40 months'}, {'measure': 'To evaluate the overall duration of response (DOR) among responders in patients treated with amivantamab in combination with concurrent TKI in patients with advanced NSCLC with ALK, ROS1, and RET gene fusions', 'timeFrame': '40 months'}, {'measure': 'To evaluate the intracranial duration of response (DOR) among responders in patients treated with amivantamab in combination with concurrent TKI in patients with advanced NSCLC with ALK, ROS1, and RET gene fusions', 'timeFrame': '40 months'}, {'measure': 'To evaluate the extracranial duration of response (DOR) among responders in patients treated with amivantamab in combination with concurrent TKI in patients with advanced NSCLC with ALK, ROS1, and RET gene fusions', 'timeFrame': '40 months'}]}, 'eligibilityModule': {'eligibilityCriteria': \"Inclusion Criteria:\\n\\n1. Provision to sign and date the informed consent form.\\n2. Stated willingness to comply with all study procedures and be available for the duration of the study.\\n3. Participant is ≥ 18 years of age.\\n4. Participant has histologic or cytologic confirmation of locally advanced (unresectable) or metastatic NSCLC with a known (and documented) ALK, ROS1, or RET fusion based on approved diagnostic testing methods specified below. Not that NGS testing is required for all participants, but screening if any of the test below are positive.\\n\\n   a. IHC: For ALK NSCLC only using the ALK D5F3 antibody b. FISH with ≥15% of 100 cells sampled constituting positivity c. NGS using a CLIA-certified test\\n5. Participants must have clinical progression on at least one prior FDA-approved TKI. They must be on a TKI at the same dose for at least 8 weeks without radiographic progression or clinical intolerance of the TKI prior to enrolling on this study. TKIs that will be considered include (but not limited to):\\n\\n   1. ALK fusions - alectinib, brigatinib, lorlatinib\\n   2. ROS1 fusions - entrectinib, lorlatinib\\n   3. RET fusions - selpercatinib, pralsetinib\\n6. Participants must have at least 1 measurable lesion by RECIST v1.1 criteria using computed tomography (CT) scan or magnetic resonance imaging (MRI).\\n\\n   1. Measurable CNS lesions ≥10mm must be captured as overall and intracranial RECIST target lesions. CNS lesions 5-9mm may be included in the intra-cranial data set alone but must be listed as non-target lesions.\\n   2. Measurable, treated brain metastases (≥ 10mm) growing after whole-brain radiotherapy (WBRT) or resection are allowed as target lesions, but lesions growing after stereotactic radiosurgery (SRS) are allowed as target lesions only if radiation necrosis or pseudoprogression is ruled out.\\n7. Participant has an Eastern Cooperative Oncology Group (ECOG) score of 0-2\\n8. Participant has a life expectancy of greater than 12 weeks, per investigator discretion.\\n9. Participant can ingest oral medications.\\n10. Participant has received the final dose of any of the following treatments/procedures with the specified minimum intervals before the first dose of study drug (unless in the opinion of the Sponsor-Investigator, the medication will not interfere with the study or compromise participant safety).\\n\\n    Chemotherapy 21 days Antibody-drug conjugate (ADC) 28 days Immune checkpoint inhibitors (ICI) 28 days Locally ablative radiotherapy 28 days Palliative radiotherapy 14 days Major surgery 28 days\\n11. Participant has adequate organ function as determined by the following laboratory values.\\n\\n    Absolute neutrophil count (ANC)\\\\* ≥ 1,500/mm3 (≥ 1.5 x One times ten to the ninth/L) Platelets† ≥ 75,000/mm3 (≥ 75 x One times ten to the ninth/L) Hemoglobin† ≥ 9 g/dL Renal function: Serum creatinine ≤ 1.5 x upper limit normal (ULN) OR creatinine clearance ≥50 mL/min/1.73 m2 via Cockcroft-Gault Liver transaminases (ALT/AST) ≤ 3 x ULN\\n    * 5 x ULN, if liver metastases are present on screening Bilirubin ≤ 1.5 x ULN\\n    * 3.0 x ULN, if patient has Gilbert's disease Amylase and lipase ≤ 1.5 x ULN\\n\\n      * Participants cannot be receiving growth factor support using granulocyte-stimulating colony factor (G-CSF) during the screening visit.\\n\\n        * Participants cannot receive transfusion support up to one week prior to the screening period.\\n12. Female participant of childbearing potential (defined as a sexually mature woman who has not undergone a hysterectomy \\\\[surgical removal of the uterus\\\\] or bilateral oophorectomy, or if ≥ 45 years old, has not been naturally postmenopausal for at least 24 consecutive months \\\\[i.e., has had menses at any time during the preceding 24 consecutive months\\\\]) must:\\n\\n    1. Have 1 negative pregnancy test as verified by an Investigator prior to starting study therapy. This applies even if the subject practices true abstinence from heterosexual contact.\\n    2. Either commit to true abstinence from heterosexual contact (which must be reviewed on a monthly basis) or agree to use and be able to comply with a barrier method plus a hormonal method of contraception without interruption 28 days prior to starting investigational product, during the study therapy (including dose interruptions), and for 3 months after discontinuation (or longer if required by local requirements) of study therapy. The method of contraception must be a barrier method plus a hormonal method to prevent pregnancy.\\n    3. Participants must agree to continue contraception throughout the study and continuing through 3 months after the last dose of study drug. Note: If the childbearing potential changes after start of the study (e.g., woman who is not heterosexually active becomes active, premenarchal woman experiences menarche) the woman must begin a highly effective method of birth control, as described above.\\n    4. A woman of childbearing potential must have a negative serum or urine (b- human chorionic gonadotropin \\\\[b-hCG\\\\]) at Screening.\\n    5. A woman must agree not to donate eggs (ova, oocytes) for the purposes of assisted reproduction during the study and for 6 months after receiving the last dose of study drug.\\n    6. A female participant must agree not to be pregnant, or breast-feeding, or planning to become pregnant while enrolled in this study or within 3 months after the last dose of study treatment.\\n13. A man who is sexually active with a woman of childbearing potential must agree to use a condom with spermicidal foam/gel/film/cream/suppository and his partner must also be practicing a highly effective method of contraception (i.e., established use of oral, injected or implanted hormonal methods of contraception; placement of an intrauterine device \\\\[IUD\\\\] or intrauterine system \\\\[IUS\\\\]). If the subject is vasectomized, he must still use a condom (with or without spermicide), but his female partner is not required to use contraception. The subject must also not donate sperm during the study and for 6 months after receiving the last dose of study drug, even if he has undergone a successful vasectomy.\\n\\nExclusion Criteria:\\n\\n1. Participant has received an investigational drug within a 28-day period (or within 5 half-lives, whichever is shorter) before the first dose of study drug or is currently participating in another interventional clinical trial, unless in the opinion of the Sponsor-Investigator, the medication will not interfere with the study procedures or compromise subject safety.\\n2. The participant cannot have ever received an EGFR TKI (e.g. osimertinib), EGFR- directed monoclonal antibody (e.g. cetuximab), MET TKI (e.g. capmatinib, tepotinib), MET-directed monoclonal antibody (e.g. amivantamab) or MET-directed antibody-drug conjugate (e.g. telisotuzumab vedotin) prior to study entry. For patients with ALK or ROS1 NSCLC, crizotinib cannot be used within 3 months of screening.\\n3. Participants who have progressed on a TKI in less than 8 weeks\\n4. The participant has evidence of neuroendocrine differentiation or small cell transformation on the screening biopsy.\\n5. The patient has no evidence of an ALK, ROS1, and RET gene fusion as determined by molecular testing. Acquired resistance mechanisms detected through NGS (or FISH) testing for which alternative therapies exist may potentially be eligible after consultation with the PI.\\n6. Participants with active, symptomatic, central nervous system disease defined as follows:\\n\\n   1. Leptomeningeal disease.\\n   2. Symptomatic cord compression from metastatic disease.\\n   3. Untreated, symptomatic brain metastases\\n   4. Patients with brain metastases may be potentially eligible provided that all the following criteria are met:\\n\\n   i. They are not on prednisolone 20mg equivalents daily prior to enrolling in the study.\\n\\n   ii. Anticonvulsants will be permitted provided the patient has been on a stable dose for a period of 2 weeks prior to Study Day 1.\\n\\n   iii. Procedural interventions (such as ventriculoperitoneal shunt) greater than 12 weeks prior to Study Day 1.\\n\\n   iv. Palliative radiotherapy (either whole brain radiotherapy or stereotactic radiosurgery) ≥ 28 days prior to screening.\\n7. Participant has active cardiovascular disease defined as the following:\\n\\n   1. Congestive heart failure (CHF), defined as New York Heart Association (NYHA) class III-IV or hospitalization for CHF within 6 months of study Day 1.\\n   2. Symptomatic acute coronary syndrome, unstable angina, or active ischemia requiring coronary artery stenting, angioplasty, or bypass grafting within 12 weeks prior to starting investigational drug.\\n   3. Participant has evidence of current, uncontrolled, clinically significant, unstable arrhythmias. Participants receiving active anti-arrhythmic therapy are not eligible with the following exceptions:\\n\\n   i. Participants with atrial fibrillation medically controlled for greater than 4 weeks prior to Study Day 1.\\n\\n   ii. Participants who have medical pacemakers for control of arrhythmias. d. Participant has medically uncontrolled hypertension (defined as ≥ 160 mmHg systolic blood pressure (SBP) and ≥ 100 mmHg diastolic blood pressure (DBP).\\n\\n   e. Clinically significant, acute deep vein thrombosis or pulmonary embolism within 6 months prior to first dose of study drug. Clinically non-significant thrombosis, such as non-obstructive catheter-associated clots or incidentally detected, asymptomatic, subsegmental pulmonary emboli are not considered exclusionary.\\n\\n   f. History of cerebrovascular accident or transient ischemic attack within12 weeks of enrollment.\\n\\n   g. QT interval corrected by Fridericia's Formula (QTcF) prolongation to \\\\> 470ms based on a 12-lead electrocardiogram.\\n8. Participant has any history of interstitial lung disease (ILD), including drug induced ILD or radiation pneumonitis requiring treatment with prolonged steroids or other immune suppressive agents that is unresolved or resolved within the last 3 months\\n9. Participant has clinical evidence or history of ongoing significant bowel obstruction limiting oral intake, active uncontrolled malabsorption syndromes, or any other gastrointestinal disorder or defect that would interfere with absorption, distribution, metabolism, or excretion of the study drug and/or predispose the subject to an increased risk of gastrointestinal toxicity.\\n10. Participant has an additional primary malignancy within 2 years prior to enrollment with following exceptions:\\n\\n    1. Adequately resected non-melanoma skin cancer.\\n    2. Superficial bladder tumors (Ta, Tis, or T1).\\n    3. Adequately treated intraepithelial carcinoma of the cervix uteri.\\n    4. Low-risk, non-metastatic prostate cancer following local treatment or ongoing active surveillance.\\n    5. Any other curatively treated in situ disease.\\n11. Participant is positive for human immunodeficiency virus (HIV), with 1 or more of the following:\\n\\n    f. Receiving ART that may interfere with study treatment (consult sponsor investigator for review of medication prior to enrollment) g. CD4 count ≤ 350 at screening h. AIDS-defining opportunistic infection within 6 months of the start of screening i. Not agreeing to start ART and be on ART \\\\> 4 weeks plus having HIV viral load \\\\< 400 copies/mL at the end of 4-week period (to ensure ART is tolerated and HIV controlled).\\n12. Participant has active/chronic, known, untreated, hepatitis B as demonstrated by a positive hepatitis B surface antigen (HBsAg). Note: Subjects with a prior history of HBV demonstrated by positive hepatitis B core antibody are eligible if they have the following at Screening:\\n\\n    j. Negative HBsAg. k. HBV DNA (viral load) below the lower limit of quantification, per local testing.\\n\\n    l. Subjects with a positive HBsAg due to recent vaccination are eligible if HBV DNA (viral load) is below the lower limit of quantification, per local testing.\\n13. Participant has active/chronic, known, untreated, hepatitis C infection as demonstrated by a positive HCV antibody with detectable HCV viral load.\\n\\n    Note: Subjects with a prior history of HCV, who have completed antiviral treatment and have subsequently documented HCV RNA below the lower limit of quantification per local testing are eligible.\\n14. Participant has a concurrent and uncontrolled medical illness which would preclude study conduct and assessment, including, but not limited to the following medical conditions: an active infection requiring systemic therapy, bleeding disorder, clinically unstable ophthalmologic condition, diabetes mellitus with end-organ damage, pulmonary diseases, or alcoholic liver disease.\\n15. Participant is a pregnant or lactating woman.\\n16. Participant has a history of severe allergic reactions to any of the study intervention components.\\n17. Participant has a medical or psychiatric condition, which might compromise their ability to give written informed consent or to comply with the study protocol visits and procedures.\\n18. Participant has immune-mediated rash from checkpoint inhibitors that has not resolved prior to enrollment.\\n19. Use of live or live-attenuated vaccines within 30 days of screening.\\n20. Participant has significant reversible toxicities from prior anti-cancer therapy that have not recovered to Grade 1 or baseline (higher grades of alopecia and neuropathy up to Grade 2 will be permitted).\\n21. Participant had major surgery excluding placement of vascular access or tumor biopsy, or had significant traumatic injury within 4 weeks before enrollment, or will not have fully recovered from surgery, or has surgery planned during the time the participant is expected to participate in the study. Note: Participants with planned surgical procedures to be conducted under local anesthesia may participate.\", 'healthyVolunteers': False, 'sex': 'ALL', 'minimumAge': '18 Years', 'stdAges': ['ADULT', 'OLDER_ADULT']}, 'contactsLocationsModule': {'centralContacts': [{'name': 'Febin Elias', 'role': 'CONTACT', 'phone': '303-724-9459', 'email': 'febin.elias@cuanschutz.edu'}], 'overallOfficials': [{'name': 'Erin Schenk, MD, PhD', 'affiliation': 'University of Colorado, Denver', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'locations': [{'facility': 'City of Hope Cancer Center', 'status': 'NOT_YET_RECRUITING', 'city': 'Duarte', 'state': 'California', 'zip': '91010', 'country': 'United States', 'contacts': [{'name': 'Rebecca Gorski', 'role': 'CONTACT', 'phone': '626-218-3250', 'email': 'rgorski@coh.org'}, {'name': 'Matthew Lee, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 34.13945, 'lon': -117.97729}}, {'facility': 'Outpatient CTRC', 'status': 'RECRUITING', 'city': 'Aurora', 'state': 'Colorado', 'zip': '80045', 'country': 'United States', 'contacts': [{'name': 'Febin Elias', 'role': 'CONTACT', 'phone': '303-724-9459', 'email': 'febin.elias@cuanschutz.edu'}, {'name': 'Erin Schenk, MD, PhD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 39.72943, 'lon': -104.83192}}, {'facility': 'University of Colorado Hospital', 'status': 'RECRUITING', 'city': 'Aurora', 'state': 'Colorado', 'zip': '80045', 'country': 'United States', 'contacts': [{'name': 'Febin Elias', 'role': 'CONTACT', 'phone': '303-724-9459', 'email': 'febin.elias@cuanschutz.edu'}, {'name': 'Benjamin Yoder', 'role': 'SUB_INVESTIGATOR'}], 'geoPoint': {'lat': 39.72943, 'lon': -104.83192}}, {'facility': 'University of Michigan Rogel Cancer Center', 'status': 'RECRUITING', 'city': 'Ann Arbor', 'state': 'Michigan', 'zip': '48109', 'country': 'United States', 'contacts': [{'name': 'Dhaman Bansal', 'role': 'CONTACT', 'email': 'shbansl@med.umich.edu'}, {'name': 'Angel Qin, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 42.27756, 'lon': -83.74088}}]}, 'ipdSharingStatementModule': {'ipdSharing': 'NO'}}, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-08-21'}, 'conditionBrowseModule': {'meshes': [{'id': 'D008175', 'term': 'Lung Neoplasms'}], 'ancestors': [{'id': 'D012142', 'term': 'Respiratory Tract Neoplasms'}, {'id': 'D013899', 'term': 'Thoracic Neoplasms'}, {'id': 'D009371', 'term': 'Neoplasms by Site'}, {'id': 'D009369', 'term': 'Neoplasms'}, {'id': 'D008171', 'term': 'Lung Diseases'}, {'id': 'D012140', 'term': 'Respiratory Tract Diseases'}], 'browseLeaves': [{'id': 'M11172', 'name': 'Lung Neoplasms', 'asFound': 'Lung Cancer', 'relevance': 'HIGH'}, {'id': 'M5546', 'name': 'Carcinoma, Non-Small-Cell Lung', 'relevance': 'LOW'}, {'id': 'M14979', 'name': 'Respiratory Tract Neoplasms', 'relevance': 'LOW'}, {'id': 'M16658', 'name': 'Thoracic Neoplasms', 'relevance': 'LOW'}, {'id': 'M11168', 'name': 'Lung Diseases', 'relevance': 'LOW'}, {'id': 'M14977', 'name': 'Respiratory Tract Diseases', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'BC04', 'name': 'Neoplasms'}, {'abbrev': 'BC08', 'name': 'Respiratory Tract (Lung and Bronchial) Diseases'}, {'abbrev': 'All', 'name': 'All Conditions'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'C000718215', 'term': 'Amivantamab-vmjw'}, {'id': 'D018033', 'term': 'Antibodies, Bispecific'}], 'ancestors': [{'id': 'D000074322', 'term': 'Antineoplastic Agents, Immunological'}, {'id': 'D000970', 'term': 'Antineoplastic Agents'}, {'id': 'D007155', 'term': 'Immunologic Factors'}, {'id': 'D045505', 'term': 'Physiological Effects of Drugs'}], 'browseLeaves': [{'id': 'M4225', 'name': 'Antibodies', 'relevance': 'LOW'}, {'id': 'M10184', 'name': 'Immunoglobulins', 'relevance': 'LOW'}, {'id': 'M20194', 'name': 'Antibodies, Bispecific', 'asFound': 'Is There', 'relevance': 'HIGH'}, {'id': 'M2889', 'name': 'Tyrosine Kinase Inhibitors', 'relevance': 'LOW'}, {'id': 'M352636', 'name': 'Amivantamab-vmjw', 'asFound': 'Custom-made', 'relevance': 'HIGH'}, {'id': 'M1346', 'name': 'Antineoplastic Agents, Immunological', 'relevance': 'LOW'}, {'id': 'M10201', 'name': 'Immunologic Factors', 'relevance': 'LOW'}, {'id': 'T22', 'name': 'Tyrosine', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'All', 'name': 'All Drugs and Chemicals'}, {'abbrev': 'ANeo', 'name': 'Antineoplastic Agents'}, {'abbrev': 'AA', 'name': 'Amino Acids'}]}}, 'hasResults': False}\n",
      "Keys for NCT01639508:\n",
      "dict_keys(['protocolSection', 'derivedSection', 'hasResults'])\n",
      "Content for NCT01639508:\n",
      "{'protocolSection': {'identificationModule': {'nctId': 'NCT01639508', 'orgStudyIdInfo': {'id': '12-097'}, 'organization': {'fullName': 'Memorial Sloan Kettering Cancer Center', 'class': 'OTHER'}, 'briefTitle': 'Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL Activity', 'officialTitle': 'A Phase II Study of Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL Activity'}, 'statusModule': {'statusVerifiedDate': '2025-06', 'overallStatus': 'RECRUITING', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2012-07', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2026-07', 'type': 'ESTIMATED'}, 'completionDateStruct': {'date': '2026-07', 'type': 'ESTIMATED'}, 'studyFirstSubmitDate': '2012-07-10', 'studyFirstSubmitQcDate': '2012-07-11', 'studyFirstPostDateStruct': {'date': '2012-07-12', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2025-06-24', 'lastUpdatePostDateStruct': {'date': '2025-06-25', 'type': 'ACTUAL'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'}, 'leadSponsor': {'name': 'Memorial Sloan Kettering Cancer Center', 'class': 'OTHER'}, 'collaborators': [{'name': 'Exelixis', 'class': 'INDUSTRY'}]}, 'descriptionModule': {'briefSummary': 'The purpose of this phase II study is to find out what effects cabozantinib (XL184) has, good and/or bad, in patients whose tumors one of the following gene changes RET, ROS1, or NTRK fusion, or increased MET or AXL activity.\\n\\nA phase II study looks at how effective a medication is at treating a specific type of cancer and collects information on the side effects of the study treatment.\\n\\nRET, ROS1, or NTRK fusion or increased MET or AXL activity gene leads to lung cancer cell growth. Cabozantinib is an oral medicine that inhibits of RET, ROS1, NTRK, MET, and AXL. In addition, this drug interferes with other cell pathways that also cause cancer cells to grow, form new blood vessels, and spread to other organs of the body. The goal of using cabozantinib is to shrink the cancer and to prevent it from growing\\n\\nCabozantinib has been studied and shown to cause cancer shrinkage in other cancers such as medullary thyroid cancer and prostate cancer. We thus have a good idea of what side-effects it causes and can anticipate them.'}, 'conditionsModule': {'conditions': ['Non-Small Cell Lung Cancer'], 'keywords': ['Lung', 'XL184 (CABOZANTINIB)', 'KIF5B/RET Positive', 'RET Fusion Positive', '12-097', 'Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL Activity']}, 'designModule': {'studyType': 'INTERVENTIONAL', 'phases': ['PHASE2'], 'designInfo': {'allocation': 'NA', 'interventionModel': 'SINGLE_GROUP', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 86, 'type': 'ESTIMATED'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'Cabozantinib', 'type': 'EXPERIMENTAL', 'description': 'This will be a single-institution, open label, two-stage, single agent trial of cabozantinib in patients with advanced NSCLCs.atients in GROUP A will have tumors with a RET fusion. Patients in GROUP B will have tumors with an NTRK fusion, or MET or AXL overexpression, amplication, or mutatation. Patients in GROUP C will have tumors with a ROS1 fusion. Patients in GROUP D will have tumors with a RET fusion and have progressed on a selective RET TKI.', 'interventionNames': ['Drug: Cabozantinib']}], 'interventions': [{'type': 'DRUG', 'name': 'Cabozantinib', 'description': 'Patients will receive cabozantinib at an initial dose of 60 mg orally daily. The drug is taken continuously over a period of 28 days (4 weeks), which constitutes one treatment cycle. Dose modifications for drug toxicity are permitted as per a prescribed algorithm. During the Treatment Period subjects will receive cabozantinib until either disease progression, the occurrence of unacceptable drug-related toxicity or for other reason(s) for subject withdrawal.', 'armGroupLabels': ['Cabozantinib']}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'objective response rate (ORR) (Group A)', 'description': 'by RECIST v1.1 criteria to cabozantinib in patients with advanced NSCLC who have tested positive for RET Fusion', 'timeFrame': '12 weeks'}, {'measure': 'objective response rate (ORR) (Group B)', 'description': 'by RECIST v1.1 criteria to cabozantinib in patients with advanced NSCLC whose tumors test positive for a ROS1 or NTRK fusion or MET or AXL overexpression, amplification, or mutation.', 'timeFrame': '12 weeks'}], 'secondaryOutcomes': [{'measure': 'progression-free survival (PFS) (Group A)', 'description': 'Progression-free (PFS) and overall survival (OS) will be calculated using Kaplan-Meyer estimators starting from the time of treatment initiation. For PFS, patients alive without evidence of progression at the end of the study will be censored at the time of the last available follow-up. For OS, patients alive at the end of the study will be censored at the time of the last available follow-up.', 'timeFrame': '3 years'}, {'measure': 'overall survival (OS) (Group A)', 'description': 'Progression-free (PFS) and overall survival (OS) will be calculated using Kaplan-Meyer estimators starting from the time of treatment initiation. For PFS, patients alive without evidence of progression at the end of the study will be censored at the time of the last available follow-up. For OS, patients alive at the end of the study will be censored at the time of the last available follow-up.', 'timeFrame': '3 years'}, {'measure': 'safety (Group A, B, C & D)', 'description': 'Observed toxicities will be individually tabulated according to CTCAE version 4.0 and summarized using descriptive statistics.', 'timeFrame': '3 years'}, {'measure': 'progression-free survival (PFS) (Group B, C & D)', 'description': 'Progression-free (PFS) and overall survival (OS) will be calculated using Kaplan-Meyer estimators starting from the time of treatment initiation. For PFS, patients alive without evidence of progression at the end of the study will be censored at the time of the last available follow-up. For OS, patients alive at the end of the study will be censored at the time of the last available follow-up with advanced NSCLCs whose tumors test positive for a ROS1 or NTRK fusion or MET or AXL overexpression or amplification who were treated with cabozantinib.', 'timeFrame': '3 years'}, {'measure': 'overall survival (OS) (Group B, C & D)', 'description': 'Progression-free (PFS) and overall survival (OS) will be calculated using Kaplan-Meyer estimators starting from the time of treatment initiation. For PFS, patients alive without evidence of progression at the end of the study will be censored at the time of the last available follow-up. For OS, patients alive at the end of the study will be censored at the time of the last available follow-up with advanced NSCLCs whose tumors test positive for a ROS1 or NTRK fusion or MET or AXL overexpression or amplification who were treated with cabozantinib.', 'timeFrame': '3 years'}], 'otherOutcomes': [{'measure': 'objective response rate (ORR) (Group D)', 'description': 'by RECIST v1.1 criteria to cabozantinib in patients with advanced NSCLC who have tested positive for RET Fusion', 'timeFrame': '12 weeks'}]}, 'eligibilityModule': {'eligibilityCriteria': \"Inclusion Criteria:\\n\\nA subject must fully meet all of the following criteria to be eligible for the study:\\n\\n1. The subject has a pathologic diagnosis of non-small cell lung carcinoma that is metastatic or unresectable.\\n2. Documented presence:\\n\\n   1. Group A: KIF5B/RET or related variant RET fusions.\\n   2. Group B: any of the following aberrations\\n\\n      ii. NTRK fusion iii. MET overexpression, amplification, or mutation iv. AXL overexpression, amplification, or mutation\\n   3. Group C: ROS1 fusion\\n   4. GROUP D: RET-fusion post-progression on selective RET inhibitor\\n3. The subject is ≥ 18 years old on the day of consent.\\n4. Measurable Disease by RECIST1.1\\n5. The subject has a Karnofsky performance status of \\\\> 70%.\\n6. The subject has organ and marrow function and laboratory values as follows:\\n\\n   1. Absolute neutrophil count (ANC) ≥ 1500/mm3 without colony stimulating factor support\\n   2. Platelets ≥ 100,000/mm3 Hemoglobin ≥ 9 g/dL\\n   3. Bilirubin ≤ 1.5 × the upper limit of normal (ULN). For subjects with known Gilbert's . disease, bilirubin ≤ 3.0 mg/dL\\n   4. Serum creatinine ≤ 1.5 × ULN or creatinine clearance (CrCl) ≥ 30 mL/min. For creatinine clearance estimation, the Cockcroft and Gault equation should be used:\\n\\n      Male: CrCl (mL/min) = (140 - age) × wt (kg) / (serum creatinine × 72) Female:\\n\\n      Multiply above result by 0.85\\n   5. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST)\\n\\n      ≤ 3.0 × ULN if no liver involvement, or ≤ 5 × ULN with liver involvement\\n   6. Urine protein/creatinine ratio (UPCR) ≤ 1 mg/mg (113.2 mg/mmol) creatinine or 24-hr urine protein of \\\\< 1 g\\n   7. Serum phosphorus, magnesium, and potassium ≥ LLN after adequate supplementation if necessary\\n   8. The subject is capable of understanding and complying with the protocol requirements and has signed the informed consent document. Sexually active subjects (men and women) must agree to use medically accepted barrier methods of contraception (eg, male or female condom) during the course of the study and for 4 months after the last dose of study drug(s), even if oral contraceptives are also used. All subjects of reproductive potential must agree to use both a barrier method and a second method of birth control. Women of childbearing potential must have a negative pregnancy test at screening.\\n   9. Women of childbearing potential include women who have experienced menarche and who have not undergone successful surgical sterilization (hysterectomy, bilateral tubal ligation, or bilateral oophorectomy) or are not postmenopausal.\\n   10. Postmenopause is defined as amenorrhea ≥ 12 consecutive months. Note:\\n\\nwomen who have been amenorrheic for 12 or more months are still considered to be of childbearing potential if the amenorrhea is possibly due to prior chemotherapy, antiestrogens, ovarian suppression or any other reversible reason.\\n\\nExclusion Criteria:\\n\\n1. Any type of systemic anticancer agent (including investigational) within 3 weeks of first dose of study treatment, or within 5 half-lives of the agent whichever is shorter. Subjects on LHRH or GnRH agonists may be maintained on these agents.\\n2. Prior treatment with cabozantinib\\n3. Radiation therapy for bone or brain metastasis within 2 weeks, any other external radiation therapy within 4 weeks of first dose of study drug. Systemic treatment with radionuclides within 4weeks. Subjects with clinically relevant ongoing complications from prior radiation therapy are not eligible.\\n4. The subject has not recovered to baseline or CTCAE ≤ Grade 1 from toxicity due to all prior therapies except alopecia and other non-clinically significant AEs.\\n5. Known uncontrolled symptomatic brain metastases or cranial epidural disease; subjects previously treated and on stable dose of corticosteroids and/or anticonvulsants for \\\\>10 days, or not requiring such medications, are eligible. Baseline brain scans are not required to confirm eligibility.\\n\\n   Radiation therapy for bone or brain metastases within 2 weeks before first dose of study drug; or any other external radiation therapy or systemic treatment with radionuclides within 4 weeks before first dose of study drug. Subjects with clinically relevant ongoing complications from prior radiation therapy are not eligible\\n6. The subject requires concomitant treatment, in therapeutic doses, unless deemed clinically unsafe to discontinue, with anticoagulants such as warfarin or warfarin-related agents, unfractionated heparin, thrombin or Factor Xa inhibitors, or antiplatelet agents (eg, clopidogrel). Low dose aspirin (≤ 100 mg/day), low-dose warfarin (≤ 1 mg/day) are permitted. Both prophylactic and/or treatment dose low molecular weight (fractionated) heparin (LMWH) are permitted and are the preferred agents to administer.\\n7. The subject has experienced any of the following within 3 months before the first dose of study treatment:\\n\\n   * clinically-significant hematemesis or gastrointestinal bleeding\\n   * Clinically-significant hemoptysis of ≥ 0.5 teaspoon (2.5ml) of red blood c. any other signs indicative of pulmonary hemorrhage\\n8. The subject has radiographic evidence of cavitating pulmonary lesion(s)\\n9. The subject has tumor in contact with invading major blood vessels\\n10. The subject has any evidence of an endotracheal or endobronchial tumor within 28 days before the first dose of cabozantinib.\\n11. The subject has uncontrolled, significant intercurrent or recent illness including, but not limited to, the following conditions:\\n\\n    * Cardiovascular disorders including Congestive heart failure (CHF): New York Heart Association (NYHA) Class III (moderate) or Class IV (severe) at the time of screening\\n\\n      * Concurrent uncontrolled hypertension defined as sustained BP ≥ 150 mm Hg systolic, or ≥ 90 mm Hg diastolic despite optimal antihypertensive treatment (Note: If there is any BP measurement that is performed within the screening period that is \\\\< 150 mm Hg systolic and \\\\<90 mm Hg diastolic, then BP does not meet definition of sustained.)\\n\\n        ---- Any congenital history of long QT syndrome.\\n      * Any of the following within 6 months before the first dose of study treatment:\\n\\n        * unstable angina pectoris\\n        * clinically-significant cardiac arrhythmias\\n        * stroke (including TIA, or other ischemic event) myocardial infarction\\n        * thromboembolic event requiring therapeutic anticoagulation except if anticoagulation is as stipulated in Exclusion Criterium #6. (Note: subjects with a venous filter (e.g. vena cava filter) are not eligible for this study)\\n    * Gastrointestinal disorders particularly those associated with a high risk of perforation or fistula formation including:\\n\\n      * Any of the following within 28 days before the first dose of study treatmentF\\n\\n        * intra-abdominal tumor/metastases invading GI mucosa (malignant abdominal ascites does not constitute mucosal invasion)\\n        * active peptic ulcer disease,\\n        * inflammatory bowel disease (including ulcerative colitis and Crohn's disease), diverticulitis, cholecystitis, symptomatic cholangitis or appendicitis\\n        * malabsorption syndrome\\n      * Any of the following within 6 months before the first dose of study treatment:\\n\\n        * history of abdominal fistula\\n        * gastrointestinal perforation\\n        * bowel obstruction or gastric outlet obstruction\\n        * intra-abdominal abscess. Note: Complete resolution of an intra-abdominal abscess must be confirmed prior to initiating treatment with cabozantinib even if the abscess occurred more that 6 months ago. GI surgery (particularly when associated with delayed or incomplete healing) within 28 days. Note: Complete healing following abdominal surgery must be confirmed prior to initiating treatment with cabozantinib even if surgery occurred more that 28 days ago.\\n    * Other disorders associated with a high risk of fistula formation including PEG tube placement within 3 months before the first dose of study therapy or concurrent evidence of intraluminal tumor involving the trachea and esophagus.\\n    * Other clinically significant disorders such as:\\n\\n      * active infection requiring systemic treatment within 28 days before the first dose of study treatment\\n      * serious non-healing wound/ulcer/bone fracture within 28 days before the first dose of study treatment\\n      * history of organ transplant\\n      * concurrent uncompensated hypothyroidism or thyroid dysfunction within 7 days before the first dose of study treatment\\n      * Major surgery (eg, thoracotomy, removal or biopsy of brain metastasis) within 3 months before Week 1 Day 1. Complete wound healing from major surgery must have occurred 1 month before Week 1 Day 1 and from minor surgery (eg, simple excision, tooth extraction) at least 10 days before Week 1 Day 1. Subjects with clinically relevant ongoing complications from prior surgery are not eligible.\\n      * history of major surgery as follows:\\n12. The subject is unable to swallow tablets\\n13. The subject has a corrected QT interval calculated by the Fridericia formula (QTcF) \\\\> 500 ms 14 days before Week 1 Day 1\\n14. The subject is pregnant or breastfeeding.\\n15. The subject has a previously identified allergy or hypersensitivity to components of the study treatment formulation.\\n16. The subject is unable or unwilling to abide by the study protocol or cooperate fully with the investigator or designee.\\n17. Uncontrolled concurrent malignancy that would limit assessment of efficacy of cabozantinib.\", 'healthyVolunteers': False, 'sex': 'ALL', 'minimumAge': '18 Years', 'stdAges': ['ADULT', 'OLDER_ADULT']}, 'contactsLocationsModule': {'centralContacts': [{'name': 'Alexander Drilon, MD', 'role': 'CONTACT', 'phone': '646-888-4206'}, {'name': 'Mark Kris, MD', 'role': 'CONTACT', 'phone': '646-888-4197'}], 'overallOfficials': [{'name': 'Alexander Drilon, MD', 'affiliation': 'Memorial Sloan Kettering Cancer Center', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'locations': [{'facility': 'Memorial Sloan Kettering Basking Ridge', 'status': 'RECRUITING', 'city': 'Basking Ridge', 'state': 'New Jersey', 'zip': '07920', 'country': 'United States', 'contacts': [{'name': 'Alexander Drilon, MD', 'role': 'CONTACT', 'phone': '646-888-4206'}], 'geoPoint': {'lat': 40.70621, 'lon': -74.54932}}, {'facility': 'Memorial Sloan Kettering Monmouth', 'status': 'RECRUITING', 'city': 'Middletown', 'state': 'New Jersey', 'zip': '07748', 'country': 'United States', 'contacts': [{'name': 'Alexander Drilon, MD', 'role': 'CONTACT', 'phone': '646-888-4206'}], 'geoPoint': {'lat': 40.39652, 'lon': -74.09211}}, {'facility': 'Memorial Sloan Kettering Bergen', 'status': 'RECRUITING', 'city': 'Montvale', 'state': 'New Jersey', 'zip': '07645', 'country': 'United States', 'contacts': [{'name': 'Alexander Drilon, MD', 'role': 'CONTACT', 'phone': '646-888-4206'}], 'geoPoint': {'lat': 41.04676, 'lon': -74.02292}}, {'facility': 'Memorial Sloan Kettering Commack', 'status': 'RECRUITING', 'city': 'Commack', 'state': 'New York', 'zip': '11725', 'country': 'United States', 'contacts': [{'name': 'Alexander Drilon, MD', 'role': 'CONTACT', 'phone': '646-888-4206'}], 'geoPoint': {'lat': 40.84288, 'lon': -73.29289}}, {'facility': 'Memorial Sloan Kettering Westchester', 'status': 'RECRUITING', 'city': 'Harrison', 'state': 'New York', 'zip': '10604', 'country': 'United States', 'contacts': [{'name': 'Alexander Drilon, MD', 'role': 'CONTACT', 'phone': '646-888-4206'}], 'geoPoint': {'lat': 40.96899, 'lon': -73.71263}}, {'facility': 'Memorial Sloan Kettering Cancer Center', 'status': 'RECRUITING', 'city': 'New York', 'state': 'New York', 'zip': '10065', 'country': 'United States', 'contacts': [{'name': 'Alexander Drilon, MD', 'role': 'CONTACT', 'phone': '646-888-4206'}, {'name': 'Mark Kris, MD', 'role': 'CONTACT', 'phone': '646-888-4197'}, {'name': 'Alexander Drilon, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 40.71427, 'lon': -74.00597}}, {'facility': 'Memorial Sloan Kettering Nassau', 'status': 'RECRUITING', 'city': 'Uniondale', 'state': 'New York', 'zip': '11553', 'country': 'United States', 'contacts': [{'name': 'Alexander Drilon, MD', 'role': 'CONTACT', 'phone': '646-888-4188'}], 'geoPoint': {'lat': 40.70038, 'lon': -73.59291}}]}, 'referencesModule': {'references': [{'pmid': '27825636', 'type': 'DERIVED', 'citation': 'Drilon A, Rekhtman N, Arcila M, Wang L, Ni A, Albano M, Van Voorthuysen M, Somwar R, Smith RS, Montecalvo J, Plodkowski A, Ginsberg MS, Riely GJ, Rudin CM, Ladanyi M, Kris MG. Cabozantinib in patients with advanced RET-rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial. Lancet Oncol. 2016 Dec;17(12):1653-1660. doi: 10.1016/S1470-2045(16)30562-9. Epub 2016 Nov 4.'}, {'pmid': '26291023', 'type': 'DERIVED', 'citation': 'Wu H, Shih JY, Yang JC. Rapid Response to Sunitinib in a Patient with Lung Adenocarcinoma Harboring KIF5B-RET Fusion Gene. J Thorac Oncol. 2015 Sep;10(9):e95-e96. doi: 10.1097/JTO.0000000000000611. No abstract available.'}, {'pmid': '23533264', 'type': 'DERIVED', 'citation': 'Drilon A, Wang L, Hasanovic A, Suehara Y, Lipson D, Stephens P, Ross J, Miller V, Ginsberg M, Zakowski MF, Kris MG, Ladanyi M, Rizvi N. Response to Cabozantinib in patients with RET fusion-positive lung adenocarcinomas. Cancer Discov. 2013 Jun;3(6):630-5. doi: 10.1158/2159-8290.CD-13-0035. Epub 2013 Mar 26.'}], 'seeAlsoLinks': [{'label': 'Memorial Sloan Kettering Cancer Center', 'url': 'http://www.mskcc.org/'}]}}, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-08-21'}, 'conditionBrowseModule': {'meshes': [{'id': 'D008175', 'term': 'Lung Neoplasms'}, {'id': 'D002289', 'term': 'Carcinoma, Non-Small-Cell Lung'}], 'ancestors': [{'id': 'D012142', 'term': 'Respiratory Tract Neoplasms'}, {'id': 'D013899', 'term': 'Thoracic Neoplasms'}, {'id': 'D009371', 'term': 'Neoplasms by Site'}, {'id': 'D009369', 'term': 'Neoplasms'}, {'id': 'D008171', 'term': 'Lung Diseases'}, {'id': 'D012140', 'term': 'Respiratory Tract Diseases'}, {'id': 'D002283', 'term': 'Carcinoma, Bronchogenic'}, {'id': 'D001984', 'term': 'Bronchial Neoplasms'}], 'browseLeaves': [{'id': 'M11172', 'name': 'Lung Neoplasms', 'asFound': 'Lung Cancer', 'relevance': 'HIGH'}, {'id': 'M5546', 'name': 'Carcinoma, Non-Small-Cell Lung', 'asFound': 'Non-small Cell Lung Cancer', 'relevance': 'HIGH'}, {'id': 'M5534', 'name': 'Carcinoma', 'relevance': 'LOW'}, {'id': 'M14979', 'name': 'Respiratory Tract Neoplasms', 'relevance': 'LOW'}, {'id': 'M16658', 'name': 'Thoracic Neoplasms', 'relevance': 'LOW'}, {'id': 'M11168', 'name': 'Lung Diseases', 'relevance': 'LOW'}, {'id': 'M14977', 'name': 'Respiratory Tract Diseases', 'relevance': 'LOW'}, {'id': 'M5540', 'name': 'Carcinoma, Bronchogenic', 'relevance': 'LOW'}, {'id': 'M5260', 'name': 'Bronchial Neoplasms', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'BC04', 'name': 'Neoplasms'}, {'abbrev': 'BC08', 'name': 'Respiratory Tract (Lung and Bronchial) Diseases'}, {'abbrev': 'All', 'name': 'All Conditions'}]}}, 'hasResults': False}\n",
      "Keys for NCT06315010:\n",
      "dict_keys(['protocolSection', 'derivedSection', 'hasResults'])\n",
      "Content for NCT06315010:\n",
      "{'protocolSection': {'identificationModule': {'nctId': 'NCT06315010', 'orgStudyIdInfo': {'id': 'MedOPP662'}, 'secondaryIdInfos': [{'id': 'CA127-1061', 'type': 'OTHER', 'domain': 'Bristol-Myers Squibb GmbH & Co'}, {'id': '2023-508112-35', 'type': 'EUDRACT_NUMBER'}], 'organization': {'fullName': 'MedSIR', 'class': 'OTHER'}, 'briefTitle': 'REPotrectinib in ROS1-positive Non-small Cell Lung Cancer Patients With Active Brain mEtastasis', 'officialTitle': 'A Phase II Study Assessing Safety and Efficacy of REPotrectinib in ROS1-positive Non-small Cell Lung Cancer Patients With Active Brain mEtastasis (REPOSE Study)', 'acronym': 'REPOSE'}, 'statusModule': {'statusVerifiedDate': '2025-06', 'overallStatus': 'RECRUITING', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2025-06-27', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2027-03', 'type': 'ESTIMATED'}, 'completionDateStruct': {'date': '2028-04', 'type': 'ESTIMATED'}, 'studyFirstSubmitDate': '2024-02-16', 'studyFirstSubmitQcDate': '2024-03-13', 'studyFirstPostDateStruct': {'date': '2024-03-18', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2025-07-21', 'lastUpdatePostDateStruct': {'date': '2025-07-22', 'type': 'ACTUAL'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'}, 'leadSponsor': {'name': 'MedSIR', 'class': 'OTHER'}, 'collaborators': [{'name': 'Medical University of Vienna', 'class': 'OTHER'}]}, 'oversightModule': {'oversightHasDmc': True, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'descriptionModule': {'briefSummary': 'REPOSE is a phase II clinical trial exploring the safety and efficacy of repotrectinib in patients with non-small cell lung cancer (NSCLC) characterized by the presence of brain metastasis (BM) and whose tumors have mutated ROS proto-oncogene 1, receptor tyrosine kinase (ROS1) gene.', 'detailedDescription': \"REPOSE is an international multicenter, open-label, single arm phase II clinical trial designed to evaluate the efficacy of repotrectinib in patients with ROS1-positive NSCLC with BM.\\n\\nUpon meeting all selection criteria, a total of 20 participants confirmed ROS1 rearrangement will be enrolled. Participants who have received prior chemotherapy, immunotherapy or other non-ROS1 tyrosine kinase inhibitor (TKI) are eligible.\\n\\nPatients will continue study treatment until end of treatment (EoT) defined as the date of disease progression, death, or discontinuation from the study treatment for any other reason. After study treatment discontinuation, all participants will undergo a safety visit (at 28 ± 7 days after last treatment dose) in order to follow up toxicities and changes in concomitant medication. Patients discontinuing the study treatment at any time will enter a post-treatment follow-up period during which survival and subsequent anticancer therapy information will be collected every 3 months (± 7 days) from the safety visit until death, lost to follow-up, elective withdrawal from the study, or the end of study (EoS), whichever occurs first. Patients who discontinue treatment without evidence of disease progression will be also followed for tumor assessments until documented progression, elective withdrawal from the study, the start of new anti-cancer treatment, or the EoS.\\n\\nEoS is estimated to occur approximately 13 months after the last patient included in the study initiates repotrectinib treatment, unless consent withdrawal, patient is lost to follow-up, death, or premature termination of the study. EoS is defined as the last data collection point at the last participant's safety visit and will occur after the study treatment termination of the last patient in the study.\\n\\nThe main objective of REPOSE study is to determine the efficacy of repotrectinib at any timepoint during the study period as determined locally by best central nervous system (CNS) response, that is in terms of intracranial objective response rate (IC-ORR).\"}, 'conditionsModule': {'conditions': ['NSCLC', 'Brain Metastases', 'ROS1 Gene Rearrangement'], 'keywords': ['Metastatic NSCLC', 'Brain metastasis', 'ROS1', 'Repotrectinib']}, 'designModule': {'studyType': 'INTERVENTIONAL', 'phases': ['PHASE2'], 'designInfo': {'allocation': 'NA', 'interventionModel': 'SINGLE_GROUP', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 20, 'type': 'ESTIMATED'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'Repotrectinib', 'type': 'EXPERIMENTAL', 'description': 'Repotrectinib 160 mg orally (PO) every day (QD) for 14 days, and 160 mg twice a day (BID) thereafter.', 'interventionNames': ['Drug: Repotrectinib']}], 'interventions': [{'type': 'DRUG', 'name': 'Repotrectinib', 'description': 'Repotrectinib is administered orally in capsule form, with each capsule containing size 0 hard gelatin 40 mg of the active compound in bottles containing 30 capsules.\\n\\nRepotrectinib is administered orally in the form of capsules. The capsules are taken by mouth and swallowed intact (without chewing, crushing, or opening) with water or another suitable liquid.', 'armGroupLabels': ['Repotrectinib'], 'otherNames': ['BMS-986472', 'TPX-0005']}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Intracranial Objective Response Rate (IC-ORR)', 'description': 'To assess the efficacy in terms of IC-ORR at any timepoint defined as the rate of patients with partial response (PR) or complete response (CR) for IC lesions, as determined locally by the investigator as judged by best CNS response according to the Response Assessment in Neuro-Oncology Brain Metastases (RANO-BM) criteria.', 'timeFrame': 'From date of inclusion until the date of first documented progression or date of death from any cause or treatment discontinuation from any other reason, whichever came first, assessed through study completion, an average of 13 months.'}], 'secondaryOutcomes': [{'measure': 'Clinical Benefit Rate (CBR) for intracranial (IC) lesions', 'description': 'To assess the efficacy in terms of CBR, defined as the rate of patients with objective response (CR or PR), or stable disease (SD) for IC lesions for at least 24 weeks, as determined locally by the investigator using RANO-BM.', 'timeFrame': 'From date of inclusion until the date of first documented progression or date of death from any cause or treatment discontinuation from any other reason, whichever came first, assessed through study completion, an average of 13 months.'}, {'measure': 'Disease Control Rate (DCR) for IC lesions', 'description': 'To assess the efficacy in terms of DCR, defined as the percentage of patients with advanced cancer whose therapeutic intervention has led to a CR, PR, or SD for IC lesions, as determined locally by the investigator using RANO-BM.', 'timeFrame': 'From date of inclusion until the date of first documented progression or date of death from any cause or treatment discontinuation from any other reason, whichever came first, assessed through study completion, an average of 13 months.'}, {'measure': 'Time to Response (TTR) for IC lesions', 'description': 'To assess the efficacy in terms of TTR, defined as the period from the treatment initiation to time of the first objective tumor response (tumor shrinkage of ≥ 30%) observed for patients who achieved a CR or PR for IC lesions, as determined locally by the investigator using RANO-BM.', 'timeFrame': 'From date of inclusion until the date of first documented progression or date of death from any cause or treatment discontinuation from any other reason, whichever came first, assessed through study completion, an average of 13 months.'}, {'measure': 'Duration of Response (DoR) for IC lesions', 'description': 'To assess the efficacy in terms of DoR, defined as the period from the first occurrence of a documented objective response to disease progression or death from any cause, observed for patients who achieved a CR or PR for IC lesions, as determined locally by the investigator using RANO-BM.', 'timeFrame': 'From date of inclusion until the date of first documented progression or date of death from any cause or treatment discontinuation from any other reason, whichever came first, assessed through study completion, an average of 13 months.'}, {'measure': 'Objective Response Rate for extracranial (EC) and overall lesions (EC-ORR)', 'description': 'To assess the efficacy in terms of EC-ORR at any timepoint defined as the rate of patients with partial response (PR) or complete response (CR) for EC and overall lesions, as determined locally by the investigator using Response Evaluation Criteria In Solid Tumors version 1.1 (RECIST v.1.1) criteria.', 'timeFrame': 'From date of inclusion until the date of first documented progression or date of death from any cause or treatment discontinuation from any other reason, whichever came first, assessed through study completion, an average of 13 months.'}, {'measure': 'CBR for EC and overall lesions', 'description': 'To assess the efficacy in terms of CBR at any timepoint defined as the rate of patients with objective response (CR or PR), or SD for EC and overall lesions, for at least 24 weeks, as determined locally by the investigator using RECIST v.1.1', 'timeFrame': 'From date of inclusion until the date of first documented progression or date of death from any cause or treatment discontinuation from any other reason, whichever came first, assessed through study completion, an average of 13 months.'}, {'measure': 'DCR for EC and overall lesions', 'description': 'To assess the efficacy in terms of DCR, defined as the percentage of patients with advanced cancer whose therapeutic intervention has led to a CR, PR, or SD for EC and overall lesions, as determined locally by the investigator using RECIST v.1.1', 'timeFrame': 'From date of inclusion until the date of first documented progression or date of death from any cause or treatment discontinuation from any other reason, whichever came first, assessed through study completion, an average of 13 months.'}, {'measure': 'TTR for EC and overall lesions', 'description': 'To assess the efficacy in terms of TTR, defined as the period from the treatment initiation to time of the first objective tumor response (tumor shrinkage of ≥ 30%) observed for patients who achieved a CR or PR for EC and overall lesions, as determined locally by the investigator using RECIST v.1.1', 'timeFrame': 'From date of inclusion until the date of first documented progression or date of death from any cause or treatment discontinuation from any other reason, whichever came first, assessed through study completion, an average of 13 months.'}, {'measure': 'DoR for EC and overall lesions', 'description': 'To assess the efficacy in terms of DoR, defined as the period from the first occurrence of a documented objective response to disease progression or death from any cause, observed for patients who achieved a CR or PR for EC and overall lesions, as determined locally by the investigator using RECIST v.1.1.', 'timeFrame': 'From date of inclusion until the date of first documented progression or date of death from any cause or treatment discontinuation from any other reason, whichever came first, assessed through study completion, an average of 13 months.'}, {'measure': 'Best percentage of change in tumor burden', 'description': 'To evaluate the best percentage of change in tumor burden determined locally by the investigator using RANO-BM criteria for IC lesions and RECIST v.1.1 for EC and overall lesions.', 'timeFrame': 'From date of inclusion until the date of first documented progression or date of death from any cause or treatment discontinuation from any other reason, whichever came first, assessed through study completion, an average of 13 months.'}, {'measure': 'Progression-Free Survival (PFS)', 'description': 'To assess the PFS, defined as the period from treatment initiation to the first occurrence of disease progression or death from any cause, whichever occurs first, determined locally per RANO-BM criteria for IC lesions and RECIST criteria v.1.1 for EC and overall lesions.', 'timeFrame': 'From date of inclusion until the date of first documented progression or date of death from any cause or treatment discontinuation from any other reason, whichever came first, assessed through study completion, an average of 13 months.'}, {'measure': 'Overall Survival (OS)', 'description': 'To determine the OS, defined as the period from treatment initiation to death from any cause, determined locally by the investigator.', 'timeFrame': 'From date of inclusion until the date of first documented progression or date of death from any cause or treatment discontinuation from any other reason, whichever came first, assessed through study completion, an average of 13 months.'}, {'measure': 'Neurologic function', 'description': 'To assess the patient neurologic function with the Neurologic Assessment in Neuro-Oncology (NANO) scale', 'timeFrame': 'From date of inclusion until the date of first documented progression or date of death from any cause or treatment discontinuation from any other reason, whichever came first, assessed through study completion, an average of 13 months.'}, {'measure': 'Quality of life (QoL) with the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-30)', 'description': \"To evaluate changes from baseline and during repotrectinib treatment in terms of patient-reported outcome (PRO) assessments of QoL and treatment-related symptoms as measured by EORTC QLQ-C30 scale.\\n\\nEORTC QLQ-C30 scale aims to measure cancer patients' physical, psychological and social functions. Scale and single items are transformed into scores ranging from 0 to 100. A high score for a functional scale represents a high level of functioning, whereas a high score for a symptom scale/single item represents a high level of symptomatology.\", 'timeFrame': 'From date of inclusion until the date of first documented progression or date of death from any cause or treatment discontinuation from any other reason, whichever came first, assessed through study completion, an average of 13 months.'}, {'measure': 'QoL with the brain cancer specific questionnaire (QLQ-C20).', 'description': 'To evaluate changes during repotrectinib treatment in terms of PRO assessments of QoL and treatment-related symptoms as measured by EORTC QLQ-C20 scale.\\n\\nEORTC QLQ-BN20 brain specific tool aims to measure the effects of brain tumors and its treatment on symptoms, functions and health-related quality of life.\\n\\nScale and single items are transformed into scores ranging from 0 to 100. A high score for a functional scale represents a high level of functioning, whereas a high score for a symptom scale/single item represents a high level of symptomatology.', 'timeFrame': 'From date of inclusion until the date of first documented progression or date of death from any cause or treatment discontinuation from any other reason, whichever came first, assessed through study completion, an average of 13 months.'}, {'measure': 'Safety and tolerability', 'description': 'To evaluate the safety and toxicity profile of treatment with of repotrectinib as per National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0.', 'timeFrame': 'Through study completion, an average of 13 months.'}], 'otherOutcomes': [{'measure': 'Exploratory endpoint: Genetic studies using blood samples to investigate the potential association with clinical outcomes', 'description': 'Gene expression profiling analyses performed on blood samples to investigate the potential association with clinical outcomes.', 'timeFrame': 'Through study completion, an average of 13 months.'}, {'measure': 'Exploratory endpoint: ROS1 gene expression analysis using baseline tissue samples to investigate the potential association with clinical outcomes', 'description': 'ROS1 gene expression analysis performed on baseline tumor tissue samples to investigate the potential association with clinical outcomes.', 'timeFrame': 'Through study completion, an average of 13 months.'}, {'measure': 'Exploratory endpoint: Analysis of medical imaging to identify potential biomarkers associated with clinical outcomes', 'description': 'Analysis of oncological biomarkers, such as growth rate of tumor derived by tumor growth rate modeling or tumor heterogeneity according to quantitative estimation through radiomics, may be performed on radiological images to investigate the potential association with clinical outcomes.', 'timeFrame': 'Through study completion, an average of 13 months.'}]}, 'eligibilityModule': {'eligibilityCriteria': \"Inclusion Criteria:\\n\\nPatients will be included in the study only if they meet all the following criteria:\\n\\n1. Patient must be capable to understand the purpose of the study and have signed written informed consent form (ICF) prior to beginning specific protocol procedures.\\n2. Female or male patients ≥ 18 years of age at the time of signing ICF.\\n3. Patients must be capable to swallow capsules intact (without chewing, crushing, or opening).\\n4. Histologically documented NSCLC.\\n5. Patients may have symptoms attributed to brain metastases.\\n6. No indication for immediate local therapy (neurosurgery, brain radiotherapy) of brain metastases per local investigator.\\n\\n   Note: in case of immediate local therapy is needed, the study's medical monitor should be consulted.\\n7. Type II leptomeningeal disease per European Association of Neuro-Oncology (EANO) - European Society for Medical Oncology (ESMO) Clinical Practice Guidelines are allowed.\\n8. Patients with confirmed ROS1 rearrangement. Prior to study enrollment, patients must have had confirmation of ROS1 rearrangement, which should have been determined locally by a certified laboratory using methods such as fluorescent in situ hybridization (FISH), next generation sequencing (NGS), quantitative PCR (qPCR), or immunohistochemistry (IHC).\\n9. Measurable disease according to RANO-BM criteria, with at least one measurable brain lesion of ≥10 mm on T1-weighted, gadolinium-enhanced magnetic resonance imaging (MRI).\\n10. Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2.\\n11. Minimum life expectancy of ≥ 6 weeks at screening.\\n12. No limit in number of prior chemotherapies, immunotherapy or other non-ROS1 TKI regimens.\\n13. Patients must not have previously received any ROS1 TKI-based treatment.\\n14. Left ventricular ejection fraction (LVEF) ≥ 50% by echocardiogram (ECHO) or multigated acquisition (MUGA) scan.\\n15. If feasible, archival tumor biopsy sample at baseline (from primary tissue or any metastatic site) should be provided.\\n16. Patient has adequate bone marrow, liver, and renal function:\\n\\n    I. Hematological (without platelet, red blood cell transfusion, and/or granulocyte colony-stimulating factor support within 7 days before first study treatment dose): White blood cell (WBC) count \\\\> 3.0 x 109/L, absolute neutrophil count (ANC) ≥ 1.5 x 109/L, platelet count ≥ 100.0 x109/L, and hemoglobin ≥ 8.0 g/dL (≥ 4.96 mmol/L).\\n\\n    II. Hepatic: Total bilirubin ≤ 1.5 times upper limit of normal (ULN) (≤ 3 in patients with liver metastases or know history of Gilbert's disease); alkaline phosphatase (ALP) ≤ 2.5 times ULN; aspartate transaminase (AST) and alanine transaminase (ALT) ≤ 3 times ULN (≤ 5 in patients with liver metastases); international normalized ratio (INR) \\\\< 1.5.\\n\\n    III. Renal: serum creatinine ≤ 1.5 x ULN or creatinine clearance ≥ 40 mL/min/1.73 m2 based on Cockcroft-Gault glomerular filtration rate estimation for patients with creatinine levels above institutional normal.\\n17. Resolution of all acute toxic effects of prior anti-cancer therapy to grade ≤ 1 as determined by the US National Cancer Institute (NCI)-Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 (v.5.0) (except for alopecia or other toxicities not considered a safety risk for the patient at investigator's discretion).\\n18. Women of childbearing potential (WOCBP) who are sexually active with a non-sterilized male partner must have a negative serum pregnancy test within 14 days before study treatment initiation. In addition, they must agree to use one highly effective method of birth control from the time of screening until 2 months after the last dose of study treatments. Female patients must refrain from egg cell donation and breastfeeding during this same period.\\n\\n    Note: Due to a potential loss of effectiveness of hormonal contraceptives caused by interaction with study intervention, if WOCBP use hormonal contraceptives (including oral hormonal contraceptives), they must use either another form of non-hormonal highly effective contraception or a reliable barrier method.\\n19. Male participants who are sexually active with a WOCBP partner must be surgically sterile or using an acceptable method of contraception from the time of screening until 4 months after the last administration of the study drug. Male participants must not donate or bank sperm during this same period.\\n20. Patient must be accessible for treatment and follow-up.\\n\\nExclusion Criteria:\\n\\nAny patient meeting ANY of the following criteria will be excluded from the study:\\n\\n1. Major surgery within four weeks of the start of treatment.\\n2. Type I leptomeningeal disease per ESMO-EANO guidelines.\\n3. Any of the following cardiac criteria:\\n\\n   I. Mean resting corrected QT interval (ECG interval measured from the onset of the QRS complex to the end of the T wave) for heart rate (QTc) \\\\> 470 msec obtained from 3 ECGs, using the screening clinic ECG machine-derived QTc value.\\n\\n   II. Any clinically important abnormalities in rhythm, conduction or morphology of resting ECG (e.g., complete left bundle branch block, third degree heart block, second degree heart block, PR interval \\\\> 250 msec).\\n\\n   III. Any factors that increase the risk of QTc prolongation or risk of arrhythmic events such as heart failure, hypokalemia, congenital long QT syndrome, family history of long QT syndrome, or any concomitant medication known to prolong the QT interval.\\n4. Clinically significant cardiovascular disease (either active or within 6 months prior to enrollment): myocardial infarction, unstable angina, coronary/peripheral artery bypass graft, symptomatic congestive heart failure (New York Heart Association Classification Class ≥ II), cerebrovascular accident or transient ischemic attack, symptomatic bradycardia, requirement for anti-arrhythmic medication. Ongoing cardiac dysrhythmias of NCI CTCAE grade ≥ 2.\\n5. Known clinically significant active infections not controlled with systemic treatment (bacterial, fungal, viral including HIV positivity).\\n6. Gastrointestinal disease (e.g., Crohn's disease, ulcerative colitis, or short gut syndrome) or other malabsorption syndromes that would impact on drug absorption.\\n7. Peripheral neuropathy grade ≥ 2.\\n8. History of extensive, disseminated, bilateral, or presence of NCI CTCAE grade 3 or 4 interstitial fibrosis or interstitial lung disease (ILD) including a history of pneumonitis, hypersensitivity pneumonitis, interstitial pneumonia, ILD, obliterative bronchiolitis, and pulmonary fibrosis. Patients with a history of prior radiation pneumonitis are not excluded.\\n9. Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or study drug administration, or that may interfere with the interpretation of study results and, in the judgment of the Investigator, would make the patient inappropriate for entry into this study or could compromise the protocol objectives in the opinion of the Investigator.\\n10. Presence or history of any other primary malignancy other than NSCLC within 5 years prior to enrollment into the study.\\n\\n    Note: Patients with a history of adequately treated basal or squamous cell carcinoma of the skin or any adequately treated in situ carcinoma may be included in the study.\\n11. Current use or anticipated need for drugs that are known to be strong Cytochrome P450, family 3, subfamily A (CYP3A) inhibitors or inducers.\\n\\n    Note: midazolam requires diligent monitoring in situations where there is an unprecedented necessity for co-administration. These cases should be discussed with the study's medical monitor.\\n12. Patients requiring concomitant use of chronic systemic (intravenously \\\\[IV\\\\] or oral) corticosteroids at doses higher than 8 mg dexamethasone per day or other immunosuppressive medications except for managing adverse events (AEs); (inhaled steroids or intra articular steroid injections are permitted in this study).\\n\\nNote: The use of stable corticosteroid therapy in patients with brain metastases should be discussed with the Sponsor's Medical Monitor.\", 'healthyVolunteers': False, 'sex': 'ALL', 'minimumAge': '18 Years', 'stdAges': ['ADULT', 'OLDER_ADULT']}, 'contactsLocationsModule': {'centralContacts': [{'name': 'MEDSIR', 'role': 'CONTACT', 'phone': '+34 93 2214135', 'email': 'contact.trials@medsir.org'}], 'overallOfficials': [{'name': 'Matthias Preusser, md', 'affiliation': 'Medical University of Vienna, Vienna General Hospital (Austria)', 'role': 'PRINCIPAL_INVESTIGATOR'}, {'name': 'Barbara Kiesewetter, MD', 'affiliation': 'Medical University of Vienna, Vienna General Hospital (Austria)', 'role': 'PRINCIPAL_INVESTIGATOR'}, {'name': 'Thorsten Füreder, MD', 'affiliation': 'Medical University of Vienna, Vienna General Hospital (Austria)', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'locations': [{'facility': 'Medizinische Universität Graz', 'status': 'RECRUITING', 'city': 'Graz', 'zip': '8010', 'country': 'Austria', 'geoPoint': {'lat': 47.06667, 'lon': 15.45}}, {'facility': 'Medical University of Vienna', 'status': 'RECRUITING', 'city': 'Vienna', 'country': 'Austria', 'geoPoint': {'lat': 48.20849, 'lon': 16.37208}}, {'facility': 'Hospital de Vinalopó', 'status': 'RECRUITING', 'city': 'Elche', 'state': 'Alicante', 'zip': '03293', 'country': 'Spain', 'geoPoint': {'lat': 38.26218, 'lon': -0.70107}}, {'facility': 'Hospital Universitari Sant Joan de Reus', 'status': 'RECRUITING', 'city': 'Reus', 'state': 'Tarragona', 'zip': '43204', 'country': 'Spain', 'geoPoint': {'lat': 41.15612, 'lon': 1.10687}}, {'facility': 'Hospital General Universitario Dr. Balmis', 'status': 'RECRUITING', 'city': 'Alicante', 'zip': '03010', 'country': 'Spain', 'geoPoint': {'lat': 38.34517, 'lon': -0.48149}}, {'facility': 'Hospital de Cruces', 'status': 'RECRUITING', 'city': 'Barakaldo', 'zip': '48903', 'country': 'Spain', 'geoPoint': {'lat': 43.29639, 'lon': -2.98813}}, {'facility': 'UOMI Cancer Center', 'status': 'RECRUITING', 'city': 'Barcelona', 'zip': '08017', 'country': 'Spain', 'geoPoint': {'lat': 41.38879, 'lon': 2.15899}}, {'facility': \"Hospital Universitari Vall d'Hebron\", 'status': 'RECRUITING', 'city': 'Barcelona', 'zip': '08035', 'country': 'Spain', 'geoPoint': {'lat': 41.38879, 'lon': 2.15899}}, {'facility': 'Hospital Beata María Ana', 'status': 'RECRUITING', 'city': 'Madrid', 'zip': '28007', 'country': 'Spain', 'geoPoint': {'lat': 40.4165, 'lon': -3.70256}}, {'facility': 'Complejo Hospitalario Universitario de Santiago (CHUS)', 'status': 'RECRUITING', 'city': 'Santiago De Compostela', 'zip': '15706', 'country': 'Spain', 'geoPoint': {'lat': 42.88052, 'lon': -8.54569}}, {'facility': 'Hospital Clínico Universitario de Valencia', 'status': 'RECRUITING', 'city': 'Valencia', 'zip': '46010', 'country': 'Spain', 'geoPoint': {'lat': 39.46975, 'lon': -0.37739}}]}}, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-08-21'}, 'conditionBrowseModule': {'meshes': [{'id': 'D009362', 'term': 'Neoplasm Metastasis'}, {'id': 'D001932', 'term': 'Brain Neoplasms'}], 'ancestors': [{'id': 'D009371', 'term': 'Neoplasms by Site'}, {'id': 'D009369', 'term': 'Neoplasms'}, {'id': 'D009385', 'term': 'Neoplastic Processes'}, {'id': 'D010335', 'term': 'Pathologic Processes'}, {'id': 'D016543', 'term': 'Central Nervous System Neoplasms'}, {'id': 'D009423', 'term': 'Nervous System Neoplasms'}, {'id': 'D001927', 'term': 'Brain Diseases'}, {'id': 'D002493', 'term': 'Central Nervous System Diseases'}, {'id': 'D009422', 'term': 'Nervous System Diseases'}], 'browseLeaves': [{'id': 'M12307', 'name': 'Neoplasm Metastasis', 'asFound': 'Metastases', 'relevance': 'HIGH'}, {'id': 'M11172', 'name': 'Lung Neoplasms', 'relevance': 'LOW'}, {'id': 'M5546', 'name': 'Carcinoma, Non-Small-Cell Lung', 'relevance': 'LOW'}, {'id': 'M5209', 'name': 'Brain Neoplasms', 'asFound': 'Brain Metastases', 'relevance': 'HIGH'}, {'id': 'M12330', 'name': 'Neoplastic Processes', 'relevance': 'LOW'}, {'id': 'M18937', 'name': 'Central Nervous System Neoplasms', 'relevance': 'LOW'}, {'id': 'M12367', 'name': 'Nervous System Neoplasms', 'relevance': 'LOW'}, {'id': 'M5204', 'name': 'Brain Diseases', 'relevance': 'LOW'}, {'id': 'M5742', 'name': 'Central Nervous System Diseases', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'BC04', 'name': 'Neoplasms'}, {'abbrev': 'BC23', 'name': 'Symptoms and General Pathology'}, {'abbrev': 'All', 'name': 'All Conditions'}, {'abbrev': 'BC08', 'name': 'Respiratory Tract (Lung and Bronchial) Diseases'}, {'abbrev': 'BC10', 'name': 'Nervous System Diseases'}]}}, 'hasResults': False}\n",
      "Keys for NCT04621188:\n",
      "dict_keys(['protocolSection', 'derivedSection', 'hasResults'])\n",
      "Content for NCT04621188:\n",
      "{'protocolSection': {'identificationModule': {'nctId': 'NCT04621188', 'orgStudyIdInfo': {'id': 'IFCT-2003'}, 'organization': {'fullName': 'Intergroupe Francophone de Cancerologie Thoracique', 'class': 'OTHER'}, 'briefTitle': 'Lorlatinib After Failure of First-line TKI in Patients With Advanced ROS1-positive NSCLC (ALBATROS)', 'officialTitle': 'A Phase II Single-group Assignment, Multicenter Study of Efficacy and Safety of Lorlatinib Monotherapy After Failure of First-line Tyrosine Kinase Inhibitor in Patients With Advanced ROS1-positive Non-small Cell Lung Cancer (ALBATROS)'}, 'statusModule': {'statusVerifiedDate': '2025-03', 'overallStatus': 'ACTIVE_NOT_RECRUITING', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2021-03-19', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2025-02-26', 'type': 'ACTUAL'}, 'completionDateStruct': {'date': '2027-02', 'type': 'ESTIMATED'}, 'studyFirstSubmitDate': '2020-11-04', 'studyFirstSubmitQcDate': '2020-11-04', 'studyFirstPostDateStruct': {'date': '2020-11-09', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2025-03-04', 'lastUpdatePostDateStruct': {'date': '2025-03-06', 'type': 'ACTUAL'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'}, 'leadSponsor': {'name': 'Intergroupe Francophone de Cancerologie Thoracique', 'class': 'OTHER'}}, 'oversightModule': {'oversightHasDmc': False, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False, 'isUsExport': False}, 'descriptionModule': {'briefSummary': 'ROS1 rearrangements are present in 1-2% of NSCLC cases and define a distinct molecular subgroup. Like ALK (anaplastic lymphoma kinase) rearrangements in NSCLC, ROS1 fusions confer sensitivity to the inhibitor crizotinib. Crizotinib, which is a tyrosine kinase inhibitor (TKI), has been shown to be effective in tumors in several retrospective studies.\\n\\nRecently the FDA approved entrectinib for the treatment of patients with ROS1-positive metastatic NSCLC. This indication is based on the results of pooled data from several trials. Together, these studies demonstrate the efficacy for entrectinib across a variety of solid tumor types including NSCLC with ROS1 fusion.\\n\\nHowever, despite the efficacy of crizotinib or entrectinib in ROS1-positive NSCLC, patients will develop resistance to these tyrosine kinase inhibitors.\\n\\nLorlatinib is a new and potent ROS1 / ALK inhibitor optimized to penetrate the blood-brain barrier. A recent study has investigated the activity of lorlatinib against the crizotinib-resistant ROS1G2032R mutation. In this situation, lorlatinib effectively inhibited the catalytic activity of recombinant ROS1G2032R resulting in an antiproliferative response. Because of its potency as an ROS1 inhibitor and its ability to suppress the resistant ROS1 mutations, lorlatinib could be a treatment of choice in ROS1-positive NSCLC.'}, 'conditionsModule': {'conditions': ['Non Small Cell Lung Cancer Metastatic'], 'keywords': ['IFCT', 'ALBATROS', 'NSCLC', 'ROS1-positive', 'monotherapy']}, 'designModule': {'studyType': 'INTERVENTIONAL', 'phases': ['PHASE2'], 'designInfo': {'allocation': 'NA', 'interventionModel': 'SINGLE_GROUP', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 54, 'type': 'ACTUAL'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'Lorlatinib', 'type': 'EXPERIMENTAL', 'description': '100 mg once daily', 'interventionNames': ['Drug: Lorlatinib']}], 'interventions': [{'type': 'DRUG', 'name': 'Lorlatinib', 'description': '100 mg once daily', 'armGroupLabels': ['Lorlatinib']}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Objective Response Rate (ORR) at 8 weeks by investigators', 'description': 'ORR is defined as the percentage of subjects with a confirmed complete response (CR) or partial response (PR) as per RECIST v1.1 criteria.', 'timeFrame': '8 weeks'}], 'secondaryOutcomes': [{'measure': 'Overall Response Rate (ORR) at 8 weeks by Independent Reviewer Committee (IRC)', 'description': 'Percentage of subjects with a confirmed at 16 weeks complete response (CR) or partial response (PR) as per RECIST v1.1 criteria.', 'timeFrame': '8 weeks'}, {'measure': 'Progression Free Survival (PFS)', 'description': 'Time between the date of first dose of study drug and the first date of documented disease progression (according to RECIST v1.1) or death (from any cause)', 'timeFrame': 'Up to 24 months'}, {'measure': 'Time to progression (TTP)', 'description': 'Time from the date of first dose of study drug to the earliest date of disease progression (according to RECIST v1.1.)', 'timeFrame': 'Up to 24 months'}, {'measure': 'Disease control rate (DCR) at 8 weeks weeks)', 'description': 'Proportion of patients have achieved a confirmed best overall response of CR, PR or SD (Stable Disease) (according to RECIST v1.1.)', 'timeFrame': '8 weeks'}, {'measure': 'Duration of response (DOR) first documented response (CR or PR) to the earliest date of disease progression, or death due to any cause.', 'description': 'Time from the date of the first documented response (CR or PR) to the earliest date of disease progression or death due to any cause.', 'timeFrame': 'Up to 24 months'}, {'measure': 'Overall survival (OS) months', 'description': 'Time from the date of first dose of study drug to the date of death due to any cause', 'timeFrame': '12 months and 24 months'}, {'measure': 'Central Nervous System (CNS) Objective response rate (C-ORR)', 'description': 'ORR estimated in patients with measurable CNS metastases at baseline.', 'timeFrame': 'Up to 24 months'}, {'measure': 'CNS duration of response (C-DOR) measurable CNS metastases at baseline.', 'description': 'DOR estimated in patients with measurable CNS metastases at baseline.', 'timeFrame': 'Up to 24 months'}, {'measure': 'Time to CNS progression', 'description': 'In patients without brain metastases baseline.', 'timeFrame': 'Up to 24 months'}, {'measure': 'Change from baseline of EuroQol Quality of Life 5-Dimension 5-Level Scale (EQ-5D-5L)', 'description': 'At all scheduled time points', 'timeFrame': 'Up to 24 months'}]}, 'eligibilityModule': {'eligibilityCriteria': \"Inclusion Criteria:\\n\\n* Signed Written Informed Consent: Subjects must have signed and dated an IRB/IEC approved written informed consent form in accordance with regulatory and institutional guidelines. This must be obtained before the performance of any protocol related procedures that are not part of normal subject care. Subjects must be willing and able to comply with scheduled visits, treatment schedule, and laboratory testing\\n* Patients with histologically or cytologically confirmed diagnosis of locally advanced not eligible to a local treatment or metastatic NSCLC (Stage IIIB, IIIC or IV accordingly to 8th classification TNM, UICC 2015) that carries an ROS1 rearrangement, as determined by the molecular biology platform of the investigator by FISH assay or by Immunohistochemistry (IHC), or Next Generation Sequencing (NGS) or RNA sequencing approach.\\n* Disease Status Requirements: Disease progression meeting RECISTv1.1 after one prior line of treatment with crizotinib or entrectinib (+ one line of chemotherapy with or without immunotherapy before TKI treatment).\\n\\nNote: patient with disease progression after treatment with another ROS1-TKI may still be eligible upon discussion with IFCT.\\n\\n* Tumor Requirements: All Patients must have at least one measurable target lesion according to RECIST v1.1. The radiological assessment has to be done within the timelines indicated. In addition, patients with asymptomatic and neurologically stable CNS metastases (including patients controlled with stable or decreasing steroid use within the last week prior to study entry) will be eligible. The brain metastases may be newly diagnosed after disease progression with crizotinib or entrectinib or be present as progressive disease after surgery, whole brain radiotherapy or stereotactic radiosurgery (see Exclusion Criterion for the lapsed time period required between the end of radiotherapy and study entry). Patients who have leptomeningeal disease (LM) or carcinomatous meningitis (CM) will be eligible if the LM/CM is visualized on MRI or if documented baseline cerebral spinal fluid (CSF) positive cytology is available and asymptomatic and neurologically stable (including patients controlled with stable or decreasing steroid use within the last week prior to study entry).\\n* Tumor Sample Requirement: Tumour biopsy sampling on fresh tissue (FFPE blocks required) obtained after progression on crizotinib or entrectinib. Tumour biopsy should be exploitable for molecular analysis. If the tumour biopsy is not exploitable, the inclusion will be allowed if two blood samples are provided for tumoral cfDNA analysis. The Sponsor will monitor a posteriori the exploitability of provided tumour biopsies and will investigate the impossibility to perform or repeat tissue tumor sampling.\\n* Age ≥18 years.\\n* Life expectancy of at least 12 weeks, in the opinion of the Investigator.\\n* Eastern Cooperative Oncology Group Performance Status (ECOG PS) ≤ 2\\n* Adequate Bone Marrow Function, including: Absolute Neutrophil Count (ANC) ≥1.5 x 109/L; Platelets ≥100 x 109/L; Hemoglobin ≥9 g/dL.\\n* Adequate Pancreatic Function, including: Serum lipase ≤1.5 x ULN.\\n* Adequate Renal Function, including: Serum creatinine ≤1.5 x ULN or estimated creatinine clearance ≥45 mL/min as calculated using the method standard for the institution.\\n* Adequate Liver Function, including: Total serum bilirubin ≤1.5 x ULN; Aspartate Aminotransferase (AST) and Alanine Aminotransferase (ALT) ≤2.5 x ULN; ≤5.0 x ULN if there is liver metastases involvement.\\n* Participants must have recovered from treatment toxicities to CTCAE Grade ≤ 1 (for participants who have developed interstitial lung disease \\\\[ILD\\\\], they must have fully recovered) except for AEs that in the investigator' judgment do not constitute a safety risk for the patient.\\n* Participants must have recovered from effects of any major surgery, or significant traumatic injury, at least 35 days before the first dose of lorlatinib\\n* For all females of childbearing potential, a negative pregnancy test must be obtained within the screening period. A patient is of childbearing potential if, in the opinion of the investigator, she is biologically capable of having children and is sexually active. Additionally, all females of childbearing potential must provide an agreement to remain abstinent or use two adequate methods of contraception, including at least one method with a failure rate of \\\\< 1% per year, during the treatment period and for at least 90 days after the last dose of study drug.\\n* For men: agreement to remain abstinent or use an effective method of contraception (e.g., condom) during the treatment period and for at least 14 weeks after the last dose of study drug and agreement to refrain from donating sperm during this same period.\\n* Evidence of a personally signed and dated informed consent document indicating that the patient has been informed of all pertinent aspects of the study.\\n* Willingness and ability to comply with the study scheduled visits, treatment plans, laboratory tests and other procedure.\\n* Participant has national health insurance coverage.\\n* Washout period: if previous progression on ROS1-TKI: 7 days from last dose of the drug. The washout period may be shortened to 2 days at investigator discretion.\\n\\nExclusion Criteria:\\n\\n* Participants with disease progression on front-line treatment with TKI i.e. crizotinib or entrectinib limited to CNS or one non-CNS site (oligo-metastasis) and eligible to a local ablative treatment (surgery or stereotaxic radiotherapy).\\n* Histological transformation with neuro-endocrine differentiation.\\n* Spinal cord compression is excluded unless the patient demonstrates good pain control attained through therapy and there is stabilization or recovery of neurological function for the 4 weeks prior to study entry.\\n* Patients with symptomatic and neurologically instable CNS metastases or leptomeningeal metastasis (including patients that require increasing doses of steroids within one week prior to Day 0 of screening phase and during the screening phase to manage CNS symptoms).\\n* Major surgery within 35 days of study entry. Minor surgical procedures (eg, port insertion, mediastinoscopy, surgical procedure for re-sampling) are not excluded, but sufficient time at investigator discretion should have passed for wound healing.\\n* Radiation therapy within 2 weeks of study entry (except palliative to relieve bone pain). Palliative radiation (≤15 fractions) must have been completed at least 48 hours prior to study entry. Stereotactic or small field brain irradiation must have completed at least 2 weeks prior to study entry. Whole brain radiation must have completed at least 4 weeks prior to study entry.\\n* Prior therapy with an antibody or drug specifically targeting T-cell co-stimulation or immune checkpoint pathways, including, but not limited to, anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-CTLA-4.\\n* Active and clinically significant bacterial, fungal, or viral infection including hepatitis B (HBV), hepatitis C (HCV), known human immunodeficiency virus (HIV), or acquired immunodeficiency syndrome (AIDS)-related illness.\\n* Clinically significant cardiovascular disease (that is, active or \\\\<3 months prior to enrollment): cerebral vascular accident/stroke, myocardial infarction, unstable angina, congestive heart failure (New York Heart Association Classification Class ≥ II), second-degree or third-degree AV block (unless paced) or any AV block with PR \\\\>220 msec.\\n* Ongoing cardiac dysrhythmias of NCI CTCAE Grade ≥2, uncontrolled atrial fibrillation of any grade, bradycardia defined as \\\\<50 bpm (unless patient is otherwise healthy such as long-distance runners, athletic patients etc.), machine-read ECG with QTc \\\\>470 msec, or congenital long QT syndrome.\\n* Patients with predisposing characteristics for acute pancreatitis according to investigator judgment (eg, uncontrolled hyperglycemia, current gallstone disease, alcoholism \\\\[more than 4 drinks on any day or 14 drinks per week where 1 drink is defined as the alcoholic beverage containing approximately 14 grams of pure alcohol, eg, 12 fl oz/360 mL regular beer or 5 fl oz/150 mL of wine\\\\] in the last month.\\n* History of bilateral or Grade 3 or 4 interstitial fibrosis or diffuse interstitial lung disease. Patients with history of prior radiation pneumonitis are not excluded.\\n* Other severe acute or chronic medical or psychiatric condition, including recent (within the past year) or active suicidal ideation or behavior, or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the patient inappropriate for entry into this study.\\n* Evidence of active malignancy (other than current NSCLC, non-melanoma skin cancer, in situ cervical cancer, papillary thyroid cancer, DCIS of the breast or localized and presumed cured prostate cancer) within the last 3 years.\\n* Active inflammatory gastrointestinal disease, chronic diarrhea, symptomatic diverticular disease or previous gastric resection or lap band.\\n* Current use or anticipated need for food or drugs prohibited (see chapter 7.9 for details).\\n* Patients presenting with abnormal Left Ventricular Ejection Fraction (LVEF) by echocardiogram or Multi-Gated Acquisition Scan (MUGA) according to institutional lower limits.\\n* Breastfeeding female patients (including patients who intend to interrupt breastfeeding).\\n* Liver disease characterized by: ALT or AST level \\\\> 3 the upper normal limit (UNL) (≥ 5 x UNL for patients with liver metastases) confirmed on 2 consecutive measures OR impaired excretory function (e.g.. hyperbilirubinemia) or synthetic function or other conditions of decompensated liver disease e.g.: coagulopathy, Hepatic encephalopathy, hypoalbuminemia, ascites and bleeding from esophageal varices OR Acute viral or autoimmune or other types of hepatitis.\", 'healthyVolunteers': False, 'sex': 'ALL', 'minimumAge': '18 Years', 'stdAges': ['ADULT', 'OLDER_ADULT']}, 'contactsLocationsModule': {'overallOfficials': [{'name': 'Denis Moro-Sibilot', 'affiliation': 'Grenoble - CHU', 'role': 'STUDY_CHAIR'}, {'name': 'Michael Duruisseaux', 'affiliation': 'Lyon - URCOT', 'role': 'STUDY_CHAIR'}], 'locations': [{'facility': \"Centre Hospitalier du Pays d'Aix\", 'city': 'Aix-en-Provence', 'zip': '13616', 'country': 'France', 'geoPoint': {'lat': 43.5283, 'lon': 5.44973}}, {'facility': 'Centre Paul Papin', 'city': 'Angers', 'zip': '49055', 'country': 'France', 'geoPoint': {'lat': 47.46667, 'lon': -0.55}}, {'facility': 'Angers - CHU', 'city': 'Angers', 'country': 'France', 'geoPoint': {'lat': 47.46667, 'lon': -0.55}}, {'facility': 'Annecy - CH', 'city': 'Annecy', 'country': 'France', 'geoPoint': {'lat': 45.9, 'lon': 6.11667}}, {'facility': 'Antony - Hôpital privé', 'city': 'Antony', 'country': 'France', 'geoPoint': {'lat': 48.75, 'lon': 2.3}}, {'facility': 'Avignon - CH', 'city': 'Avignon', 'country': 'France', 'geoPoint': {'lat': 43.94834, 'lon': 4.80892}}, {'facility': 'Centre Hospitalier de la Côte Basque', 'city': 'Bayonne', 'zip': '64100', 'country': 'France', 'geoPoint': {'lat': 43.48333, 'lon': -1.48333}}, {'facility': 'Bordeaux - CHU', 'city': 'Bordeaux', 'country': 'France', 'geoPoint': {'lat': 44.84044, 'lon': -0.5805}}, {'facility': 'Bordeaux - Institut Bergonie', 'city': 'Bordeaux', 'country': 'France', 'geoPoint': {'lat': 44.84044, 'lon': -0.5805}}, {'facility': 'Bordeaux - Polyclinique', 'city': 'Bordeaux', 'country': 'France', 'geoPoint': {'lat': 44.84044, 'lon': -0.5805}}, {'facility': 'AP-HP Hôpital Ambroise Paré', 'city': 'Boulogne', 'zip': '92104', 'country': 'France', 'geoPoint': {'lat': 46.79346, 'lon': -1.3194}}, {'facility': 'Caen - CHU Côte de Nacre', 'city': 'Caen', 'zip': '14000', 'country': 'France', 'geoPoint': {'lat': 49.18585, 'lon': -0.35912}}, {'facility': 'Chauny - CH', 'city': 'Chauny', 'country': 'France', 'geoPoint': {'lat': 49.61514, 'lon': 3.21857}}, {'facility': 'Cholet - CH', 'city': 'Cholet', 'country': 'France', 'geoPoint': {'lat': 47.06667, 'lon': -0.88333}}, {'facility': 'Clermont-Ferrand - CHU', 'city': 'Clermont-Ferrand', 'country': 'France', 'geoPoint': {'lat': 45.77966, 'lon': 3.08628}}, {'facility': 'Colmar - CH', 'city': 'Colmar', 'country': 'France', 'geoPoint': {'lat': 48.08333, 'lon': 7.36667}}, {'facility': 'Centre Hospitalier Intercommunal de Créteil', 'city': 'Créteil', 'zip': '94000', 'country': 'France', 'geoPoint': {'lat': 48.78333, 'lon': 2.46667}}, {'facility': 'Dijon - CRLCC', 'city': 'Dijon', 'country': 'France', 'geoPoint': {'lat': 47.31667, 'lon': 5.01667}}, {'facility': 'CHRU Grenoble', 'city': 'Grenoble', 'country': 'France', 'geoPoint': {'lat': 45.16667, 'lon': 5.71667}}, {'facility': 'Centre Hospitalier - Pneumologie', 'city': 'Le Mans', 'zip': '72000', 'country': 'France', 'geoPoint': {'lat': 48.0, 'lon': 0.2}}, {'facility': 'Hôpital Calmette', 'city': 'Lille', 'zip': '59037', 'country': 'France', 'geoPoint': {'lat': 50.63297, 'lon': 3.05858}}, {'facility': 'Centre Léon Bérard', 'city': 'Lyon', 'zip': '69373', 'country': 'France', 'geoPoint': {'lat': 45.74848, 'lon': 4.84669}}, {'facility': 'Institut Paoli Calmettes', 'city': 'Marseille', 'zip': '13273', 'country': 'France', 'geoPoint': {'lat': 43.29551, 'lon': 5.38958}}, {'facility': 'Marseille Hôpital Nord', 'city': 'Marseille', 'zip': '13915', 'country': 'France', 'geoPoint': {'lat': 43.29551, 'lon': 5.38958}}, {'facility': 'GRH Mulhouse Sud-Alsace', 'city': 'Mulhouse', 'country': 'France', 'geoPoint': {'lat': 47.75, 'lon': 7.33333}}, {'facility': 'AP-HP Hôpital Cochin', 'city': 'Paris', 'zip': '75014', 'country': 'France', 'geoPoint': {'lat': 48.85341, 'lon': 2.3488}}, {'facility': 'AP-HP Hopital Tenon - Pneumologie', 'city': 'Paris', 'zip': '75020', 'country': 'France', 'geoPoint': {'lat': 48.85341, 'lon': 2.3488}}, {'facility': 'AP-HP Hôpital Bichat', 'city': 'Paris', 'zip': '75877', 'country': 'France', 'geoPoint': {'lat': 48.85341, 'lon': 2.3488}}, {'facility': 'Paris - Curie', 'city': 'Paris', 'country': 'France', 'geoPoint': {'lat': 48.85341, 'lon': 2.3488}}, {'facility': 'Lyon - URCOT', 'city': 'Pierre-Bénite', 'country': 'France', 'geoPoint': {'lat': 45.7009, 'lon': 4.82511}}, {'facility': 'Rouen - CHU', 'city': 'Rouen', 'country': 'France', 'geoPoint': {'lat': 49.44313, 'lon': 1.09932}}, {'facility': 'Nouvel Hôpital Civil - Hôpitaux Universitaires de Strasbourg', 'city': 'Strasbourg', 'zip': '67091', 'country': 'France', 'geoPoint': {'lat': 48.58392, 'lon': 7.74553}}, {'facility': 'Hôpital Foch', 'city': 'Suresnes', 'zip': '92151', 'country': 'France', 'geoPoint': {'lat': 48.87143, 'lon': 2.22929}}, {'facility': 'CHU Toulouse - Pneumologie', 'city': 'Toulouse', 'country': 'France', 'geoPoint': {'lat': 43.60426, 'lon': 1.44367}}, {'facility': 'CHU Bretonneau', 'city': 'Tours', 'zip': '37044', 'country': 'France', 'geoPoint': {'lat': 47.38333, 'lon': 0.68333}}, {'facility': 'Valenciennes - Clinique', 'city': 'Valenciennes', 'country': 'France', 'geoPoint': {'lat': 50.35, 'lon': 3.53333}}, {'facility': 'Vandoeuvre-lès-Nancy - CHU', 'city': 'Vandœuvre-lès-Nancy', 'country': 'France', 'geoPoint': {'lat': 48.65, 'lon': 6.18333}}]}, 'referencesModule': {'seeAlsoLinks': [{'label': 'Description IFCT website', 'url': 'http://www.ifct.fr/index.php/fr/la-recherche/item/2215-ifct-2003-albatros'}]}}, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-08-21'}, 'conditionBrowseModule': {'meshes': [{'id': 'D008175', 'term': 'Lung Neoplasms'}, {'id': 'D002289', 'term': 'Carcinoma, Non-Small-Cell Lung'}], 'ancestors': [{'id': 'D012142', 'term': 'Respiratory Tract Neoplasms'}, {'id': 'D013899', 'term': 'Thoracic Neoplasms'}, {'id': 'D009371', 'term': 'Neoplasms by Site'}, {'id': 'D009369', 'term': 'Neoplasms'}, {'id': 'D008171', 'term': 'Lung Diseases'}, {'id': 'D012140', 'term': 'Respiratory Tract Diseases'}, {'id': 'D002283', 'term': 'Carcinoma, Bronchogenic'}, {'id': 'D001984', 'term': 'Bronchial Neoplasms'}], 'browseLeaves': [{'id': 'M11172', 'name': 'Lung Neoplasms', 'asFound': 'Lung Cancer', 'relevance': 'HIGH'}, {'id': 'M5546', 'name': 'Carcinoma, Non-Small-Cell Lung', 'asFound': 'Non-small Cell Lung Cancer', 'relevance': 'HIGH'}, {'id': 'M5534', 'name': 'Carcinoma', 'relevance': 'LOW'}, {'id': 'M14979', 'name': 'Respiratory Tract Neoplasms', 'relevance': 'LOW'}, {'id': 'M16658', 'name': 'Thoracic Neoplasms', 'relevance': 'LOW'}, {'id': 'M11168', 'name': 'Lung Diseases', 'relevance': 'LOW'}, {'id': 'M14977', 'name': 'Respiratory Tract Diseases', 'relevance': 'LOW'}, {'id': 'M5540', 'name': 'Carcinoma, Bronchogenic', 'relevance': 'LOW'}, {'id': 'M5260', 'name': 'Bronchial Neoplasms', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'BC04', 'name': 'Neoplasms'}, {'abbrev': 'BC08', 'name': 'Respiratory Tract (Lung and Bronchial) Diseases'}, {'abbrev': 'All', 'name': 'All Conditions'}]}, 'interventionBrowseModule': {'browseLeaves': [{'id': 'M2889', 'name': 'Tyrosine Kinase Inhibitors', 'relevance': 'LOW'}, {'id': 'T22', 'name': 'Tyrosine', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'All', 'name': 'All Drugs and Chemicals'}, {'abbrev': 'AA', 'name': 'Amino Acids'}]}}, 'hasResults': False}\n",
      "Keys for NCT05681780:\n",
      "dict_keys(['protocolSection', 'derivedSection', 'hasResults'])\n",
      "Content for NCT05681780:\n",
      "{'protocolSection': {'identificationModule': {'nctId': 'NCT05681780', 'orgStudyIdInfo': {'id': 'MCC-21971'}, 'organization': {'fullName': 'H. Lee Moffitt Cancer Center and Research Institute', 'class': 'OTHER'}, 'briefTitle': 'Clinical Trial of CD40L-Augmented TIL for Patients With EGFR, ALK, ROS1 or HER2-Driven NSCLC', 'officialTitle': 'Clinical Trial of CD40L-augmented Tumor Infiltrating Lymphocytes (CD40L TIL) for Patients With Oncogene-Driven Advanced Non-Small Cell Lung Cancer (NSCLC)'}, 'statusModule': {'statusVerifiedDate': '2025-05', 'overallStatus': 'RECRUITING', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2023-03-10', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2025-12', 'type': 'ESTIMATED'}, 'completionDateStruct': {'date': '2027-12', 'type': 'ESTIMATED'}, 'studyFirstSubmitDate': '2022-12-28', 'studyFirstSubmitQcDate': '2022-12-28', 'studyFirstPostDateStruct': {'date': '2023-01-12', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2025-05-05', 'lastUpdatePostDateStruct': {'date': '2025-05-07', 'type': 'ACTUAL'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'}, 'leadSponsor': {'name': 'H. Lee Moffitt Cancer Center and Research Institute', 'class': 'OTHER'}}, 'oversightModule': {'oversightHasDmc': True, 'isFdaRegulatedDrug': True, 'isFdaRegulatedDevice': False}, 'descriptionModule': {'briefSummary': 'To determine the effect of a special preparation of cells, called tumor-infiltrating lymphocytes (TIL) stimulated with CD40L, when given with the drug nivolumab, for patients with EGFR, ALK, ROS1, or HER2-genomically altered lung cancer.'}, 'conditionsModule': {'conditions': ['Non Small Cell Lung Cancer', 'Stage IV Non-small Cell Lung Cancer', 'Recurrent Non Small Cell Lung Cancer'], 'keywords': ['Lung Cancer', 'Tumor-Infiltrating Lymphocytes', 'EGFR Mutation', 'ALK Rearrangement', 'ROS1 Rearrangement', 'ERBB2 Mutation', 'HER2 Exon 20 Mutation']}, 'designModule': {'studyType': 'INTERVENTIONAL', 'phases': ['PHASE1'], 'designInfo': {'allocation': 'NA', 'interventionModel': 'SINGLE_GROUP', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 20, 'type': 'ESTIMATED'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'TIL+ Nivolumab', 'type': 'EXPERIMENTAL', 'description': 'Nivolumab infusion every 3 weeks prior to lymphodepletion chemotherapy with cyclophosphamide/fludarabine, TIL infusion and interleukin-2. Then nivolumab infusion every 4 weeks up to 12 months.', 'interventionNames': ['Biological: Tumor-infiltrating Lymphocytes (TIL)', 'Drug: Nivolumab', 'Drug: Cyclophosphamide', 'Drug: Fludarabine', 'Other: Tumor-infiltrating Lymphocyte Therapy', 'Drug: Interleukin-2 (IL2)']}], 'interventions': [{'type': 'BIOLOGICAL', 'name': 'Tumor-infiltrating Lymphocytes (TIL)', 'description': \"Tumor harvest for TIL growth in the lab: A sample of the participant's tumor will be collected and sent to the lab for TIL growth. TIL will be prepared and cryopreserved.\", 'armGroupLabels': ['TIL+ Nivolumab'], 'otherNames': ['TIL']}, {'type': 'DRUG', 'name': 'Nivolumab', 'description': 'Nivolumab (Opdivo®), 360 mg, IV infusion every 3 weeks prior to TIL infusion, and then after TIL infusion 480 mg ever 4 weeks for up to 12 months.', 'armGroupLabels': ['TIL+ Nivolumab'], 'otherNames': ['Opdivo']}, {'type': 'DRUG', 'name': 'Cyclophosphamide', 'description': 'Cyclophosphamide will be administered on days -7 and -6.', 'armGroupLabels': ['TIL+ Nivolumab'], 'otherNames': ['Cytoxan']}, {'type': 'DRUG', 'name': 'Fludarabine', 'description': 'Fludarabine will then be infused per institutional standard on Days -7 to -3.', 'armGroupLabels': ['TIL+ Nivolumab'], 'otherNames': ['Fludara']}, {'type': 'OTHER', 'name': 'Tumor-infiltrating Lymphocyte Therapy', 'description': 'On day 0, all patients will receive a dose infusion TIL cells.', 'armGroupLabels': ['TIL+ Nivolumab'], 'otherNames': ['TIL']}, {'type': 'DRUG', 'name': 'Interleukin-2 (IL2)', 'description': 'Participants will receive IL-2 for up to 6 doses, based on participants tolerance and investigator judgement. This will be given after the infusion of the T-cells.', 'armGroupLabels': ['TIL+ Nivolumab'], 'otherNames': ['IL2']}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Adverse Events (AE)', 'description': 'To characterize the safety profile of CD40L-augmented TIL administered with nivolumab.', 'timeFrame': 'Up to 18 Months'}], 'secondaryOutcomes': [{'measure': 'Objective Response Rate (ORR)', 'description': 'Proportion of patients with complete response + partial response (CR+PR) per Response Evaluation Criteria in Solid Tumors (RECIST v1.1)', 'timeFrame': 'Up to 5 Years'}, {'measure': 'Duration of Response (DOR)', 'description': 'The time from the date of the first documentation of initial response (CR or PR) to the date of the first documentation of progressive disease (PD) or death due to any cause.', 'timeFrame': 'Up to 5 years'}, {'measure': 'Overall Survival (OS)', 'description': 'The time length of patients living from the date of TIL infusion', 'timeFrame': 'Up to 5 Years'}]}, 'eligibilityModule': {'eligibilityCriteria': \"Inclusion Criteria:\\n\\n* Age greater than or equal to 18 years\\n* Diagnosis of stage IV or recurrent non-small cell lung cancer (NSCLC) with an activating genomic alteration within either: EGFR, ALK, ROS1, or ERBB2 receptor tyrosine kinase domains\\n* ECOG performance status of 0 or 1\\n* Expected survival ≥ 4 months\\n* Participants must have had disease progression after at least one prior line of systemic therapy for NSCLC, including appropriate prior targeted therapy for cases in which a targeted therapy is conventionally used for this genomic alteration, prior to initiating nivolumab trial therapy\\n* Measurable disease, not including any lesion that is used for TIL harvest, prior to initiation of nivolumab trial therapy\\n* In accordance with the criteria above, safely accessible tumor for TIL harvest by excisional biopsy expected to yield 1.5 cm3 of tissue, in aggregate\\n* Participants with known brain metastases are eligible for study enrollment if the brain metastases have received appropriate central nervous system-directed therapy or are found to be clinically stable ≤ 10 mm when comparing scans obtained during the screening period with a scan obtained ≥28 days prior, or if the treating physician determines that immediate CNS-specific treatment is not required prior to the first cycle of therapy. Please also refer to eligibility section on corticosteroids below.\\n* Adequate normal organ and marrow function as defined below:\\n* a. Hemoglobin ≥ 9.0 g/dL, with transfusions permissible;\\n* b. Absolute neutrophil count (ANC) ≥ 1000 per mm3);\\n* c. Platelet count ≥ 75,000 per mm3, without platelet transfusions for 7 days;\\n* d. Prothrombin Time ≤ 1.7x the institutional upper limit of normal (ULN), unless participant is receiving intended anticoagulant therapy.\\n* e. Serum bilirubin ≤ 2.0x the institutional ULN, or ≤ 4.0x ULN if confirmed Gilbert's syndrome (persistent or recurrent hyperbilirubinemia that is predominantly unconjugated in the absence of hemolysis or hepatic pathology) with PI approval.\\n* f. AST/ALT ≤ 2.5x institutional ULN unless liver metastases are present, in which case it must be ≤ 5x ULN\\n* g. Serum creatinine of ≤ 1.5x institutional ULN, or ≥30 mL/min for participant with creatinine levels \\\\>1.5 × institutional ULN\\n* h. Albumin ≥ 2.0 g/dl\\n* Pulmonary function tests within past 4 months showing DLCO ≥45% of predicted. Adjusted DLCO based on hemoglobin concentration should be used, if available.\\n* Human immunodeficiency virus (HIV)-infected participants must be receiving on effective antiretroviral therapy for past 6 months with undetectable viral load and normal CD4 count\\n* Participants with history of chronic hepatitis B virus (HBV) infection must have undetectable HBV viral load on suppressive therapy, if indicated, and no overt cirrhosis\\n* Participants with a history of hepatitis C virus (HCV) infection must have been treated and cured. For participants with HCV infection who are currently on treatment, they must have an undetectable HCV viral load and no overt cirrhosis\\n* Participants with a prior or concurrent malignancy must have a natural history which does not have the potential to interfere with safety or efficacy assessment of the investigational regimen\\n\\nExclusion Criteria:\\n\\n* No more than six prior lines of systemic therapy for NSCLC\\n* No prior PD-1 or PD-L1 inhibitor treatment for metastatic NSCLC. Examples of inhibitors include: nivolumab, atezolizumab, pembrolizumab, avelumab, cemplimumab, spartalizumab, or durvalumab.\\n* Participants with rapidly progressing tumors, as judged by the investigator\\n* Active or prior documented autoimmune disease within the past 2 years. NOTE: Subjects with vitiligo, Grave's disease, limited site eczema, or limited site plaque psoriasis not requiring systemic treatment (within the past 2 years), or other autoimmune conditions which are not expected to recur, are allowed after approval from the medical monitor or PI\\n* Active leptomeningeal or pachymeningeal metastases, or carcinomatous meningitis. This is due to prognostic implications and timeline for cell therapy\\n* Has a diagnosis of primary immunodeficiency or is receiving chronic systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to enrollment.\\n* a. Oral hydrocortisone, only for the purposes of a documented adrenal insufficiency diagnosis, is permitted if ≤ 25 mg daily total dose\\n* b. Inhaled, intranasal, or topical corticosteroids are permitted\\n* Uncontrolled intercurrent illness including, but not limited to, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia (other than atrial fibrillation or supraventricular tachycardia), and significant ≥85% carotid artery stenosis\\n* Unresolved toxicity (grade 2) from previous anti-cancer therapy. Participants with irreversible toxicity that is not reasonably expected to be exacerbated by the investigational product may be included (e.g., hearing loss, peripheral neuropathy)\\n* Mean QT interval corrected for heart rate (QTc) ≥480 ms calculated from electrocardiograms (EKGs) using Bazett's Correction\\n* Participants with active systemic infections requiring intravenous antibiotics within 1 week prior to nivolumab. Prophylactic, empiric, or suppressive antibiotics are permitted with sponsor approval\\n* History of allogeneic organ transplant\\n* Participants with psychiatric illness/social situations that would limit compliance with study requirements\\n* Participants with a history of anaphylaxis to beta-lactam antibiotics. Patients may be evaluated for reported history by conducting a history and physical, and a skin test/challenge where appropriate under medical guidance\", 'healthyVolunteers': False, 'sex': 'ALL', 'minimumAge': '18 Years', 'stdAges': ['ADULT', 'OLDER_ADULT']}, 'contactsLocationsModule': {'centralContacts': [{'name': 'Ben Creelan', 'role': 'CONTACT', 'phone': '813-745-4541', 'email': 'Ben.Creelan@moffitt.org'}], 'overallOfficials': [{'name': 'Ben Creelan, MD, MS', 'affiliation': 'Moffitt Cancer Center', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'locations': [{'facility': 'Moffitt Cancer Center', 'status': 'RECRUITING', 'city': 'Tampa', 'state': 'Florida', 'zip': '33612', 'country': 'United States', 'contacts': [{'name': 'Tanner Pearson', 'role': 'CONTACT', 'phone': '813-745-6552', 'email': 'Tanner.Pearson@moffitt.org'}, {'name': 'Ben Creelan, MD, MS', 'role': 'PRINCIPAL_INVESTIGATOR'}, {'name': 'Daniel Abate Daga, PhD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 27.94752, 'lon': -82.45843}}]}, 'referencesModule': {'references': [{'pmid': '34385708', 'type': 'RESULT', 'citation': 'Creelan BC, Wang C, Teer JK, Toloza EM, Yao J, Kim S, Landin AM, Mullinax JE, Saller JJ, Saltos AN, Noyes DR, Montoya LB, Curry W, Pilon-Thomas SA, Chiappori AA, Tanvetyanon T, Kaye FJ, Thompson ZJ, Yoder SJ, Fang B, Koomen JM, Sarnaik AA, Chen DT, Conejo-Garcia JR, Haura EB, Antonia SJ. Tumor-infiltrating lymphocyte treatment for anti-PD-1-resistant metastatic lung cancer: a phase 1 trial. Nat Med. 2021 Aug;27(8):1410-1418. doi: 10.1038/s41591-021-01462-y. Epub 2021 Aug 12.'}]}, 'ipdSharingStatementModule': {'ipdSharing': 'NO'}}, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-08-21'}, 'conditionBrowseModule': {'meshes': [{'id': 'D008175', 'term': 'Lung Neoplasms'}, {'id': 'D002289', 'term': 'Carcinoma, Non-Small-Cell Lung'}], 'ancestors': [{'id': 'D012142', 'term': 'Respiratory Tract Neoplasms'}, {'id': 'D013899', 'term': 'Thoracic Neoplasms'}, {'id': 'D009371', 'term': 'Neoplasms by Site'}, {'id': 'D009369', 'term': 'Neoplasms'}, {'id': 'D008171', 'term': 'Lung Diseases'}, {'id': 'D012140', 'term': 'Respiratory Tract Diseases'}, {'id': 'D002283', 'term': 'Carcinoma, Bronchogenic'}, {'id': 'D001984', 'term': 'Bronchial Neoplasms'}], 'browseLeaves': [{'id': 'M11172', 'name': 'Lung Neoplasms', 'asFound': 'Lung Cancer', 'relevance': 'HIGH'}, {'id': 'M5546', 'name': 'Carcinoma, Non-Small-Cell Lung', 'asFound': 'Non-small Cell Lung Cancer', 'relevance': 'HIGH'}, {'id': 'M14850', 'name': 'Recurrence', 'relevance': 'LOW'}, {'id': 'M5534', 'name': 'Carcinoma', 'relevance': 'LOW'}, {'id': 'M14979', 'name': 'Respiratory Tract Neoplasms', 'relevance': 'LOW'}, {'id': 'M16658', 'name': 'Thoracic Neoplasms', 'relevance': 'LOW'}, {'id': 'M11168', 'name': 'Lung Diseases', 'relevance': 'LOW'}, {'id': 'M14977', 'name': 'Respiratory Tract Diseases', 'relevance': 'LOW'}, {'id': 'M5540', 'name': 'Carcinoma, Bronchogenic', 'relevance': 'LOW'}, {'id': 'M5260', 'name': 'Bronchial Neoplasms', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'BC04', 'name': 'Neoplasms'}, {'abbrev': 'BC08', 'name': 'Respiratory Tract (Lung and Bronchial) Diseases'}, {'abbrev': 'All', 'name': 'All Conditions'}, {'abbrev': 'BC23', 'name': 'Symptoms and General Pathology'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'D003520', 'term': 'Cyclophosphamide'}, {'id': 'D000077594', 'term': 'Nivolumab'}, {'id': 'C024352', 'term': 'Fludarabine'}, {'id': 'D007376', 'term': 'Interleukin-2'}], 'ancestors': [{'id': 'D007166', 'term': 'Immunosuppressive Agents'}, {'id': 'D007155', 'term': 'Immunologic Factors'}, {'id': 'D045505', 'term': 'Physiological Effects of Drugs'}, {'id': 'D018501', 'term': 'Antirheumatic Agents'}, {'id': 'D018906', 'term': 'Antineoplastic Agents, Alkylating'}, {'id': 'D000477', 'term': 'Alkylating Agents'}, {'id': 'D045504', 'term': 'Molecular Mechanisms of Pharmacological Action'}, {'id': 'D000970', 'term': 'Antineoplastic Agents'}, {'id': 'D019653', 'term': 'Myeloablative Agonists'}, {'id': 'D000074322', 'term': 'Antineoplastic Agents, Immunological'}, {'id': 'D000082082', 'term': 'Immune Checkpoint Inhibitors'}, {'id': 'D018712', 'term': 'Analgesics, Non-Narcotic'}, {'id': 'D000700', 'term': 'Analgesics'}, {'id': 'D018689', 'term': 'Sensory System Agents'}, {'id': 'D018373', 'term': 'Peripheral Nervous System Agents'}], 'browseLeaves': [{'id': 'M6727', 'name': 'Cyclophosphamide', 'asFound': 'Tablet', 'relevance': 'HIGH'}, {'id': 'M283230', 'name': 'Fludarabine', 'asFound': 'Bone', 'relevance': 'HIGH'}, {'id': 'M1854', 'name': 'Nivolumab', 'asFound': 'Diagnostic', 'relevance': 'HIGH'}, {'id': 'M10411', 'name': 'Interleukin-2', 'asFound': 'Older Adults', 'relevance': 'HIGH'}, {'id': 'M225513', 'name': 'Fludarabine phosphate', 'relevance': 'LOW'}, {'id': 'M10212', 'name': 'Immunosuppressive Agents', 'relevance': 'LOW'}, {'id': 'M10201', 'name': 'Immunologic Factors', 'relevance': 'LOW'}, {'id': 'M20604', 'name': 'Antirheumatic Agents', 'relevance': 'LOW'}, {'id': 'M20942', 'name': 'Antineoplastic Agents, Alkylating', 'relevance': 'LOW'}, {'id': 'M3820', 'name': 'Alkylating Agents', 'relevance': 'LOW'}, {'id': 'M1346', 'name': 'Antineoplastic Agents, Immunological', 'relevance': 'LOW'}, {'id': 'M2342', 'name': 'Immune Checkpoint Inhibitors', 'relevance': 'LOW'}, {'id': 'M4032', 'name': 'Analgesics', 'relevance': 'LOW'}, {'id': 'M20786', 'name': 'Analgesics, Non-Narcotic', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'ANeo', 'name': 'Antineoplastic Agents'}, {'abbrev': 'ARhu', 'name': 'Antirheumatic Agents'}, {'abbrev': 'All', 'name': 'All Drugs and Chemicals'}, {'abbrev': 'Analg', 'name': 'Analgesics'}]}}, 'hasResults': False}\n",
      "Keys for NCT05351320:\n",
      "dict_keys(['protocolSection', 'derivedSection', 'hasResults'])\n",
      "Content for NCT05351320:\n",
      "{'protocolSection': {'identificationModule': {'nctId': 'NCT05351320', 'orgStudyIdInfo': {'id': 'FL006-IIT-002'}, 'organization': {'fullName': 'Shandong Cancer Hospital and Institute', 'class': 'OTHER'}, 'briefTitle': 'WX-0593 Combined With Concurrent Chemoradiotherapy in Unresectable Locally Advanced NSCLC', 'officialTitle': 'A Phase II Study of WX-0593 Combined With Concurrent Chemoradiotherapy in the Treatment of Unresectable Locally Advanced Non-small Cell Lung Cancer (NSCLC) With Activating Mutation of ALK or ROS1'}, 'statusModule': {'statusVerifiedDate': '2022-04', 'overallStatus': 'RECRUITING', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2022-04-30', 'type': 'ESTIMATED'}, 'primaryCompletionDateStruct': {'date': '2026-04-30', 'type': 'ESTIMATED'}, 'completionDateStruct': {'date': '2026-05-30', 'type': 'ESTIMATED'}, 'studyFirstSubmitDate': '2022-04-24', 'studyFirstSubmitQcDate': '2022-04-24', 'studyFirstPostDateStruct': {'date': '2022-04-28', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2022-04-24', 'lastUpdatePostDateStruct': {'date': '2022-04-28', 'type': 'ACTUAL'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR_INVESTIGATOR', 'investigatorFullName': 'Jinming Yu', 'investigatorTitle': 'Director of the hospital', 'investigatorAffiliation': 'Shandong Cancer Hospital and Institute'}, 'leadSponsor': {'name': 'Jinming Yu', 'class': 'OTHER'}}, 'oversightModule': {'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'descriptionModule': {'briefSummary': 'The aim of this trial is to evaluate the safety of WX-0593 combined with concurrent chemoradiotherapy in unresectable, locally advanced non-small cell lung cancer (NSCLC) with activating mutation of ALK or ROS1. This trial consists of two parts. In Part 1, approximately 8 patients will be included and receive WX-0593 maintenance until disease progression or unacceptable toxicity. In Part 2, approximately 32 patients will be included and receive WX-0593 monotherapy for 1-2 cycles and subsequently with concurrent chemoradiation, followed by WX-0593 maintenance until disease progression or unacceptable toxicity.'}, 'conditionsModule': {'conditions': ['Non-small Cell Lung Cancer (NSCLC)'], 'keywords': ['NSCLC, Unresectable , Radiochemotherapy, WX-0593']}, 'designModule': {'studyType': 'INTERVENTIONAL', 'phases': ['PHASE2'], 'designInfo': {'allocation': 'NA', 'interventionModel': 'SINGLE_GROUP', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 40, 'type': 'ESTIMATED'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'WX-0593 single arm', 'type': 'EXPERIMENTAL', 'description': 'Part 1: Participants will receive WX-0593 monotherapy until disease progression or unacceptable toxicity.\\n\\nPart 2: Participants will receive 1 or 2 cycles of WX-0593 monotherapy and subsequently with concurrent chemoradiation, followed by WX-0593 monotherapy until disease progression or unacceptable toxicity.', 'interventionNames': ['Drug: WX-0593 Tablets', 'Drug: chemotherapy', 'Radiation: Thoracic Radiation Therapy（TRT）']}], 'interventions': [{'type': 'DRUG', 'name': 'WX-0593 Tablets', 'description': 'WX-0593 60 mg, tablets, orally, once daily for 7 days, followed by WX-0593 180 mg, tablets, orally, once daily', 'armGroupLabels': ['WX-0593 single arm'], 'otherNames': ['Iruplinalkib']}, {'type': 'DRUG', 'name': 'chemotherapy', 'description': 'Platinum-based chemotherapy', 'armGroupLabels': ['WX-0593 single arm']}, {'type': 'RADIATION', 'name': 'Thoracic Radiation Therapy（TRT）', 'description': 'Five days a week to accept chest radiotherapy, once per day, every time 1.8-2.0 Gy, total dose 54-66 Gy', 'armGroupLabels': ['WX-0593 single arm']}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Percentage of Participants Who Develop Grade 3 or Higher drug-related Pneumonitis', 'timeFrame': 'within 90 days after radiation therapy'}], 'secondaryOutcomes': [{'measure': 'Progression Free Survival (PFS)', 'description': 'PFS is defined as the time from the first dose of study drug to the first documented disease progression or death due to any cause, whichever occurs first', 'timeFrame': '24 months'}, {'measure': 'Overall Survival (OS)', 'description': 'OS is defined as the time from the first dose of study drug to death due to any cause.', 'timeFrame': '24 months'}, {'measure': 'Adverse Events (AEs)', 'description': 'Percentage of participants who experienced one or more AEs.', 'timeFrame': '24 months'}, {'measure': 'Disease control rate (DCR)', 'timeFrame': '24 months'}, {'measure': 'Objective response rate (ORR)', 'timeFrame': '24 months'}]}, 'eligibilityModule': {'eligibilityCriteria': \"Inclusion Criteria:\\n\\n* Male or female aged 18 years or older;\\n* Pathologically confirmed NSCLC who present with investigator-assessed previously untreated, unresectable, locally advanced (Stage II、III) disease (according to TMN staging of AJCC version 8);\\n* Has active mutation of ALK or ROS1;\\n* Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-1;\\n* Has at least one evaluable lesion (according to RECIST 1.1);\\n* Have adequate pulmonary function test as a forced expiratory volume in 1 second (FEV1) \\\\>50% of predicted normal volume and carbon monoxide lung diffusing capacity (DLCO) \\\\>40% of predicted normal value;\\n* Have adequate organ and marrow function;\\n* If participant is a woman of childbearing potential (WOCBP), must agree to follow the contraceptive guidance from written informed consent until at least 180 days after the last dose of study treatment. The female participant should have negative serum pregnancy test within 7 days prior to the first dose of study drug, and not breastfeeding;\\n* A male participant must agree to use contraception from written informed consent until at least 180 days after the last dose of study treatment.\\n\\nExclusion Criteria:\\n\\n* Diagnosed other malignant tumor besides NSCLC within 5 years prior to study entry;\\n* Mixed small cell and non-small cell lung cancer histology;\\n* Has received prior therapy with any ALK TKI;\\n* Has a history of extensive diffuse/bilateral interstitial fibrosis, or grade 3 or 4 pulmonary fibrosis or interstitial lung disease prior to the first dose of study drug.\\n\\nHas a known history of active tuberculosis; severe infection within 4 weeks prior to study entry;\\n\\n* History of primary immunodeficiency;\\n* Active or prior documented autoimmune disease within the past 2 years. NOTE: Patients with vitiligo, Grave's disease, or psoriasis not requiring systemic treatment (within the past 2 years) are not excluded.\", 'healthyVolunteers': False, 'sex': 'ALL', 'minimumAge': '18 Years', 'stdAges': ['ADULT', 'OLDER_ADULT']}, 'contactsLocationsModule': {'centralContacts': [{'name': 'Jinming Yu, PhD', 'role': 'CONTACT', 'phone': '8613806406293', 'email': 'jn7984729@public.jn.sd.cn'}, {'name': 'Linlin Wang, PhD', 'role': 'CONTACT', 'phone': '8613793187739', 'email': 'wanglinlinatjn@163.com'}], 'locations': [{'facility': 'Shandong Cancer Hospital and Institute', 'status': 'RECRUITING', 'city': 'Jinan', 'state': 'Shandong', 'zip': '250117', 'country': 'China', 'contacts': [{'name': 'Jinming Yu, PhD', 'role': 'CONTACT'}], 'geoPoint': {'lat': 36.66833, 'lon': 116.99722}}]}}, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-08-21'}, 'conditionBrowseModule': {'meshes': [{'id': 'D008175', 'term': 'Lung Neoplasms'}, {'id': 'D002289', 'term': 'Carcinoma, Non-Small-Cell Lung'}], 'ancestors': [{'id': 'D012142', 'term': 'Respiratory Tract Neoplasms'}, {'id': 'D013899', 'term': 'Thoracic Neoplasms'}, {'id': 'D009371', 'term': 'Neoplasms by Site'}, {'id': 'D009369', 'term': 'Neoplasms'}, {'id': 'D008171', 'term': 'Lung Diseases'}, {'id': 'D012140', 'term': 'Respiratory Tract Diseases'}, {'id': 'D002283', 'term': 'Carcinoma, Bronchogenic'}, {'id': 'D001984', 'term': 'Bronchial Neoplasms'}], 'browseLeaves': [{'id': 'M11172', 'name': 'Lung Neoplasms', 'asFound': 'Lung Cancer', 'relevance': 'HIGH'}, {'id': 'M5546', 'name': 'Carcinoma, Non-Small-Cell Lung', 'asFound': 'Non-small Cell Lung Cancer', 'relevance': 'HIGH'}, {'id': 'M5534', 'name': 'Carcinoma', 'relevance': 'LOW'}, {'id': 'M14979', 'name': 'Respiratory Tract Neoplasms', 'relevance': 'LOW'}, {'id': 'M16658', 'name': 'Thoracic Neoplasms', 'relevance': 'LOW'}, {'id': 'M11168', 'name': 'Lung Diseases', 'relevance': 'LOW'}, {'id': 'M14977', 'name': 'Respiratory Tract Diseases', 'relevance': 'LOW'}, {'id': 'M5540', 'name': 'Carcinoma, Bronchogenic', 'relevance': 'LOW'}, {'id': 'M5260', 'name': 'Bronchial Neoplasms', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'BC04', 'name': 'Neoplasms'}, {'abbrev': 'BC08', 'name': 'Respiratory Tract (Lung and Bronchial) Diseases'}, {'abbrev': 'All', 'name': 'All Conditions'}]}}, 'hasResults': False}\n",
      "Keys for NCT07110259:\n",
      "dict_keys(['protocolSection', 'derivedSection', 'hasResults'])\n",
      "Content for NCT07110259:\n",
      "{'protocolSection': {'identificationModule': {'nctId': 'NCT07110259', 'orgStudyIdInfo': {'id': 'NSCLC-DeepGEM-RCT-2025'}, 'organization': {'fullName': 'The First Affiliated Hospital of Guangzhou Medical University', 'class': 'OTHER'}, 'briefTitle': 'AI-Based DeepGEM Tool for Predicting Gene Mutations in NSCLC Patients: A Randomized Controlled Study', 'officialTitle': 'Application of the Artificial Intelligence-Based Gene Mutation Prediction Tool DeepGEM in Patients With Non-Small Cell Lung Cancer (NSCLC): A Prospective, Multicenter, Randomized Controlled Trial'}, 'statusModule': {'statusVerifiedDate': '2025-07', 'overallStatus': 'NOT_YET_RECRUITING', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2025-07-31', 'type': 'ESTIMATED'}, 'primaryCompletionDateStruct': {'date': '2028-07-31', 'type': 'ESTIMATED'}, 'completionDateStruct': {'date': '2028-07-31', 'type': 'ESTIMATED'}, 'studyFirstSubmitDate': '2025-07-31', 'studyFirstSubmitQcDate': '2025-07-31', 'studyFirstPostDateStruct': {'date': '2025-08-07', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2025-07-31', 'lastUpdatePostDateStruct': {'date': '2025-08-07', 'type': 'ACTUAL'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR_INVESTIGATOR', 'investigatorFullName': 'Jianxing He', 'investigatorTitle': 'Clinical Professor', 'investigatorAffiliation': 'The First Affiliated Hospital of Guangzhou Medical University'}, 'leadSponsor': {'name': 'Jianxing He', 'class': 'OTHER'}, 'collaborators': [{'name': 'Guangzhou Kingmed Diagnostics Co., Ltd.', 'class': 'UNKNOWN'}]}, 'oversightModule': {'oversightHasDmc': False, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'descriptionModule': {'briefSummary': 'This prospective, multicenter, randomized controlled trial aims to evaluate the clinical utility of DeepGEM, an artificial intelligence (AI)-based mutation prediction tool based on histopathological whole-slide images, in patients with non-small cell lung cancer (NSCLC). The study will assess whether DeepGEM can facilitate molecular testing, increase targeted therapy utilization, and improve survival outcomes in a real-world clinical setting. Patients with stage II-IV treatment-naïve NSCLC and qualified pathology slides for DeepGEM analysis will be enrolled. Eligible participants with AI-predicted EGFR, ALK, or ROS1 mutations will be randomized in a 4:1 ratio to either the DeepGEM-informed group (clinicians can access AI results to guide further testing and treatment) or the standard care group (clinicians are blinded to AI results and follow routine care).'}, 'conditionsModule': {'conditions': ['Non Small Cell Lung Caner'], 'keywords': ['Artificial intelligence', 'gene mutations']}, 'designModule': {'studyType': 'INTERVENTIONAL', 'phases': ['NA'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'HEALTH_SERVICES_RESEARCH', 'maskingInfo': {'masking': 'SINGLE', 'whoMasked': ['INVESTIGATOR']}}, 'enrollmentInfo': {'count': 950, 'type': 'ESTIMATED'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'DeepGEM-Informed Group', 'type': 'EXPERIMENTAL', 'description': 'Participants whose clinicians are provided with DeepGEM-predicted mutation status (EGFR/ALK/ROS1). Physicians may choose to proceed with molecular testing and initiate targeted therapy based on AI predictions.', 'interventionNames': ['Other: DeepGEM-guided Molecular Testing and Treatment']}, {'label': 'Standard Care Group', 'type': 'ACTIVE_COMPARATOR', 'description': 'Participants whose clinicians do not receive DeepGEM prediction results and manage the case per standard diagnostic and treatment protocols without AI support.', 'interventionNames': ['Other: Standard Diagnostic Pathway']}], 'interventions': [{'type': 'OTHER', 'name': 'DeepGEM-guided Molecular Testing and Treatment', 'description': 'Artificial intelligence-based mutation prediction using DeepGEM to guide clinical decision-making for molecular testing and therapy selection.', 'armGroupLabels': ['DeepGEM-Informed Group']}, {'type': 'OTHER', 'name': 'Standard Diagnostic Pathway', 'description': 'DeepGEM is used for eligibility screening, but its results are withheld. Clinicians manage patients per standard diagnostic and treatment practices.', 'armGroupLabels': ['Standard Care Group']}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Overall Survival (OS)', 'description': 'Comparison of OS between the DeepGEM-informed group and the standard care group.', 'timeFrame': 'From randomization to death from any cause, assessed up to 36 months'}, {'measure': 'Targeted Therapy Utilization Rate', 'description': 'Proportion of participants receiving molecularly matched targeted therapies based on standard genetic testing.', 'timeFrame': 'Up to 6 months post-randomization'}], 'secondaryOutcomes': [{'measure': 'Molecular Testing Rate', 'description': 'Proportion of participants who undergo molecular testing after initial DeepGEM prediction.', 'timeFrame': 'Up to 3 months'}, {'measure': 'Prediction Concordance', 'description': 'Concordance between DeepGEM-predicted mutation status and results from PCR or NGS molecular testing.', 'timeFrame': 'Up to 3 months'}, {'measure': 'Cost-effectiveness of DeepGEM', 'description': 'Evaluation of cost per targeted therapy initiated and cost per life-year gained in the DeepGEM group versus standard care.', 'timeFrame': 'Up to 12 months'}]}, 'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\n\\n* Age between 18 and 75 years, inclusive, at the time of enrollment.\\n* Histologically or cytologically confirmed non-small cell lung cancer (NSCLC) with clinical stage II-IV as per the 8th edition of the AJCC staging system.\\n* Availability of qualified histopathological whole-slide images that can be reviewed through the KindMED system(DeepGEM).\\n* Successful mutation prediction of EGFR, ALK, or ROS1 by the DeepGEM AI tool.\\n* No prior systemic anti-cancer therapy, including chemotherapy, targeted therapy, or immunotherapy.\\n* Willing and able to comply with study requirements, including follow-up and treatment; written informed consent must be provided.\\n\\nExclusion Criteria:\\n\\n* Prior systemic anti-tumor therapy (chemotherapy, radiotherapy, targeted therapy-including but not limited to monoclonal antibodies or tyrosine kinase inhibitors) before enrollment.\\n* Failure of DeepGEM analysis or unqualified histopathological image quality.\\n* History of any other malignancy within the past 5 years, except for adequately treated basal cell carcinoma of the skin or in situ carcinoma (e.g., cervical carcinoma in situ).\\n* Cognitive or psychological barriers to understanding or accepting AI-based prediction or molecular testing.\\n* Pregnant or breastfeeding women, or women of childbearing potential who are not using effective contraception.\\n* Any other clinical condition that, in the opinion of the investigators, may interfere with the study protocol or compromise participant safety, including poor compliance with study procedures.', 'healthyVolunteers': False, 'sex': 'ALL', 'minimumAge': '18 Years', 'maximumAge': '75 Years', 'stdAges': ['ADULT', 'OLDER_ADULT']}, 'contactsLocationsModule': {'centralContacts': [{'name': 'Jianxing He, PhD', 'role': 'CONTACT', 'phone': '13802777270', 'email': 'hejx@vip.163.com'}, {'name': 'Wenhua Liang, PhD', 'role': 'CONTACT', 'phone': '13710249454', 'email': '550627660@qq.com'}]}, 'ipdSharingStatementModule': {'ipdSharing': 'NO'}}, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-08-21'}, 'conditionBrowseModule': {'browseLeaves': [{'id': 'M11172', 'name': 'Lung Neoplasms', 'relevance': 'LOW'}, {'id': 'M5546', 'name': 'Carcinoma, Non-Small-Cell Lung', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'BC04', 'name': 'Neoplasms'}, {'abbrev': 'BC08', 'name': 'Respiratory Tract (Lung and Bronchial) Diseases'}, {'abbrev': 'All', 'name': 'All Conditions'}]}}, 'hasResults': False}\n",
      "Keys for NCT04042558:\n",
      "dict_keys(['protocolSection', 'derivedSection', 'hasResults'])\n",
      "Content for NCT04042558:\n",
      "{'protocolSection': {'identificationModule': {'nctId': 'NCT04042558', 'orgStudyIdInfo': {'id': 'GFPC 06-2018'}, 'organization': {'fullName': 'Centre Francois Baclesse', 'class': 'OTHER'}, 'briefTitle': 'A Study Evaluating Platinum-Pemetrexed-Atezolizumab (+/-Bevacizumab) for Patients With Stage IIIB/IV Non-squamous Non-small Cell Lung Cancer With EGFR Mutations, ALK Rearrangement or ROS1 Fusion Progressing After Targeted Therapies', 'officialTitle': 'A Multicentre Phase II, Open-label, Non-randomized Study Evaluating Platinum-Pemetrexed-Atezolizumab (+/- Bevacizumab) for Patients With Stage IIIB/IV Non-squamous Non-small Cell Lung Cancer With EGFR Mutations, ALK Rearrangement or ROS1 Fusion Progressing After Targeted Therapies', 'acronym': 'GFPC 06-2018'}, 'statusModule': {'statusVerifiedDate': '2025-05', 'overallStatus': 'COMPLETED', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2019-09-26', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2021-10-22', 'type': 'ACTUAL'}, 'completionDateStruct': {'date': '2025-04-09', 'type': 'ACTUAL'}, 'studyFirstSubmitDate': '2019-07-29', 'studyFirstSubmitQcDate': '2019-08-01', 'studyFirstPostDateStruct': {'date': '2019-08-02', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2025-05-27', 'lastUpdatePostDateStruct': {'date': '2025-05-31', 'type': 'ACTUAL'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'}, 'leadSponsor': {'name': 'Centre Francois Baclesse', 'class': 'OTHER'}, 'collaborators': [{'name': 'GFPC', 'class': 'UNKNOWN'}]}, 'oversightModule': {'oversightHasDmc': True, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False, 'isUsExport': False}, 'descriptionModule': {'briefSummary': 'The objective of this study is to assess the efficacy of the combination of Platinum (carboplatin or cisplatin), Pemetrexed, Atezolizumab+/- Bevacizumab if eligible, in stage IIIB/IV non-squamous non-small cell lung cancer patients with progression-enhancing mutations following targeted therapies.', 'detailedDescription': 'In patients with an EGFR mutation, several phase III studies comparing EGFR tyrosine kinase inhibitors (TKIs) with chemotherapy have shown a benefit of TKI over chemotherapy, with no demonstrated benefit on overall survival. After a first line of treatment with a TKI, most patients progress and are eligible according to the mechanism of progression to a TKI of 3rd generation in case of T790M resistance or chemotherapy. In patients with ALK translocation, crizotinib has been shown to be beneficial in first line compared to a platinum doublet.Despite these major advances, most patients are progressing after targeted treatments and chemotherapy and are facing the problem of anti-PD1 / PDL1 treatment.'}, 'conditionsModule': {'conditions': ['NSCLC Stage IIIB', 'NSCLC Stage IV', 'EGFR Gene Mutation', 'ALK Gene Rearrangement Positive', 'ROS1 Gene Mutation']}, 'designModule': {'studyType': 'INTERVENTIONAL', 'phases': ['PHASE2'], 'designInfo': {'allocation': 'NON_RANDOMIZED', 'interventionModel': 'PARALLEL', 'interventionModelDescription': 'Open-label, multicentre, non-randomized two parallel cohorts phase II study', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 150, 'type': 'ACTUAL'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'Cohort with Bevacizumab', 'type': 'EXPERIMENTAL', 'description': '4 cycles of induction every 3 weeks with :\\n\\n* Carboplatin area under curve 6 mg/mL per minute per IV route or Cisplatin 75 mg/m² per IV route\\n* Pemetrexed 500 mg/m² per IV route\\n* Atezolizumab 1200 mg per IV route\\n* Bevacizumab 15 mg/kg per IV route For patients without disease progression, treatment will be followed by maintenance therapy by Atezolizumab + Pemetrexed and Bevacizumab administered at the same dosage on 3-week cycles', 'interventionNames': ['Drug: Carboplatin + Pemetrexed + Atezolizumab + Bevacizumab']}, {'label': 'Cohort without Bevacizumab', 'type': 'EXPERIMENTAL', 'description': '4 cycles of induction every 3 weeks with :\\n\\n* Carboplatin area under curve 6 mg/mL per minute per IV route or Cisplatin 75 mg/m² per IV route\\n* Pemetrexed 500 mg/m² per IV route\\n* Atezolizumab 1200 mg per IV route For patients without disease progression, treatment will be followed by maintenance therapy by Atezolizumab + Pemetrexed administered at the same dosage on 3-week cycles', 'interventionNames': ['Drug: Carboplatin + Pemetrexed + Atezolizumab']}], 'interventions': [{'type': 'DRUG', 'name': 'Carboplatin + Pemetrexed + Atezolizumab + Bevacizumab', 'description': '4 cycles of induction every 3 weeks of cisplatine,pemetrexed, atezolizumab + bevacizumab and patients without disease progression, treatment will be followed by maintenance therapy by Atezolizumab + Pemetrexed +/- Bevacizumab administered at the same dosage on 3-week cycles', 'armGroupLabels': ['Cohort with Bevacizumab']}, {'type': 'DRUG', 'name': 'Carboplatin + Pemetrexed + Atezolizumab', 'description': 'Carboplatin + Pemetrexed + Atezolizumab', 'armGroupLabels': ['Cohort without Bevacizumab']}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Objective response rate (ORR) according to RECIST 1.1', 'timeFrame': 'After the end of 4 cycles (15 weeks)'}], 'secondaryOutcomes': [{'measure': 'The progression-free survival (PFS)', 'timeFrame': '1 year'}, {'measure': 'The overall survival', 'timeFrame': '1 year'}, {'measure': 'The duration of response', 'timeFrame': '1 year'}]}, 'eligibilityModule': {'eligibilityCriteria': \"Inclusion Criteria:\\n\\n* Patient older than 18 years\\n* Subject affiliated to an appropriate social security system\\n* Signed informed consent before any trial related activities and according to local guidelines\\n* ECOG performance status of 0 or 1\\n* Histologically or cytologically confirmed, stage IIIB/IV non-squamous NSCLC (per the Union Internationale contre le Cancer/American Joint Committee on Cancer staging system, 7th edition).\\n* Patient with a sensitizing mutation in the EGFR gene must have experienced disease progression (during or after treatment) or intolerance to treatment with one or more EGFR TKIs, such as erlotinib, gefitinib, osimertinib or another EGFR TKI appropriate for the treatment of EGFR-mutant NSCLC. Patients with stage IIIB had to be not operable (that means not eligible for radiochemotherapy followed by a maintenance treatment by Durvalumab)\\n* Patient with an ALK fusion oncogene (confirmed in local laboratory) must have experienced disease progression (during or after treatment) or intolerance to treatment with one or more ALK inhibitors (i.e., crizotinib, alectinib, ceritinib) appropriate for the treatment of NSCLC in patients having an ALK fusion oncogene\\n* Patient with a ROS1 fusion oncogene (confirmed in local laboratory) must have experienced disease progression (during or after treatment) or intolerance to treatment with one or more ROS inhibitors (i.e., crizotinib,) appropriate for the treatment of NSCLC in patients having an ROS1 fusion oncogene\\n* No prior chemotherapy treatment for Stage IV non-squamous NSCLC except if less than 3 cycles, with treatment free-interval of at least 1 year from C1 since last chemotherapy\\n* Patient who has received prior neo-adjuvant, adjuvant chemotherapy, radiotherapy, or chemoradiotherapy with curative intent for non-metastatic disease must have experienced a treatment-free interval of at least 6 months from C1since the last chemotherapy, radiotherapy, or chemoradiotherapy\\n* Patient with an history of asymptomatic CNS metastases is eligible, provided he meets all of the following criteria:\\n\\n  * Only supratentorial and cerebellar metastases allowed (i.e., no metastases to midbrain, pons, medulla, or spinal cord)\\n  * No ongoing requirement for corticosteroids as therapy for CNS disease\\n  * No stereotactic radiation within 7 days or whole-brain radiation within 14 days prior to inclusion\\n* Measurable disease, as defined by RECIST v1.1\\n* Adequate hematologic and end-organ function, defined by the following laboratory\\n* Adequate method of contraception during the treatment period and at least 5 months after the last dose of atezolizumab or 6 months after the last dose of chemotherapy\\n\\nExclusion Criteria:\\n\\nCancer-specific exclusions\\n\\n* Active CNS metastases as determined by CT or magnetic resonance imaging (MRI) evaluation during screening and prior radiographic assessments\\n* Spinal cord compression not definitively treated with surgery and/or radiation or previously diagnosed and treated spinal cord compression without evidence that disease has been clinically stable for \\\\> or = 2 weeks prior to C1\\n* Leptomeningeal disease (Presence of cancer cells in cerebral CSF or MRI with leptomeningeal lesion strongly suspected of leptomeningeal disease )\\n* Uncontrolled tumour-related pain\\n* Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures (once monthly or more frequently); Patients with indwelling catheters (e.g., PleurX) are allowed.\\n* Uncontrolled or symptomatic hypercalcemia (\\\\>1.5 mmol/L ionized calcium or calcium \\\\>12 mg/dL or corrected serum calcium \\\\> ULN)\\n* Malignancies other than NSCLC within 5 years prior to C1, with the exception of those with a negligible risk of metastasis or death treated with expected curative outcome (such as adequately treated carcinoma in situ of the cervix, basal or squamous-cell skin cancer, localized prostate cancer treated surgically with curative intent, ductal carcinoma in situ treated surgically with curative intent)\\n\\nGeneral medical exclusions\\n\\n* Women who are pregnant, lactating, or intending to become pregnant during the study\\n* History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins\\n* Known hypersensitivity or allergy to biopharmaceuticals produced in Chinese hamster ovary cells or any component of the atezolizumab formulation\\n* History of autoimmune disease, including but not limited to myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis associated with antiphospholipid syndrome, Wegener's granulomatosis, Sjogren's syndrome, Guillain-Barré syndrome, multiple sclerosis, vasculitis, or glomerulonephritis\\n\\n  * Patients with a history of autoimmune-related hypothyroidism on a stable dose of thyroid replacement hormone are eligible for this study.\\n  * Patients with controlled Type 1 diabetes mellitus on a stable dose of insulin regimen are eligible for this study\\n  * Patients with eczema, psoriasis, lichen simplex chronicus, or vitiligo with dermatologic manifestations only are permitted provided that they meet the following conditions:\\n  * Rash must cover less than 10 percent of body surface area (BSA).\\n  * No acute exacerbations of underlying condition within the previous 12 months (not requiring PUVA \\\\[psoralen plus ultraviolet A radiation\\\\], methotrexate, retinoids, biologic agents, oral calcineurin inhibitors, high-potency or oral steroids)\\n* History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis on screening chest CT scan; History of radiation pneumonitis in the radiation field (fibrosis) is permitted.\\n* Positive test for HIV. All patients will be tested for HIV prior to C1 into the study; patients who test positive for HIV will be excluded from the study.\\n* Patients with active hepatitis B (chronic or acute; defined as having a positive hepatitis B surface antigen \\\\[HBsAg\\\\] test at screening) or hepatitis C. Patients with past hepatitis B virus (HBV) infection or resolved HBV infection (defined as the presence of hepatitis B core antibody \\\\[HBcAb\\\\] and absence of HBsAg) are eligible only if they are negative for HBV DNA. Patients positive for hepatitis C virus (HCV) antibody are eligible only if PCR is negative for HCV RNA.\\n* Active tuberculosis\\n* Severe infections within 4 weeks prior to C1, including, but not limited to, hospitalization for complications of infection, bacteremia, or severe pneumonia\\n* Received therapeutic oral or IV antibiotics within 1 week prior to C1; Patients receiving prophylactic antibiotics (e.g., for prevention of a urinary tract infection or to prevent chronic obstructive pulmonary disease exacerbation) are eligible.\\n* Significant cardiovascular disease, such as New York Heart Association cardiac disease (Class II or greater), myocardial infarction, or cerebrovascular accident within 3 months prior to inclusion, unstable arrhythmias, or unstable angina\\n* Major surgical procedure other than for diagnosis within 28 days prior to C1 or anticipation of need for a major surgical procedure during the course of the study\\n* Any other diseases, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that may affect the interpretation of the results or renders the patient at high risk from treatment complications\\n* Symptomatic brain metastases;\\n* Patients with illnesses or conditions that interfere with their capacity to understand, follow and/or comply with study procedures\\n* Concurrent participation in any therapeutic clinical trial\\n* Patient deprived of liberty or placed under the authority of a tutor\\n* Assessed by the investigator to be unable or unwilling to comply with the requirements of the protocol\\n\\nExclusion criteria related to medications\\n\\n* Any approved anti-cancer therapy, including hormonal therapy within 7 days prior to C1 of study treatment.\\n* Treatment with any other investigational agent with therapeutic intent within 28 days prior to C1\\n* Prior treatment with CD137 agonists or immune checkpoint blockade therapies, anti-PD-1, and anti-PD-L1 therapeutic antibodies\\n\\n  * Patients who have had prior anti-cytotoxic T-lymphocyte associated antigen 4 (CTLA-4) treatment may be enrolled, provided the following requirements are met:\\n  * Last dose of anti-CTLA-4 at least 6 weeks prior to C1\\n  * No history of severe immune-related adverse effects from anti-CTLA-4 (NCI CTCAE Grade 3/4)\\n* Treatment with systemic immunostimulatory agents (including, but not limited to, interferons, interleukin 2) within 4 weeks or 5 half-lives of the drug, whichever is longer, prior to C1 ; Prior treatment with cancer vaccines is allowed.\\n* Treatment with systemic immunosuppressive medications (including, but not limited to, corticosteroids, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor \\\\[anti-TNF\\\\] agents) within 2 weeks prior to C1\\n\\nExclusion criteria related to chemotherapy\\n\\n* History of allergic reactions to cisplatin, carboplatin, or other platinum-containing compounds\\n* Patients with hearing impairment (cisplatin)\\n* Grade \\\\> or = 2 peripheral neuropathy as defined by NCI CTCAE v5.0 (cisplatin)\\n* CRCL \\\\< 60 mL/min for cisplatin or \\\\< 45 mL/min for carboplatin using the Cockcroft-Gault Method\\n\\nExclusion criteria related to Bevacizumab\\n\\n* Medically uncontrolled hypertension (defined as PAS\\\\>150 and/or PAD \\\\>100 mmHg)\\n* Prior history of hypertensive crisis or hypertensive encephalopathy\\n* Clinically significant cardiovascular disease (within 6 months prior to C1) that is uncontrolled by medication or may interfere with administration of trial treatment:\\n\\n  * Aortic aneurysm requiring surgical repair\\n  * Recent arterial thrombosis\\n  * Haemoptysis (\\\\>one-half teaspoon of bright red blood per episode (within one months prior to C1) (grade 2 haemoptysis)\\n* History of documented haemorrhagic diathesis or coagulopathy\\n* History of abdominal or tracheosphageal fistula or perforation within 6 months prior to C1\\n* Core biopsy or other minor surgical procedure within 7 days before bevacizumab\\n* Clinical signs or gastrointestinal obstruction or requirement for routine parenteral hydration, nutrition or tube feeding\\n* Evidence of abdominal free air not explained by paracentesis or recent surgical procedure\\n* Major surgery within 28 days before C1\\n* Serious, non-healing wound, active ulcer or untreated bone fracture\\n* Proteinuria \\\\>1g/24h urine collection\\n* All patient with \\\\>2+ protein on dipstick urinalysis at baseline must undergo a 24-hour urine collection and must demonstrate \\\\< or = 1g of protein in 24 hours.\\n* Known sensitivity to any component of bevacizumab\\n* Radiation therapy within 21 days before C1 (except Symptomatic lesions amenable to palliative radiotherapy)\\n* Adequate hematologic, liver, and renal function required (including creatinine clearance 45 mL/min at baseline and 45 mL/min before the start of any subsequent cycle using the Cockcroft-Gault Method.\", 'healthyVolunteers': False, 'sex': 'ALL', 'minimumAge': '18 Years', 'maximumAge': '75 Years', 'stdAges': ['ADULT', 'OLDER_ADULT']}, 'contactsLocationsModule': {'locations': [{'facility': 'CHU', 'city': 'Angers', 'country': 'France', 'geoPoint': {'lat': 47.46667, 'lon': -0.55}}, {'facility': 'Centre Hospitalier', 'city': 'Annecy', 'country': 'France', 'geoPoint': {'lat': 45.9, 'lon': 6.11667}}, {'facility': 'CHU-Hôpital MORVAN', 'city': 'Brest', 'country': 'France', 'geoPoint': {'lat': 48.3903, 'lon': -4.48628}}, {'facility': 'CHU Lyon Louis Pradel', 'city': 'Bron', 'country': 'France', 'geoPoint': {'lat': 45.73333, 'lon': 4.91667}}, {'facility': 'Centre François Baclesse', 'city': 'Caen', 'zip': '14076', 'country': 'France', 'geoPoint': {'lat': 49.18585, 'lon': -0.35912}}, {'facility': 'CHU Gabriel MONTPIED', 'city': 'Clermont-Ferrand', 'country': 'France', 'geoPoint': {'lat': 45.77966, 'lon': 3.08628}}, {'facility': 'CHIC', 'city': 'Créteil', 'country': 'France', 'geoPoint': {'lat': 48.78333, 'lon': 2.46667}}, {'facility': 'CHU', 'city': 'Grenoble', 'country': 'France', 'geoPoint': {'lat': 45.16667, 'lon': 5.71667}}, {'facility': 'CHD Vendée La Roche sur Yon', 'city': 'La Roche sur Yon', 'country': 'France', 'geoPoint': {'lat': 46.66667, 'lon': -1.43333}}, {'facility': 'CHU Réunion St Denis', 'city': 'La Réunion', 'country': 'France', 'geoPoint': {'lat': 44.29707, 'lon': 0.11776}}, {'facility': 'CHU Réunion St Pierre', 'city': 'La Réunion', 'country': 'France', 'geoPoint': {'lat': 44.29707, 'lon': 0.11776}}, {'facility': 'CHU', 'city': 'Lille', 'country': 'France', 'geoPoint': {'lat': 50.63297, 'lon': 3.05858}}, {'facility': 'CHU Limoges', 'city': 'Limoges', 'country': 'France', 'geoPoint': {'lat': 45.83153, 'lon': 1.25781}}, {'facility': 'Centre Léon Bérard', 'city': 'Lyon', 'country': 'France', 'geoPoint': {'lat': 45.74848, 'lon': 4.84669}}, {'facility': 'CHU Lyon, Croix-Rousse,', 'city': 'Lyon', 'country': 'France', 'geoPoint': {'lat': 45.74848, 'lon': 4.84669}}, {'facility': 'Hôpital Nord', 'city': 'Marseille', 'country': 'France', 'geoPoint': {'lat': 43.29551, 'lon': 5.38958}}, {'facility': 'CHR Orléans', 'city': 'Orléans', 'country': 'France', 'geoPoint': {'lat': 47.90289, 'lon': 1.90389}}, {'facility': 'Hopital Foch', 'city': 'Paris', 'country': 'France', 'geoPoint': {'lat': 48.85341, 'lon': 2.3488}}, {'facility': 'institut Curie', 'city': 'Paris', 'country': 'France', 'geoPoint': {'lat': 48.85341, 'lon': 2.3488}}, {'facility': 'HIA Percy', 'city': 'Percy', 'country': 'France', 'geoPoint': {'lat': 48.91714, 'lon': -1.18916}}, {'facility': 'Hôpital Haut Lévêque,Centre François Magendie', 'city': 'Pessac', 'country': 'France', 'geoPoint': {'lat': 44.81011, 'lon': -0.64129}}, {'facility': 'CHU', 'city': 'Pierre-Bénite', 'country': 'France', 'geoPoint': {'lat': 45.7009, 'lon': 4.82511}}, {'facility': 'CHU', 'city': 'Rennes', 'country': 'France', 'geoPoint': {'lat': 48.11198, 'lon': -1.67429}}, {'facility': 'CHU', 'city': 'Rouen', 'country': 'France', 'geoPoint': {'lat': 49.44313, 'lon': 1.09932}}, {'facility': 'ICLN, St Priez en Jarez', 'city': 'Saint-Priest-en-Jarez', 'country': 'France', 'geoPoint': {'lat': 45.47501, 'lon': 4.37614}}, {'facility': 'Centre Paul Strauss', 'city': 'Strasbourg', 'country': 'France', 'geoPoint': {'lat': 48.58392, 'lon': 7.74553}}, {'facility': 'HIA St Anne', 'city': 'Toulon', 'country': 'France', 'geoPoint': {'lat': 43.12442, 'lon': 5.92836}}, {'facility': 'CHU', 'city': 'Toulouse', 'country': 'France', 'geoPoint': {'lat': 43.60426, 'lon': 1.44367}}, {'facility': 'Centre Hospitalier Bretagne Atlantique', 'city': 'Vannes', 'country': 'France', 'geoPoint': {'lat': 47.66667, 'lon': -2.75}}, {'facility': 'Centre Hospitalier', 'city': 'Villefranche', 'country': 'France'}, {'facility': 'HIA R.Picqué', 'city': \"Villenave-d'Ornon\", 'country': 'France', 'geoPoint': {'lat': 44.77327, 'lon': -0.5442}}]}}, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-08-21'}, 'conditionBrowseModule': {'meshes': [{'id': 'D002289', 'term': 'Carcinoma, Non-Small-Cell Lung'}], 'ancestors': [{'id': 'D002283', 'term': 'Carcinoma, Bronchogenic'}, {'id': 'D001984', 'term': 'Bronchial Neoplasms'}, {'id': 'D008175', 'term': 'Lung Neoplasms'}, {'id': 'D012142', 'term': 'Respiratory Tract Neoplasms'}, {'id': 'D013899', 'term': 'Thoracic Neoplasms'}, {'id': 'D009371', 'term': 'Neoplasms by Site'}, {'id': 'D009369', 'term': 'Neoplasms'}, {'id': 'D008171', 'term': 'Lung Diseases'}, {'id': 'D012140', 'term': 'Respiratory Tract Diseases'}], 'browseLeaves': [{'id': 'M11172', 'name': 'Lung Neoplasms', 'relevance': 'LOW'}, {'id': 'M5546', 'name': 'Carcinoma, Non-Small-Cell Lung', 'asFound': 'Non-small Cell Lung Cancer', 'relevance': 'HIGH'}, {'id': 'M5534', 'name': 'Carcinoma', 'relevance': 'LOW'}, {'id': 'M5540', 'name': 'Carcinoma, Bronchogenic', 'relevance': 'LOW'}, {'id': 'M5260', 'name': 'Bronchial Neoplasms', 'relevance': 'LOW'}, {'id': 'M14979', 'name': 'Respiratory Tract Neoplasms', 'relevance': 'LOW'}, {'id': 'M16658', 'name': 'Thoracic Neoplasms', 'relevance': 'LOW'}, {'id': 'M11168', 'name': 'Lung Diseases', 'relevance': 'LOW'}, {'id': 'M14977', 'name': 'Respiratory Tract Diseases', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'BC04', 'name': 'Neoplasms'}, {'abbrev': 'BC08', 'name': 'Respiratory Tract (Lung and Bronchial) Diseases'}, {'abbrev': 'All', 'name': 'All Conditions'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'D000068258', 'term': 'Bevacizumab'}, {'id': 'C000594389', 'term': 'Atezolizumab'}, {'id': 'D016190', 'term': 'Carboplatin'}, {'id': 'D000068437', 'term': 'Pemetrexed'}, {'id': 'D000911', 'term': 'Antibodies, Monoclonal'}], 'ancestors': [{'id': 'D000074322', 'term': 'Antineoplastic Agents, Immunological'}, {'id': 'D000970', 'term': 'Antineoplastic Agents'}, {'id': 'D020533', 'term': 'Angiogenesis Inhibitors'}, {'id': 'D043924', 'term': 'Angiogenesis Modulating Agents'}, {'id': 'D006133', 'term': 'Growth Substances'}, {'id': 'D045505', 'term': 'Physiological Effects of Drugs'}, {'id': 'D006131', 'term': 'Growth Inhibitors'}, {'id': 'D004791', 'term': 'Enzyme Inhibitors'}, {'id': 'D045504', 'term': 'Molecular Mechanisms of Pharmacological Action'}, {'id': 'D005493', 'term': 'Folic Acid Antagonists'}, {'id': 'D019384', 'term': 'Nucleic Acid Synthesis Inhibitors'}, {'id': 'D000082082', 'term': 'Immune Checkpoint Inhibitors'}, {'id': 'D007155', 'term': 'Immunologic Factors'}], 'browseLeaves': [{'id': 'M246', 'name': 'Bevacizumab', 'asFound': 'Test', 'relevance': 'HIGH'}, {'id': 'M18650', 'name': 'Carboplatin', 'asFound': 'Total', 'relevance': 'HIGH'}, {'id': 'M264', 'name': 'Pemetrexed', 'asFound': 'Assigned', 'relevance': 'HIGH'}, {'id': 'M6182', 'name': 'Cisplatin', 'relevance': 'LOW'}, {'id': 'M349417', 'name': 'Atezolizumab', 'asFound': 'Medicine', 'relevance': 'HIGH'}, {'id': 'M4225', 'name': 'Antibodies', 'relevance': 'LOW'}, {'id': 'M10184', 'name': 'Immunoglobulins', 'relevance': 'LOW'}, {'id': 'M4230', 'name': 'Antibodies, Monoclonal', 'asFound': 'Medicine', 'relevance': 'HIGH'}, {'id': 'M1346', 'name': 'Antineoplastic Agents, Immunological', 'relevance': 'LOW'}, {'id': 'M22318', 'name': 'Angiogenesis Inhibitors', 'relevance': 'LOW'}, {'id': 'M9231', 'name': 'Growth Inhibitors', 'relevance': 'LOW'}, {'id': 'M7951', 'name': 'Enzyme Inhibitors', 'relevance': 'LOW'}, {'id': 'M8618', 'name': 'Folic Acid', 'relevance': 'LOW'}, {'id': 'M17546', 'name': 'Vitamin B Complex', 'relevance': 'LOW'}, {'id': 'M8619', 'name': 'Folic Acid Antagonists', 'relevance': 'LOW'}, {'id': 'M2342', 'name': 'Immune Checkpoint Inhibitors', 'relevance': 'LOW'}, {'id': 'M10201', 'name': 'Immunologic Factors', 'relevance': 'LOW'}, {'id': 'T447', 'name': 'Folinic Acid', 'relevance': 'LOW'}, {'id': 'T475', 'name': 'Vitamin B9', 'relevance': 'LOW'}, {'id': 'T446', 'name': 'Folic Acid', 'relevance': 'LOW'}, {'id': 'T448', 'name': 'Folate', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'ANeo', 'name': 'Antineoplastic Agents'}, {'abbrev': 'All', 'name': 'All Drugs and Chemicals'}, {'abbrev': 'Micro', 'name': 'Micronutrients'}, {'abbrev': 'Hemat', 'name': 'Hematinics'}, {'abbrev': 'Vi', 'name': 'Vitamins'}]}}, 'hasResults': False}\n",
      "Keys for NCT03721120:\n",
      "dict_keys(['protocolSection', 'derivedSection', 'hasResults'])\n",
      "Content for NCT03721120:\n",
      "{'protocolSection': {'identificationModule': {'nctId': 'NCT03721120', 'orgStudyIdInfo': {'id': 'ET18-086 LIBELULE'}, 'organization': {'fullName': 'Centre Leon Berard', 'class': 'OTHER'}, 'briefTitle': 'Evaluation of the Feasibility and Clinical Relevance of Liquid Biopsy in Patients With Suspicious Metastatic Lung Cancer', 'officialTitle': 'A Randomized Phase III Clinical Trial to Evaluate the Feasibility and Clinical Relevance of Liquid Biopsy in Patients With Suspicious Metastatic Lung Cancer', 'acronym': 'LIBELULE'}, 'statusModule': {'statusVerifiedDate': '2025-08', 'overallStatus': 'COMPLETED', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2019-04-10', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2023-07-01', 'type': 'ACTUAL'}, 'completionDateStruct': {'date': '2023-07-01', 'type': 'ACTUAL'}, 'studyFirstSubmitDate': '2018-10-17', 'studyFirstSubmitQcDate': '2018-10-25', 'studyFirstPostDateStruct': {'date': '2018-10-26', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2025-08-07', 'lastUpdatePostDateStruct': {'date': '2025-08-08', 'type': 'ACTUAL'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'}, 'leadSponsor': {'name': 'Centre Leon Berard', 'class': 'OTHER'}}, 'oversightModule': {'oversightHasDmc': False, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False, 'isUsExport': False}, 'descriptionModule': {'briefSummary': 'Lung cancer is diagnosed at metastatic stage in 60% of the cases. For these patients, first-line treatment is based on histology and molecular characterization of non-squamous non-small cell lung cancer (NSCLC). Thus, quality and quantity of tumor tissue are crucial to determine the appropriate treatment (targeted therapies, chemotherapy and immunotherapy).\\n\\nHowever, in routine practice, tissue quality and quantity can be limited (25%), resulting in the need for tumor rebiopsy for molecular analysis. Therefore, lung cancer patients often experience substantial delays before treatment initiation that may be associated with worse patient experience of subsequent cancer care and poorer clinical outcomes.\\n\\n\"Liquid biopsies\" (LB) are used to detect genomic alterations in cell-free circulating DNA (cfDNA). Since very recently, they are routinely used in reference centers for the detection of EGFR-mutations when tissue is not sufficient for molecular characterization. Importantly, the feasibility and clinical relevance of systematic liquid biopsies in routine practice has never been evaluated in patients with suspicious advanced lung cancer.\\n\\nInvestigators hypothesize that using systematic LB in patients with clinical suspicion of metastatic lung cancer may reduce time-to-treatment initiation and avoid tissue rebiopsy.\\n\\nInvestigators performed a retrospective study including 250 NSCLC patients treated in a tertiary Cancer Center and in the University Hospital of Lyon, France. The mean time-to-appropriate frontline treatment initiation (TTI) was 42+/-22.5 days. With the use of LB at the time of first consultation, the investigators believe it is possible to reduce the mean TTI down to 33 days (21% reduction in TTI) in the overall population with suspicious metastatic lung cancer, including a 50% and 40% reduction in TTI for EGFR/ALK/ROS1/BRAF V600E subgroups and KRAS/LKB1/ERBB2/c-MET/BRAF non V600E subgroups, respectively.\\n\\nInvestigators therefore designed a \"real-life\" randomized study to evaluate the feasibility and clinical relevance of LB to decrease the TTI, which may in turn improve patients\\' outcome. Genomic analyses of circulating cfDNA will be performed using a robust and highly sensitive technology (InVision®), that profiles the presence of genomic aberrations in a panel of 35 genes including mutations, insertion/deletions and rearrangements, including all actionable alterations required to initiate the appropriate first-line therapy (EGFR-, ALK-, ROS1 and BRAF V600E).'}, 'conditionsModule': {'conditions': ['Metastatic Lung Cancer']}, 'designModule': {'studyType': 'INTERVENTIONAL', 'phases': ['NA'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'DIAGNOSTIC', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 319, 'type': 'ACTUAL'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'Liquid biopsy', 'type': 'EXPERIMENTAL', 'description': 'Liquid biopsy will be performed at the first visit using InVisionFirst®. Treatment will be determined by (i) genomic characterization in plasma for patients with druggable alteration in first-line, (ii) after pathology results (including assessment of PD-L1 level of expression by immunohistochemistry) for patients with an informative molecular characterization on plasma and no druggable alteration in first-line and (iii) after pathology results and tissue molecular characterization for the remaining patients.', 'interventionNames': ['Diagnostic Test: InvisionFirst® molecular panel']}, {'label': 'Cytological or histological sampling', 'type': 'NO_INTERVENTION', 'description': 'During the first visit, cytological or histological sampling will be planned and treatment will be initiated according to European Society of Medical Oncology (ESMO) recommendations; in case of a tissue sample inadequate for genomic characterization, physicians may resort to liquid biopsy according to their usual practice and available technology.'}], 'interventions': [{'type': 'DIAGNOSTIC_TEST', 'name': 'InvisionFirst® molecular panel', 'description': 'During the first visit, liquid biopsy will be performed using the InVisionFirst® panel. Cytological or histological sampling will be planned. According to InVisionFirst® results, treatment will be initiated:\\n\\n* regardless of cytological/histological and tissue molecular analysis in case of EGFR, BRAF V600E-mutation, ALK- or ROS1-rearrangement identified on InvisionFirst® panel.\\n* regardless of molecular characterization performed on tissue sample in case of ERBB2-, BRAF non V600E-, c-MET-, KRAS-,LKB1-, NTRK and/or RET mutation on InVisionFirst® panel. Treatment will be based on pathology results and if appropriate on PD-L1 level of expression.\\n* for patients with none of the previous alterations, treatment will be initiated after obtaining pathology results and genomic characterization from the tumor tissue analysis.', 'armGroupLabels': ['Liquid biopsy']}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Time-to-appropriate Treatment Initiation (TTI)', 'description': \"It is defined as the time between the date of randomization and the date of appropriate-treatment initiation (whatever the start date occurs before or after the biopsy results). As all the patients will receive an appropriate-treatment, no censored data are expected, thus the TTI will be analyzed as a continuous outcome. Appropriate treatment is defined as follow:\\n\\n* Based on contributive results on tissue OR liquid biopsy:\\n\\n  * EGFR- or BRAF V600E-mutations, ALK- or ROS1- rearrangements: specific targeted therapies\\n  * None of the four previous alterations: investigator's choice (chemotherapy and/or immunotherapy or targeted therapies based on pathology results, PD-L1 expression and access to therapies in the context of Temporary Used Authorization or clinical trials)\\n* In case of non-contributive results on tissue AND liquid biopsy: any treatment initiated by investigator (chemotherapy or immunotherapy based on pathology results and PD-L1 level of expression).\", 'timeFrame': 'From date of randomisation to start date of appropriate treatment , assessed up to 12 months'}], 'secondaryOutcomes': [{'measure': 'Rate of treatment initiated before molecular results', 'description': 'Defined as the proportion of patients with a treatment initiated without any available molecular results (tissue and liquid biopsy)', 'timeFrame': 'From date of randomisation to 12 months'}, {'measure': 'Time to availability of informative molecular pathology results', 'description': 'Defined as the time from randomization to date of availability of informative molecular pathology results (positive or negative).', 'timeFrame': 'From date of randomisation to date of molecular results, assessed up to 12 months'}, {'measure': 'Progression Free Survival (PFS)', 'description': 'Defined as the time from randomization to the date of the first documented clinical or radiological progression (as per RECIST version 1.1.) or death due to any cause.Patients who have not progressed or died at the time of analysis will be censored at the time of the latest date of assessment.', 'timeFrame': 'From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 30 months'}, {'measure': 'Incidence of diagnostic test-emergent adverse events', 'description': 'Safety assessed according to the National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) version5', 'timeFrame': 'From date of randomization to follow-up visit month 12 or death due to any cause, whichever came first, assessed up to 30 months'}, {'measure': \"The impact of cancer on the patient's quality of life using the European Organisation for Research and Treatment of Cancer (EORTC) quality-of-life core questionnaire (QLQ-C30)\", 'description': '64 questions related to cancer impact on health and daily activities composed this questionnaire. Each item has to be graded from 1 to 4 (1 = not at all, 4= very much). More the score is high, worst the quality of life is.', 'timeFrame': 'At baseline, at Day 21 post-baseline, at the time of treatment initiation (within 6 weeks after baseline), at 8 weeks post treatment initiation and every 3 months post initiation of treatment until 12 months'}, {'measure': 'Evaluation of lung cancer symptoms impact on health and daily activities using the Lung Cancer Symptoms Scale (LCSS) questionnaire', 'description': '10 questions related to lung cancer symptoms impact on health and daily activities composed this questionnaire. Each item has to be graded from 1 to 10. More the score is high, worst the quality of life is.', 'timeFrame': 'At baseline, at Day 21 post-baseline, at the time of treatment initiation (within 6 weeks after baseline), at 8 weeks post treatment initiation and every 3 months post initiation of treatment until 12 months'}, {'measure': 'Evaluation of anxiety and depression level using Hospital Anxiety and Depression (HAD)Scale', 'description': '6 questions related to anxiety and 6 questions related to depression composed this questionnaire. Each item has to be graded from 0 to 3. More the score of anxiety or depression is high, worst the quality of life is.', 'timeFrame': 'At baseline, at Day 21 post-baseline, at the time of treatment initiation (within 6 weeks after baseline), and at 8 weeks post treatment initiation'}, {'measure': 'Concordance between molecular status on tissue and liquid biopsies in the experimental arm', 'description': 'Evaluated by the proportion of discordances (error rates) between tissue and liquid biopsies for the mutational status.', 'timeFrame': 'From date of randomization to follow-up visit month 12 or death due to any cause, whichever came first, assessed up to 30 months'}, {'measure': 'Biopsy avoidance rate in the experimental arm', 'description': 'Be defined as the proportion of patients with an initial non-informative tissue biopsy and an informative liquid biopsy allowing appropriate treatment initiation without need for tissue rebiopsy.', 'timeFrame': 'From date of randomization to follow-up visit month 12 or death due to any cause, whichever came first, assessed up to 30 months'}, {'measure': 'The cost analysis', 'description': 'All costs items related to the stratégies and supported by the payers will be collected prospectively for each patient. Mean total costs will be calculated for the 2 stratégies and be compared between the arms.', 'timeFrame': 'From date of randomization to follow-up visit month 12 or death due to any cause, whichever came first, assessed up to 30 months'}, {'measure': 'The effectiveness analysis using the EuroQoL 5 Dimensions 5 Levels (EQ-5D-5L)', 'description': 'Preferences will be measured using EuroQoL 5 Dimensions 5 Levels questionnaire. Five attributes will therefore be investigated: mobility, self-care, usual activity, pain/discomfort, and anxiety/depression. Each attributes having five levels (from \"able to \\\\[...\\\\]\"/\"no pain/discomfort/anxiety/depression\" to \"unable to \\\\[...\\\\]\"/ \"extremely pain/discomfort/anxiety/depression\"). More the patient is unable to doing daily activities and painful/anxious, worst the quality-adjusted life-year (QALYs) is.', 'timeFrame': 'At baseline, at Day 21 post-baseline, at the time of treatment initiation (within 6 weeks after baseline), at 8 weeks post treatment initiation and every 3 months post initiation of treatment until 12 months'}, {'measure': 'QALYS comparaison between 2 arms', 'description': 'Mean QALYs (based on EQ-5D-5L score) will be calculated for each arm and will be compared between the 2 arms.', 'timeFrame': 'At baseline, at Day 21 post-baseline, at the time of treatment initiation (within 6 weeks after baseline), at 8 weeks post treatment initiation and every 3 months post initiation of treatment until 12 months'}, {'measure': 'The budget impact analysis in experimental arm', 'description': 'The Liquid biopsy using the InVisionFirst® cost, the evolution of market shares, the data pertaining to the target population, and the costs involved with treating the pathologies will be analysed to to estimate the budget impact on the French National Health Insurance of the generalization of innovative Liquid biopsy using the InVisionFirst® panel strategy.', 'timeFrame': 'From date of randomization to follow-up visit month 12 or death due to any cause, whichever came first, assessed up to 30 months'}, {'measure': 'Exploratory objectives : Whole-exome sequencing', 'description': 'Additional mandatory 10 ml DNA STRECK tubes will be collected for patients signing study consent.', 'timeFrame': 'At baseline, at the time of treatment initiation (within 6 weeks after baseline), at 8 weeks after the treatment initiation, and at the progression if occured within 12 month post-baseline.'}, {'measure': 'Exploratory objectives : miRNA profiling', 'description': 'Additional mandatory 10 ml RNA STRECK tubes will be collected for patients signing study consent.', 'timeFrame': 'At baseline, at the time of treatment initiation (within 6 weeks after baseline), at 8 weeks after the treatment initiation, and at the progression if occured within 12 month post-baseline.'}]}, 'eligibilityModule': {'eligibilityCriteria': \"Inclusion Criteria:\\n\\n* Age ≥ 18 years;\\n* Patients with clinico-radiological suspicious presentation of stage IV lung cancer;\\n* No prior chemotherapy for locally advanced or metastatic NSCLC;\\n* Eastern Cooperative Oncology Group (ECOG) Performance Status 0-2 (Appendix 2);\\n* Life expectancy \\\\> 12 weeks;\\n* No contraindication to systemic lung cancer treatment;\\n* Covered by a medical insurance;\\n* Signed informed consent prior to any study-specific procedure;\\n* No prior biopsy or cytology for lung cancer diagnosis.\\n\\nExclusion Criteria:\\n\\n* Pregnant or breastfeeding women;\\n* Patient concurrently using other approved or investigational antineoplastic agents;\\n* Major concurrent disease affecting cardiovascular system, liver, kidneys, hematopoietic system or else considered as clinically important by the investigator and that could be incompatible with patient's participation in this trial or would likely interfere with study procedures or results;\\n* Prior history of malignancies other than study disease (except for basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the cervix) unless the patient has been free of the disease for at least 3 years;\\n* Patient requiring tutorship or curatorship.\", 'healthyVolunteers': False, 'sex': 'ALL', 'minimumAge': '18 Years', 'stdAges': ['ADULT', 'OLDER_ADULT']}, 'contactsLocationsModule': {'locations': [{'facility': 'Centre Hospitalier de Bayeux', 'city': 'Bayeux', 'zip': '14400', 'country': 'France', 'geoPoint': {'lat': 49.27732, 'lon': -0.7039}}, {'facility': 'Hopital Louis Pradel', 'city': 'Bron', 'zip': '69677', 'country': 'France', 'geoPoint': {'lat': 45.73333, 'lon': 4.91667}}, {'facility': 'Centre François Baclesse', 'city': 'Caen', 'zip': '14000', 'country': 'France', 'geoPoint': {'lat': 49.18585, 'lon': -0.35912}}, {'facility': 'Centre Maurice Tubiana', 'city': 'Caen', 'zip': '14000', 'country': 'France', 'geoPoint': {'lat': 49.18585, 'lon': -0.35912}}, {'facility': 'Infirmerie Protestante', 'city': 'Caluire et Cuire', 'zip': '69641', 'country': 'France', 'geoPoint': {'lat': 45.79041, 'lon': 4.84112}}, {'facility': 'Centre Hospitalier Public du Cotentin', 'city': 'Cherbourg', 'zip': '50100', 'country': 'France', 'geoPoint': {'lat': 49.63984, 'lon': -1.61636}}, {'facility': 'CH Les Oudairies', 'city': 'La Roche-sur-Yon', 'zip': '85925', 'country': 'France', 'geoPoint': {'lat': 46.66667, 'lon': -1.43333}}, {'facility': 'Hôpital Privé Jean Mermoz', 'city': 'Lyon', 'zip': '69008', 'country': 'France', 'geoPoint': {'lat': 45.74848, 'lon': 4.84669}}, {'facility': 'Centre Leon Berard', 'city': 'Lyon', 'zip': '69373', 'country': 'France', 'geoPoint': {'lat': 45.74848, 'lon': 4.84669}}, {'facility': 'Groupe Hospitalier de la région de Mulhouse et Sud-Alsace', 'city': 'Mulhouse', 'zip': '68051', 'country': 'France', 'geoPoint': {'lat': 47.75, 'lon': 7.33333}}, {'facility': 'Centre Hospitalier Annecy Genevois', 'city': 'Pringy', 'zip': '74374', 'country': 'France', 'geoPoint': {'lat': 45.94622, 'lon': 6.12608}}, {'facility': 'Institut de Cancérologie Lucien Neuwirth', 'city': 'Saint-Priest-en-Jarez', 'zip': '42271', 'country': 'France', 'geoPoint': {'lat': 45.47501, 'lon': 4.37614}}, {'facility': 'CHRU Saint-Etienne', 'city': 'Saint-Étienne', 'zip': '42277', 'country': 'France', 'geoPoint': {'lat': 45.43389, 'lon': 4.39}}, {'facility': 'Centre Paul Strauss', 'city': 'Strasbourg', 'zip': '67065', 'country': 'France', 'geoPoint': {'lat': 48.58392, 'lon': 7.74553}}, {'facility': 'Hôpital Nord-Ouest', 'city': 'Villefranche-sur-Saône', 'zip': '69655', 'country': 'France', 'geoPoint': {'lat': 45.98333, 'lon': 4.71667}}, {'facility': 'Médiôle Lyon-Villeurbanne', 'city': 'Villeurbanne', 'zip': '69100', 'country': 'France', 'geoPoint': {'lat': 45.76667, 'lon': 4.88333}}]}}, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-08-21'}, 'conditionBrowseModule': {'meshes': [{'id': 'D008175', 'term': 'Lung Neoplasms'}], 'ancestors': [{'id': 'D012142', 'term': 'Respiratory Tract Neoplasms'}, {'id': 'D013899', 'term': 'Thoracic Neoplasms'}, {'id': 'D009371', 'term': 'Neoplasms by Site'}, {'id': 'D009369', 'term': 'Neoplasms'}, {'id': 'D008171', 'term': 'Lung Diseases'}, {'id': 'D012140', 'term': 'Respiratory Tract Diseases'}], 'browseLeaves': [{'id': 'M11172', 'name': 'Lung Neoplasms', 'asFound': 'Lung Cancer', 'relevance': 'HIGH'}, {'id': 'M14979', 'name': 'Respiratory Tract Neoplasms', 'relevance': 'LOW'}, {'id': 'M16658', 'name': 'Thoracic Neoplasms', 'relevance': 'LOW'}, {'id': 'M11168', 'name': 'Lung Diseases', 'relevance': 'LOW'}, {'id': 'M14977', 'name': 'Respiratory Tract Diseases', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'BC04', 'name': 'Neoplasms'}, {'abbrev': 'BC08', 'name': 'Respiratory Tract (Lung and Bronchial) Diseases'}, {'abbrev': 'All', 'name': 'All Conditions'}]}}, 'hasResults': False}\n",
      "Keys for NCT04777084:\n",
      "dict_keys(['protocolSection', 'derivedSection', 'hasResults'])\n",
      "Content for NCT04777084:\n",
      "{'protocolSection': {'identificationModule': {'nctId': 'NCT04777084', 'orgStudyIdInfo': {'id': 'LIVE'}, 'organization': {'fullName': 'Hunan Province Tumor Hospital', 'class': 'OTHER'}, 'briefTitle': 'The Efficacy and Safety of the Bispecific Anti-PD-1/PD-L1 Antibody IBI318 Combined with Lenvatinib in NSCLC.', 'officialTitle': 'A Prospective, Multi-cohort Clinical Research of Efficacy and Safety of Bispecific Anti-PD-1 / PD-L1 Antibody IBI318 Combined with Lenvatinib in the Treatment of Advanced NSCLC'}, 'statusModule': {'statusVerifiedDate': '2025-03', 'overallStatus': 'RECRUITING', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2021-08-01', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2024-12-30', 'type': 'ACTUAL'}, 'completionDateStruct': {'date': '2025-12-25', 'type': 'ESTIMATED'}, 'studyFirstSubmitDate': '2021-02-27', 'studyFirstSubmitQcDate': '2021-03-01', 'studyFirstPostDateStruct': {'date': '2021-03-02', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2025-03-03', 'lastUpdatePostDateStruct': {'date': '2025-03-05', 'type': 'ACTUAL'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'PRINCIPAL_INVESTIGATOR', 'investigatorFullName': 'Yongchang Zhang', 'investigatorTitle': 'Professor, Deputy Director of Thoracic Oncology Department', 'investigatorAffiliation': 'Hunan Province Tumor Hospital'}, 'leadSponsor': {'name': 'Hunan Province Tumor Hospital', 'class': 'OTHER'}}, 'oversightModule': {'oversightHasDmc': False, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False, 'isUsExport': False}, 'descriptionModule': {'briefSummary': 'The study is a prospective multi-cohort clinical study. Cohort A is evaluating the efficacy and safety of IBI318 in combined with lenvatinib in advanced NSCLC patients who had failed first-line PD-1/PD-L1 inhibitor therapy. Cohort B is the efficacy and safety of advanced NSCLC with EGFR-sensitive mutation /ALK fusion after EGFR-TKI /ALK-TKI treatment resistance. Cohort C is the efficacy and safety of first-line treatment of advanced NSCLC with negative PD-L1 expression and EGFR, ALK, and ROS1 wild-type. After being screened to meet the inclusion criteria, they will receive IBI318 combined with lenvatinib until the disease progresses, death, toxicity is intolerable, informed consent is withdrawn, new anti-tumor therapy is started, or the treatment is terminated for other reasons specified in the plan.', 'detailedDescription': 'The study is a prospective multi-cohort clinical study. Cohort A is evaluating the efficacy and safety of IBI318 in combined with lenvatinib in advanced NSCLC patients who had failed first-line PD-1/PD-L1 inhibitor therapy. Cohort B is the efficacy and safety of advanced NSCLC with EGFR-sensitive mutation /ALK fusion after EGFR-TKI /ALK-TKI treatment resistance. Cohort C is the efficacy and safety of first-line treatment of advanced NSCLC with negative PD-L1 expression and EGFR, ALK, and ROS1 wild-type.\\n\\nAfter being screened to meet the inclusion criteria, they will receive IBI318 combined with lenvatinib until the disease progresses, death, toxicity is intolerable, informed consent is withdrawn, new anti-tumor therapy is started, or the treatment is terminated for other reasons specified in the plan. During the treatment, RECIST v1.1 was used for clinical tumor imaging evaluation, once every 6 weeks; after 24 weeks of medication, evaluation can be done every 8 weeks.\\n\\nSubjects receiving IBI318 combined with lenvatinib have the first evidence of imaging PD according to RECIST v1.1. If the subject is clinically stable, there is no evidence of rapid imaging progress, and the investigator assesses that it can continue from the study If the patient is benefited from the drug, the subject can continue the current study treatment, and the imaging evaluation must be repeated at least 6 weeks (± 7 days) later for confirmation. If PD is confirmed by re-assessment, the subject should stop the study treatment; if PD is not confirmed, the study treatment will continue, and the assessment will be carried out at the time point of the imaging examination plan specified in the plan until the PD is confirmed by imaging.'}, 'conditionsModule': {'conditions': ['Non-Small Cell Lung Cancer']}, 'designModule': {'studyType': 'INTERVENTIONAL', 'phases': ['PHASE2'], 'designInfo': {'allocation': 'NON_RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 120, 'type': 'ESTIMATED'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'Cohort A', 'type': 'EXPERIMENTAL', 'description': 'Cohort A is evaluating the efficacy and safety of IBI318 in combined with lenvatinib in advanced NSCLC patients who had failed first-line PD-1/PD-L1 inhibitor therapy.', 'interventionNames': ['Drug: IBI318']}, {'label': 'Cohort B', 'type': 'EXPERIMENTAL', 'description': 'Cohort B is the efficacy and safety of advanced NSCLC with EGFR-sensitive mutation /ALK fusion after EGFR-TKI /ALK-TKI treatment resistance.', 'interventionNames': ['Drug: IBI318']}, {'label': 'Cohort C', 'type': 'EXPERIMENTAL', 'description': 'Cohort C is the efficacy and safety of first-line treatment of advanced NSCLC with negative PD-L1 expression and EGFR, ALK, and ROS1 wild-type.', 'interventionNames': ['Drug: IBI318']}], 'interventions': [{'type': 'DRUG', 'name': 'IBI318', 'description': 'IBI318, 300 mg, administered by intravenous infusion on the first day of each cycle, 1 cycle every 2 weeks (Q2W), continuous medication; lenvatinib 8 mg, orally, continued medication until disease progression, death, toxicity is intolerable, Withdrawal of informed consent, start a new anti-tumor treatment or terminate the treatment for other reasons specified in the plan, the maximum use time is 2 years.', 'armGroupLabels': ['Cohort A', 'Cohort B', 'Cohort C']}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': '12 weeks ORR', 'description': 'Defined as the proportion of subjects achieving a complete remission (CR) or partial remission (PR) at around 12 weeks after the start of study treatment among all subjects.', 'timeFrame': '1 year'}], 'secondaryOutcomes': [{'measure': 'PFS', 'description': 'Defined as the time from the beginning of treatment to the first imaging disease progression or death (whichever occurs first)', 'timeFrame': '1 year'}, {'measure': 'DCR', 'description': 'Defined as the proportion of subjects with complete remission (CR), partial remission (PR) and stable disease (SD) to the total subjects', 'timeFrame': '1 year'}, {'measure': 'DOR', 'description': 'Defined as the time interval from the first record of disease remission to disease progression or death (whichever occurs first)', 'timeFrame': '1 year'}, {'measure': 'OS', 'description': 'Defined as the time from the start of treatment to the death of the subject due to any cause.', 'timeFrame': '1 year'}, {'measure': 'BOR', 'description': 'Defined as the proportion of subjects in complete remission (CR) and partial remission (PR) to the total subjects', 'timeFrame': '1 year'}, {'measure': 'adverse events (safety)', 'description': 'Number of participants with adverse events (AEs) according to CTCAE 5.0', 'timeFrame': '1 year'}]}, 'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\n\\n* Eligible subjects selected for this study must meet all of the following criteria:\\n\\n  1. Sign written informed consent before implementing any trial-related procedures;\\n  2. Age ≥18 years old and ≤75 years old;\\n  3. No limit on the gender;\\n  4. Cohort A: histological or cytological confirmed locally advanced (IIIB-IIIC) or metastatic (stage IV) NSCLC (International Association for the Study of Lung Cancer and Joint Committee on the American Classification of Cancer, TNM Lung cancer stage 8) without EGFR gene sensitive mutations, ALK gene fusion or ROS1 gene fusion confirmed by histological specimens, Relapse after failure of first-line anti-PD-1 /PD-L1 antibody therapy, as follows:\\n\\n  <!-- -->\\n\\n  1. Only one anti-PD-1/PD-L1 antibody monotherapy or combination therapy is accepted in the advanced stage of the disease, and other immunotherapy is not allowed;\\n  2. Previous anti-PD-1/L1 antibody monotherapy or combination therapy has the best curative effect (according to RECIST 1.1 criteria) as partial remission, complete remission, or stable disease for ≥6 months (defined as within 6 months from the first medication) No disease progression has occurred);\\n  3. Disease progression confirmed by imaging studies occurred during or after the most recent treatment.\\n\\nCohort B: histological or cytological confirmed locally advanced (IIIB-IIIC) or metastatic (stage IV) NSCLC (International Association for the Study of Lung Cancer and Joint Committee on the American Classification of Cancer, TNM Lung cancer stage 8) with histologically confirmed EGFR-sensitive mutations or ALK fusion, Relapse after failure of anti-EGFR-TKI or ALK-TKI therapy, as follows:\\n\\nIn patients with EGFR-tKI sensitive mutations, the specific history of previous EGFR-TKI treatment can be one of the following:\\n\\n1. There is no T790M mutation in 20 exon after the failure of previous one or two generations of EGFR-TKI (including gefitinib, erlotinib, icotinib and afatinib);\\n2. The 20 exon T790M mutation occurred after the treatment failure of the first or second generation EGFR-TKI monotherapy (including gefitinib, erlotinib, icotinib, and afatinib, etc.), and disease progression recurred after treatment with osimertinib or other third generation EGFR-TKI;\\n3. Failure of prior osimertinib or other third-generation EGFR-TKI therapy as first-line therapy (regardless of EGFR T790M mutation status);\\n4. Those who are allowed to receive neoadjuvant/adjuvant targeted therapy in the early stage and develop drug resistance after subsequent adjuvant targeted therapy, and their drug resistance status meets one of the three requirements of appeal.\\n\\n   For patients with ALK fusion NSCLC, disease progression should occur after adequate ALK-TKI treatment, and there is no opportunity for subsequent targeted therapy.\\n\\n   Cohort C: Locally advanced NSCLC that is not suitable for radical surgery or radiotherapy, or that has relapsed without systematic treatment, or that has metastasized without systematic treatment and is negative for PD-L1 expression. Patients who have previously received neoadjuvant or adjuvant therapy can also receive neoadjuvant or adjuvant therapy (but neoadjuvant or adjuvant therapy is chemotherapy/radiotherapy, not immunotherapy), and the end of neoadjuvant/adjuvant therapy should be ≥6 months after tumor progression; If the pathological type is adenocarcinoma, the absence of EGFR-sensitive mutations or ALK fusion or ROS1 fusion should be confirmed. Negative expression of PD-L1 was defined as TPS \\\\<1% using 22C3 test.\\n\\n5. According to the evaluation criteria for the efficacy of solid tumors (RECIST v1.1 version), there is at least one imaging measurable lesion. The lesions located in the radiation field of the previous radiotherapy can be regarded as measurable lesions if the progress is confirmed; 6. Subjects with brain metastases asymptomatic or with stable symptoms after local treatment are allowed to be included in the group, as long as the subjects meet the following conditions:\\n\\n1. There are measurable lesions outside the central nervous system;\\n2. no symptoms of the central nervous system or no worsening of symptoms within at least 2 weeks;\\n3. No need for glucocorticoid therapy, or stop glucocorticoid therapy within 7 days before the first administration, or the dosage of glucocorticoid is stable and reduced to less than 10mg/day prednisone (or equivalent dose) within 7 days before the first administration ; 7. Subjects are allowed to receive palliative radiotherapy (including craniocerebral radiotherapy for symptomatic brain metastases), but the radiotherapy must be completed at least 1 week before enrollment, and the radiotherapy-related toxicity should be restored to less than or equal to 1 degree (CTCAE 5.0, except for hair loss).\\n\\n8. ECOG score 0-1 points; 9. Expected survival time\\\\> 3 months; 10. Sufficient organ function, subjects need to meet the following laboratory indicators:\\n\\n1. The absolute value of neutrophils (ANC) ≥1.5x109/L when no granulocyte colony-stimulating factor is used in the past 14 days;\\n2. In the case of no blood transfusion in the past 14 days, platelets ≥100×109/L;\\n3. In the past 14 days without blood transfusion or erythropoietin, hemoglobin\\\\>9g/dL;\\n4. Total bilirubin≤1.5×upper limit of normal (ULN);\\n5. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) within ≤2.5×ULN (subjects with liver metastases are allowed to have ALT or AST ≤5×ULN);\\n6. Serum creatinine ≤1.5×ULN and creatinine clearance rate (calculated by Cockcroft-Gault formula) ≥50ml/min;\\n7. Good coagulation function, defined as International Normalized Ratio (INR) or Prothrombin Time (PT) ≤ 1.5 times ULN;\\n8. Normal thyroid function is defined as thyroid-stimulating hormone (TSH) within the normal range. If the baseline TSH is out of the normal range, subjects whose total T3 (or FT3) and FT4 are within the normal range can also be included in the group;\\n9. Myocardial enzyme spectrum is within the normal range (for example, simple laboratory abnormalities that are judged by the investigator to be of no clinical significance are also allowed to be included in the group); 11. For female subjects of childbearing age, a urine or serum pregnancy test and the result should be negative within 3 days before receiving the first study drug administration (day 1 of cycle 1). If the urine pregnancy test result cannot be confirmed as negative, a blood pregnancy test is required. Women of non-bearing age are defined as at least 1 year after menopause, or have undergone surgical sterilization or hysterectomy; 12. If there is a risk of conception, all subjects (whether male or female) need to adopt a low annual failure rate during the entire treatment period until 120 days after the last study drug administration (or 180 days after the last study drug administration) Less than 1% of contraceptive measures; 13. Blood pressure can be adequately controlled with or without anti hypertensive medication, defined as blood pressure≤150/ 90 mm Hg, and blood pressure was under stable control within 1 week before randomization.\\n\\n14. Patients must have recovered from toxicity or complications if they have previously received surgery or radiation \\\\> 30Gy.\\n\\nExclusion Criteria:\\n\\n* Subjects who meet the following criteria cannot be selected for this study:\\n\\n  1. The pathology is small cell lung cancer (SCLC), including lung cancer mixed with SCLC and NSCLC;\\n  2. There is imaging evidence of tumor voids, tumor inclusion or invasion of large vessels. In addition, the proximity of the tumor to the large blood duct should be considered and the risk of severe bleeding associated with tumor shrinkage/necrosis after lenvatinib treatment should be excluded. (The large vessels in the chest include the main pulmonary artery, left pulmonary artery, right pulmonary artery, 4 pulmonary veins, superior vena cava, inferior vena cava and aorta);\\n  3. To cohort A: subjects who have previously used anti-PD-1, PD-L1 or other immunotherapy and meet the following conditions:\\n\\n  <!-- -->\\n\\n  1. The toxicity that caused permanent discontinuation occurred before the termination of immunotherapy;\\n  2. Prior to the administration of the study drug, the toxicity of the previous immunotherapy has not recovered or has not recovered to level 0-1. Asymptomatic and stable control of endocrine toxicity level 2 with appropriate replacement therapy is allowed to enter the group;\\n  3. Adverse events that require additional immunosuppressive agents in addition to corticosteroids, or adverse events that still recur in the use of corticosteroids during previous immunotherapy.\\n\\nTo cohort B and C: Prior treatment: anti-PD-1, anti-PD-L1, or anti-PD-L2 drugs or drugs that target another stimulating or co-inhibiting T-cell receptor (including but not limited to CTLA-4, OX-40, CD137, etc.); Anti-pd-1, anti-PD-L1, or anti-PD-L2 drugs or drugs that target another stimulating or co-inhibiting T cell receptor (including but not limited to CTLA-4, OX-40, CD137, etc.); 4. Have received the following treatments:\\n\\n1. Received systemic anti-tumor therapy within 2 weeks before treatment, such as chemotherapy, targeted therapy, immunotherapy (including Chinese herbal medicine with anti-tumor indications), etc.;\\n2. Previously received lenvatinib, bevacizumab, anlotinib monotherapy, or in combination with anti-PD-1 / PD-L1 drugs\\n3. Have received any investigational drug treatment within 4 weeks before treatment;\\n4. Received large doses of immunosuppressive drugs within 4 weeks before treatment (systemic glucocorticoid exceeding 10mg/day prednisone or its equivalent dose);\\n5. Received live attenuated vaccine within 4 weeks before treatment (or plan to receive live attenuated vaccine during the study period);\\n6. Have received major surgery (such as open cavity, thoracotomy, or Kaifu surgery), or unhealed surgical wounds, ulcers or fractures within 4 weeks before treatment.\\n\\n5. Clinically significant cardiovascular damage occurred within 12 months of the first dose of study treatment.\\n\\n6. Gastrointestinal diseases that may affect oral absorption of study drugs. 7. Prior gastrointestinal or grade ≥3 non-gastrointestinal fistula. 8. A history of other malignancies is known, and unless the participant has undergone potentially curative treatment, there is no evidence of disease recurrence in the 3 years since the start of that treatment.\\n\\n9. Severe allergy to IBI318 and lenvatinib. 10. There is clinically uncontrollable pleural effusion/abdominal effusion (subjects who do not need to drain the effusion or stop drainage for 3 days without a significant increase in effusion can be included in the group); 11. Subjects who have received thoracic radiotherapy of greater than 30 Gy within 6 months before treatment or palliative radiotherapy of 30 Gy or less within 7 days before treatment (allowing palliative treatment of bone lesions or intracranial lesions) Radiation Therapy); 12. An active autoimmune disease that requires systemic treatment (such as the use of disease-relieving drugs, glucocorticoids, or immunosuppressive agents) occurred within 2 years before the first administration. Alternative therapies (such as thyroxine, insulin, or physiological glucocorticoids for adrenal or pituitary insufficiency, etc.) are not considered systemic treatments; 13. Known allogeneic organ transplantation (except corneal transplantation) or allogeneic hematopoietic stem cell transplantation; 14. Before starting treatment, have not fully recovered from toxicity and/or complications caused by any intervention (ie, ≤ Grade 1 or reached baseline, excluding fatigue or hair loss); 15. Known history of human immunodeficiency virus (HIV) infection (ie HIV 1/2 antibody positive); 16. Untreated active hepatitis B (defined as HBsAg positive and the number of HBV-DNA copies detected at the same time is greater than the upper limit of the normal value of the laboratory department of the research center);\\n\\nNote: Hepatitis B subjects who meet the following criteria can also be included in the group:\\n\\n1. Before the first administration, the HBV viral load is less than 1000 copies/ml (200 IU/ml), and the subject should receive anti-HBV treatment during the entire study chemotherapy drug treatment to avoid viral reactivation\\n2. For subjects with anti-HBc (+), HBsAg (-), anti-HBs (-) and HBV viral load (-), there is no need to receive preventive anti-HBV treatment, but close monitoring of virus reactivation is required 17. Active HCV infected subjects (HCV antibody-positive and HCV-RNA level is higher than the lower limit of detection); 18. Live vaccines have been vaccinated within 30 days before the first administration (cycle 1, day 1); Note: It is allowed to receive inactivated virus vaccine for seasonal influenza injection within 30 days before the first administration; however, it is not allowed to receive live attenuated influenza vaccine for intranasal administration.\\n\\n19. Pregnant or lactating women; 20. There are any serious or uncontrollable systemic diseases, such as:\\n\\n1. The resting electrocardiogram has major abnormalities in rhythm, conduction or morphology that are severe and difficult to control, such as complete left bundle branch block, heart block above degree II, ventricular arrhythmia or atrial fibrillation;\\n2. Left ventricular ejection fraction (LVEF) was lower than normal; 3）QTc interval is extended to more than 480 ms；\\n\\n4) Unstable angina pectoris, congestive heart failure, chronic heart failure of New York Heart Association (NYHA) grade ≥ 2; 5) Myocardial infarction occurred within 6 months before enrollment; 6) A history of non-infectious pneumonia requiring glucocorticoid treatment within 1 year before the first administration, or current clinically active interstitial lung disease; 7) Active tuberculosis; 8) There is an active or uncontrolled infection that requires systemic treatment; 9) There is clinically active diverticulitis, abdominal abscess, gastrointestinal obstruction; 10) Liver diseases such as liver cirrhosis, decompensated liver disease, acute or chronic active hepatitis; 11) Poor control of diabetes (fasting blood glucose (FBG)\\\\> 10mmol/L); 12) Urine routines suggest that urine protein is ≥++, and the 24-hour urine protein quantification is confirmed to be greater than 1.0 g; 13) Subjects who have mental disorders and cannot cooperate with treatment; 21. The medical history or disease evidence, abnormal treatment or laboratory test values that may interfere with the test results, prevent the subject from participating in the study, or the investigator believes that it is not suitable for inclusion this research.', 'healthyVolunteers': False, 'sex': 'ALL', 'minimumAge': '18 Years', 'maximumAge': '75 Years', 'stdAges': ['ADULT', 'OLDER_ADULT']}, 'contactsLocationsModule': {'centralContacts': [{'name': 'Yongchang Yongchang, MD', 'role': 'CONTACT', 'phone': '+8613873123436', 'phoneExt': '7+861383123436', 'email': 'zhangyongchang@csu.edu.cn'}, {'name': 'Nong Yang, MD', 'role': 'CONTACT', 'phone': '+8613055193557', 'phoneExt': '+8613873123436', 'email': 'yangnong0217@163.com'}], 'overallOfficials': [{'name': 'Yongchang Zhang, MD', 'affiliation': 'Hunan Cancer Hospital', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'locations': [{'facility': 'Hunan Cancer hospital', 'status': 'RECRUITING', 'city': 'Changsha', 'state': 'Hunan', 'country': 'China', 'contacts': [{'name': 'Yongchang Zhang, MD', 'role': 'CONTACT', 'phone': '+86 731 89762321', 'email': 'zhangyongchang@csu.edu.cn'}], 'geoPoint': {'lat': 28.19874, 'lon': 112.97087}}]}, 'ipdSharingStatementModule': {'ipdSharing': 'NO'}}, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-08-21'}, 'conditionBrowseModule': {'meshes': [{'id': 'D002289', 'term': 'Carcinoma, Non-Small-Cell Lung'}], 'ancestors': [{'id': 'D002283', 'term': 'Carcinoma, Bronchogenic'}, {'id': 'D001984', 'term': 'Bronchial Neoplasms'}, {'id': 'D008175', 'term': 'Lung Neoplasms'}, {'id': 'D012142', 'term': 'Respiratory Tract Neoplasms'}, {'id': 'D013899', 'term': 'Thoracic Neoplasms'}, {'id': 'D009371', 'term': 'Neoplasms by Site'}, {'id': 'D009369', 'term': 'Neoplasms'}, {'id': 'D008171', 'term': 'Lung Diseases'}, {'id': 'D012140', 'term': 'Respiratory Tract Diseases'}], 'browseLeaves': [{'id': 'M11172', 'name': 'Lung Neoplasms', 'relevance': 'LOW'}, {'id': 'M5546', 'name': 'Carcinoma, Non-Small-Cell Lung', 'asFound': 'Non-small Cell Lung Cancer', 'relevance': 'HIGH'}, {'id': 'M5534', 'name': 'Carcinoma', 'relevance': 'LOW'}, {'id': 'M5540', 'name': 'Carcinoma, Bronchogenic', 'relevance': 'LOW'}, {'id': 'M5260', 'name': 'Bronchial Neoplasms', 'relevance': 'LOW'}, {'id': 'M14979', 'name': 'Respiratory Tract Neoplasms', 'relevance': 'LOW'}, {'id': 'M16658', 'name': 'Thoracic Neoplasms', 'relevance': 'LOW'}, {'id': 'M11168', 'name': 'Lung Diseases', 'relevance': 'LOW'}, {'id': 'M14977', 'name': 'Respiratory Tract Diseases', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'BC04', 'name': 'Neoplasms'}, {'abbrev': 'BC08', 'name': 'Respiratory Tract (Lung and Bronchial) Diseases'}, {'abbrev': 'All', 'name': 'All Conditions'}]}, 'interventionBrowseModule': {'browseLeaves': [{'id': 'M4225', 'name': 'Antibodies', 'relevance': 'LOW'}, {'id': 'M10184', 'name': 'Immunoglobulins', 'relevance': 'LOW'}, {'id': 'M353738', 'name': 'Lenvatinib', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'All', 'name': 'All Drugs and Chemicals'}, {'abbrev': 'ANeo', 'name': 'Antineoplastic Agents'}]}}, 'hasResults': False}\n"
     ]
    }
   ],
   "source": [
    "# Show NCT07020221 keys\n",
    "for nct_id in nct_ids:\n",
    "    nct_file = f\"{nct_id}.json\"\n",
    "    with open(nct_file, 'r') as file:\n",
    "        nct_content = json.load(file)\n",
    "    # Print the keys of the specific NCT ID\n",
    "    print(f\"Keys for {nct_id}:\")\n",
    "    print(nct_content.keys())\n",
    "\n",
    "    # Print the content of the specific NCT ID\n",
    "    print(f\"Content for {nct_id}:\")\n",
    "    print(nct_content)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "/scratch/mgeorges/conda_envs/unsloth_env/lib/python3.11/site-packages/tqdm/auto.py:21: TqdmWarning: IProgress not found. Please update jupyter and ipywidgets. See https://ipywidgets.readthedocs.io/en/stable/user_install.html\n",
      "  from .autonotebook import tqdm as notebook_tqdm\n",
      "/scratch/mgeorges/conda_envs/unsloth_env/lib/python3.11/site-packages/transformers/utils/hub.py:105: FutureWarning: Using `TRANSFORMERS_CACHE` is deprecated and will be removed in v5 of Transformers. Use `HF_HOME` instead.\n",
      "  warnings.warn(\n"
     ]
    }
   ],
   "source": [
    "from sklearn.cluster import KMeans, DBSCAN\n",
    "from sklearn.metrics.pairwise import cosine_similarity\n",
    "import numpy as np\n",
    "from sklearn.neighbors import NearestNeighbors\n",
    "\n",
    "from transformers import AutoTokenizer, AutoModel\n",
    "import torch\n",
    "import numpy as np\n",
    "\n",
    "# Load the BiomedBERT model and tokenizer\n",
    "model_name = \"/scratch/mgeorges/TrialMatchAI/TrialMatchAI/models/models/biomedner_multi\"\n",
    "tokenizer = AutoTokenizer.from_pretrained(model_name, local_files_only=True)\n",
    "model = AutoModel.from_pretrained(model_name, local_files_only=True)\n",
    "\n",
    "# Load model and tokenizer\n",
    "\"\"\" model_name = \"microsoft/BiomedNLP-PubMedBERT-base-uncased-abstract-fulltext\"\n",
    "tokenizer = AutoTokenizer.from_pretrained(model_name)\n",
    "model = AutoModel.from_pretrained(model_name) \"\"\"\n",
    "\n",
    "# Function to encode text into embeddings\n",
    "def encode_text(text, tokenizer, model):\n",
    "    # Tokenize the input text\n",
    "    inputs = tokenizer(text, return_tensors=\"pt\", truncation=True, padding=True, max_length=512)\n",
    "    with torch.no_grad():\n",
    "        outputs = model(**inputs)\n",
    "    # Mean pooling to get a single embedding vector\n",
    "    embeddings = outputs.last_hidden_state.mean(dim=1).squeeze().numpy()\n",
    "    return embeddings\n",
    "\n",
    "def encode_text_with_sliding_window(text, tokenizer, model, max_length=512, stride=256):\n",
    "    # Tokenize the text into chunks\n",
    "    inputs = tokenizer(\n",
    "        text,\n",
    "        return_tensors=\"pt\",\n",
    "        truncation=True,\n",
    "        padding=True,\n",
    "        max_length=max_length,\n",
    "        stride=stride,\n",
    "        return_overflowing_tokens=True,\n",
    "        return_offsets_mapping=False,\n",
    "    )\n",
    "    \n",
    "    # Extract only the relevant inputs for the model\n",
    "    input_ids = inputs[\"input_ids\"]\n",
    "    attention_mask = inputs[\"attention_mask\"]\n",
    "\n",
    "    # Process each chunk and aggregate embeddings\n",
    "    with torch.no_grad():\n",
    "        outputs = model(input_ids=input_ids, attention_mask=attention_mask)\n",
    "    \n",
    "    # Mean pooling across all chunks\n",
    "    chunk_embeddings = outputs.last_hidden_state.mean(dim=1)  # Mean pooling for each chunk\n",
    "    aggregated_embedding = chunk_embeddings.mean(dim=0).squeeze().numpy()  # Aggregate across chunks\n",
    "    return aggregated_embedding\n",
    "\n",
    "def preprocess_text(content):\n",
    "    # Extract relevant fields\n",
    "    if 'protocolSection' in content:\n",
    "        content = content['protocolSection']\n",
    "        if 'eligibilityModule' in content:\n",
    "            eligibility = content['eligibilityModule'].get('eligibilityCriteria', '')\n",
    "            conditions = content['conditionsModule'].get('condition', '')\n",
    "            locations = content['eligibilityModule'].get('location', '')\n",
    "            brief_title = content['identificationModule'].get('briefTitle', '')\n",
    "            brief_summary = content['descriptionModule'].get('briefSummary', '')\n",
    "            detailed_description = content['descriptionModule'].get('detailedDescription', '')\n",
    "    else:\n",
    "        eligibility = content.get('eligibility_criteria', '')\n",
    "        conditions = content.get('condition', '')\n",
    "        locations = content.get('location', '')\n",
    "        brief_title = content.get('brief_title', '')\n",
    "        brief_summary = content.get('brief_summary', '')\n",
    "\n",
    "    # Check if any field is empty and print a warning\n",
    "    if not (eligibility or conditions or brief_summary or detailed_description):\n",
    "        print(f\"Warning: No relevant fields found in content: {content}\")\n",
    "        if not brief_summary:\n",
    "            brief_summary = \"No brief summary provided.\"\n",
    "        if not eligibility:\n",
    "            eligibility = \"No eligibility criteria provided.\"\n",
    "        if not conditions:\n",
    "            conditions = \"No conditions provided.\"\n",
    "        if not detailed_description:\n",
    "            detailed_description = \"No detailed description provided.\"\n",
    "\n",
    "    # Concatenate fields into a single string\n",
    "    combined_text = f\"{brief_summary} {conditions}\"\n",
    "    return combined_text\n",
    "\n",
    "def extract_vectors(json_contents):\n",
    "    # Create vectors from eligibility criteria text\n",
    "    enriched_vectors = []\n",
    "    for idx, content in enumerate(json_contents):  # Assuming json_contents contains your trial data\n",
    "        combined_text = preprocess_text(content)\n",
    "        combined_text = gene_mutations[idx] * 3 + \" \" + combined_text  # Add gene mutation to the text\n",
    "        embedding = encode_text_with_sliding_window(combined_text, tokenizer, model)\n",
    "        enriched_vectors.append(embedding)\n",
    "\n",
    "    return np.array(enriched_vectors)\n",
    "\n",
    "# Step 2: Normalize vectors\n",
    "def normalize_vectors(vectors):\n",
    "    norms = np.linalg.norm(vectors, axis=1, keepdims=True)\n",
    "    return vectors / norms\n",
    "\n",
    "# Step 3: Perform KNN clustering\n",
    "def knn_clustering(vectors, n_neighbors):\n",
    "    knn = NearestNeighbors(n_neighbors=n_neighbors, metric='cosine')\n",
    "    knn.fit(vectors)\n",
    "    distances, indices = knn.kneighbors(vectors)\n",
    "    return distances, indices\n",
    "\n",
    "def kmeans_clustering(vectors, n_clusters, dbscan=False):\n",
    "    # Add DBScan\n",
    "    if dbscan:\n",
    "        clustering = DBSCAN(eps=0.3, min_samples=10, metric='cosine')\n",
    "        labels = clustering.fit_predict(vectors)\n",
    "        return labels\n",
    "    kmeans = KMeans(n_clusters=n_clusters, random_state=42)\n",
    "    labels = kmeans.fit_predict(vectors)\n",
    "    return labels\n",
    "\n",
    "# Step 4: Validate cluster tightness\n",
    "def validate_cluster(distances, threshold=0.1):\n",
    "    # Ensure all distances are below the threshold for a \"tight\" cluster\n",
    "    return np.all(distances[:, 1:] < threshold)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "Token indices sequence length is longer than the specified maximum sequence length for this model (580 > 512). Running this sequence through the model will result in indexing errors\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Max token length: 580\n",
      "Average token length: 122.93939393939394\n"
     ]
    }
   ],
   "source": [
    "def analyze_token_lengths(json_contents, tokenizer):\n",
    "    lengths = []\n",
    "    for content in json_contents:\n",
    "        combined_text = preprocess_text(content)\n",
    "        tokens = tokenizer(combined_text, truncation=False, return_tensors=\"pt\")\n",
    "        lengths.append(len(tokens['input_ids'][0]))\n",
    "    return lengths\n",
    "\n",
    "# Analyze token lengths\n",
    "token_lengths = analyze_token_lengths(json_contents, tokenizer)\n",
    "print(f\"Max token length: {max(token_lengths)}\")\n",
    "print(f\"Average token length: {np.mean(token_lengths)}\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 24,
   "metadata": {},
   "outputs": [],
   "source": [
    "eligibility_vectors = extract_vectors(json_contents)\n",
    "normalized_vectors = normalize_vectors(eligibility_vectors)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "distances, indices = knn_clustering(normalized_vectors, n_neighbors=10)\n",
    "cluster_labels = kmeans_clustering(normalized_vectors, n_clusters=3, dbscan=False)\n",
    "\n",
    "# Validate cluster tightness\n",
    "print(distances)\n",
    "print(indices)\n",
    "is_tight = validate_cluster(distances, threshold=0.03)\n",
    "print(f\"Are the clusters tight? {'Yes' if is_tight else 'No'}\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 29,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "[1 2 0 2 0 2 0 1 2 2 0 0 0 2 0 2 2 1 1 0 0 2 1 1 1 2 1 2 1 0 1 1 1]\n"
     ]
    }
   ],
   "source": [
    "print(cluster_labels)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 30,
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "/scratch/mgeorges/conda_envs/unsloth_env/lib/python3.11/site-packages/umap/umap_.py:1952: UserWarning: n_jobs value 1 overridden to 1 by setting random_state. Use no seed for parallelism.\n",
      "  warn(\n"
     ]
    },
    {
     "data": {
      "image/png": "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",
      "text/plain": [
       "<Figure size 640x480 with 2 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "import umap.umap_ as umap\n",
    "import matplotlib.pyplot as plt\n",
    "\n",
    "# Reduce dimensionality with UMAP\n",
    "umap_reducer = umap.UMAP(n_components=2, random_state=42)\n",
    "reduced_vectors = umap_reducer.fit_transform(normalized_vectors)\n",
    "\n",
    "# Plot the clusters\n",
    "plt.scatter(reduced_vectors[:, 0], reduced_vectors[:, 1], c=cluster_labels, cmap='viridis', s=50)\n",
    "plt.title(\"UMAP Visualization of Gene Mutation Clusters\")\n",
    "plt.colorbar(label=\"Cluster Label\")\n",
    "plt.show()"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# An experiment to improve the clustering"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "metadata": {},
   "outputs": [],
   "source": [
    "import re\n",
    "from sklearn.cluster import KMeans, DBSCAN\n",
    "from sklearn.metrics.pairwise import cosine_similarity\n",
    "from sklearn.feature_extraction.text import TfidfVectorizer\n",
    "import numpy as np\n",
    "from sklearn.neighbors import NearestNeighbors\n",
    "from collections import Counter\n",
    "import pandas as pd\n",
    "\n",
    "from transformers import AutoTokenizer, AutoModel\n",
    "import torch\n",
    "\n",
    "class ImprovedTrialClustering:\n",
    "    def __init__(self, model_name, tokenizer, model):\n",
    "        self.tokenizer = tokenizer\n",
    "        self.model = model\n",
    "        self.biomarker_keywords = {\n",
    "            'EGFR': ['egfr', 'epidermal growth factor receptor', 'erlotinib', 'gefitinib', 'osimertinib', \n",
    "                     'afatinib', 'dacomitinib', 'exon 19', 'exon 21', 't790m', 'l858r'],\n",
    "            'KRAS': ['kras', 'kirsten rat sarcoma', 'g12c', 'g12d', 'g12v', 'sotorasib', 'adagrasib',\n",
    "                     'amg 510', 'mrtx849', 'krasg12c'],\n",
    "            'ROS1': ['ros1', 'c-ros oncogene 1', 'crizotinib', 'ceritinib', 'alectinib', 'entrectinib',\n",
    "                     'lorlatinib', 'ros1 fusion', 'ros1 rearrangement']\n",
    "        }\n",
    "    \n",
    "    def extract_biomarker_mentions(self, text):\n",
    "        \"\"\"Extract and count biomarker mentions from text\"\"\"\n",
    "        text_lower = text.lower()\n",
    "        biomarker_counts = {}\n",
    "        \n",
    "        for biomarker, keywords in self.biomarker_keywords.items():\n",
    "            count = sum(text_lower.count(keyword) for keyword in keywords)\n",
    "            biomarker_counts[biomarker] = count\n",
    "            \n",
    "        return biomarker_counts\n",
    "    \n",
    "    def preprocess_text_enhanced(self, content, focus_biomarker=None):\n",
    "        \"\"\"Enhanced preprocessing with biomarker-specific focus\"\"\"\n",
    "        # Extract relevant fields\n",
    "        if 'protocolSection' in content:\n",
    "            content = content['protocolSection']\n",
    "            eligibility = content.get('eligibilityModule', {}).get('eligibilityCriteria', '')\n",
    "            conditions = content.get('conditionsModule', {}).get('conditions', [])\n",
    "            if isinstance(conditions, list):\n",
    "                conditions = ' '.join(conditions)\n",
    "            brief_title = content.get('identificationModule', {}).get('briefTitle', '')\n",
    "            brief_summary = content.get('descriptionModule', {}).get('briefSummary', '')\n",
    "            detailed_description = content.get('descriptionModule', {}).get('detailedDescription', '')\n",
    "            intervention_desc = content.get('armsInterventionsModule', {}).get('interventions', [])\n",
    "            if isinstance(intervention_desc, list):\n",
    "                intervention_desc = ' '.join([str(i.get('description', '')) for i in intervention_desc])\n",
    "        else:\n",
    "            eligibility = content.get('eligibility_criteria', '')\n",
    "            conditions = content.get('conditions', '')\n",
    "            brief_title = content.get('brief_title', '')\n",
    "            brief_summary = content.get('brief_summary', '')\n",
    "            detailed_description = content.get('detailed_description', '')\n",
    "            intervention_desc = content.get('intervention_description', '')\n",
    "\n",
    "        # Create biomarker-focused text segments\n",
    "        biomarker_relevant_text = self.extract_biomarker_segments(\n",
    "            eligibility + ' ' + brief_summary + ' ' + brief_title + ' ' + intervention_desc,\n",
    "            focus_biomarker\n",
    "        )\n",
    "        \n",
    "        # Combine with conditions but weight biomarker-relevant content more\n",
    "        if focus_biomarker:\n",
    "            combined_text = f\"{focus_biomarker} \" * 2 + f\"{biomarker_relevant_text} {conditions} {brief_summary}\"\n",
    "        else:\n",
    "            combined_text = f\"{biomarker_relevant_text} {conditions} {brief_summary}\"\n",
    "            \n",
    "        return combined_text.strip()\n",
    "    \n",
    "    def extract_biomarker_segments(self, text, focus_biomarker=None):\n",
    "        \"\"\"Extract text segments most relevant to biomarkers\"\"\"\n",
    "        sentences = re.split(r'[.!?]+', text)\n",
    "        relevant_sentences = []\n",
    "        \n",
    "        if focus_biomarker and focus_biomarker in self.biomarker_keywords:\n",
    "            keywords = self.biomarker_keywords[focus_biomarker]\n",
    "            for sentence in sentences:\n",
    "                sentence_lower = sentence.lower()\n",
    "                if any(keyword in sentence_lower for keyword in keywords):\n",
    "                    relevant_sentences.append(sentence.strip())\n",
    "        else:\n",
    "            # Extract any biomarker-relevant sentences\n",
    "            all_keywords = []\n",
    "            for keywords in self.biomarker_keywords.values():\n",
    "                all_keywords.extend(keywords)\n",
    "            \n",
    "            for sentence in sentences:\n",
    "                sentence_lower = sentence.lower()\n",
    "                if any(keyword in sentence_lower for keyword in all_keywords):\n",
    "                    relevant_sentences.append(sentence.strip())\n",
    "        \n",
    "        return ' '.join(relevant_sentences) if relevant_sentences else text\n",
    "    \n",
    "    def encode_text_with_sliding_window(self, text, max_length=512, stride=256):\n",
    "        \"\"\"Enhanced encoding with better aggregation\"\"\"\n",
    "        if not text.strip():\n",
    "            # Return zero vector for empty text\n",
    "            return np.zeros(512)  # Assuming 768 dim for BERT models\n",
    "            \n",
    "        inputs = self.tokenizer(\n",
    "            text,\n",
    "            return_tensors=\"pt\",\n",
    "            truncation=True,\n",
    "            padding=True,\n",
    "            max_length=max_length,\n",
    "            stride=stride,\n",
    "            return_overflowing_tokens=True,\n",
    "            return_offsets_mapping=False,\n",
    "        )\n",
    "        \n",
    "        input_ids = inputs[\"input_ids\"]\n",
    "        attention_mask = inputs[\"attention_mask\"]\n",
    "        \n",
    "        with torch.no_grad():\n",
    "            outputs = self.model(input_ids=input_ids, attention_mask=attention_mask)\n",
    "        \n",
    "        # Weighted mean pooling based on attention\n",
    "        chunk_embeddings = outputs.last_hidden_state\n",
    "        attention_weights = attention_mask.unsqueeze(-1).float()\n",
    "        \n",
    "        # Apply attention-weighted pooling for each chunk\n",
    "        weighted_embeddings = (chunk_embeddings * attention_weights).sum(dim=1) / attention_weights.sum(dim=1)\n",
    "        \n",
    "        # Aggregate across chunks with more weight on first chunk (usually most important)\n",
    "        chunk_weights = np.array([1.0] + [0.7] * (len(weighted_embeddings) - 1))\n",
    "        chunk_weights = chunk_weights / chunk_weights.sum()\n",
    "        \n",
    "        aggregated_embedding = np.average(weighted_embeddings.numpy(), axis=0, weights=chunk_weights)\n",
    "        return aggregated_embedding\n",
    "    \n",
    "    def create_multi_representation_vectors(self, json_contents, gene_mutations):\n",
    "        \"\"\"Create multiple representations for better clustering\"\"\"\n",
    "        vectors_dict = {\n",
    "            'biomarker_focused': [],\n",
    "            'clinical_focused': [],\n",
    "            'combined': []\n",
    "        }\n",
    "        \n",
    "        for idx, content in enumerate(json_contents):\n",
    "            focus_biomarker = gene_mutations[idx] if idx < len(gene_mutations) else None\n",
    "            \n",
    "            # Biomarker-focused representation\n",
    "            biomarker_text = self.preprocess_text_enhanced(content, focus_biomarker)\n",
    "            biomarker_vec = self.encode_text_with_sliding_window(biomarker_text)\n",
    "            \n",
    "            # Clinical-focused representation (eligibility + conditions)\n",
    "            clinical_text = self.extract_clinical_text(content)\n",
    "            clinical_vec = self.encode_text_with_sliding_window(clinical_text)\n",
    "            \n",
    "            # Combined representation (weighted average)\n",
    "            combined_vec = 0.6 * biomarker_vec + 0.4 * clinical_vec\n",
    "            \n",
    "            vectors_dict['biomarker_focused'].append(biomarker_vec)\n",
    "            vectors_dict['clinical_focused'].append(clinical_vec)\n",
    "            vectors_dict['combined'].append(combined_vec)\n",
    "        \n",
    "        return {k: np.array(v) for k, v in vectors_dict.items()}\n",
    "    \n",
    "    def extract_clinical_text(self, content):\n",
    "        \"\"\"Extract clinical information without biomarker bias\"\"\"\n",
    "        if 'protocolSection' in content:\n",
    "            content = content['protocolSection']\n",
    "            eligibility = content.get('eligibilityModule', {}).get('eligibilityCriteria', '')\n",
    "            conditions = content.get('conditionsModule', {}).get('conditions', [])\n",
    "            if isinstance(conditions, list):\n",
    "                conditions = ' '.join(conditions)\n",
    "        else:\n",
    "            eligibility = content.get('eligibility_criteria', '')\n",
    "            conditions = content.get('conditions', '')\n",
    "        \n",
    "        return f\"{eligibility} {conditions}\".strip()\n",
    "    \n",
    "    def hierarchical_clustering_by_biomarker(self, json_contents, gene_mutations, similarity_threshold=0.8):\n",
    "        \"\"\"Perform hierarchical clustering within each biomarker group\"\"\"\n",
    "        biomarker_groups = {}\n",
    "        \n",
    "        # Group trials by biomarker\n",
    "        for idx, biomarker in enumerate(gene_mutations):\n",
    "            if biomarker not in biomarker_groups:\n",
    "                biomarker_groups[biomarker] = []\n",
    "            biomarker_groups[biomarker].append(idx)\n",
    "        \n",
    "        all_clusters = []\n",
    "        cluster_metadata = []\n",
    "        \n",
    "        for biomarker, indices in biomarker_groups.items():\n",
    "            if len(indices) < 2:\n",
    "                continue\n",
    "                \n",
    "            # Extract vectors for this biomarker group\n",
    "            biomarker_contents = [json_contents[i] for i in indices]\n",
    "            biomarker_mutations = [gene_mutations[i] for i in indices]\n",
    "            \n",
    "            vectors_dict = self.create_multi_representation_vectors(biomarker_contents, biomarker_mutations)\n",
    "            \n",
    "            # Use combined representation for clustering\n",
    "            vectors = vectors_dict['combined']\n",
    "            vectors_normalized = self.normalize_vectors(vectors)\n",
    "            \n",
    "            # Compute similarity matrix\n",
    "            similarity_matrix = cosine_similarity(vectors_normalized)\n",
    "            \n",
    "            # Form tight clusters based on similarity threshold\n",
    "            clusters = self.form_tight_clusters(similarity_matrix, similarity_threshold)\n",
    "            \n",
    "            # Map back to original indices and store\n",
    "            for cluster in clusters:\n",
    "                if len(cluster) >= 3:  # Minimum cluster size\n",
    "                    original_cluster = [indices[i] for i in cluster]\n",
    "                    all_clusters.append(original_cluster)\n",
    "                    cluster_metadata.append({\n",
    "                        'biomarker': biomarker,\n",
    "                        'size': len(cluster),\n",
    "                        'avg_similarity': np.mean([similarity_matrix[i, j] for i in cluster for j in cluster if i != j])\n",
    "                    })\n",
    "        \n",
    "        return all_clusters, cluster_metadata\n",
    "    \n",
    "    def form_tight_clusters(self, similarity_matrix, threshold=0.8):\n",
    "        \"\"\"Form tight clusters based on similarity threshold\"\"\"\n",
    "        n = len(similarity_matrix)\n",
    "        clusters = []\n",
    "        used = set()\n",
    "        \n",
    "        for i in range(n):\n",
    "            if i in used:\n",
    "                continue\n",
    "                \n",
    "            cluster = [i]\n",
    "            used.add(i)\n",
    "            \n",
    "            # Find all similar trials\n",
    "            for j in range(i + 1, n):\n",
    "                if j in used:\n",
    "                    continue\n",
    "                    \n",
    "                # Check if j is similar to all trials in current cluster\n",
    "                if all(similarity_matrix[j, k] >= threshold for k in cluster):\n",
    "                    cluster.append(j)\n",
    "                    used.add(j)\n",
    "            \n",
    "            clusters.append(cluster)\n",
    "        \n",
    "        return clusters\n",
    "    \n",
    "    def normalize_vectors(self, vectors):\n",
    "        \"\"\"Normalize vectors for cosine similarity\"\"\"\n",
    "        norms = np.linalg.norm(vectors, axis=1, keepdims=True)\n",
    "        norms[norms == 0] = 1  # Avoid division by zero\n",
    "        return vectors / norms\n",
    "    \n",
    "    def evaluate_cluster_quality(self, vectors, labels):\n",
    "        \"\"\"Evaluate clustering quality metrics\"\"\"\n",
    "        unique_labels = np.unique(labels)\n",
    "        metrics = {}\n",
    "        \n",
    "        for label in unique_labels:\n",
    "            if label == -1:  # Skip noise points in DBSCAN\n",
    "                continue\n",
    "                \n",
    "            cluster_indices = np.where(labels == label)[0]\n",
    "            if len(cluster_indices) < 2:\n",
    "                continue\n",
    "                \n",
    "            cluster_vectors = vectors[cluster_indices]\n",
    "            \n",
    "            # Intra-cluster similarity\n",
    "            similarities = cosine_similarity(cluster_vectors)\n",
    "            avg_similarity = np.mean(similarities[np.triu_indices_from(similarities, k=1)])\n",
    "            \n",
    "            metrics[f'cluster_{label}'] = {\n",
    "                'size': len(cluster_indices),\n",
    "                'avg_intra_similarity': avg_similarity,\n",
    "                'indices': cluster_indices.tolist()\n",
    "            }\n",
    "        \n",
    "        return metrics\n",
    "\n",
    "# Usage example:\n",
    "def run_improved_clustering(json_contents, gene_mutations, tokenizer, model):\n",
    "    clustering = ImprovedTrialClustering(None, tokenizer, model)\n",
    "    \n",
    "    # Method 1: Hierarchical clustering by biomarker\n",
    "    clusters, metadata = clustering.hierarchical_clustering_by_biomarker(\n",
    "        json_contents, gene_mutations, similarity_threshold=0.75\n",
    "    )\n",
    "    \n",
    "    print(f\"Found {len(clusters)} tight clusters:\")\n",
    "    for i, (cluster, meta) in enumerate(zip(clusters, metadata)):\n",
    "        print(f\"Cluster {i}: {meta['biomarker']} - Size: {meta['size']}, Avg similarity: {meta['avg_similarity']:.3f}\")\n",
    "    \n",
    "    # Method 2: Multi-representation approach\n",
    "    vectors_dict = clustering.create_multi_representation_vectors(json_contents, gene_mutations)\n",
    "    \n",
    "    \"\"\" # Compare different representations\n",
    "    for rep_type, vectors in vectors_dict.items():\n",
    "        vectors_norm = clustering.normalize_vectors(vectors)\n",
    "        \n",
    "        # DBSCAN clustering\n",
    "        dbscan = DBSCAN(eps=0.3, min_samples=3, metric='cosine')\n",
    "        labels = dbscan.fit_predict(vectors_norm)\n",
    "        \n",
    "        # Evaluate quality\n",
    "        quality_metrics = clustering.evaluate_cluster_quality(vectors_norm, labels)\n",
    "        \n",
    "        print(f\"\\n{rep_type.upper()} representation:\")\n",
    "        print(f\"Number of clusters: {len(set(labels)) - (1 if -1 in labels else 0)}\")\n",
    "        print(f\"Noise points: {sum(1 for l in labels if l == -1)}\")\n",
    "        \n",
    "        for cluster_id, metrics in quality_metrics.items():\n",
    "            print(f\"  {cluster_id}: size={metrics['size']}, similarity={metrics['avg_intra_similarity']:.3f}\") \n",
    "    \"\"\"\n",
    "    \n",
    "    return clusters, metadata, vectors_dict"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 8,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Found 3 tight clusters:\n",
      "Cluster 0: KRAS - Size: 11, Avg similarity: 0.981\n",
      "Cluster 1: EGFR - Size: 11, Avg similarity: 0.982\n",
      "Cluster 2: ROS1 - Size: 11, Avg similarity: 0.989\n"
     ]
    }
   ],
   "source": [
    "clusters, metadata, vectors_dict = run_improved_clustering(json_contents, gene_mutations, tokenizer, model)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 9,
   "metadata": {},
   "outputs": [],
   "source": [
    "import umap\n",
    "import matplotlib.pyplot as plt\n",
    "import numpy as np\n",
    "from sklearn.preprocessing import LabelEncoder\n",
    "from sklearn.metrics.pairwise import cosine_similarity\n",
    "\n",
    "def visualize_hierarchical_clusters(vectors, clusters, metadata, gene_mutations, save_path=None):\n",
    "    \"\"\"\n",
    "    Create UMAP visualization for hierarchical clustering results.\n",
    "    \n",
    "    Args:\n",
    "        vectors: Single vector representation used for clustering\n",
    "        clusters: List of cluster indices from hierarchical clustering\n",
    "        metadata: Cluster metadata from hierarchical clustering\n",
    "        gene_mutations: Original biomarker labels\n",
    "        save_path: Optional path to save the figure\n",
    "    \"\"\"\n",
    "    \n",
    "    # Create cluster labels for all trials\n",
    "    cluster_labels = np.full(len(gene_mutations), -1)  # Initialize with -1 (unclustered)\n",
    "    \n",
    "    for cluster_id, cluster_indices in enumerate(clusters):\n",
    "        for idx in cluster_indices:\n",
    "            cluster_labels[idx] = cluster_id\n",
    "    \n",
    "    # Encode biomarker labels for coloring\n",
    "    le = LabelEncoder()\n",
    "    biomarker_encoded = le.fit_transform(gene_mutations)\n",
    "    biomarker_names = le.classes_\n",
    "    \n",
    "    # Create figure with two subplots\n",
    "    fig, (ax1, ax2) = plt.subplots(1, 2, figsize=(15, 6))\n",
    "    fig.suptitle('UMAP Visualization of Hierarchical Clustering Results', fontsize=16)\n",
    "    \n",
    "    colors = ['purple', 'teal', 'gold']  # Colors for different biomarkers\n",
    "    \n",
    "    # Apply UMAP\n",
    "    reducer = umap.UMAP(\n",
    "        n_neighbors=15,\n",
    "        min_dist=0.1,\n",
    "        n_components=2,\n",
    "        metric='cosine',\n",
    "        random_state=42\n",
    "    )\n",
    "    \n",
    "    embedding = reducer.fit_transform(vectors)\n",
    "    \n",
    "    # Left subplot: Colored by biomarker\n",
    "    for biomarker_idx, biomarker_name in enumerate(biomarker_names):\n",
    "        mask = biomarker_encoded == biomarker_idx\n",
    "        ax1.scatter(\n",
    "            embedding[mask, 0], \n",
    "            embedding[mask, 1],\n",
    "            c=colors[biomarker_idx % len(colors)],\n",
    "            label=f'{biomarker_name}',\n",
    "            alpha=0.7,\n",
    "            s=80,\n",
    "            edgecolors='white',\n",
    "            linewidth=0.5\n",
    "        )\n",
    "    \n",
    "    # Add cluster boundaries\n",
    "    for cluster_id, cluster_indices in enumerate(clusters):\n",
    "        cluster_embedding = embedding[cluster_indices]\n",
    "        # Draw a convex hull around each cluster\n",
    "        if len(cluster_indices) >= 3:  # Need at least 3 points for hull\n",
    "            try:\n",
    "                from scipy.spatial import ConvexHull\n",
    "                hull = ConvexHull(cluster_embedding)\n",
    "                for simplex in hull.simplices:\n",
    "                    ax1.plot(cluster_embedding[simplex, 0], \n",
    "                           cluster_embedding[simplex, 1], \n",
    "                           'k--', alpha=0.5, linewidth=1)\n",
    "            except:\n",
    "                pass  # Skip if ConvexHull fails\n",
    "    \n",
    "    ax1.set_title('Clusters by Biomarker')\n",
    "    ax1.legend()\n",
    "    ax1.grid(True, alpha=0.3)\n",
    "    \n",
    "    # Right subplot: Colored by cluster ID\n",
    "    unique_cluster_labels = [i for i in range(len(clusters))]\n",
    "    cluster_colors = plt.cm.Set1(np.linspace(0, 1, len(clusters)))\n",
    "    \n",
    "    for cluster_id, cluster_indices in enumerate(clusters):\n",
    "        cluster_embedding = embedding[cluster_indices]\n",
    "        ax2.scatter(\n",
    "            cluster_embedding[:, 0],\n",
    "            cluster_embedding[:, 1],\n",
    "            c=[cluster_colors[cluster_id]],\n",
    "            label=f'Cluster {cluster_id} ({metadata[cluster_id][\"biomarker\"]})',\n",
    "            alpha=0.7,\n",
    "            s=80,\n",
    "            edgecolors='white',\n",
    "            linewidth=0.5\n",
    "        )\n",
    "    \n",
    "    # Mark unclustered points if any\n",
    "    unclustered_mask = cluster_labels == -1\n",
    "    if np.any(unclustered_mask):\n",
    "        ax2.scatter(\n",
    "            embedding[unclustered_mask, 0],\n",
    "            embedding[unclustered_mask, 1],\n",
    "            c='gray',\n",
    "            label='Unclustered',\n",
    "            alpha=0.5,\n",
    "            s=40\n",
    "        )\n",
    "    \n",
    "    ax2.set_title('Clusters by Hierarchy')\n",
    "    ax2.legend()\n",
    "    ax2.grid(True, alpha=0.3)\n",
    "    \n",
    "    plt.tight_layout()\n",
    "    \n",
    "    if save_path:\n",
    "        plt.savefig(save_path, dpi=300, bbox_inches='tight')\n",
    "    \n",
    "    plt.show()\n",
    "    \n",
    "    # Print cluster statistics\n",
    "    print(\"=== CLUSTER STATISTICS ===\")\n",
    "    for i, (cluster_indices, meta) in enumerate(zip(clusters, metadata)):\n",
    "        print(f\"Cluster {i}: {meta['biomarker']}\")\n",
    "        print(f\"  Size: {meta['size']}\")\n",
    "        print(f\"  Avg Similarity: {meta['avg_similarity']:.3f}\")\n",
    "        print(f\"  Trial indices: {cluster_indices}\")\n",
    "        print()\n",
    "    \n",
    "    # Overall statistics\n",
    "    total_clustered = sum(len(cluster) for cluster in clusters)\n",
    "    total_trials = len(gene_mutations)\n",
    "    \n",
    "    print(f\"Summary:\")\n",
    "    print(f\"  Total trials: {total_trials}\")\n",
    "    print(f\"  Clustered trials: {total_clustered}\")\n",
    "    print(f\"  Coverage: {total_clustered/total_trials*100:.1f}%\")\n",
    "    print(f\"  Number of clusters: {len(clusters)}\")\n",
    "    \n",
    "    return embedding\n",
    "\n",
    "def analyze_cluster_separation(vectors, clusters, metadata):\n",
    "    \"\"\"\n",
    "    Analysis of how well separated the hierarchical clusters are by using intra and inter cluster distances and similarity.\n",
    "    \"\"\"\n",
    "    print(\"\\n=== CLUSTER SEPARATION ANALYSIS ===\\n\")\n",
    "    \n",
    "    # Normalize vectors for cosine similarity\n",
    "    norms = np.linalg.norm(vectors, axis=1, keepdims=True)\n",
    "    norms[norms == 0] = 1  # Avoid division by zero\n",
    "    vectors_norm = vectors / norms\n",
    "    \n",
    "    # Calculate cluster centroids\n",
    "    cluster_centroids = []\n",
    "    for cluster_indices in clusters:\n",
    "        cluster_vectors = vectors_norm[cluster_indices]\n",
    "        centroid = np.mean(cluster_vectors, axis=0)\n",
    "        cluster_centroids.append(centroid)\n",
    "    \n",
    "    # Calculate inter-cluster similarities\n",
    "    if len(cluster_centroids) > 1:\n",
    "        centroid_similarities = cosine_similarity(cluster_centroids)\n",
    "        \n",
    "        print(\"Inter-cluster similarities (centroid-to-centroid):\")\n",
    "        for i, meta_i in enumerate(metadata):\n",
    "            for j, meta_j in enumerate(metadata):\n",
    "                if i < j:  # Only upper triangle\n",
    "                    sim = centroid_similarities[i, j]\n",
    "                    print(f\"  {meta_i['biomarker']} <-> {meta_j['biomarker']}: {sim:.3f}\")\n",
    "    \n",
    "    # Calculate within vs between cluster statistics\n",
    "    print(f\"\\nIntra vs Inter-cluster analysis:\")\n",
    "    for i, (cluster_indices, meta) in enumerate(zip(clusters, metadata)):\n",
    "        cluster_vectors = vectors_norm[cluster_indices]\n",
    "        \n",
    "        # Intra-cluster similarity\n",
    "        if len(cluster_vectors) > 1:\n",
    "            intra_similarities = cosine_similarity(cluster_vectors)\n",
    "            # Take mean of upper triangle (excluding diagonal)\n",
    "            mask = np.triu(np.ones_like(intra_similarities, dtype=bool), k=1)\n",
    "            intra_sim = np.mean(intra_similarities[mask])\n",
    "        else:\n",
    "            intra_sim = 1.0\n",
    "        \n",
    "        # Inter-cluster similarity (to all other clusters)\n",
    "        inter_sims = []\n",
    "        for j, other_cluster_indices in enumerate(clusters):\n",
    "            if i != j:\n",
    "                other_vectors = vectors_norm[other_cluster_indices]\n",
    "                inter_sim_matrix = cosine_similarity(cluster_vectors, other_vectors)\n",
    "                inter_sims.append(np.mean(inter_sim_matrix))\n",
    "        \n",
    "        min_inter_sim = min(inter_sims) if inter_sims else 0.0\n",
    "        avg_inter_sim = np.mean(inter_sims) if inter_sims else 0.0\n",
    "        \n",
    "        separation_score = intra_sim - avg_inter_sim\n",
    "        print(f\"  {meta['biomarker']}: intra={intra_sim:.3f}, \"\n",
    "              f\"inter_avg={avg_inter_sim:.3f}, inter_min={min_inter_sim:.3f}, \"\n",
    "              f\"separation={separation_score:.3f}\")\n",
    "\n",
    "# Simple usage function\n",
    "def create_umap_visualization(vectors, clusters, metadata, gene_mutations, save_path=None):\n",
    "    \"\"\"\n",
    "    Simple wrapper to create visualization and analysis\n",
    "    \n",
    "    Args:\n",
    "        vectors: Embedding vectors (from hierarchical clustering)\n",
    "        clusters: Cluster indices from hierarchical_clustering_by_biomarker()\n",
    "        metadata: Metadata from hierarchical_clustering_by_biomarker()\n",
    "        gene_mutations: List of biomarker labels\n",
    "        save_path: Optional path to save figure\n",
    "    \"\"\"\n",
    "    \n",
    "    embedding = visualize_hierarchical_clusters(\n",
    "        vectors, clusters, metadata, gene_mutations, save_path\n",
    "    )\n",
    "    \n",
    "    analyze_cluster_separation(vectors, clusters, metadata)\n",
    "    \n",
    "    return embedding"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "/scratch/mgeorges/conda_envs/unsloth_env/lib/python3.11/site-packages/umap/umap_.py:1952: UserWarning: n_jobs value 1 overridden to 1 by setting random_state. Use no seed for parallelism.\n",
      "  warn(\n"
     ]
    },
    {
     "data": {
      "image/png": "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",
      "text/plain": [
       "<Figure size 1500x600 with 2 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "=== CLUSTER STATISTICS ===\n",
      "Cluster 0: KRAS\n",
      "  Size: 11\n",
      "  Avg Similarity: 0.981\n",
      "  Trial indices: [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10]\n",
      "\n",
      "Cluster 1: EGFR\n",
      "  Size: 11\n",
      "  Avg Similarity: 0.982\n",
      "  Trial indices: [11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21]\n",
      "\n",
      "Cluster 2: ROS1\n",
      "  Size: 11\n",
      "  Avg Similarity: 0.989\n",
      "  Trial indices: [22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32]\n",
      "\n",
      "Summary:\n",
      "  Total trials: 33\n",
      "  Clustered trials: 33\n",
      "  Coverage: 100.0%\n",
      "  Number of clusters: 3\n",
      "\n",
      "=== CLUSTER SEPARATION ANALYSIS ===\n",
      "\n",
      "Inter-cluster similarities (centroid-to-centroid):\n",
      "  KRAS <-> EGFR: 0.997\n",
      "  KRAS <-> ROS1: 0.997\n",
      "  EGFR <-> ROS1: 0.998\n",
      "\n",
      "Intra vs Inter-cluster analysis:\n",
      "  KRAS: intra=0.981, inter_avg=0.982, inter_min=0.981, separation=-0.001\n",
      "  EGFR: intra=0.982, inter_avg=0.983, inter_min=0.981, separation=-0.000\n",
      "  ROS1: intra=0.989, inter_avg=0.984, inter_min=0.983, separation=0.005\n"
     ]
    }
   ],
   "source": [
    "# Create the vectors you used for clustering if not already done (probably keep the 'combined' representation)\n",
    "# clustering = ImprovedTrialClustering(None, tokenizer, model)\n",
    "# vectors_dict = clustering.create_multi_representation_vectors(json_contents, gene_mutations)\n",
    "vectors = vectors_dict['combined']  # Or whichever representation used\n",
    "\n",
    "# Create UMAP visualization\n",
    "embedding = create_umap_visualization(\n",
    "    vectors, clusters, metadata, gene_mutations, \n",
    "    save_path=\"hierarchical_clusters_umap.png\"\n",
    ")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 10,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "[[0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10], [11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21], [22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32]]\n"
     ]
    }
   ],
   "source": [
    "print(clusters)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "# Save clusters and metadata to CSV\n",
    "def save_clusters_to_csv(clusters, metadata, gene_mutations, filename=\"clusters_metadata.csv\"):\n",
    "    \"\"\"\n",
    "    Save clusters and their metadata to a CSV file.\n",
    "    \n",
    "    Args:\n",
    "        clusters: List of cluster indices\n",
    "        metadata: List of metadata dictionaries\n",
    "        gene_mutations: Original biomarker labels\n",
    "        filename: Output CSV filename\n",
    "    \"\"\"\n",
    "    rows = []\n",
    "    for cluster_id, (cluster_indices, meta) in enumerate(zip(clusters, metadata)):\n",
    "        for idx in cluster_indices:\n",
    "            rows.append({\n",
    "                'Trial NCT ID': nct_ids[idx],\n",
    "                'Cluster ID': cluster_id,\n",
    "                'Biomarker': meta['biomarker'],\n",
    "                'Trial Index': idx,\n",
    "                'Gene Mutation': gene_mutations[idx]\n",
    "            })\n",
    "    \n",
    "    df = pd.DataFrame(rows)\n",
    "    df.to_csv(filename, index=False)\n",
    "    print(f\"Clusters and metadata saved to {filename}\")\n",
    "\n",
    "# Save to CSV\n",
    "save_clusters_to_csv(clusters, metadata, gene_mutations, filename=\"../../data/clusters_metadata.csv\")"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# Generation of Ideal Patients Dataset (Using Llama 3 8B Instruct)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "from transformers import pipeline\n",
    "import os\n",
    "import json\n",
    "import random\n",
    "from typing import List, Dict\n",
    "import sys\n",
    "sys.path.append('../../')  # Adjust path as needed to import from parent directory\n",
    "from utils.gpt.gpt_generate_ideal_candidates import (\n",
    "    extract_age_gender_from_summary,\n",
    "      extract_main_condition_from_summary,\n",
    "        generate_synonyms,\n",
    "          generate_conditions,\n",
    "            split_into_sentences,\n",
    "              generate_summary\n",
    ")\n",
    "from langchain_huggingface import HuggingFacePipeline\n",
    "from langchain.schema import HumanMessage\n",
    "# Initialize the language model (e.g., Llama 3-8b)\n",
    "\n",
    "generator = pipeline(\n",
    "    \"text-generation\",\n",
    "    model=\"meta-llama/Meta-Llama-3-8B-Instruct\",  # or llama3.1/3.3, depending on what you downloaded\n",
    "    device_map=\"auto\",\n",
    "    torch_dtype=\"auto\",\n",
    "    max_new_tokens=512,\n",
    ")\n",
    "\n",
    "llm = HuggingFacePipeline(pipeline=generator)\n",
    "\n",
    "def extract_common_criteria_with_model(trials: List[Dict]) -> str:\n",
    "    \"\"\"\n",
    "    Uses a generative model to extract common inclusion criteria across all trials in a cluster.\n",
    "    \"\"\"\n",
    "    all_criteria = \" \".join([trial.get(\"eligibility_criteria\", \"\") for trial in trials])\n",
    "    prompt = f\"\"\"\n",
    "    You are a medical expert. Based on the following eligibility criteria from multiple clinical trials, extract the common inclusion criteria that apply to all trials. Provide the output as a concise paragraph.\n",
    "    Eligibility Criteria: {all_criteria}\n",
    "    \"\"\"\n",
    "    response = llm.invoke([HumanMessage(content=prompt)])\n",
    "    return response.content.strip()\n",
    "\n",
    "def generate_cluster_patient_profiles(cluster_trials: List[Dict], cluster_id: str, num_patients: int = 100) -> List[Dict]:\n",
    "    \"\"\"\n",
    "    Generates ideal patient profiles for a cluster of trials.\n",
    "\n",
    "    Steps:\n",
    "      1. Extract common inclusion criteria across all trials in the cluster using a generative model.\n",
    "      2. Randomize patient attributes (age, gender, condition) while ensuring they meet the common criteria.\n",
    "      3. Generate patient profiles based on the common criteria and randomized attributes.\n",
    "\n",
    "    Args:\n",
    "      cluster_trials (List[Dict]): List of trial data dictionaries for the cluster.\n",
    "      cluster_id (str): Identifier for the cluster.\n",
    "      num_patients (int): Number of patient profiles to generate.\n",
    "\n",
    "    Returns:\n",
    "      List[Dict]: List of generated patient profiles.\n",
    "    \"\"\"\n",
    "    # Combine all eligibility criteria from the trials in the cluster\n",
    "    all_criteria = \" \".join([trial.get(\"eligibility_criteria\", \"\") for trial in cluster_trials])\n",
    "    \n",
    "    # Use the generative model to extract common inclusion criteria\n",
    "    prompt = f\"\"\"\n",
    "    You are a medical expert. Based on the following eligibility criteria from multiple clinical trials, extract the common inclusion criteria that apply to all trials. Provide the output as a concise paragraph.\n",
    "    Eligibility Criteria: {all_criteria}\n",
    "    \"\"\"\n",
    "    response = llm.invoke([HumanMessage(content=prompt)])\n",
    "    common_criteria = response.content.strip()\n",
    "    print(f\"Common criteria for cluster {cluster_id}: {common_criteria}\")\n",
    "    \n",
    "    # Extract all unique conditions from the trials in the cluster\n",
    "    all_conditions = list(set(\n",
    "        trial.get(\"condition\", \"\") if isinstance(trial.get(\"condition\"), str) else \" \".join(trial.get(\"condition\", []))\n",
    "        for trial in cluster_trials\n",
    "    ))\n",
    "    \n",
    "    # Generate patient profiles\n",
    "    patients = []\n",
    "    for i in range(num_patients):\n",
    "        # Randomize age and gender\n",
    "        age = random.randint(18, 80)  # Example age range\n",
    "        gender = random.choice([\"male\", \"female\"])\n",
    "        \n",
    "        # Randomize condition\n",
    "        condition = random.choice(all_conditions) if all_conditions else \"Condition not specified\"\n",
    "        \n",
    "        # Generate patient profile\n",
    "        raw_description = generate_summary(\n",
    "            details=[common_criteria],\n",
    "            conditions=[condition],\n",
    "            age_spec=f\"aged {age} years old; gender must be {gender}\"\n",
    "        )\n",
    "        age, gender = extract_age_gender_from_summary(raw_description)\n",
    "        main_condition = extract_main_condition_from_summary(raw_description)\n",
    "        synonyms = generate_synonyms(main_condition)\n",
    "        conditions_from_note = generate_conditions(raw_description)\n",
    "        if main_condition not in conditions_from_note:\n",
    "            conditions = [main_condition] + conditions_from_note\n",
    "        else:\n",
    "            conditions = conditions_from_note\n",
    "        \n",
    "        patient_profile = {\n",
    "            \"raw_description\": raw_description,\n",
    "            \"age\": age,\n",
    "            \"gender\": gender,\n",
    "            \"main_condition\": main_condition,\n",
    "            \"synonyms\": synonyms,\n",
    "            \"conditions\": conditions,\n",
    "            \"split_raw_description\": split_into_sentences(raw_description),\n",
    "            \"ground_nctid\": f\"Cluster-{cluster_id}-Patient-{i+1}\"\n",
    "        }\n",
    "        patients.append(patient_profile)\n",
    "    \n",
    "    return patients\n",
    "\n",
    "def process_clusters(cluster_indices: Dict[str, List[str]], trial_folder: str, output_file: str):\n",
    "    \"\"\"\n",
    "    Processes clusters of trials to generate ideal patients for each cluster.\n",
    "    - `cluster_indices`: A dictionary where keys are cluster IDs and values are lists of trial file names.\n",
    "    - `trial_folder`: Path to the folder containing trial JSON files.\n",
    "    - `output_file`: Path to save the generated patient profiles.\n",
    "    \"\"\"\n",
    "    results = {}\n",
    "    for cluster_id, trial_files in cluster_indices.items():\n",
    "        print(f\"Processing cluster {cluster_id} with {len(trial_files)} trials...\")\n",
    "        \n",
    "        # Load trials for the cluster\n",
    "        cluster_trials = []\n",
    "        for trial_file in trial_files:\n",
    "            trial_path = os.path.join(trial_folder, trial_file)\n",
    "            try:\n",
    "                with open(trial_path, 'r') as f:\n",
    "                    trial_data = json.load(f)\n",
    "                    cluster_trials.append(trial_data)\n",
    "            except Exception as e:\n",
    "                print(f\"Failed to load trial {trial_file}: {e}\")\n",
    "        \n",
    "        # Generate patients for the cluster\n",
    "        patients = generate_cluster_patient_profiles(cluster_trials, cluster_id)\n",
    "        results[cluster_id] = patients\n",
    "    \n",
    "    # Save results to the output file\n",
    "    with open(output_file, 'w') as out_file:\n",
    "        json.dump(results, out_file, indent=2)\n",
    "    \n",
    "    print(f\"Processing complete. Results saved to {output_file}\")\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "unsloth_env",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.11.13"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
